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Abstract 
The present work is devoted to study synthesis and modification of 1H-pyrazolo[3,4-
b]pyridin-3(2H)-ones, which could result in appearance of a number of biological activities. 
1H-Pyrazolo[3,4-b]pyridin-3(2H)-one derived moieties and their modifications were prepared 
using classical approaches involving [3+3] cyclocondensations of enamine containing 
heterocycles and bielectrophiles, inverse electron-demand Diels-Alder reactions, and 
palladium-catalyzed C-C coupling reactions. N-Nucleosides of purine analogues were 
synthesized using a modified silyl Hilbert-Jones method while acyclic nucleoside analogues 
were obtained using N-alkylation with alkyl bromides. Scope and limitations of the 
hydrogenation of the pyridine ring of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones were studied. 
 
 
Kurzbeschreibung  
 
Die vorliegende Arbeit untersucht Synthese und Modifikation  von  1H-Pyrazolo[3,4-
b]pyridin-3(2H)-onen, die potentielle biologische Aktivität zeigen können. 1H-Pyrazolo[3,4-
b]pyridin-3(2H)-one und deren Derivate wurden durch [3+3] Zyklokondensation von 
Enamin-enthaltenden Heterozyklen und Bielektrophilen, durch Diels-Alder Reaktionen mit 
inversem Elektronenbedarf sowie durch Palladium katalysierte Kupplungsreaktionen 
synthetisiert. N-Glykolysierte Purine wurden nach einer modifizierten Silyl Hilbert-Jones 
Methode synthetisiert. Die entsprechenden azyklischen Derivate wurden durch N-Alkylierung 
mit Bromalkanen gewonnen. Anwendungsbreite und Grenzen der Hydrierung von 1H-
pyrazolo[3,4-b]pyridin-3(2H)-onen wurden untersucht. 
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Abbreviations  
Ac  Acetyl  
ADA  Adenosine deaminase  
AIDS  Acquired immunodeficiency syndrome 
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Ph  Phenyl  
PTSA  p-Toluenesulphonic acid  
RNA  Ribonucleic acid  
RT  Room temperature 
SCID  Severe combined immunodeficiency 
t-Bu  tert-Butyl  
TEA  Triethylamine 
Tf   Triflate  
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TMSOTf  Trimethylsilyl trifluromethanesulphonate  
TLC  Thin layer chromatography  
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1. Background 
 
Purines, pyrimidines and their nucleosides are building blocks of DNA and RNA and 
therefore possess a fundamental importance in all living systems.1,2 They have been playing a 
major role in treating tumors and viruses, and act as selective inhibitors of certain obligatory 
enzymes for cancer or viral replication3, or as nucleic acid chain terminators which interrupt 
the replication of cancer cells or a virus.4 The emergence of acquired immunodeficiency 
syndrome (AIDS) stimulated extensive antiviral research in the past several decades. The 
study of anti-HIV chemotherapy has promoted a rapid progress of medicinal chemistry, 
molecular virology as well as an understanding of the mechanism of action of antiviral agents. 
Among the medicals currently approved for the treatment of AIDS, hepatitis B and C, and 
infections by herpes viruses, nucleoside analogs play a major role. 
1.1. Some important members of the enzyme family 
Adenosine deaminase (ADA) and Inosine-5′-monophosphate dehydrogenase (IMPDH) 
are considered one of the key enzymes of purine metabolism.5 ADA catalyses deamination of 
adenosine to inosine via formation of covalent hydrate: 5b,c 
 
 
O
OH
OHOH
N
NN
N
NH2
adenosine
O
OH
OHOH
N
NHN
N
O
OH
OHOH
N
NHN
N
inosine
H2N OH O
 
Scheme 1. Adenosine deamination catalyzed by ADA. 
 
Present in virtually all mammalian cells, primary function of ADA is the development and 
maintenance of the immune system.5c ADA association has also been observed with epithelial 
cell differentiation, neurotransmission, and gestation maintenance.6 It has also been proposed 
that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids 
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and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins.5b 
Meanwhile, IMPDH has an essential role in providing precursors for DNA and RNA 
bioysynthesis.6 IMPDH catalyzes oxidation of inosine monophosphate to xanthosine 
monophosphate:  
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Scheme 2. IMPDH catalyzed oxidation of inosine monophosphate. 
 
IMPDH also plays a role in signal transduction pathways that mediate cell differentiation. As 
purine metabolism is largely conserved across all known organisms, so is the structure and 
function of IMPDH.5d,7 
Both ADA and IMPDH enzymes recently became important targets for drug design,8 since it 
was found that dysfunction of ADA and IMPDH is involving many diseases including AIDS,9 
severe combined immunodeficiency (SCID),10 tuberculosis,11 Parkinson’s disease,12 viral 
hepatitis,13 autism,14 bacterial meningitis 15 and several forms of cancer.16  
Deficient levels of ADA have also been associated with pulmonary inflammation, thymic cell 
death, and defective T-cell receptor signaling.17 Conversely, mutations causing this enzyme to 
be overexpressed are one cause of hemolytic anemia.18  
IMPDH expression is found to be upregulated in tumor tissues and tumor cell lines.19 
1.2. Antimetabolites  
Design and synthesis of antimetabolites – substances bearing a close structural resemblance to 
those required for normal physiological functioning – is one of most popular strategies of 
drug development. Antimetabolite drugs were among the first effective chemotherapeutic 
agents discovered so far. Generally, antimetabolites are purine, pyrimidine or folic acid 
analogues; they induce cell death during the S phase of cell growth when incorporated into 
RNA and DNA or inhibit enzymes needed for nucleic acid production.20 
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Few examples of antimetabolites are outlined in Figure 1. Cytarabine is 
a chemotherapy agent used mainly in the treatment of cancers of white blood cells such 
as acute myeloid leukemia and non-Hodgkin lymphoma.21 Cytarabine mimics deoxycitidine, 
a component of DNA, and is the first of a series of cancer drugs that altered the sugar 
component of nucleosides instead of base.22 Tenofovir is a useful drug in HIV-1 treatment,23 
while nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. 
Acyclovir is one of the most commonly used antiviral drugs, primarily used for the treatment 
of herpes simplex virus infections.24 Mercaptopurine is used to treat leukemia,25 psoriatic 
arthritis,26 and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis).27 
It has demonstrated some in vitro effectiveness against Mycobacterium paratuberculosis.28  
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Figure 1. Antimetabolites used in pharmacy. 
 
 
1.3. Design of purine isosteres 
Bioisosteric replacements in organic molecules have been broadly studied to understand their 
affect on several parameters including size of the molecule, conformation, inductive and 
mesomeric effects, polarizability, H-bond formation capacity, pKa, solubility, hydrophobicity, 
reactivity, stability.29 Bioisosterism represents one approach used for the rational modification 
of lead compounds in order to increase selectivity, stability, improve pharmacokinetics 
(solubility-hydrophobicity). Biosterically modified compounds often have decreased toxicity 
and less side effects when interacting with target enzyme compared to parent compounds.30  
One of the most common and powerful isosteric replacements is substitution of hydrogen by 
fluorine. Selective introduction of fluorine into a bioactive substance as an isosteric 
replacement of hydrogen or as an isopolar mimic of hydroxyl group, frequently leads to a 
dramatic change in biological activities and becomes an important strategy in the design and 
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discovery of novel drug candidates. The impact rendered by fluorine on molecular properties 
has been well studied and described in the literature.31-33 
The reason for the incorporation of one or more fluorine atoms into biologically active 
molecules is based on the following characteristics of fluorinated compounds: 1, 31-33 
1) fluorine is the second smallest atom and closely mimics hydrogen without much 
distortion of the geometry; 
2) fluorine is the most electronegative element which can serve as an isopolar and 
isosteric mimic of a hydroxyl group since the C–F bond length (1.35 Å) is close to 
the C–O bond length (1.43 Å), as well as fluorine is a hydrogen-bond acceptor; 
3) strength of the C–F bond exceeds that of the C–H bond which often results in 
increased biological and chemical stability of organofluorine compounds. Therefore 
fluorine can be placed on easily oxidized positions to increase stability during 
metabolic processes.  
Instead of fluorine alone, the trifluoromethyl group CF3 may be used as alternative electron-
withdrawing group.1, 29a In fact, the trifluoromethyl group is considered as isosterically close 
to the amino group (NH2),31c,e and many enzymes tolerate the exchange of an amino by a 
trifluoromethyl group. At the same time, the structural fragment CF2 which is sterically 
similar to the CH2 group, contrasting sharply with the latter in polarity and reactivity.34 In 
particular, CF2 is thought to be an isopolar and isosteric substitute for oxygen.35 
The occurrence of a fluorine substituent in commercial pharmaceutical compounds continues 
to increase by 2% in 1970 to about 20-25% at present. The figures are higher (currently above 
28%) in agrochemicals.32a To date there are known more than 200 pharmaceuticals with at 
least one fluorine substituent.31b, 32b This is a high number considering that fluoroorganic 
compounds are almost absent from nature. Countless yet still appearing reports and reviews 
31-33
 emphasize the significance and actuality of organofluorine chemistry.  
Introduction of fluorine into an organic molecule can be performed by direct selective 
fluorination of target or by the building block method, when fluorinated intermediates are 
used in cyclisation reactions.36-39 Some of the common fluorinating agents are shown in 
Figure 2:  
  
 14 
N
SF3
N NMe
F F
Me
O
N
O
SF3
DAST DFI Deoxofluor
N+
N+
F
Cl
2BF4- S
N
S
F
OO OO
Selectfluor NFSI
A
B
C
O
Si
Me
Me
Me
N
Me
Me
CF3
O
Si
Me
Me
Me
F
F
F
Ruppert-Prakash Trifluoroacetamide
 
Figure 2.  Examples of safe and selective fluorination agents. (A) Nucleophilic agents; (B) 
electrophilic agents, and (C) reagents to introduce CF3 groups. 
 
 
In nucleoside chemistry, Selecfluor is widely used to introduce a fluorine atom into 
heterocyclic bases via electrophilic substitution.40,41 Selecfluor can also selectively fluorinate 
certain sugar moieties, which possess electron-rich double bonds via an electrophilic 
addition.42,43 Meanwhile, DAST is the most versatile reagent for fluorination of sugar moiety 
– it provides a one-step exchange of a hydroxyl group by fluorine. It can replace primary, 
secondary, tertiary and allylic hydroxyl groups by fluorine in excellent yields. For most 
substrates, SN2 displacement of hydroxyl by fluorine occurs with a complete inversion of 
configuration. DAST can also convert most aldehydes and ketones to the corresponding gem-
difluorides.33a, 44  
1.4. Fluorinated nucleosides 
Fluoroorganic molecules are rare in nature, while naturally occurring fluorinated nucleosides 
are even more uncommon. Nucleocidin (Figure 3) is the first naturally occurring derivative 
of a fluoro sugar.45, 46 It was first isolated as an anti-trypanosome antibiotic from the 
fermenatation broth of Streptomices calvus.47,48 
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 Figure 3.  Nucleocidin - natural fluorinated nucleoside.  
 
Introduction of at least one fluorine atom either into sugar or heterocyclic part usually leads to 
transformation of natural or less active synthetic nucleosides into fluoro derivatives bearing 
pharmacologically attractive properties.49-53 
Fluorine is an obvious choice for incorporating into sugar-modified nucleoside analogues, 
since fluorine can be considered as reasonable mimic of either a hydrogen atom or a hydroxyl 
group. There has been a significant amount of research into fluorinated nucleoside analogues 
as potential treatments for cancer and viral infection.54-63 
Currently several potent anti-viral and anti-cancer fluorinated nucleosides and their precursors 
are widely used. Fludarabine phosphate31f, 64 is an excellent example of the influence of 
fluorine on molecule. Fludarabine is a fluorinated analog of a purine nucleoside antiviral 
agent vidarabine. The disadvantage of vidarabine is that it is prone to deamination by ADA. 
The metabolite hypoxantine still possesses antiviral activity, but is 10-fold less potent than 
vidarabine.65 Unlike vidarabine, fludarabine is resistant to deamination by adenosine 
deaminase, thanks to stabilizing effect of fluorine. Fludarabine is successfully used for 
treatment of several types of leukemias and lympfomas.66-69 Figure 4 shows the variety of 
commercial fluorinated drugs.  
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Figure 4. Popular fluorinated antiviral and anti-cancer drugs. 
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Many aspects of the chemistry of fluorinated nucleosides have been investigated in last 
decades focusing generally on the synthesis of fluorinated nucleosides that contain a 
fluorinated glykone moiety. Several excellent reviews have been published concentrated 
mainly on sugar-fluorinated nucleosides.33a,49,78 
 
Nucleosides bearing a highly fluorinated moieties deserve a special attention. Nucleic acid-
based fluorinated derivatives, e.g., nucleosides or oligonucleotides connected to highly 
fluorinated chains, have been investigated recently due to their high potential for biomedical 
applications. It has been reported that highly fluorinated derivatives possess unique properties, 
including chemical and biological inertness, strong hydro- and lipophobia.79,80 Due to their 
unique properties, fluorocarbon chains represent a useful building block for the construction 
of supramolecular systems. Perfluoroalkyl chains have a larger cross section and are more 
rigid than their hydrogenated counterparts. They are considerably more hydrophobic and are 
lipophobic as well. As a result, when dispersed in water, fluorinated amphiphiles exhibit an 
enhanced capacity to self-assemble into highly stable and well-defined assemblies such as 
films, membranes, micelles, vesicles and other stable supramolecular systems.81 
Highly fluorinated chains enhance stability, low permeability to both hydrophilic and 
lipophilic material and reduce interaction with biological media. These fluorinated 
amphiphiles possess a considerable potential for the delivery of materials such as drugs, 
prodrugs, markers, contrast agents and nucleic acids.82 Recently, group of Barthélémy 
reported on the synthesis and biological properties of oligonucleotides bearing 
polyflouroalkyl-chain (Figure 5).83 It was reported that conjugation of fluorocarbon chain to 
the oligonucleotide allows the delivery of highly polyanionic oligonucleotides into human 
cells, while incorporation of non-fluorinated analogues in cells was unsuccessful.  
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Figure 5. Polyfluorinated oligonucleotide. 
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1.5. Goals and tasks of current work 
The amount of manuscripts and reviews still appearing on nucleoside and fluorine chemistry 
clearly indicates the actuality of the field. The group of Professor Langer has made a great 
contribution in progress of fluorine and nucleoside chemistry, and [3+3] cyclisations.84,85 One 
of latest is study of other members of deazapurine family – imidazo[4,5-b]pyridines and their 
corresponding N-nucleosides were studied by Ostrovskyi.86,87  
My work is partly based on previous studies88,89 of Dr. Iaroshenko and Prof. Dr. Groth. They 
have previously developed syntheses of several fluorinated purines, purine nucleosides and 
their mimetics.  
 
The goal of current work is design and synthesis of new potential drug-like scaffolds, i.e. 
polyfluorinated purine isosters bearing a 1H-pyrazolo[3,4-b]pyridin-3(2H)-one core.  
To achieve the goal of this work, next chapters are dedicated to the design and synthesis of 
novel 1H-pyrazolo[3,4-b]pyridin-3(2H)-one analogues bearing a variety of substituents at 
positions 1-, 2-, 4-, 5- and 6- in order to develop a library of compounds for biological 
evaluation.  
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2. Results and discussions 
2.1. Design and synthesis of novel deazapurine analogues bearing 
a 1H-pyrazolo[3,4-b]pyridin-3(2H)-one core 
The subject of current part of this work is to develop a facile methodology for the preparation 
of novel compounds with potential biological activity bearing a 1H-pyrazolo[3,4-b]pyridin-
3(2H)-one core.  
2.1.1. Introduction 
The 1H-pyrazolo[3,4-b]pyridine 1 framework is a key structural fragment of many 
heterocyclic compounds showing a broad spectrum of biological activity.90-102 
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Studies of the last decade show that heterocycles of this class possess antiviral99a, anti-
tumor99b, anti-inflammatory104, anti-microbial105, and anti-parasitic properties.106 
Fluorinated pyrazolo-[3,4-b]pyridines are also believed to be candidates for medications and 
considered to be potential inhibitors of ADA and IMPDH.107 Primary attention has been given 
to the synthesis of CF3-containing pyrazolo[3,4-b]pyridine.97a 
The literature indicates different synthetic approaches to pyrazolo[3,4-b]pyridines. 
Condensation of the aminopyrazoles with α,β-unsaturated compounds is among them.96b 
Chanikov et al. recently synthesized a set of novel, fluoroalkyl-containing pyrazolo[3,4-
b]pyridine derivatives which are considered as promising drug precursors.108 
Similar to pyrazolo[3,4-b]pyridines, also 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2 can possess 
biological activity. It is known that the nitrogen atom at the position 7 of the purine 
framework plays an important role in the substrate/inhibitor recognition of the ADA enzyme 
family, since the amino acid asparagine forms a hydrogen bond with the nitrogen stabilizing 
the transition state of the adenosine deamination. Purine-like inhibitors which possess no 
nitrogen at position 7 are not recognized by the enzyme. This problem can be solved by 
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introducing small polar substituents located at a carbon atom, which are isosteric to the 
nitrogen atom (e. g., F, OH, O=, NH2- and others capable for hydrogen bonding). Therefore, 
pyrazolo[3,4-b]pyridin-3-ones can serve as a core for novel, pharmacologically important 
purine isosteres.  
Recently, few studies of compounds bearing core of pyrazolo[3,4-b]pyridin-3-ones appeared. 
Capelli et al. found that compounds 3 are promising cardiovascular system regulators.109  
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Group of Khouili recently published synthesis of 5 via condensation of 3-amino-1-
phenylpyrazolin-5-one 4 with 2-pyrone derivatives.110 
 
NH2
N
N
O
+
O O
R2
R1
N
N
N
H
O
R5
R4
R3
+
N
N
H
N
O
O
O
4 5
 
 
Scheme 3. Synthesis of pyrazolo[3,4-b]pyridin-3-ones. 
 
2.1.2. Synthesis of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 
2.1.2.1. Reaction between 3-amino-1H-pyrazol-5(4H)-ones and 1,3-diketones 
It has been reported that heteroannulation of electron-enriched heterocycles and 
bielectrophilic building blocks results in fused heterocyclic systems with the desired 
substitution pattern.85,86 This concept has recently gained broad popularity of building up 
polyfluoro-substituted heterocyclic systems. It opens a wide range of practical routes towards 
fluorinated purine analogues and number of fluorine containing small heterocycles.  
We decided to use 1-substituted 3-amino-1H-pyrazol-5(4H)-ones 4 and 1,3-diketones 6 as 
building blocks in order to obtain desired products. Compounds 4 are easily accessible in a 
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reaction of ethylcyanoacetate and corresponding hydrazine in the presence of sodium ethylate 
as described by Weissberger and Porter in 1940-ies.112 Diketones 6 were purchased from 
chemical supply companies or synthesized using classical Claisen condensation.113  
Under harsh conditions in relatively short time reaction between 3-amino-1-phenyl-1H-
pyrazol-5(4H)-one 4a and 1,1,1-trifluoropentane-2,4-dione 6a resulted in desired product 2a 
as a single stereoisomer. The same procedure was repeated but 1-methyl derivate 4b instead 
of 4a was employed, giving product 2b in good yield (Scheme 4).  
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H
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i
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N
N
N
H
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Scheme 4. Synthesis of 2a and 2b. i – AcOH; 118 oC, 2h. 
 
 
Although two isomers 2 and 7 are possible, cyclocondensation showed excellent 
regioselectivity and only 2 was isolated. Likewise, reactions between 3-amino-1H-pyrazol-
5(4H)-ones 4 and 1,3-diketones 6 resulted in 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2c-ai as 
single isomers (Table 1). 
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Table 1. Synthesis and yields of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2a-ai 
 
 Yield (2)a 
F3C Me
O O
 
6a N
N
N
H
Ph
O CF3
Me
 
2a, 82% 
N
N
N
H
Me
O CF3
Me
 
2b, 63% 
F3C Ph
O O
 
6b N
N
N
H
Ph
O CF3
Ph
 
2c, 98% 
N
N
N
H
Me
O CF3
Ph
 
2d, 74% 
F3C CF3
O O
 
6c N
N
N
H
Ph
O CF3
CF3
 
2e, 89% 
N
N
N
H
Me
O CF3
CF3
 
2f, 86% 
F3C
O O
S
 
6d 
N
N
N
H
Ph
O CF3
S
 
2g, 81% 
N
N
N
H
Me
O CF3
S
 
2h, 99% 
F3C OEt
O O
 
6e N
N
N
H
Ph
O CF3
OH
 
2i, 52% 
N
N
N
H
Me
O CF3
OH
 
2j, 77% 
ClF2C Me
O O
 
6f N
N
N
H
Ph
O CF2Cl
Me
 
2k, 64% 
N
N
N
H
Me
O CF2Cl
Me
 
2l, 74% 
O O
MeO
O
OMe
OMe
6g 
N
N
N
H
Ph
O
O OMe
OMe
OMe
 
2m, 70% 
N
N
N
H
Me
O
O OH
OMe
OMe
2n, 85% 
F3C
O O
OCF2H
6h 
N
N
N
H
Ph
O CF3
OCF2H
2o, 69% 
N
N
N
H
Me
O CF3
OCF2H
2p, 99% 
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 Yield (2)a  Yield (2)a 
F3C
O O
O
 
6i 
N
N
N
H
Ph
O CF3
O
 
2q, 89% 
F3C
O O Br
 
6s 
N
N
N
H
Ph
O CF3
Br
 
2aa, 91% 
ClF2C
O O
Cl
 
6j 
N
N
N
H
Me
O CF2Cl
Cl
2r, 96% 
F3CF2C
O O Br
 
6t 
N
N
N
H
Ph
O CF2CF3
Br
 
2ab, 88% 
O O
EtO
O
Me
 
6k 
N
N
N
H
Ph
O
O OEt
Me
2s, 65% 
F3CF2CF2C
O O Br
 
6u 
N
N
N
H
Ph
O CF2CF2CF3
Br
 
2ac, 79% 
Me
O O
 
6l 
N
N
N
H
Ph
O Me
 
2t, 69% 
F3C
O O
Br
 
6v 
N
N
N
H
Ph
O CF3
Br
 
2ad, 97% 
O O
MeO
O
Me
 
6m 
N
N
N
H
Ph
O
O OMe
Me
 
2u, 80% 
F3CF2C
O O
Br
 
6w 
N
N
N
H
Ph
O CF2CF3
Br
 
2ae, 91% 
F3CF2C
O O
 
6n 
N
N
N
H
Ph
O CF2CF3
 
2v, 81% 
F3CF2CF2C
O O
Br
 
6x 
N
N
N
H
Ph
O CF2CF2CF3
Br
 
2af, 94% 
F3CF2CF2C
O O
 
6o 
N
N
N
H
Ph
O CF2CF2CF3
 
2w, 76% 
F3C
O O
Br
 
6y 
N
N
N
H
Ph
O CF3
Br
 
2ag, 79% 
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 Yield (2)a  Yield (2)a 
F3C
O O
N
 
6p 
N
N
N
H
Ph
O CF3
N
 
2x, 92% 
F3CF2C
O O
Br
 
6z 
N
N
N
H
Ph
O CF2CF3
Br
 
2ah, 80% 
F3CF2C
O O
N
 
6q 
N
N
N
H
Ph
O CF2CF3
N
 
2y, 95% 
F3CF2CF2C
O O
Br
6aa 
N
N
N
H
Ph
O CF2CF2CF3
Br
 
2ai, 85% 
F3CF2CF2C
O O
N
 
6r 
N
N
N
H
Ph
O CF2CF2CF3
N
 
2z, 97% 
  
a 
– yields refer to pure isolated products 
 
 
 
New synthesized 1H-pyrazolo[3,4-b]pyridin-3-ones 2 are crystalline compounds, often with 
high melting points. Colours, depending on substitutes, change from white to yellow to black.  
The structures of all compounds 2 were characterized by 1H, 13C NMR, IR spectral data as 
well as MS, HRMS and elemental analysis. Many of synthesized pyrazolo[3,4-b]pyridin-3-
ones, especially 2-methyl derivatives are low soluble in most popular solvents even at high 
temperature and they tend to crystallize as long needles. Therefore in some cases 
characterization of compounds using NMR spectroscopy failed, especially 13C NMR spectral 
analysis, which requires high concentration of analyte because of high substitution rate. 
However, even when the compound is more soluble, polyfluoroalkyl groups, if present, 
appear as undecipherable multiplets. The presence of fluorinated alkyl groups was confirmed 
by 19F NMR and, indirectly by spectral analysis of previously synthesized diketones. Those 
are highly soluble compounds and because of hydrogen close to polyfluoroalkyl group, 13C 
spectral signals of the latter are intensive enough to see exact multiplicity even in case of n-
C3F7. 
19F NMR analysis helped to determine position of perfluoroalkyl group in pyrazolo[3,4-
b]pyridin-3-ones. It was helpful especially in case if 2 was bearing CF3 group. All CF3 group 
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containing products were compared to 2e and 2f. Bearing two CF3 groups which appear in 
19NMR spectra at positions -61 ppm (4-CF3) and -67 ppm (6-CF3), both are excellent 
symmetric model compounds. Nitrogen at position 7 shifts the signal of 6-CF3 to lower field 
causing a small but notable difference. Since other CF3 containing pyrazolo[3,4-b]pyridin-3-
ones show a signal at around -61, there is no doubt that trifluoromethyl group is placed at 
position C4.  
The structure of 2g was independently confirmed by X-ray analysis (Figure 6).  
 
 
 
Figure 6. Ortep plot of 2-phenyl-6-(thiophen-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one 2g. Crystal solvate with DMSO. 
 
 
 
The fact that only one stereoisomere 2 was isolated is explained by reaction mechanism, 
outlined in Scheme 5. Most electron-deficient carbon of 1,3-diketone, which exists in its enol 
form, according to 1H NMR spectra of synthesized diketones, attacks to most electron-rich 
position of 4, forming Michael adduct, which undergoes intramolecular cyclisation and, with 
water elimination, aromatization. Thus, the more electron-rich substituent will always be at 
the position C4 of the molecule of 2.   
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Scheme 5. Mechanism of formation of 1H-pyrazolo[3,4-b]pyridin-3-ones 2. 
 
2.1.2.2. Modification of pyrazolo[3,4-b]pyridin-3-ones via carbon-carbon coupling 
reactions 
Bromine-containing pyrazolo[3,4-b]pyridin-3-ones 2aa-ai were prepared with a particular 
goal – to expand structural diversity via palladium-catalyzed carbon-carbon (C-C) coupling 
reactions114 namely the Suzuki-Miyaura coupling,115 the Heck116 and the Sonogashira117 
reaction. These are probably the most important C-C coupling reactions; they are catalyzed by 
palladium and have been abundantly used in syntheses and widely studied in recent decades.  
The father of palladium-catalysed coupling chemistry is generally considered to be Professor 
Richard Heck. Although first discovered by Mizoroki, it was through work of Heck in the 
early 1970s that the Pd-catalysed reactions became widely known and applied.118 The Heck 
reaction is broadly defined as the palladium-catalyzed coupling of alkenyl or aryl (sp2) halides 
or triflates with alkenes to yield products which formally result from the substitution of a 
hydrogen atom in the alkene coupling partner. Heck reaction is considered as best evolved, 
including a multitude of asymmetric variants. 
Seeking for the best conditions for all three reactions was based on principal similarities of 
our substrates with successful examples published. In quest of best conditions the low 
solubility of substrate had to be taken in mind.  
Heck reaction was the first to perform. Just few trials helped to find optimal conditions for 
Heck reaction: synthesis of 9a was performed in a pressure tube, under inert atmosphere. 1 
Equivalent of 6-(3-bromophenyl)-4-(perfluoropropyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one 2af, 3 equivalents of 4-tert-buthylstyrene 8, 4 equivalents of triethylamine, catalyst 
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PdCl2(PPh3)2 (4mol%) and dry DMF as solvent were used. Reaction resulted in expected 
product 9a (Scheme 6).  
 
N
N
N
H
O
Ph
CF2CF2CF3
2af
t -Bu
8
Br
N
N
N
H
O
Ph
CF2CF2CF3
9a
t -Bu
i
 
 
Scheme 6. Heck coupling between 2af and 4-t-buthylstyrene. i – TEA, 4eq; PdCl2(PPh3)2, 
4mol%; DMF, 140 oC, 8h. 
 
 
Same protocol was applied in other reactions between pyrazolo[3,4-b]pyridin-3-ones 2  and 4-
tert-buthylstyrene 8 (Table 2). Reactions of 3-bromophenyl and 4-bromophenyl derivatives 
resulted in desired products which were afforded in good yields. The situation was different 
when 2-bromophenyl derivatives were used - after repeated trials only starting material was 
isolated. Most probably, Br atom is too sterically hindered to enter the reaction. 
 
 
Table 2. Synthesis and yields of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 9a-c 
 
 Yield (9)a 
N
N
N
H
Ph
O CF2CF2CF3
Br
 
2af 
N
N
N
H
Ph
O CF2CF2CF3
t-Bu
 
9a, 77% 
N
N
N
H
Ph
O CF3
Br
 
2ag 
N
N
N
H
Ph
O CF3
t-Bu
 
9b, 81% 
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 Yield (9)a 
N
N
N
H
Ph
O CF2CF2CF3
Br
 
2ai 
N
N
N
H
Ph
O CF2CF2CF3
t-Bu
9c, 84% 
a 
– yields refer to pure isolated products 
 
 
All synthesized compounds were characterized by 1H, 13C NMR, IR spectral data as well as 
MS, HRMS and elemental analysis. Similar to their precursors, also the products 9 are poorly 
soluble thus burdening spectral analysis. An attempt to grow a crystal was partially successful 
– a crystal of 9b was obtained which gave proof of structure (Figure 7). However, the quality 
of the crystal was too low to obtain precise crystal parameters. 
 
 
 
 
Figure 7. Crystal structure of 9b (crystal solvate with DMSO). 
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Contended with successful results, we decided to try reactivity of alkenes bearing electron-
withdrawing group. Ethylacrylate 10 was considered as attractive reagent. Similar conditions 
as in synthesis of 9 were used here. In contrast with the latter, reaction of 2ad with 
ethylacrylate went an unexpected pathway. Besides Heck coupling, another process – Michael 
addition of ethylacrylate at position N1 – took place simultaneously giving a mixture of two 
products – 11a and 12a (Scheme 7). 
 
 
N
N
N
H
O
Ph
CF3
2ad
i
O
OEt
Br
N
N
N
H
O
Ph
CF3
OEt
O
N
N
N
O
Ph
CF3
OEt
O
OEtO
+
12a
11a
  
Scheme 7. Heck coupling between 2ad and ethylacrylate. i – TEA, 4eq; PdCl2(PPh3)2, 
4mol%; DMF, 100 oC, 20h. 
 
 
Likwise, reaction between other brominated pyrazolo[3,4-b]pyridin-3-ones 2  and 
ethylacrylate was performed. Again, ortho-Br in 2ac proved to be too sterically hindered to 
enter the reaction; only Michael addition occurred giving product 13 (Scheme 8).  
 
 
N
N
N
H
O
Ph
CF2CF2CF3
2ac
i
O
OEt
N
N
N
O
Ph
CF2CF2CF3
13
O
OEt
Br Br
 
Scheme 8. Reaction between 2ac and ethylacrylate. i – TEA, 4eq; PdCl2(PPh3)2, 4mol%; 
DMF, 100 oC, 12h. 
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Reaction products and yields are summarized in Table 3.  
 
 
Table 3. Synthesis and yields of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 11-13. 
 
 Products and yieldsa 
N
N
N
H
Ph
O CF2CF2CF3
Br
 
2ac 
N
N
N
Ph
O CF2CF2CF3
Br
OEtO
 
13, 70% 
 
N
N
N
H
Ph
O CF3
Br
 
2ad 
N
N
N
H
Ph
O CF3
OEt
O
 
11a, 42% 
N
N
N
Ph
O CF3
OEt
O
OEtO
 
12a, 18% 
N
N
N
H
Ph
O CF2CF3
Br
 
2ah 
N
N
N
H
Ph
O CF2CF3
OEt
O
 
11b, 34% 
N
N
N
Ph
O CF2CF3
OEt
O
OEtO
 
12b, 24% 
a 
– yields refer to pure isolated products 
 
 
In order to obtain higher yields of desired product 11, several optimizations were performed – 
1.2 eq of ethylacrylate instead of 3eq were used, also reaction time and temperature was 
modified. Although by decreasing the amount of ethylacrylate, reaction time and temperature, 
higher yields of desired product 11 could be isolated, the formation of side product 12 was 
unavoidable. Reaction at N1 is possible because of the basic effect of TEA – an anion at N1 is 
formed, which is followed by attack of ethylacrylate via Michael addition. The most 
convenient way to desired product 11 would be introduction of appropriate N-protecting 
group and subsequent deprotection after Heck reaction has taken place. The protecting group 
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has to be easily removable, but at the same time it has to be stable during Heck reaction. This 
means looking for possibly mildest conditions since many amine protecting groups are easily 
cleaved when heated or treated with acid or base. Possible choices would be p-toluenesulfonic 
(tosyl-) or benzyl-groups, since they are stable in highly basic media in high temperatures.119  
Structures of 11 – 13 were confirmed by 1H, 13C NMR, IR spectral data as well as MS, 
HRMS and elemental analysis.  
 
Similar to ethylacrylate, acrylonitrile was introduced in the reaction. Again, Br in ortho- 
position proves to be unreactive – instead of Heck reaction different process took place and 
N1 Michael adduct 15 instead of expected product 16 formed (Scheme 9). 
 
 
N
N
N
H
O
Ph
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N
N
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N
N
N
H
O
Ph
CF3
15
CN
Br
not
i
 
 
Scheme 9. Reaction of 2aa with acrylonitrile. i – TEA, 4eq; PdCl2(PPh3)2, 4mol %; DMF, 90 
oC, 24h. 
 
 
Structure of 15 was confirmed by 1H, 13C NMR, IR spectral data as well as MS, HRMS and 
elemental analysis. The main evidence of direction the reaction took is two triplets (2 protons 
each) in 1H NMR spectra; two signals indicating CH2 in DEPT spectra and doublets in mass 
spectra proving the presence of Br.  
Unfortunately, because of limited time further reactions with acrylonitrile were not performed 
but it is most probable that if Br atom is located at meta- or para- positions, two processes – 
Heck and Michael addition – would occur simultaneously, and an appropriate protecting 
group of nitrogen would lead the reaction in desired way.  
Although reactions of 2 with ethylacrylate and acrylonitrile did not go entirely the desired 
path, the products 12, 13 and 15 still have potential to be biologically active substances. Both 
propanenitrile and ethylpropanoate groups can be referred to as acyclic sugar analogues. 
Besides they can be employed in several reactions giving new kinds of products. 
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Unsuccessful experiments 
After countless trials we had to admit that Suzuki-Miyaura and Sonogashira reactions do not 
give satisfactory results. In Sonogashira reactions, complete conversion of starting materials 
was observed, but TLC showed that mixture of highly polar compounds was formed and 
separation by column chromotagrophy was impossible. To the contrary, in Suzuki-Miyaura 
reaction only starting material was isolated; the main reason for the failure is the low 
solubility of substrate or inorganic base. Clearly, different approach must be used. Recently, 
the synthesis of tubercidine analogues with anti-cancer activity was patented120 where target 
compounds were afforded from 7-iodotubercidine 17 via Suzuki-Miyaura and Sonogashira 
reactions. Suzuki-Miyaura cross coupling reactions of 7-iodotubericidine with corresponding 
aryl and hetaryl boronic acids were performed under aqueous conditions,121 while ethynyl 
derivative 20 was prepared by Sonogashira reaction of 17 with trimethylsilylacetylene 19. 
 
O
OH
OHOH
N
N
N
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N
N
NH2
20
TMS
i
i i
 
 
Scheme 10. Cross-coupling reactions of 7-iodotubercidine described in literature.Reagents 
and conditions: i – Pd(OAc)2, TPPTS, Na2CO3, CH3CN/H2O, 80 oC, 1h; ii – 
PdCl2(PPh3)2, TEA, DMF, RT, 16h. 
 
 
This strategy would be convenient also in my current work. Nucleosides are more soluble 
than their corresponding aglykones, and position N1 is protected thus avoiding unwanted 
reaction path. Probably, it would be possible to perform also Heck reaction without need to 
seek for appropriate N-protecting group. 
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2.1.3. Synthesis of dichromeno[4,3-b]pyrazolo[4,3-e]pyridine-6,8-diones 
Being interested in the development of new methods of pyrazolo[3,4-b]pyridin-3-one 
construction, we considered coumarine scaffolds as building blocks in cyclocondesation 
reactions with 1-substituted 3-amino-1H-pyrazol-5(4H)-ones. The latter are formally 
condensed enamines, and therefore could be considered as useful binucleophiles.  
 
We decided to use 3-acyl-4-chlorocoumarines which were afforded from commercially 
available 4-hydroxycoumarine in one pot synthesis developed recently by the group of 
Langer.122 Since 3-acyl-4-chlorocoumarines 21 proved to be sensitive to moisture, reaction 
between 5-aminopyrazolone 4a and 21a was performed in a pressure tube under inert 
atmosphere; dry DMF was used as solvent and TMSCl as water scavenger (Scheme 11). 
Trying different reaction temperatures (RT to 120 oC) and reaction times (up to 12 h), we 
found that dichromeno[4,3-b]pyrazolo[4,3-e]pyridine-6,8-dione 22a can be afforded in good 
yield when heated at 83 oC for 3h.  
Although two isomers 22a and 23a are possible, the cyclocondensation showed excellent 
regioselectivity and only one stereoisomere 22a was observed and isolated. 
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Scheme 11. Synthesis of dichromeno[4,3-b]pyrazolo[4,3-e]pyridine-6,8-dione 22a.                 
i – TMSCl, DMF, 83 oC, 3h. 
 
 
 
The same protocol was applied in synthesis of other dichromeno[4,3-b]pyrazolo[4,3-
e]pyridine-6,8-diones 22b-d. Like in first synthesis, formation of reaction product 22 instead 
of 23 was observed.  
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Table 4. Synthesis and yields of dichromeno[4,3-b]pyrazolo[4,3-e]pyridine-6,8-diones 22a-d 
 
 Yield (2)a 
O
Cl
CF3
O
O
 
21a 
N
O
N
N
H
Ph
OCF3O
 
22a, 65% 
N
O
N
N
H
Me
OCF3O
 
22b, 57% 
O
Cl O
O
O
OMe
 
21b 
N
O
N
N
H
Ph
OO
O OMe
 
22c, 60% 
N
O
N
N
H
Me
OO
O OMe
 
22d, 68% 
a 
– yields refer to pure isolated products 
 
 
Products 22 are crystalline compounds with high melting points. Yields of isolated 
cycloadducts are reduced because of instability of 3-acyl-4-chlorocoumarines 21. An evidence 
of side-reactions and degradation of starting materials was the intensive black color of 
reaction mixture and observation of highly polar compounds on TLC.  
The structures of dichromeno[4,3-b]pyrazolo[4,3-e]pyridine-6,8-diones 22 were characterized 
by 1H, 13C NMR, IR spectral data as well as MS, HRMS and elemental analysis. 19F NMR 
was used to prove the presence of CF3 group for 22a and 22b. Unfortunately, low solubility in 
most popular solvents made characterization of 22b and 22d by NMR spectroscopy difficult.  
The main proof for the structure of 22 is based on 13C NMR spectra. Studies of theoretically 
estimated 13C NMR spectra show only one notable difference (Figure 8). The atom C6a 
(marked with red) theoretically appears at 122 ppm in case if 22 is formed, while in case of 23 
the same atom would appear at 138 ppm. All experimentally measured 13C NMR spectra 
show a signal at 118 ppm which is clear evidence towards structure 22. 2D NMR 
measurements of 22a show correlation between CCF3 and carbonyl group. 
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Figure 8. Estimated 13C NMR signals of 22a and 23a. 
 
 
Proposed mechanism involves Michael addition of α,γ-dielectrophile to heterocycle leading to 
intermediate A, which undergoes intramolecular cyclisation to B and, with subsequent water 
elimination, formation of 22 (Scheme 12). 
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Scheme 12.  Mechanism of formation of dichromeno[4,3-b]pyrazolo[4,3-e]pyridine-6,8-
diones 22. 
 
 
We tried opening the pyrone ring using KOH in MeOH or hydrazine hydrate (Scheme 13). 
Significant, in both cases, addition of base resulted in immediate color change of yellow 
solution to dark red mixture. Unfortunately, both methods gave an unseparatable mixture of 
highly polar compounds.  
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Scheme 13. Unsuccessful ring-opening reactions of 22. 
 
2.1.4. Synthesis of 5-substituted pyrazolo[3,4-b]pyridin-3-ones 
Next, we decided to modify the pyrazolo[3,4-b]pyridin-3-one 2 system by introducing a 
substituent at position C5 which was unsubstituted in all previously synthesized pyrazolo[3,4-
b]pyridin-3-ones. 
N
HN
N
H
2
O
 
 
 
We considered an introduction of different functionalities using several dielectropfiles 26 – 28 
(Scheme 14), but all attempts to find appropriate conditions and isolate desired products 
failed – unseparatable mixture of highly polar compounds formed. 
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Scheme 14. Unsuccessful trials to form 5-substituted pyrazolo[3,4-b]pyridin-3-ones. 
  
 36 
Therefore, a different strategy to obtain 5-substituted pyrazolo[3,4-b]pyridin-3-ones had to be 
found. A recent study123 of the reactivity of 5-bromo-1,2,3-triazine 32 catched our attention. It 
is well known fact that inverse electron demand Diels-Alder (DAInv) reactions of electron-
deficient heterocyclic azadienes have been used as powerful cycloaddition reactions central to 
a series of natural product total syntheses whose structures possess highly functionalized 
heterocyclic ring systems not easily accessed by conventional methods.124 Several studies 
have demonstrated the ability of 1,2,3-triazines to participate in inverse electron demand 
Diels-Alder reactions, typically with enamine125 and ynamine126 dienophiles. Br atom as C5 
substituent converts 1,2,3-triazine into a heterocyclic azadiene system with a reaction scope 
that portends extensive synthetic utility, substantially expanding the range of participating 
dienophiles.123 
 
N
N
N
Br
32
EDG
+
N
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Scheme 15. Inverse electron demand Diels-Alder (DAInv) reaction of 1,2,3-triazine.  
 
 
Therefore we decided to use 5-bromo-1,2,3-triazine 32 to bring a Br atom into C-5 position 
thus opening a scope for further reactions namely Suzuki-Miyaura, Sonogashira and Heck. 
The synthesis of 32 was performed according to a known method127 using 4-bromopyrazole 
and hydroxylamine-O-sulfonic acid with subsequent oxidative ring expansion by treatment 
with NaIO4. 4-Bromopyrazole was synthesized in excellent yield in a reaction of 
unsubstituted pyrazole with N-bromosuccinimide in CCl4.128  
Next, we conducted a trial experiment by stirring a mixture of 5-bromo-1,2,3-triazine 32 and 
3-amino-1-phenyl-1H-pyrazol-5(4H)-one 4a in acetic acid at RT overnight. A small amount 
of brown solid was isolated which, according to 1H NMR spectra, proved to be the desired 
product 33a. The yield of less than 20% is explained with instability of bromotriazine under 
acidic conditions. Therefore isopropanol was used as solvent and during stirring a reaction 
mixture under reflux for 2 hours, formation of product as brown precipitation was observed. 
Filtration and washing with hot ethanol gave 96% yield of desired 5-bromo-2-phenyl-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one 33a (Scheme 16). To our disappointment, product showed 
limited solubility in all popular solvents thus limiting the scope of further applications. As 
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expected, use of 3-amino-1-methyl-1H-pyrazol-5(4H)-one 4b gave a quantitative yield of 
insoluble pyrazolo[3,4-b]pyridine-3-one 33b.  
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Scheme 16. Synthesis of 5-bromo-1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 33. 
 
 
As indicated before, the reaction between 1,2,3-triazine and electron-rich heterocycles is 
classified as an inverse electron demand Diels-Alder reaction. Intermediate A is formed by 
attack of dienophile 4 on diene 32, subsequent elimination of N2 leads to intermediate B, 
which turns into target product 33 by elimination of NH3 (Scheme 17). 
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Scheme 17. Mechanism of formation of 5-bromo-1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 33. 
 
 
The fact that pyrazolo[3,4-b]pyridine-3-ones 33 are insoluble in most solvents, makes the use 
of these compounds as substrates for further syntheses difficult. Attempts to perform Suzuki-
Miyaura coupling failed completely since we could not find a solvent to dissolve the 
substrates.  
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2.1.5. Conclusions 
In conclusion of this chapter, a set of 51 by far unknown deazapurine analogues is 
synthesized. Bearing a strong-withdrawing group these compounds are potential inhibitors of 
ADA and IMPDH, and can show a broad variety of biological activities. For example, (E)-6-
(4-(4-tert-butylstyryl)phenyl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-
one 9b can be potential liquid crystal, since it is a long, thin molecule with a relatively low 
melting point.  
Most target substances are obtained in moderate to excellent yields using classical approach 
involving [3+3] cyclocondesation of enamine fragment-containing heterocycle – 
aminopyrazolone – and bielectrophiles – 1,3-diketones or 3-acyl-4-chlorocoumarines. Inverse 
demand Diels-Alder reaction was applied for synthesis of 5-substituted pyrazolo[3,4-
b]pyridin-3-ones. Modification of bromine-containing pyrazolo[3,4-b]pyridin-3-ones was 
performed using Pd-catalyzed reactions.  
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2.2. Design and synthesis of novel deazapurine glycosides as 
potential inhibitors of adenosine deaminase and inosine-5′-
monophosphate dehydrogenase 
 
Present part of this work is focused on synthesis of glycosides and their analogues, employing 
a selection of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones described in previous chapter. 
2.2.1. Introduction 
As it was indicated before, nucleosides, especially fluorinated derivatives, have found 
widespread applications in chemistry, physics, and biology. Our subject of interest, inhibition 
of ADA and IMPHD, is listed among them.  
The key step of inosine formation via ADA-catalyzed deamination is the nucleophilic 
addition of water to position 6 of the adenine fragment.129 A study of Lindell et al, which was 
based on calculations of the enthalpy of covalent hydration of a number of different 
nucleosides, proved that a stronger electron-withdrawing character of the aglycone facilitates 
the hydration process by increasing the absolute value of enthalpy.130, 131 
To inhibit an enzyme, it is obligatory to match the requirements of the targeted binding 
pocket. The sterical similarity of the trifluoromethyl and the amino group, in combination 
with the highly withdrawing character of the CF3 residue, makes 4- or 6-trifluoromethyl-
substituted 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones interesting substrates for studies of ADA 
or IMPHD inhibition.  
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Scheme 18. Possible interraction of target molecules with ADA and IMPDH. 
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Similar to the CF3 group, the presence of the polyfluorinated group can facilitate the addition 
of a water molecule and the formed hydrate will coordinate on the ADA’s cofactor zinc 
moiety with OH function leading to the enzyme inhibition. It is also known that the fluorine 
atoms of perfluoroalkanes show affinity to Lewis acidic metal cations,31c, 132 such as Li+, Al3+, 
Ga3+, Mg2+, and Zn2+. Since the active site of ADA-type inhibitors possesses an incorporated 
zinc cation, it could be advantageous to introduce perfluoroalkyl groups in the inhibitor. The 
Rf groups would interact with the metal cation and result in the formation of a stable associate 
and enzyme inactivation. Besides, it is been reported that polyfluoro group, incorporated in 
nucleoside, increases bioavailability of the molecule.83 
 
2.2.2. Synthesis of N-nucleosides of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones  
The advantages of CF3 and polyfluoroalkyl groups listed previously directed us into design of 
1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2 described in previous chapter. Now, motivated by 
biological importance of nucleosides, we decided to transform both fluorinated and non-
fluorinated pyrazolo[3,4-b]pyridin-3-ones into potentially useful nucleosides and their 
analogues.  
There are different applicable approaches to the synthesis of a variety of nucleosides. 
Theoretically they can be classified into four categories based on the strategies they use: 
1) Construction of an aglycone unit upon a carbohydrate moiety;  
2) Construction of a carbohydrate moiety upon an aglycone unit;  
3) Direct coupling of a carbohydrate moiety with a preformed aglycone unit;  
4) Modification of the existing N-nucleosides.  
 
Since we have synthesized a variety of N-deprotected deazapurine analogues, direct coupling 
with a carbohydrate moiety is most convenient way to achieve N-nucleosides. Following 
work done by us includes synthesis of both cyclic nucleosides and molecules which could be 
referred as acyclic analogues of nucleosides.  
 
2.2.2.1. Cyclic nucleosides 
As mentioned above, we decided to attach carbohydrate moiety directly to our heterocycles. 
After studying a number of glycosilations most suitable method was selected. The so-called 
silyl Hilbert-Jones method133 is based on a preliminary activation of heterocyclic moiety with 
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N,O-bis(trimethylsilyl)acetamide (BSA), resulting in generation of N-silylated intermediate, 
which reacts with peracylated sugar in presence of weak Lewis acid, such as TMSOTf. 
Following this method, Dr. Ostrowski from our group successfuly synthesized a handful of 
nucleosides.86, 87 
Three peracetylated carbohydrates were chosen - 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose 34, 
1,2,3,4,6-penta-O-acetyl-β-D-glucose 35 and 1,2,3,4-tetra-O-acetyl-α-L-rhamnose 36. The 
choice of above mentioned sugars was based on fact that all of them are components of 
naturally occurring nucleosides and, in fact, α-L-rhamnose is one of only three naturally 
occurring α-sugars.  
In the first step of reaction, 1.1 equiv. of BSA was added to a suspension of 2a in dry 
acetonitrile and the mixture was heated at reflux for 20 minutes, during this time a clear 
solution was formed - this indicates the successful initial silylation. In the next step, without 
isolation of intermediate, a solution of 1.1 equiv. of acetylated sugar in CH3CN and catalytic 
amount of TMSOTf (25 mol%) was added and refluxing continued (Scheme 19). The 
progress was monitored with TLC. After refluxing for 2 hours, conversion of most of 
pyrazolo[3,4-b]pyridinone 2a was observed. To attain complete conversion, heating was 
prolonged up to 12 hours but, as it was observed by TLC, continuous decomposition of 
product takes place. Therefore, reaction time was limited to 2 hours.  
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Scheme 19. Synthesis of nucleosides. Conditions: i – dry CH3CN, BSA, TMSOTf, 82 oC, 2h. 
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Likewise, other 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2, 9, 11, and 33, and dichromeno[4,3-
b]pyrazolo[4,3-e]pyridine-6,8-diones 22 were engaged in glycosylation reactions giving 
corresponding nucleosides 37-39. An overwiev of successfuly isolated nucleosides is 
summarized in Table 5. 
 
Table 5. Synthesis and yields of nucleosides 37-39 
 
 Product and yield a 
N
N
N
H
Ph
O CF3
Me
 
2a 
N
N
N
Ph
Me
CF3O
O
OAc
OAc
AcO
 
37a, 80% 
N
N
N
Ph
Me
CF3O
O
OAc
OAc
AcO
AcO
 
38a, 76% 
N
N
N
Ph
Me
CF3O
O OAc
OAcAcO
Me
 
39a, 68% 
N
N
N
H
Ph
O CF3
Ph
 
2c 
N
N
N
Ph
Ph
CF3O
O
OAc
OAc
AcO
 
37b, 80% 
N
N
N
Ph
Ph
CF3O
O OAc
AcO
OAc
AcO
 
38b, 80% 
N
N
N
Ph
Ph
CF3O
O OAc
OAcAcO
Me
 
39b, 44% 
N
N
N
H
Me
O CF3
Ph
 
2d 
N
N
N
Me
Ph
CF3O
O
OAc
OAc
AcO
 
37c, 69% 
N
N
N
Me
Ph
CF3O
O OAc
AcO
OAc
AcO
38c, 78% 
N
N
N
Me
Ph
CF3O
O OAc
OAcAcO
Me
 
39c, 58% 
N
N
N
H
Me
O CF3
CF3
 
2f 
N
N
N
Me
CF3
CF3O
O
OAc
OAc
AcO
 
37d, 92% 
  
N
N
N
H
Ph
O CF3
S
 
2g 
N
N
N
Ph
CF3O
O
OAc
OAc
AcO
S
 
37e, 94% 
N
N
N
Ph
CF3O
S
O OAc
AcO OAc
AcO
38e, 86% 
O OAc
OAc
AcO
Me
N
N
N
Ph
CF3O
S
39e, 86% 
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 Product and yield a 
N
N
N
H
Ph
O CF3
O
 
2i 
N
N
N
Ph
O CF3
O
OAc
OAc
AcO
O
37f, 83% 
  
N
N
N
H
Ph
O CF3
OCF2H
2r 
N
N
N
Ph
CF3O
OCF2H
O
OAc
OAcOAc
37g, 84% 
N
N
N
Ph
CF3O
OCF2HO
OAc
OAc
OAc
OAc
38g, 74% 
N
N
N
Ph
CF3O
OCF2H
O
OAc
Me
AcO
OAc
39g, 61% 
N
N
N
H
Me
O CF3
OCF2H
2s 
N
N
N
CF3O
OCF2H
O
OAc
OAcOAc
Me
37h, 59% 
N
N
N
Me
CF3O
OCF2HO
OAc
OAc
OAc
OAc
38h, 69% 
N
N
N
Me
CF3O
OCF2H
O
OAc
Me
AcO
OAc
39h, 64% 
N
N
N
H
Ph
O
O OMe
Me
2u 
N
N
N
Ph
O
O OMe
Me
O
OAc
OAcOAc
37i, 87% 
N
N
N
Ph
O
O OMe
Me
O OAc
AcO
OAcAcO
38i, 94% 
N
N
N
Ph
O
O OMe
Me
O OAc
OAc
Me
AcO
39i, 59% 
N
N
N
H
Ph
O CF2CF3
Ph
 
2v 
N
N
N
Ph
Ph
CF2CF3O
O
OAc
OAc
AcO
 
37j, 82% 
N
N
N
Ph
Ph
CF2CF3O
O
AcO
OAc
OAc
Me
 
39j, 85% 
N
N
N
H
Ph
O CF2CF2CF3
Ph
 
2w 
N
N
N
Ph
Ph
CF2CF2CF3O
O
OAc
OAc
AcO
37k, 76% 
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 Product and yield a 
N
N
N
H
Ph
O CF3
N
 
2x 
N
N
N
Ph
CF3O
N
O
OAc
OAc
AcO
37l, 82% 
N
N
N
CF3O
N
O
OAc
AcO
OAcAcO
Ph
38l, 68% 
N
N
N
Ph
CF3O
N
O
AcO
OAc
OAc
Me
39l, 84% 
N
N
N
H
Ph
O CF2CF3
N
 
2y 
N
N
N
Ph
CF2CF3O
N
O
OAc
OAc
AcO
 
37m, 82% 
N
N
N
Ph
CF2CF3O
N
O
AcO
OAc
OAc
Me
 
39m, 83% 
N
N
N
H
Ph
O CF2CF2CF3
N
 
2z 
N
N
N
Ph
CF2CF2CF3O
N
O
OAc
OAc
AcO
 
37n, 85% 
N
N
N
Ph
CF2CF2CF3O
N
O
AcO
OAc
OAc
Me
 
39n, 84% 
N
N
N
H
Ph
O CF2CF2CF3
t-Bu
 
9a 
N
N
N
Ph
CF2CF2CF3O
O
OAc
OAc
AcO
t-Bu
37o, 70% 
N
N
N
Ph
CF2CF2CF3O
O
OAc
OAc
AcO
AcO
t-Bu
38o, 71% 
N
N
N
H
Ph
O CF2CF2CF3
t-Bu
9b 
N
N
N
Ph
CF2CF2CF3O
O
OAc
OAc
AcO
t-Bu
 
37p, 55% 
N
N
N
CF2CF2CF3O
t -Bu
O
OAc
OAc
AcO
AcO
38p, 62% 
N
N
N
H
Ph
O CF3
t-Bu
9c 
N
N
N
Ph
CF3O
O
OAc
OAc
AcO
t-Bu
 
37q, 82% 
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 Product and yield a 
N
N
N
H
Ph
O CF3
OEt
O
11a 
N
N
N
Ph
CF3O
O
OAc
OAc
AcO
O
OEt
 
37r, 79% 
 
N
N
N
H
O
Br
Ph
 
33a 
N
N
N
Ph
O
O
OAc
OAcOAc
Br
 
37s, 64% 
  
N
O
N
N
H
Ph
OCF3O
 
22a 
N
O
N
N
OCF3O
Ph
O OAc
OAc
AcO
 
37t, 76% 
N
O
N
N
OCF3O
Ph
O
OAc
OAc
AcO
AcO
 
38t, 65% 
N
O
N
N
H
Me
OCF3O
 
22b 
N
O
N
N
OCF3O
Me
O OAc
OAc
AcO
 
37u, 68% 
 
N
O
N
N
H
Ph
OO
O OMe
 
22c 
N
O
N
N
OCO2MeO
Ph
O
OAc
OAc
AcO
37v, 79% 
N
O
N
N
OCO2MeO
Ph
O
OAc
OAc
AcO
AcO
38v, 73% 
N
O
N
N
OCO2MeO
Ph
O
OAc
Me
OAc
AcO
 
39v, 67% 
N
O
N
N
H
Me
OO
O OMe
 
22d 
N
O
N
N
OCO2MeO
Me
O
OAc
OAc
AcO
 
37w, 81% 
N
O
N
N
OCO2MeO
Me
O
OAc
OAc
AcO
AcO
 
38w, 57% 
a 
– yields refer to pure isolated products 
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Reactions with ribose 34 and rhamnose 36 give better results than reactions with glucose 35. 
Higher yields were observed for ribosides and rhamnosides and parallel decomposition 
seemed to be slower than in case of the synthesis of glucosides 38. Also, 38 decomposes 
during storage. 
All synthesized nucleosides were characterized by 1H, 13C NMR, IR spectral data as well as 
MS, HRMS and elemental analysis. Br-containing nucleoside 37s was charachterised only by 
1H NMR since the compound proved to be unstable.  
 
In case of 37f and 37g, structure was independantely confirmed by X-ray analysis. To 
simplify the view of structure, hydrogen atoms are not shown (Figure 9).  
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Figure 9. Ortep plot of 37f and 37g. 
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The possible mechanism of the reaction, and in agreement with that reported by Ostrovskyi,87 
is generally similar to the known mechanistic pathway for naturally occurring purines.134 
First, pyrazolo[3,4-b]pyridine-3-one is being silylated by BSA, subsequent rearrangement 
(intermediate A) by action of TMSOTf follows. Subsequently, intermediate A attacks cyclic 
cation B, which is formed via nucleophilic attack of the neighboring acetyl group on the 
deacetylated anomeric position of sugar. This results in formation of the desired nucleoside.  
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Scheme 20. Mechanism of glycosilation reaction. 
 
The next task was the deprotection of the products. Several methods have been described, 
marking two as most effective:135 cleavage of the acetyl group can be performed by hot 
aqueous methylamine 136 or ammonia in methanol.137  
The second procedure required more continuous stirring (up to 24 hours), but it is milder thus 
lowering the possibility of decomposition of substrate. The only byproduct formed is 
acetamide, which can be easily separated by column chromatography or even by sublimation 
under vacuum. Therefore, we employed ammonia in methanol for deprotection of 37a and an 
overnight stirring yielded in deprotected nucleoside 40a (Scheme 21). 
 
N
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Scheme 21. Deprotection of acetylated nucleoside 37a. i – NH3/MeOH, RT, overnight. 
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The same procedure was successfully applied to afford other deprotected nucleosides 40-42. 
Most of previously synthesized nucleosides were deacetylated in excellent yields (Table 6).  
 
Table 6. Deprotected glycosides and yields 
 
Product and yield a 
Ribosides: 
N
N
N
Ph
Me
CF3O
O OH
OH
HO
 
40a, 96% 
N
N
N
Ph
Ph
CF3O
O
OH
OH
HO
 
40b, 92% 
N
N
N
Me
Ph
CF3O
O
OH
OH
HO
 
40c, 95% 
N
N
N
Ph
CF3O
O
OH
OH
HO
S
 
40e, 89% 
N
N
N
Ph
CF3O
O
OH
OH
HO
O
 
40f, 93% 
N
N
N
Ph
CF3O
OCF2H
O
OH
OHOH
40g, 98% 
N
N
N
Ph
O
O OH
CH3
O
OH
OHOH
 
40i, 89% 
N
N
N
Ph
Ph
CF2CF3O
O
OH
OH
HO
 
40j, 91% 
N
N
N
Ph
Ph
CF2CF2CF3O
O
OH
OH
HO
 
40k, 85% 
N
N
N
Ph
CF3O
N
O OH
OH
HO
 
40l, 93% 
N
N
N
Ph
CF2CF3O
N
O
OH
OH
HO
 
40m, 91% 
N
N
N
Ph
CF2CF2CF3O
N
O OH
OH
HO
 
40n, 92% 
N
N
N
Ph
CF2CF2CF3O
O
OH
OH
HO
t-Bu
 
40o, 92% 
N
N
N
Ph
CF2CF2CF3O
O
OH
OH
HO
t-Bu
 
40p, 88% 
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Product and yield a 
N
O
N
N
OCF3O
Ph
O OH
OH
HO
 
40t, 95% 
N
O
N
N
OCF3O
Me
O OH
OH
HO
 
40u, 92% 
N
O
N
N
OO
Me
O OH
OH
HO
O NH2
 
40w, 95% 
Glycosides: 
N
N
N
Ph
Me
CF3O
O
OH
OH
HO
HO
 
41a, 91% 
N
N
N
Ph
Ph
CF3O
O OH
HO
OH
HO
 
41b, 94% 
N
N
N
Me
Ph
CF3O
O OH
HO
OH
HO
 
41c, 93% 
N
N
N
Ph
CF3O
S
O OH
HO
OH
HO
 
41e, 90% 
N
N
N
Me
CF3O
OCF2H
O
OH
HO
OHHO
41h, 94% 
N
N
N
Ph
O
O OH
Me
O OH
HO OH
HO
 
41i, 97% 
N
N
N
Ph
CF3O
OCF2H
O
OH
HO
OHHO
41g, 96% 
N
N
N
CF3O
N
O
OH
HO
OHHO
Ph
 
41l, 85% 
N
O
N
N
OCF3O
Ph
O
OH
OH
HO
HO
41t, 89% 
N
O
N
N
OO
Me
O
OH
OH
HO
HO
O OH
 
41w, 91% 
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Product and yield a 
Rhamnosides: 
N
N
N
Ph
Me
CF3O
O OH
OH
HO
Me
 
42a, 90% 
N
N
N
Ph
Ph
CF3O
O OH
OHHO
Me
 
42b, 93% 
N
N
N
Me
Ph
CF3O
O OH
OHHO
Me
 
42c, 90% 
O OH
OH
HO
Me
N
N
N
Ph
CF3O
S
 
42e, 97% 
N
N
N
Ph
CF3O
OCF2H
O
OH
Me
HO
OH
42g, 88% 
N
N
N
Me
CF3O
OCF2H
O
OH
Me
HO
OH
42h, 91% 
N
N
N
Ph
O
O OH
Me
O OH
OH
Me
HO
 
42i, 90% 
  
a 
– yields refer to pure isolated products 
 
 
In case of 1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-2-methyl-4,6-bis(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one 37d attempts of deprotection led to decomposition of 
substrate. The most possible explanation would be instability of pyridine ring because of 
prescence of two electron-withdrawing groups CF3. Also deprotection of 37s, a 5-bromo-
substituted nucleoside, failed, since the compound decomposes during storage. 
It is interesting that the ester group of glycosylated 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 4, 
38i and 39i were transformed into primary amides. Introduction of the amide residue could 
only increase the binding affinity to the target enzyme. The ester group-containing molecules 
37i, 38i and 39i were also deprotected using hydrazine hydrate; besides cleavage of acetyl 
groups, transformation of ester group into corresponding hydrazide occured (Scheme 22). 
Products 43-45 were formed as yellow precipitates which could be easily filtrated and washed 
to afford the target product in quantitative yields. 
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Scheme 22. Deprotection of acetylated nucleosides 37-39i. i – N2H4•H2O, MeOH, RT, 24h. 
 
 
All deprotected nucleosides were charachterized using 1H NMR, 13C NMR, 19F NMR 
techniques, also IR, mass and HRMS spectra were obtained as well as elemental analysis. 2D 
NMR measurements were performed to tie up C-H and O-H protons of sugar part with the 
signals of 1H NMR. The structures of 40b, 40t and 42g were confirmed by X-ray analysis.  
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N
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Figure 10. Ortep plots of 40b (solvate with EtOH), 40t and 42g. 
 
 
In addition, the X-ray structure of 40t represents a helpful proof of the structure of starting 
material 22a, since 2D NMR measurements of 22a-d could not be obtained because of low 
solubility, as indicated before.  
 
 
2.2.2.2. Acyclic nucleosides 
The interest in acyclic nucleosides began in the mid-1970s when Aciclovir was first reported 
as a potent anti-herpes drug.138 Most of the antiviral compounds that are currently used in the 
treatment of HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV 
(cytomegalovirus) can be described as acyclic nucleoside analogues. Among these agents, 
acyclovir and gancyclovir (Figure 11) were reported to be efficient antiviral agents with low 
host toxicity.139 Also pencyclovir, a carba analogue of gancyclovir, were found to be more 
potent and highly selective antiviral agent against HSV and VZV.140 These cyclovirs and their 
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analogues have stimulated extensive research in the synthesis of new acyclic analogues 
mimicking the sugar portion of naturally occurring nucleosides.24 
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Figure 11. Acyclic nucleosides with antiviral activity. 
 
 
 
ADA is an enzyme that catalyzes the hydrolytic deamination of various purine nucleosides 
but its use can be extended to carbocyclonucleosides or acyclonucleosides as well.8a A classic 
example of ADA inhibitor is erythro-9-(2-hydroxy-3-nonyl)adenine 46 which can be 
classified as acyclic nucleoside analogue.5a In another study, compounds 47 with a number of 
functionalized groups attached to the alkyl side chain, were evaluated as phosphate mimics on 
the basis of their ability to inhibit purine nucleoside phosphorylase (PNP).141  
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Figure 12. Biologically active acyclic analogues of nucleosides. 
 
 
In present study alkyl chains were attached to position C1 of pyrazolo[3,4-b]pyridin-3-ones 2 
by performing direct N-alkylation using different alkyl halides. Trial experiments showed that 
corresponding alkyl chlorides are too inactive to enter the reaction. Therefore, only bromides 
48-50 were chosen for N-alkylation. Reaction between 2a and (3-bromopropyl)benzene 48 
resulted in according 1-alkyl-pyrazolo[3,4-b]pyridin-3-one 51a (Scheme 23).  
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Scheme 23. Synthesis of 1-alkyl-pyrazolo[3,4-b]pyridin-3-one 51a. i - K2CO3 (3eq), DMF, 
90oC, 6h.  
 
 
Likewise, other 1-alkyl-pyrazolo[3,4-b]pyridin-3-ones 51b-f were obtained in excellent yields 
(Table 7). 
 
Table 7. Synthesis of 1-alkyl-pyrazolo[3,4-b]pyridin-3-ones 51 a-f 
 
  Yield (51)a 
N
N
N
H
Ph
O CF3
Me
 
2a 
Ph Br
 
 
48 
N
N
N
Ph
O CF3
Me
Ph
 
51a, 90% 
 
N
N
N
H
Ph
O CF3
Ph
 
2c 
Ph
Br
 
 
49 
N
N
N
Ph
Ph
CF3O
Ph
 
51b, 89% 
N
N
N
H
Ph
O CF3
Ph
 
2c 
Ph Br
 
 
48 
N
N
N
Ph
O CF3
Ph
Ph
 
51c, 88% 
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  Yield (51)a 
N
N
N
H
Ph
O CF3
Ph
 
2c 
MeO
O
Br
 
 
50 
N
N
N
Ph
Ph
CF3O
MeO
O
 
51d, 79% 
N
N
N
H
Ph
O CF3
CF3
 
2e 
Ph
Br
 
 
49 
N
N
N
Ph
CF3
CF3O
Ph
 
51e, 87% 
N
N
N
H
Ph
O CF3
CF3
 
2e 
Ph Br
 
 
48 
N
N
N
Ph
CF3
CF3O
Ph
 
51f, 91% 
a
 - yields refer to pure isolated products 
 
 
1-Alkyl-pyrazolo[3,4-b]pyridin-3-ones 51 are bright yellow crystalline compounds with low 
melting points, except 51a and 51f, which are oils. Unlike starting materials 2, compounds 
51a–f are soluble in many common organic solvents. The structures of all afforded 
compounds 51 were characterized by 1H, 13C, 19F NMR, IR spectral data as well as MS, 
HRMS and elemental analysis. The structure of 51b was independently confirmed by X-ray 
analysis (Figure 13).  
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Figure 13. Ortep plot of 1-phenethyl-2,6-diphenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one 51b. 
 
 
As mentioned before, the NH2 group has an undisputable biological importance. Many drugs 
are designed to mimic or to interfere with the action of natural amine neurotransmitters. 
Therefore we decided to exchange the metoxy group of 51d to an amino or hydrazine group. 
Compound 51d was treated with saturated ammonia in methanol and hydrazine hydrate 
(Scheme 24). As the result, an undecipherable mixture of compounds was isolated; mass 
spectroscopy indicates some evidence towards polymerization, considering that the prescence 
of fragments with high mass was observed. 
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Scheme 24. Unsuccessful reactions of 51d. 
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2.2.3. Conclusions 
In a conclusion of this chapter, a number of new potential ADA and IMPDH inhibitors, 
nucleosides based on pyrazolo[3,4-b]pyridin-3-one core, were synthesized. Cyclic nucleosides 
were synthesized using a modified silyl Hilbert-Jones method while acyclic analogues were 
obtained using simple N-alkylation with alkyl bromides. Both cyclic and acyclic nucleosides, 
bearing an electron-withdrawing group at position C-4 and/or C-6 of aglycone moiety, 
possess potential biological activity. A number of tests, aiming biological evaluation of 
prepared substrates are currently in progress.  
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2.3. Synthesis of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-
3(2H)-ones  
The subject of the present part of this work is the synthesis of 4,5,6,7-tetrahydro-1H-
pyrazolo[3,4-b]pyridin-3(2H)-ones via catalytic hydrogenation of 1H-pyrazolo[3,4-b]pyridin-
3(2H)-ones and corresponding nucleosides. Catalytic hydrogenation of dichromeno[4,3-
b]pyrazolo[4,3-e]pyridine-6,8-diones and corresponding nucleosides is examined. 
2.3.1. Introduction 
One of the most popular strategies in drug design to reach the best inhibition of an enzyme is 
to mimic the transition state of its activity.31e Such purine analogues as conformycin 54, 
pentostatin 55 and their analogues 56 and 57 (Figure 14) represent ADA transition-state 
analogous inhibitors 5c, 142, 143 un which show a strong, nearly irreversible interaction with the 
receptor.  
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Figure 14. Purine analogues mimicking transition state of ADA activity. 
 
 
The studies suggest that purines and their isosters, which possess a tetrahedral carbon atom 
and bear a polar group coordinated to the Zn2+ ion (Zn2+ is known as cofactor of ADA), can 
be considered as potential ADA inhibitors. Several methods can be considered to afford a 
purine analogue bearing tetrahedrally coordinated carbon, but one of most convenient is 
preliminary construction of aromatic ring system and subsequent hydrogenation of target ring. 
 
In 1955 Mauzerall and Westheimer144 showed for the first time that 1,4-dihydropyridines, also 
known as Hantzsch esters,145 are able to reduce carbonyl compounds by a direct hydrogen 
transfer to the substrate. Since then a broad range of transfer hydrogenations conducted with 
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Hantzsch esters in combination with different Lewis acids and additives has been reported.146 
Hydrogenation of substrates such as N-unprotected imines, enamines, and N-heteroaromatic 
compounds remained challenging until it was discovered that Brønsted acids may be used as 
activators of C=N bonds. Group of Rueping has made a great contribution in development of 
Brønsted acid catalyzed hydrogenations using Hantzsch esters as hydride source.147 
Hantzsch esters are commonly known as synthetic analogues of nicotinamide adenine 
dinucleotide (NADH). NADH is an important co-factor in nature, which serves as a hydride 
source for a broad variety of reductions, including reductive aminations.148 
2.3.2. Hydrogenation of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 
We studied the reduction of the pyridine ring of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2 
following  a described procedure147c-e using p-toluenesulphonic acid PTSA as catalyst 
(Scheme 25). Regardless of carcinogenic properties, benzene was chosen as solvent because 
it gave the highest yields of the reaction. Hantszch ester 58 was synthesized according to a 
classical but effective method developed in the 19th century145.  
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Scheme 25. Hydrogenation of 1H-pyrazolo[3,4-b]pyridin-3(2H)-one 2a. i – PTSA, benzene, 
60 oC, 12h.  
 
 
A number of previously synthesized 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2 were used for 
the hydrogenation reaction giving the desired products 59a-g (Table 8).  
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Table 8. Synthesis of 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 59 a-g 
 
 Yield (59)a 
N
N
N
H
Ph
O CF3
Me
 
2a 
N
H
N
N
H
Ph
O CF3
Me
 
59a, 96% 
N
N
N
H
Ph
O CF3
Ph
 
2c 
N
H
N
N
H
Ph
O CF3
Ph
 
59b, 70% 
N
N
N
H
Ph
O
O OMe
OMe
OMe
 
2m 
N
H
N
N
H
Ph
O
O OH
OMe
OMe
 
59c, 47% 
N
N
N
H
Ph
O CF3
OCF2H
2o 
N
H
N
N
H
Ph
O CF3
OCF2H
 
59d, 65% 
N
N
N
H
Ph
O
O OEt
Me
 
2s 
N
H
N
N
H
Ph
O
O OH
Me
 
59e, 51% 
N
N
N
H
Ph
O
O OMe
Me
 
2u 
N
H
N
N
H
Ph
O
O OMe
Me
 
59f, 73% 
N
N
N
H
Ph
CF3O
 
2aj* 
N
H
N
N
H
Ph
CF3O
 
59g, 57% 
a yields refer to pure isolated products 
*starting material provided by Zorik Chilingaryan 
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According to TLC, the reactions yielded single diastereomers. In addition, the NMR spectra 
do not indicate a mixture of diastereomers in the isolated products. The yields of products 59 
are influenced by the presence of moisture and most probably by steric factors of substitute at 
C-6. All 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 59 were characterized by 
1H, 13C NMR, and IR spectral data as well as by MS, HRMS and elemental analysis. 2D 
NMR measurements were performed, but no correlations were found which could 
unambigiously assign the isolated diastereomer. 19F NMR spectroscopy also proved to be a 
convenient tool to control the conversion of the starting material during the reaction, since the 
chemical shift of the CF3 group located at the sp2 carbon is about -61 ppm while at its location 
at a sp3 carbon results of a shift to -68 ppm. The structure of 59a was confirmed by x-ray 
analysis (Figure 15).  
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Figure 15. Ortep plot of 59a. Crystal solvate with MeOH. 
 
 
X-ray analysis shows that 59a is solvated by methanol forming a hydrogen bond with the 
carbonyl moiety. It proves that the carbonyl group at position 2 of the pyrazolo[3,4-b]pyridin-
3-one participates in hydrogen bonding probably will interact with the asparagine rest in the 
ADA’s active pocket. The X-ray experiment shows that the product possesses a trans 
configuration. 
The possible mechanism of the cascade hydrogenation is in agreement with the one proposed 
by Rueping147d as outlined in Scheme 26. The first step is protonation of the pyrazolo[3,4-
b]pyridin-3(2H)-one 2 through the PTSA to generate the iminium ion A. Subsequent transfer 
of the first hydride from the dihydropyridine 58 generates enamine 60 and pyridinium salt B, 
which undergoes proton transfer to regenerate PTSA and Hantzsch pyridine 61. The enamine 
60 reacts in a second cycle with PTSA to produce iminium C, which is again subjected to 
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hydride transfer to give the desired 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
59. Subsequent proton transfer recycles PTSA and generates a second equivalent of the 
Hantzsch pyridine 61. The formation of intermediates A and C in this mechanistic pathway 
explains the lower yields of hydrogenated products 59 in case of bulky substituents located at 
position 6. Because of steric reasons PTSA cannot stabilize the iminium cation.  
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Scheme 26. Mechanism of hydrogenation of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones 2. 
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Unsuccessful experiments 
Besides the above mentioned successful hydrogenations, a number of experiments failed. The 
substrates which proved to be inactive in the catalytic hydrogenation are listed below (Figure 
16). 
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Figure 16. Compounds unable undergo cascade hydrogenation using Brønsted acid. 
 
 
Unreactive compounds can be devided in three groups: first, compounds with bulky 
substituents near the pyridine nitrogen; second, substrates bearing electron-withdrawing 
groups at position C-6; third, insoluble substrates.  
As indicated before, bulky substituents were probably the reason of low yields of 59. 
Substituents as tetraacetylribose in 37a, or deprotected ribose in 40a or even the heavy 
structure of 22a itself eliminates the possibility that catalyst could stabilize the iminium cation 
which leads to subsequent hydride attachment to a molecule. 
Compounds 2f, 63 and 64 proved to be useless for hydrogenation. Electron-withdrawing 
substituent at C-6 prevents formation of the imminium cation since nitrogen has become less 
electron-rich.  
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The insolubility of some selected substrates led to failure of reaction. Unfortunately, after 
several try-outs we could not find a suitable solvent which could dissolve the substrate and 
provide a favourable environment for hydrogenation. 
2.3.3. Conclusions 
In a conclusion of the present chapter, the possibility and limitations of hydrogenation of 
pyridine ring of 1H-pyrazolo[3,4-b]pyridin-3(2H)-ones were studied. It was found that in 
order to perform successful hydrogenation of pyridine ring, nitrogen atom has to be spatially 
free, and neighbouring carbon has to be furnished with electron-donating group which favours 
formation of imminium cation and stabilizes it. Library of possible ADA and IMPDH 
inhibitors was supplemented with seven new 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-
3(2H)-ones, which represent transition-state of substrate, interfered either by ADA or 
IMPDH. Biological evaluation of these compounds is currently in progress.  
Results outlined in the current chapter are a promising start for further experiments namely 
asymmetric hydrogenation using chiral Brønsted acids in order to obtain single diastereomers.   
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3. General conclusions and graphical overview 
 
In a conclusion of this work, a variety of new deazapurine analogues and their nucleosides 
were synthesized. Bearing a strong electron withdrawing group, these compounds are 
potential inhibitors of ADA and IMPDH and may show a broad variety of biological 
activities.  
Most target substances are obtained in moderate to excellent yields via a classical approach 
involving [3+3] cyclocondesation of heterocycles containing an enamine fragment, such as 
aminopyrazolones. As bielectrophiles 1,3-diketones or 3-acyl-4-chlorocoumarines were used. 
Inverse electron demand Diels-Alder reactions were applied for the synthesis of 5-substituted 
pyrazolo[3,4-b]pyridin-3-ones.  Modification of bromine-containing pyrazolo[3,4-b]pyridin-
3-ones was performed using Pd-catalyzed reactions. Classical nucleosides were synthesized 
using a modified silyl Hilbert-Jones method, while acyclic analogues were obtained using N-
alkylation with alkyl bromides. Cascade hydrogenation of 1H-pyrazolo[3,4-b]pyridin-3(2H)-
ones using PTSA as catalyst and Hantzsch ester as hydride source was performed. 
Preliminary biological evaluation in collaboration with Dr. Meyer zu Schwabedissen 
(University of Basel) indicates a potent activity of several newly synthesized compounds. 
Several representatives show strong antagonistic action on human smooth muscle cells. Most 
potent compounds are now under study as novel, cell-selective drug-candidate for 
endovascular implants.  
 
Schemes 27-30 give a brief overwiev of compounds synthesized in this work. 
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Scheme 27.  3-amino-1H-pyrazol-5(4H)-ones – useful building blocks for synthsesis of 
purine isosteres. 
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Scheme 28. Modification of pyrazolo[3,4-b]pyridin-3-ones. 
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Scheme 29. Synthesis of N-nucleosides of pyrazolo[3,4-b]pyridin-3-ones. 
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Scheme 30. Synthesis of N-nucleosides with potential biological importance. 
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Appendix 1. Experimental Part 
 
A.1. General: analytical equipment, chemicals and work technique  
  
NMR Spectroscopy: 1H NMR spectra and 13C NMR spectra were recorded on Bruker 
instruments AVANCE 250, ARX 300, and AVANCE 500 using the solvent internal standard 
(CDCl3 7.26 ppm and 77.16 ppm, DMSO-d6 2.50 ppm and 39.52 ppm, (CD3)2CO 2.05 ppm 
and 29.84 ppm). 19F NMR spectra were recorded on AVANCE 250 and ARX 300 
respectively considering CFCl3 signal as a zero point of the scale. All chemical shifts are 
given in ppm. All coupling constants J are indicated in Hz. Multiplicities are given as follows: 
s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = multiplet, br = broad 
signal. More complex coupling patterns are represented by combinations of the respective 
symbols. For example, td indicates a triplet of doublets with the larger coupling constant 
associated with the first symbol (here: triplet).  
The 1H and 13C NMR signals were assigned by DEPT and two-dimensional 1H-1H COSY, 1H-
1H NOESY and 1H-13C correlation spectra (HMBC and HSQC). 
 
Mass spectrometry (MS) and high resolution MS (HRMS):  
a) Finnigan MAT 95 XP (Thermo Electron Corporation), EI, 70 eV;  
b) GC 6890/ MS D 5973 (Agilent Technologies), MS(GC), 70 eV.  
 
Infrared spectroscopy (IR): Nicolet 380 FT-IR spectrometer with ATR sampling technique 
for solids as well as liquids. Signal characterization: (w) = weak, (m) = medium, (s) = strong, 
(br) = broad.  
  
Elemental analysis (EA): Flash EA 1112 (Thermoquest).  
  
X-ray crystallography: Bruker Apex Kappa-II diffractometer with CCD camera (Mo-Kα 
radiation and graphite monochromator, λ = 0.71073 Å). The space group is determined by the 
XPREP program and the structures were solved via the SHELX-97 program package. 
Refinements were carried out according to the minimum square error method.  
 
Thin layer chromatography (TLC): Merck HPTLC silica gel 60 F254 (aluminium sheets 
20x20 cm). Detection with UV light at 254 and 366 nm; if necessary, development with 
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vanillin-sulfuric acid solution (1 g of vanillin, 14 mL of acetic acid and 1 mL of conc. sulfuric 
acid in 85 mL of methanol). 
 
Melting Points: Micro heating table HMK 67/1825 Kuestner (Büchi apparatus). The melting 
points are uncorrected.  
  
Column chromatography: Separation on Acros or Merck silica gel 60 Å (0.060-0.200 mm, 
70-230 mesh). Eluents were distilled before use.  
  
All chemicals and dry solvents were purchased from the standard chemical suppliers and used 
without further purification. 
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 A.2. Procedures and spectroscopic data  
 
A.2.1. General procedure for synthesis of compounds 2 
Appropriate 5-amino-1H-pyrazol-3(2H)-one 4 (1 mmol) and corresponding 1,3-diketone 4 
(1.2 mmol) were placed in a flask set with reflux and dissolved in AcOH (20 mL). The 
mixture was heated under reflux for 1-8 h (controlled by TLC). Then the solution was 
evaporated under reduced pressure, treated with H2O, filtered, dried under reduced pressure 
and recrystallized from an appropriate solvent or subjected to column chromatography (silica 
gel; eluent: n-heptane/ethylacetate).  
 
6-Methyl-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2a) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 1,1,1-trifluoropentane-2,4-dione  6a (185 mg, 1.2 
mmol), 2a was isolated via crystallization from isopropanol as gray 
crystals (249 mg, 82%); mp 181-182 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3H, CH3), 7.27 (t, 3JH,H = 7.8 Hz, 1H, Ph), 7.33 
(s, 1H, H-5), 7.50 (t, 3JH,H = 7.8 Hz, 2H, Ph), 7.90 (d, 3JH,H = 7.8 Hz, 2H, Ph), 12.36 (br s, 1H, 
NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 24.0 (CH3), 102.6 (C-3a), 112.5 (C-5), 119.8 
(CHAr), 121.8 (q, 1JC,F = 274.4 Hz, CF3), 125.4, 129.0 (CHAr), 134.7 (q, 2JC,F = 35.3 Hz, 
CCF3), 137.1, 155.6 (CAr), 156.1 (C=O), 164.0 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -
61.34 (s). IR (ATR, cm-1): v~ = 3030 (w), 1644 (m), 1593 (w), 1499 (w), 1385 (w), 1278 (m), 
1243 (m), 1148 (s), 1140 (s), 860 (m), 755 (m), 719 (m), 683 (s). MS (EI, 70 eV): m/z (%) = 
295 (2) [M++2], 294 (16) [M++1], 293 (100) [M+], 273 (15), 264 (52), 187 (7), 160 (6), 77 
(28), 51 (8). HRMS (ESI): calcd for C14H11F3N3O ([M+1]+) 294.0849, found 294.0852. Anal. 
Calcd for C14H10F3N3O: C, 57.34; H, 3.44; N, 14.33. Found: C, 57.03; H, 3.39; N, 14.10. 
 
2,6-Dimethyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2b) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (113 mg, 
1 mmol) and 1,1,1-trifluoropentane-2,4-dione 6a (185 mg, 1.2 
mmol), 2b was isolated via crystallization from isopropanol as gray 
solid (146 mg, 63%); mp 259-261 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.60 (s, 3H, CCH3), 3.40 (s, 3H, NCH3), 7.30 (s, 1H, H-
5), 11.79 (br s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 24.5 (CCH3), 30.3 (NCH3), 
101.1 (C-3a), 112.6 (C-5), 122.1 (q, 1JC,F = 274.0 Hz, CF3), 128.6 (C-6), 133.5 (q, 2JC,F = 34.7 
N
N
N
H Me
CF3O
N
N
N
H
Me
Me
O CF3
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Hz, CCF3), 155.9 (C=O), 163.7 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.24 (s). IR 
(ATR, cm-1): v~ = 2901 (w), 2683 (w), 1667 (w), 1628 (m), 1610 (s), 1435 (m), 1380 (m), 
1328 (m), 1280 (m), 1244 (m), 1224 (m), 1146 (s), 1127 (s), 939 (m), 896 (w), 864 (m), 770 
(m), 690 (m), 636 (m). MS (EI, 70 eV): m/z (%) = 232 (11) [M++1], 231 (100) [M+], 203 (29), 
188 (6), 182 (6), 160 (23), 155 (7), 43 (7). HRMS (ESI): calcd for C9H9F3N3O ([M+1]+) 
232.0692, found 232.0695. Anal. Calcd for C9H8F3N3O: C, 46.76; H, 3.49; N, 18.18. Found: 
C, 46.19; H, 3.14; N, 18.32. 
 
2,6-Diphenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2c) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 4,4,4-trifluoro-1-phenylbutane-1,3-dione 6b (259 
mg, 1.2 mmol), 2c was isolated via crystallization from benzene as 
green crystals (348 mg, 98%); mp 172-173 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.31 (t, 3JH,H = 7.4 Hz, 1H, Ph), 7.51-7.57 (m, 5H, Ph), 
7.89-7.92 (m, 2H, Ph), 8.01 (s, 1H, H-5), 8.25 (br s, 2H, Ph), 12.30 (br s, 1H, NH). 13C NMR 
(62.9 MHz, DMSO-d6): δ = 103.1 (C-3a), 110.7 (C-5), 120.0 (CHAr), 121.9 (q, 1JC,F = 274.7 
Hz, CF3), 125.7, 127.6, 128.2, 129.0, 130.9 (CHAr), 135.1 (q, 2JC,F = 35.7 Hz, CCF3), 136.6, 
136.6, 155.4 (CAr), 157.6 (C=O), 161.2 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.17 
(s). IR (ATR, cm-1): v~ = 3067 (w), 1650 (m), 1593 (m), 1496 (m), 1371 (m), 1261 (s), 1190 
(m), 1143 (s), 981 (m), 774 (m), 750 (s), 711 (m), 688 (s), 673 (s). MS (EI, 70 eV): m/z (%) = 
357 (2) [M++2], 356 (21) [M++1], 355 (100) [M+], 335 (13), 326 (35), 222 (6), 102 (6), 77 
(21), 51 (5). HRMS (ESI): calcd for C19H13F3N3O ([M+1]+) 356.1005, found 356.1009. Anal. 
Calcd for C19H12F3N3O: C, 64.23; H, 3.40; N, 11.83. Found: C, 64.26; H, 3.38; N, 11.77. 
 
2-Methyl-6-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2d) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (113 
mg, 1 mmol) and 4,4,4-trifluoro-1-phenylbutane-1,3-dione 6b (259 
mg, 1.2 mmol), 2d was isolated via crystallization from benzene as 
yellow crystals (217 mg, 74%); mp 318-320 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.45 (s, 3H, CH3), 7.53-7.57 
(m, 3H, Ph), 7.89 (s, 1H, H-5), 8.18-8.21 (m, 2H, Ph), 12.05 (br s, 1H, NH). 13C NMR (62.9 
MHz, DMSO-d6): δ = 30.4 (CH3), 102.0 (C-3a), 109.3 (q, 3JC,F = 5.5 Hz, C-5), 122.1 (q, 1JC,F 
= 275.1 Hz, CF3), 127.5, 129.0, 130.7 (CHAr), 134.5 (q, 2JC,F = 35.3 Hz, CCF3), 137.0, 155.6 
(CAr), 156.0 (C=O), 160.0 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.03 (s). IR (ATR, 
N
N
N
H
CF3O
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N
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cm-1): v~ = 3068 (w), 2896 (w), 1666 (w), 1629 (m), 1607 (m), 1369 (m), 1276 (m), 1259 (m), 
1236 (m), 1178 (m), 1133 (s), 856 (m), 766 (s), 686 (s). MS (EI, 70 eV): m/z (%) = 294 (16) 
[M++1], 293 (100) [M+], 265 (33), 222 (14), 102 (7), 77 (4), 51 (2). HRMS (EI): calcd for 
C14H10F3N3O ([M]+) 293.07705, found 293.077730. Anal. Calcd for C14H10F3N3O: C, 57.34; 
H, 3.44; N, 14.33. Found: C, 57.38; H, 3.49; N, 13.92. 
 
2-Phenyl-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2e) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 1,1,1,5,5,5-hexafluoropentane-2,4-dione 6c 
(250 mg, 1.2 mmol), 2e was isolated via crystallization from 
benzene as yellow crystals (309 mg, 89%); mp 200-202 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.35 (t, 3JH,H = 7.4 Hz, 1H, Ph), 7.53-7.58 (m, 2H, Ph), 
7.84 (s, 1H, H-5), 7.87-7.90 (m, 2H, Ph), 12.77 (br s, 1H, NH). 13C NMR (62.9 MHz, DMSO-
d6): δ = 107.6 (C-3a), 109.2 (C-5), 120.1 (CHAr), 120.7 (q, 1JC,F = 275.0 Hz, CF3), 121.3 (q, 
1JC,F = 275.4 Hz, CF3), 126.4, 129.2 (CHAr), 135.9 (CAr), 138.3 (q, 2JC,F = 36.6 Hz, CCF3), 
150.3 (q, 2JC,F = 35.3 Hz, CCF3), 154.1 (C=O), 155.7 (C-7a). 19F NMR (282 MHz, DMSO-d6): 
δ = -61.13 (s, 3F, C=CCF3), -66.62 (s, 3F, N=CCF3). IR (ATR, cm-1): v~ = 3061 (w), 3007 
(w), 2917 (w), 1676 (w), 1661 (w), 1646 (w), 1604 (w), 1498 (w), 1273 (s), 1151 (s), 1140 
(s), 992 (w), 890 (w), 752 (m), 684 (m). MS (EI, 70 eV): m/z (%) = 347 [M]+ (100), 328 (13), 
318 (33), 298 (12), 77 (20). HRMS (EI): calcd for C14H7F6N3O ([M]+) 347.05, found 
347.0493. Anal. Calcd for C14H7F6N3O: C, 48.43; H, 2.03; N, 12.10. Found: C, 48.67; H, 
1.96; N, 11.91. 
 
2-Methyl-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2f) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (113 
mg, 1 mmol) and 1,1,1,5,5,5-hexafluoropentane-2,4-dione 6c (250 
mg, 1.2 mmol), 2f was isolated via crystallization from benzene as 
yellow crystals (245 mg, 86%); mp 236-238 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.51 (s, 3H, CH3), 7.71 (s, 1H, H-5), 12.78 (br s, 1H, 
NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 30.7 (CH3), 106.2 (C-3a), 108.2 (C-5), 120.7 (q, 
1JC,F = 274.9 Hz, CF3), 121.3 (q, 1JC,F = 274.9 Hz, CF3), 135.8 (q, 2JC,F = 36.5 Hz, CCF3), 
149.2 (q, 2JC,F = 35.1 Hz, CCF3), 153.7 (C=O), 154.0 (C-7a). 19F NMR (282 MHz, DMSO-d6): 
δ = -61.10 (s, C=CCF3), -66.62 (s, N=CCF3). IR (ATR, cm-1): v~ = 2911 (w), 2655 (w), 1674 
(w), 1639 (m), 1268 (m), 1232 (m), 1191 (m), 1144 (s), 1096 (m), 1005 (m), 941 (w), 879 
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(m), 773 (m), 745 (w), 700 (m), 667 (m), 640 (m). MS (EI, 70 eV): m/z (%) = 286 (16) 
[M++1], 285 (100) [M+], 266 (28), 242 (13), 236 (28), 214 (16), 195 (12), 163 (15), 144 (14), 
133 (14). HRMS (EI): calcd for C9H5F6N3O ([M]+) 285.03313, found 285.032980. Anal. 
Calcd for C9H5F6N3O: C, 37.91; H, 1.77; N, 14.76. Found: C, 37.71; H, 1.87; N, 14.58. 
 
2-Phenyl-6-(thiophen-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2g) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 4,4,4-trifluoro-1-(thiophen-2-yl)butane-1,3-
dione 6c (267 mg, 1.2 mmol), 2g was isolated via crystallization 
from benzene as yellow crystals (293 mg, 81%); mp 207-208 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.25-7.31 (m, 2H, Ar/Hetar), 7.48-7.54 (m, 2H, 
Ar/Hetar), 7.86-7.88 (m, 2H, Ar/Hetar), 7.89-7.90 (m, 1H, Ar/Hetar), 8.02 (1H, s, H-5), 8.25 
(1H, dd, 3JH,H = 4.0 Hz, 4JH,H = 1.0 Hz, Hetar), 12.31 (1H, s, H-1). 13C NMR (62.8 MHz, 
DMSO-d6): δ = 102.4 (C-3a), 109.5 (t, 3JC,F = 5.0 Hz, C-5), 119.9 (CHAr), 121.8 (q, 1JC,F = 
274.6 Hz, CF3), 125.6, 128.9, 129.1, 129.8, 131.9 (CHAr), 135.0 (q, 2JC,F = 35.8 Hz, CCF3), 
136.6, 142.5, 155.4 (CAr), 156.6 (C=O), 157.4 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -
61.27 (s). IR (ATR, cm-1): v~ = 3067 (w), 2863 (w), 1645 (m), 1588 (m), 1532 (w), 1497 (w), 
1425 (m), 1398 (m), 1377 (m), 1348 (w), 1262 (m), 1234 (m), 1178 (m), 1140 (s), 1093 (m), 
966 (w), 750 (m), 717 (s), 680 (m). MS (EI, 70 eV): m/z (%) = 362 (20) [M++1], 361 (100) 
[M+], 341 (11), 332 (26), 77 (18). HRMS (ESI): calcd for C17H11F3N3OS ([M+1]+) 
362.05694, found 362.0574. Anal. Calcd for C17H10F3N3OS: C, 56.51; H, 2.79; N, 11.63. 
Found: C, 56.59; H, 2.74; N, 11.48. 
 
2-Methyl-6-(thiophen-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2h) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b 
(113 mg, 1 mmol) and 4,4,4-trifluoro-1-(thiophen-2-
yl)butane-1,3-dione 6d (267 mg, 1.2 mmol), 2h was isolated 
via crystallization from benzene as yellow crystals (275 mg, 
92%); mp 354-356 oC. 
1H NMR (300 MHz, DMSO-d6): 3.41 (s, 3H, CH3), 7.24 (dd, 3JH,H = 5.1 Hz, 3JH,H = 3.8 Hz, 
1H, Hetar), 7.83 (dd, 3JH,H = 5.1 Hz, 3JH,H = 1.1 Hz, 1H, Hetar), 7.90 (s, 1H, H-5), 8.17 (dd, 
3JH,H = 3.8 Hz, 3JH,H = 1.1 Hz, 1H, Hetar) 12.07 (s, 1H, NH). 13C NMR (75.5 MHz, DMSO-
d6): δ = 30.3 (CH3), 101.6 (C-3a), 108.3 (q, 3JC,F = 5.3 Hz, C-5), 121.9 (q, 1JC,F = 274.5 Hz, 
N
N
N
H
O CF3
S
N
N
N
H
Me
O CF3
S
  
 87 
CF3), 129.0, 129.2, 131.3 (CHHetar), 134.4 (q, 2JC,F = 35.7 Hz, CCF3), 142.7, 155.5 (CAr), 155.6 
(C=O), 155.7 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.13 (s). IR (ATR, cm-1): v~ = 
2881 (w), 2673 (w), 1651 (w), 1627 (w), 1605 (m), 1538 (w), 1423 (m), 1378 (w), 1349 (w), 
1289 (w), 1261 (m), 1239 (m), 1149 (m), 1130 (s), 1065 (w), 1035 (w), 941 (w), 849 (m), 710 
(m), 690 (s). MS (EI, 70 eV): m/z (%) = 300 (15) [M++1], 299 (87) [M+], 298 (100), 271 (27), 
256 (35), 228 (19), 227 (26), 108 (19). HRMS (ESI): calcd for C12H9F3N3OS ([M+1]+) 
300.04129, found 300.04143. Anal. Calcd for C12H8F3N3OS: C, 48.16; H, 2.69; N, 14.04. 
Found: C, 48.20; H, 2.73; N, 13.83. 
 
6-Hydroxy-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2i) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and ethyl 4,4,4-trifluoro-3-oxobutanoate 6e (221 
mg, 1.2 mmol), 2i was isolated via crystallization from toluene 
as colorless solid (154 mg, 52%); mp 296-298 oC. 
1H NMR (250 MHz, DMSO-d6): δ = 6.53 (s, 1H, H-5), 7.22-7.28 (m, 1H, Ph), 7.45-7.51 (m, 
2H, Ph), 7.71-7.74 (m, 2H, Ph), 11.77 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 
102.3 (C-3a), 112.5 (C-5), 120.1 (CHAr), 121.6 (q, 1JC,F = 274.2 Hz, CF3), 125.3, 129.0 
(CHAr), 135.6 (CAr), 136.4 (q, 2JC,F = 33.4 Hz, CCF3), 137.2 (CAr), 155.3 (C=O), 164.8 (C-7a). 
19F NMR (235 MHz, DMSO-d6): δ = -63.07 (s). IR (ATR, cm-1): v~ = 3066 (br w), 2991 (w), 
2849 (w), 2713 (w), 1651 (m), 1594 (m), 1585 (m), 1537 (w), 1496 (w), 1463 (m), 1358 (m), 
1283 (m), 1194 (m), 1160 (m), 1140 (s), 1082 (w), 988 (m), 908 (w), 956 (m), 780 (m), 750 
(m). MS (EI, 70 eV): m/z (%) = 296 (19) [M++1], 295 (100) [M+], 275 (15), 266 (20), 132 
(13), 77 (70), 51 (14), 29 (16). HRMS (ESI): calcd for C13H9F3N3O2 ([M+1]+) 296.06414, 
found 296.06449. Anal. Calcd for C13H8F3N3O2: C, 52.89; H, 2.73; N, 14.23. Found: C, 
53.00; H, 2.80; N, 14.11. 
 
6-Hydroxy-2-methyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2j) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (113 
mg, 1 mmol) and ethyl 4,4,4-trifluoro-3-oxobutanoate 6e (221 
mg, 1.2 mmol), 2j was isolated via crystallization from benzene 
as colorless solid (180 mg, 77%); mp 299-301 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.41 (s, 3H, CH3), 6.34 (s, 1H, H-5), 12.13 (s, 2H, NH, 
OH). 13C NMR (62.9 MHz, DMSO-d6): δ = 32.0 (CH3), 108.2 (C-3a), 113.5 (C-5), 119.6 (C-
6), 124.6 (q, 1JC,F = 274.0 Hz, CF3), 134.7 (q, 2JC,F = 34.8 Hz, CCF3), 150.7 (C=O), 163.5 (C-
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7a). 19F NMR (282 MHz, DMSO-d6): δ = -63.45 (s). IR (ATR, cm-1): v~ = 2929 (br w), 2482 
(br), 1651 (w), 1644 (m), 1584 (w), 1563 (m), 1434 (m), 1373 (w), 1336 (w), 1284 (s), 1254 
(s), 1231 (s), 1207 (m), 1187 (s), 1140 (s), 1055 (w), 1025 (m), 949 (m), 905 (m), 862 (m), 
713 (m), 605 (m). MS (EI, 70 eV): m/z (%) = 234 (7) [M++1], 233 (100) [M+], 232 (15), 213 
(60), 190 (21), 171 (27), 143 (20), 142 (12), 92 (20), 64 (12), 43 (57). HRMS (ESI): calcd for 
C8H7F3N3O2 ([M+1]+) 234.04849, found 234.04891. Anal. Calcd for C8H6F3N3O2: C, 41.21; 
H, 2.59; N, 24.45. Found: C, 41.58; H, 2.71; N, 24.19. 
 
4-(Chlorodifluoromethyl)-6-methyl-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2k) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-chloro-1,1-difluoropentane-2,4-dione 
6f (205 mg, 1.2 mmol), 2k was isolated via crystallization from 
toluene as gray solid (198 mg, 64%); mp 162-164 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3H, CH3), 7.24-7.29 (m, 2H, Ar), 7.48-7.53 (m, 
2H, Ar), 7.89-7.92 (m, 2H, Ar), 12.30 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 
24.4 (CH3), 100.1 (C-3a), 110.8 (C-5), 123.3 (t, 1JC,F = 290.0 Hz, CF2Cl), 127.5, 129.0, 130.7 
(CHAr), 137.0 (CAr), 139.6 (t, 2JC,F = 29.0 Hz, CCF2Cl), 155.8 (CAr), 155.9 (C=O), 163.5 (C-
7a). 19F NMR (282 MHz, DMSO-d6): δ = -50.67 (s). IR (ATR, cm-1): v~ = 3418 (w), 2667 (w), 
1651 (m), 1589 (s), 1487 (m), 1359 (m), 1306 (s), 1278 (m), 1208 (s), 1112 (m), 1033 (m), 
970 (s). MS (EI, 70 eV): m/z (%) = 311 (36) [M++2], 310 (18) [M++1], 309 (100) [M+], 289 
(21), 280 (18), 274 (13), 245 (15), 77 (39). HRMS (EI): calcd for C14H10ClF2N3O ([M]+) 
309.04750, found 309.048136. Anal. Calcd for C14H10ClF2N3O: C, 54.29; H, 3.25; N, 13.57. 
Found: C, 54.46; H, 3.18; N, 13.37. 
 
4-(Chlorodifluoromethyl)-2,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2l) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (113 
mg, 1 mmol) and 1-chloro-1,1-difluoropentane-2,4-dione 6f (205 
mg, 1.2 mmol), 2l was isolated via crystallization from benzene as 
yellow solid (269 mg, 74%); mp 256-258 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.59 (s, 3H, CCH3), 3.40 (s, 3H, NCH3), 7.22 (s, 1H, H-
5), 11.76 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 24.5 (CCH3), 30.3 (NCH3), 
100.1 (C-3a), 110.8 (C-5), 123.4 (t, 1JC,F = 290.9 Hz, CF2Cl), 139.7 (t, 2JC,F = 29.5 Hz, 
CCF2Cl), 155.9 (CCH3), 156.0 (C=O), 163.6 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -
50.27 (s). IR (ATR, cm-1): v~ = 2911 (w), 2725 (w), 1661 (w), 1627 (m), 1605 (s), 1432 (w), 
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1410 (w), 1376 (m), 1327 (w), 1280 (w), 1208 (m), 1115 (s), 1035 (m), 964 (s), 833 (s), 753 
(s). MS (EI, 70 eV): m/z (%) = 249 (34) [M++2], 248 (14) [M++1], 247 (100) [M+], 219 (26), 
212 (23), 176 (11), 160 (10), 43 (8). HRMS (ESI): calcd for C9H9ClF2N3O ([M+1]+) 
248.0397, found 248.04. Anal. Calcd for C9H8ClF2N3O: C, 43.65; H, 3.26; N, 16.97. Found: 
C, 43.79; H, 3.16; N, 16.70. 
 
Methyl 6-(3,4-dimethoxyphenyl)-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (2m) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 
4a (175 mg, 1 mmol) and methyl 4-(3,4-
dimethoxyphenyl)-2,4-dioxobutanoate 6g (320 mg, 1.2 
mmol), 2m was isolated via crystallization from benzene 
as orange solid (284 mg, 70%); mp 165-167 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.85 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.95 (s, 3H, 
CO2CH3), 7.11-7.14 (m, 1H, Ar), 7.27 (t, 3JH,H = 7.4 Hz, 1H, Ar), 7.48-7.54 (m, 2H, Ar), 7.79-
7.85 (m, 2H, Ar), 7.89-7.94 (m, 3H, Ar), 11.86 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-
d6): δ = 52.8, 55.6 (OCH3), 103.8 (C-3a), 110.3, 111.7, 112.2, 119.6, 120.8, 125.3, 129.0 
(CHAr), 129.4, 137.1, 139.1, 149.0, 151.3 (CAr), 156.7 (C=O), 160.3 (C-7a), 165.5 (CO2CH3). 
IR (ATR, cm-1): v~ = 2961 (w), 2841 (w), 1678 (w), 1586 (m), 1516 (m), 1446 (m), 1427 (m), 
1281 (m), 1255 (s), 1219 (s), 1152 (m), 1040 (m), 1022 (m), 761 (s), 691 (m). MS (EI, 70 
eV): m/z (%) = 406 (25) [M++1], 405 (100) [M+], 361 (15), 347 (19), 345 (31), 77 (16). 
HRMS (ESI): calcd for C22H20N3O5 ([M+1]+) 406.1407, found 406.1408. Anal. Calcd for 
C22H19N3O5: C, 65.18; H, 4.72; N, 10.37. Found: C, 65.48; H, 4.74; N, 10.34. 
 
6-(3,4-dimethoxyphenyl)-2-methyl-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-b]pyridine-4-
carboxylic acid (2n) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 
4b (113 mg, 1 mmol) and methyl 4-(3,4-
dimethoxyphenyl)-2,4-dioxobutanoate 6g (320 mg, 1.2 
mmol), 2n was isolated via crystallization from 
isopropanol as yellow solid (280 mg, 85%); mp 316-318 
oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.59 (s, 3H, NCH3), 3.84 (s, 3H, OCH3), 3.87 (s, 3H, 
OCH3), 7.08 (d, 3JH,H = 8.5 Hz, 1H, Ar), 7.67-7.73 (m, 2H, Ar), 7.95 (s, 1H, H-5), 12.96 (s, 
1H, NH), 16.22 (s, 1H, OH). 13C NMR (62.9 MHz, DMSO-d6): δ = 31.1 (NCH3), 55.5, 55.6 
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(OCH3), 102.2 (C-3a), 110.0, 111.7, 113.9, 120.7 (CHAr), 129.4, 137.0, 149.0, 151.2, 153.9 
(CAr), 157.0 (C=O), 160.5 (C-7a), 164.3 (CO2H). IR (ATR, cm-1): v~ = 3078 (w), 2944 (w), 
1717 (w), 1620 (m), 1589 (s), 1515 (m), 1428 (m), 1417 (m), 1354 (m), 1238 (s), 1217 (s), 
1143 (m), 1024 (m), 766 (s). MS (EI, 70 eV): m/z (%) = 330 (20) [M++1], 329 (93) [M+], 286 
(32), 285 (100), 284 (33), 270 (13), 242 (13), 227 (9). HRMS (ESI): calcd for C16H16N3O5 
([M+1]+) 330.1084, found 330.1083. Anal. Calcd for C16H15N3O5: C, 58.36; H, 4.59; N, 
12.76. Found: C, 58.65; H, 4.61; N, 12.70. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (2o) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 
4a (175 mg, 1 mmol) and 1-(4-(difluoromethoxy) 
phenyl)-4,4,4-trifluorobutane-1,3-dione 6h (339 mg, 1.2 
mmol), 2o was isolated via crystallization from benzene 
as yellow solid (291 mg, 69%); mp 179-181 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.29 (t, 1JF,H = 73.7 Hz, OCF2H), 7.31-7.38 (m, 3H, Ar), 
7.50-7.56 (m, 2H, Ar), 7.91-7.95 (m, 3H, H-5, Ar), 8.31 (d, 3JH,H = 8.5 Hz, 2H, Ar), 12.03 (s, 
1H, NH). 13C NMR (75.5 MHz, DMSO-d6): δ = 102.8 (C-3a), 110.1 (q, 3JC,F = 5.6 Hz, C-5), 
115.7 (t, 1JC,F = 258.9 Hz, OCF2H), 118.6, 119.9, 125.3, 128.6, 129.2 (CHAr), 133.4 (CAr), 
135.1 (q, 2JC,F = 35.0 Hz, CCF3), 136.5 (CAr), 152.7 (t, 3JC,F = 4.0 Hz, COCF2H), 155.2 (CAr), 
157.4 (C=O), 160.0 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.10 (s, 3F, CF3), -82.72 
(s, 2F, OCF2H). IR (ATR, cm-1): v~ = 3070 (w), 1666 (m), 1598 (m), 1486 (w), 1373 (m), 
1278 (m), 1262 (m), 1233 (m), 1184 (m), 1140 (s), 1122 (s), 1037 (s), 982 (m), 841 (m), 813 
(m), 754 (s), 714 (s), 673 (s). MS (EI, 70 eV): m/z (%) = 422 (22) [M++1], 421 (100) [M+], 
392 (23), 77 (53), 51 (21). HRMS (ESI): calcd for C20H13F5N3O2 ([M+1]+) 422.09224, found 
422.09288. Anal. Calcd for C20H12F5N3O2: C, 57.01; H, 2.87; N, 9.97. Found: C, 56.99; H, 
3.05; N, 9.98. 
 
2-Methyl-6-(4-(difluoromethoxy)phenyl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (2p) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4b 
(175 mg, 1 mmol) and 1-(4-(difluoromethoxy)phenyl)-
4,4,4-trifluorobutane-1,3-dione 6h (339 mg, 1.2 mmol), 2p 
was isolated via crystallization from benzene as yellow 
solid (356 mg, 99%); mp >375 oC. 
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1H NMR (300 MHz, DMSO-d6): δ = 3.44 (s, 3H, CH3), 7.31-7.36 (m, 2H, Ar), 7.38 (t, 1JF,H = 
74.0 Hz, 1H, OCF2H), 7.91 (s, 1H, H-5), 8.26-8.30 (m, 2H, Ar), 12.04 (s, 1H, NH). 13C NMR 
(75.5 MHz, DMSO-d6): δ = 30.4 (CH3), 102.2 (C-3a), 109.4 (q, 3JC,F = 5.0 Hz, C-5), 116.1 (t, 
1JC,F = 258.0 Hz, OCF2H), 118.6 (CHAr), 122.0 (q, 1JC,F = 275.0 Hz, CF3), 129.4 (CHAr), 133.6 
(CAr), 134.6 (q, 2JC,F = 35.8 Hz, CCF3), 152.9 (t, 3JC,F = 3.0 Hz, COCF2H), 155.6 (CAr), 155.9 
(C=O), 159.1 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.01 (s, 3F, CF3), -82.65 (s, 2F, 
CF2H). IR (ATR, cm-1): v~ = 2929 (w), 2767 (w), 1668 (w), 1632 (m), 1584 (m), 1435 (m), 
1371 (m), 1244 (m), 1227 (m), 1133 (s), 1049 (m), 839 (m), 770 (m), 702 (w), 648 (m), 623 
(m) cm-1. MS (EI, 70 eV): m/z (%) = 360 (17) [M++1], 359 (100) [M+], 331 (41), 288 (9), 51 
(11), 43 (8). HRMS (EI): calcd for C15H10F5N3O2 ([M]+) 359.06877, found 359.06824. Anal. 
Calcd for C15H10F5N3O2: C, 50.15; H, 2.81; N, 11.70. Found: C, 50.40; H, 2.65; N, 11.58. 
 
6-(Furan-2-yl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2q) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 4,4,4-trifluoro-1-(furan-2-yl)butane-1,3-
dione 6i (247 mg, 1.2 mmol), 2q was isolated via 
crystallization from benzene as yellow crystals (307 mg, 89%); 
mp 192-193 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 6.78 (dd, 1H, 3JH,H = 3.5 Hz, 4JH,H = 1.7 Hz, Hetar), 7.30 
(t, 3JH,H = 7,4 Hz, 1H, Ar), 7.50-7.55 (m, 3H, Ar/Hetar), 7.77 (s, 1H, H-5), 7.87-7.90 (m, 2H, 
Ar/Hetar), 8.04 (d, 4JH,H = 1.7 Hz, 1H, Hetar), 12.31 (s, 1H, H-1). 13C NMR (62.8 MHz, 
DMSO-d6): δ = 102.4 (C-3a), 108.8 (C-5), 113.2, 113.6, 119.9 (CHAr), 121.7 (q, 1JC,F = 274.7 
Hz, CF3), 125.6, 129.1 (CHAr), 135.0 (q, 2JC,F = 35.9 Hz, CCF3), 136.6 (CAr), 146.6 (CHAr), 
151.3, 152.3 (CAr), 155.3 (C=O), 157.5 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.50 
(s). IR (ATR, cm-1): v~ = 3074 (w), 1650 (m), 1604 (m), 1595 (m), 1572 (m), 1482 (m), 1459 
(m), 1406 (m), 1360 (m), 1309 (w), 1273 (m), 1262 (m), 1185 (m), 1144 (s), 1097 (m), 983 
(m), 749 (s). MS (EI, 70 eV): m/z (%) = 346 (20) [M++1], 345 (100) [M+], 325 (11), 316 (26), 
77 (19). HRMS (ESI): calcd for C17H11F3N3O2 ([M+1]+) 346.0798, found 346.0799. Anal. 
Calcd for C17H10F3N3O2: C, 59.14; H, 2.92; N, 12.17. Found: C, 59.25; H, 2.78; N, 12.02. 
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4-(Chlorodifluoromethyl)-6-(4-chlorophenyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (2r) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b 
(113 mg, 1 mmol) and 4-chloro-1-(4-chlorophenyl)-4,4-
difluorobutane-1,3-dione 6j (320 mg, 1.2 mmol), 2r was 
isolated via crystallization from benzene as yellow crystals 
(330 mg, 96%); mp 273-275 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.47 (s, 3H, CH3), 6.89 (s, 1H, H-5), 7.50 (d, 3JH,H = 8.6 
Hz, 2H, Ar), 8.07 (d, 3JH,H = 8.6 Hz, 2H, Ar). 13C NMR (75.5 MHz, DMSO-d6): δ = 31.9 
(CH3), 94.5 (C-3a), 99.3 (t, 3JC,F = 6.6 Hz, C-5), 124.9 (t, 1JC,F = 291.1 Hz, CClF2), 128.5, 
128.6 (CHAr), 133.6, 138.5 (CAr), 139.4 (t, 2JC,F = 27.8 Hz, CCClF2), 153.8 (CAr), 155.5 
(C=O), 156.2 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -48.67 (s). IR (ATR, cm-1): v~ = 
2916 (w), 2766 (w), 1665 (w), 1631 (m), 1584 (s), 1427 (m), 1402 (m), 1360 (m), 1276 (m), 
1206 (m), 1144 (m), 1090 (s), 916 (m), 833 (s). MS (EI, 70 eV): m/z (%) = 345 (13) [M++1], 
344 (100) [M+], 225 (31), 135 (33), 91 (11), 77 (69), 51 (12), 43 (38). HRMS (ESI): calcd for 
C14H10Cl2F2N3O ([M+1]+) 344.0098, found 344.0094. Anal. Calcd for C14H9Cl2F2N3O: C, 
48.86; H, 2.64; N, 12.21. Found: C, 49.02; H, 2.55; N, 11.93.  
 
Ethyl 3-oxo-2-phenyl-6-m-tolyl-2,3-dihydro-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
(2s) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and ethyl 2,4-dioxo-4-m-tolylbutanoate 
6k (281 mg, 1.2 mmol), 2s was isolated by column 
chromatography as brown solid (231 mg, 65%); mp 174-
176 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.38 (t, 3JH,H = 7.2 Hz, 3H, OCH2CH3), 2.42 (s, 3H, 
CH3), 4.43 (q, 3JH,H = 7.2 Hz, 2H, OCH2CH3), 7.29 (t, 3JH,H = 7.4 Hz, 1H, Ar), 7.36 (d, 3JH,H = 
7.4 Hz, 1H, Ar), 7.44 (t, 3JH,H = 7.4 Hz, 1H, Ar), 7.50-7.55 (m, 2H, Ar), 7.91 (d, 3JH,H = 7.9 
Hz, 3H, Ar), 8.00 (d, 3JH,H = 7.9 Hz, 1H, Ar), 8.05 (s, 1H, H-5), 11.90 (s, 1H, NH). 13C NMR 
(75.5 MHz, DMSO-d6): δ = 14.0 (CH2CH3), 21.5 (CH3), 61.9 (CH2), 104.4 (C-3a), 112.5 (C-
5), 119.7, 124.6, 125.4, 127.9, 128.9, 129.1, 131.3 (CHAr), 137.0, 138.3, 139.6, 140.0, 156.6 
(CAr), 157.5 (C=O), 160.7 (C-7a), 164.9 (CO2Et). IR (ATR, cm-1): v~ = 2979 (w), 1729 (w), 
1682 (w), 1651 (m), 1581 (s), 1496 (m), 1371 (m), 1346 (m), 1260 (s), 1206 (m), 1156 (m), 
1037 (m), 1022 (m), 752 (s), 684 (s). MS (EI, 70 eV): m/z (%) = 375 (3) [M++2], 374 (24) 
[M++1], 373 (100) [M+], 327 (15), 301 (63), 272 (14), 77 (25). HRMS (ESI): calcd for 
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C22H20N3O3 ([M+1]+) 374.1499, found 374.1504. Anal. Calcd for C22H19N3O3: C, 70.76; H, 
5.13; N, 11.25. Found: C, 70.86; H, 4.98; N, 11.08. 
 
4-Methyl-2,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2t) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 1-phenylbutane-1,3-dione 6l (194 mg, 1.2 
mmol), 2t was isolated by column chromatography as pink 
crystals (208 mg, 69%); mp 200-202 oC. 
1H NMR (300 MHz, DMSO-d6): 2.74 (s, 3H, CH3), 7.27 (t, 3JH,H = 7.7 Hz, 1H, Ar), 7.49-7.60 
(m, 6H, Ar), 7.96 (d, 3JH,H = 7.7 Hz, 2H, Ar), 8.16 (m, 2H, Ar), 11.44 (s, 1H, NH). 13C NMR 
(75.5 MHz, DMSO-d6): δ = 16.9 (CH3), 108.0 (C-3a), 115.6 (C-5), 119.2, 124.8, 127.2, 128.8, 
129.0, 130.0 (CHAr), 136.6, 136.7, 137.5, 155.4 (CAr), 159.3 (C=O), 160.3 (C-7a). IR (ATR, 
cm-1): v~ = 2994 (w), 2850 (w), 1638 (m), 1587 (m), 1496 (m), 1430 (m), 1389 (m), 1344 (m), 
1300 (m), 1276 (m), 1208 (m), 1070 (w), 1025 (w), 911 (m), 856 (m), 769 (m), 748 (m), 681 
(m). MS (EI, 70 eV): m/z (%) = 302 (22) [M++1], 301 (100) [M+], 272 (37), 77 (11). HRMS 
(ESI): calcd for C19H16N3O ([M+1]+) 302.1388, found 302.1291. Anal. Calcd for C19H15N3O: 
C, 75.73; H, 5.02; N, 13.94. Found: C, 76.84; H, 5.67; N, 12.97. 
 
Methyl 3-oxo-2-phenyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
(2u) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and methyl 2,4-dioxo-4-p-tolylbutanoate 
6m (264 mg, 1.2 mmol), 2u was isolated by column 
chromatography as brown solid (287 mg, 80%); mp 110-
112 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.38 (s, 3H, CH3), 3.95 (s, 3H, OCH3), 7.28 (t, 3JH,H = 
7.8 Hz, 1H, Ar), 7.36 (2H, d, 3JH,H = 7.8 Hz, Ar), 7.49-7.54 (m, 2H, Ar), 7.89-7.92 (m, 3H, H-
5, Ar), 8.09-8.12 (m, 2H, Ar), 11.93 (s, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6): δ = 20.9 
(CH3), 52.8 (OCH3), 104.3 (C-3a), 112.6, 119.7, 125.4, 127.3, 129.0, 129.6 (CHAr), 134.2, 
137.0, 139.1, 140.6, 156.5 (CAr), 157.5 (C=O), 160.5 (C-7a), 165.3 (CO2CH3). IR (ATR, cm-
1): v~ = 3042 (br), 1732 (w), 1682 (w), 1651 (m), 1645 (m), 1582 (s), 1496 (m), 1435 (w), 
1393 (w), 1371 (m), 1349 (m), 1300 (w), 1271 (m), 1240 (m), 1185 (m), 1174 (m), 1094 (w), 
1034 (m), 821 (m), 751 (m), 688 (m), 676 (m). MS (EI, 70 eV): m/z (%) = 360 [M+1]+ (35), 
359 [M]+ (100), 327 (30), 302 (30), 301 (99), 300 (22), 299 (87), 272 (31), 77 (56). HRMS 
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(ESI): calcd for C21H18N3O3 ([M+1]+) 360.13427, found 360.13471. Anal. Calcd for 
C21H17N3O3: C, 70.18; H, 4.77; N, 11.69. Found: C, 70.53; H, 4.69; N, 11.47. 
 
4-(Perfluoroethyl)-2,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2v) 
 Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 4,4,5,5,5-pentafluoro-1-phenylpentane-1,3-dione 
6n (319 mg, 1.2 mmol), 2v was isolated by column 
chromatography as yellow crystals (328 mg, 81%); mp 192-194 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.30 (t, 3JH,H = 7,4 Hz, 1H, Ph), 7.50-7.58 (m, 5H, Ph), 
7.89-7.92 (m, 2H, Ph), 7.94 (s, 1H, H-5), 8.22-8.26 (m, 2H, Ph), 12.34 (s, 1H, NH). 13C NMR 
(62.9 MHz, DMSO-d6): δ = 104.3 (C-3a), 112.3 (t, 3JH,H = 6.0 Hz, C-5), 120.2, 125.7, 127.6, 
129.1, 129.1, 131.1 (CHAr), 134.6 (t, 2JH,H = 26.1 Hz, CCF2CF3), 136.5, 136.6, 155.1 (CAr), 
157.6 (C=O), 160.9 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -82.65 (s, 3F, CF3), -110.55 
(s, 2F, CF2). IR (ATR, cm-1): v~ = 3066 (w), 1660 (w), 1594 (m), 1578 (m), 1488 (w), 1327 
(m), 1272 (m), 1219 (s), 1186 (m), 1147 (s), 1048 (s), 727 (s), 687 (s). MS (EI, 70 eV): m/z 
(%) = 407 (3) [M++2], 406 (23) [M++1], 405 (100) [M+], 376 (23), 77 (17). HRMS (ESI): 
calcd for C20H13F5N3O ([M+1]+) 406.0973, found 406.0973. Anal. Calcd for C20H12F5N3O: C, 
59.27; H, 2.98; N, 10.37. Found: C, 59.42; H, 2.78; N, 10.68. 
 
4-(Perfluoropropyl)-2,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2w) 
 Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 4,4,5,5,6,6,6-heptafluoro-1-
phenylhexane-1,3-dione 6o (379 mg, 1.2 mmol), 2w was 
isolated by column chromatography as yellow crystals (346 
mg, 76%); mp 201-203 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.31-7.36 (m, 1H, Ph), 7.52-7.58 (m, 5H, Ph), 7.89-7.95 
(m, 4H, Ph, H-5), 8.28-8.31 (m, 1H, Ph), 12.42 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-
d6): δ = 108.5 (C-3a), 115.1 (t, 3JH,H = 6.0 Hz, C-5), 120.2, 125.8, 127.7, 128.1, 129.1, 131.0 
(CHAr), 133.4 (t, 2JH,H = 26.1 Hz, CCF2CF3), 136.5, 151.8, 155.1 (CAr), 156.7 (C=O), 160.9 
(C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -79.61 (t, 3JF,F = 9.2 Hz, 3F, CF3), -113.26 (q, 
3JF,F = 9.2 Hz, 2F, CF2), -125.48 (s, 2F, CF2). IR (ATR, cm-1): v~ = 3065 (w), 3035 (w), 1659 
(m), 1591 (m), 1487 (w), 1433 (w), 1393 (w), 1363 (m), 1273 (m), 1229 (s), 1201 (m), 1179 
(s), 1145 (m), 1109 (s), 1003 (w), 916 (w), 853 (w), 808 (w), 754 (m), 730 (s), 685 (s), 637 
(m). MS (EI, 70 eV): m/z (%) = 456 (23) [M++1], 455 (100) [M+], 426 (16), 307 (8), 77 (27). 
N
N
N
H
O CF2CF3
N
N
N
H
O CF2CF2CF3
  
 95 
HRMS (ESI): calcd for C21H13F7N3O ([M+1]+) 456.09414, found 456.0947. Anal. Calcd for 
C21H12F7N3O: C, 55.39; H, 2.66; N, 9.23. Found: C, 55.54; H, 2.67; N, 9.30. 
 
2-Phenyl-6-(pyridin-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2x) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 4,4,4-trifluoro-1-(pyridin-2-yl)butane-1,3-
dione 6p (261 mg, 1.2 mmol), 2x was isolated via 
crystallization from ethanol as dark red crystals (328 mg, 92%); 
mp 250-252 oC. 
IR (ATR, cm-1): v~ = 3083 (w), 3034 (w), 1603 (w), 1574 (w), 1538 (w), 1505 (w), 1480 (w), 
1456 (w), 1373 (w), 1323 (w), 1273 (m), 1193 (m), 1121 (s), 1064 (m), 1036 (m), 1027 (m), 
987 (m), 788 (m), 775 (m), 757 (m), 734 (m), 690 (s), 666 (s), 538 (m). MS (EI, 70 eV): m/z 
(%) = 357 (21) [M++1], 356 (100) [M+], 251 (34), 203 (21), 78 (18), 77 (46), 51 (17). HRMS 
(ESI): calcd for C18H12F3N4O ([M+1]+) 357.09577, found 357.09625. Anal. Calcd for 
C18H11F3N4O: C, 60.68; H, 3.11; N, 15.72. Found: C, 60.82; H, 3.15; N, 15.68.  
 
4-(Perfluoroethyl)-2-phenyl-6-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2y) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 4,4,5,5,5-pentafluoro-1-(pyridin-2-
yl)pentane-1,3-dione 6q (321 mg, 1.2 mmol), 2y was 
isolated via crystallization from ethanol as dark red crystals 
(386 mg, 95%); mp 302-303 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.34-7.38 (m, 1H, Ar), 7.53-7.58 (m, 2H, Ar), 7.68 (br s, 
1H, Ar), 7.96-8.01 (m, 3H, Ar), 8.11 (br s, 1H, Ar), 8.72 (br s, 1H, Ar), 8.86 (br s, 1H, Ar), 
12.65 (s, 1H, NH). 19F NMR (282 MHz, DMSO-d6): δ = -81.86 (s, 3F, CF3), -115.43 (s, 2F, 
CF2). IR (ATR, cm-1): v~ = 3083 (w), 3034 (w), 1605 (w), 1538 (w), 1504 (w), 1480 (m), 1459 
(w), 1322 (m), 1206 (s), 1176 (m), 1147 (m), 1120 (m), 1085 (m), 1061 (m), 1033 (s), 1024 
(s), 955 (m), 826 (m), 786 (s), 774 (s), 744 (s), 685 (s), 568 (m). MS (EI, 70 eV): m/z (%) = 
407 (22) [M++1], 406 (100) [M+], 301 (27), 273 (15), 204 (12), 78 (19), 77 (52), 51 (16). 
HRMS (EI): calcd for C19H11F5N4O ([M]+) 406.08475, found 406.08423. Anal. Calcd for 
C19H11F5N4O: C, 56.16; H, 2.73; N, 13.79. Found: C, 56.37; H, 2.74; N, 13.75. 
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4-(Perfluoropropyl)-2-phenyl-6-(pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (2z) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 4,4,5,5,6,6,6-heptafluoro-1-(pyridin-2-
yl)hexane-1,3-dione 6r (381 mg, 1.2 mmol), 2z was isolated 
via crystallization from ethanol as dark red crystals (443 mg, 
97%); mp 275-277 oC. 
IR (ATR, cm-1): v~ = 3076 (w), 3043 (w), 1603 (w), 1564 (w), 1538 (w), 1499 (w), 1480 (m), 
1460 (w), 1334 (m), 1323 (m), 1203 (s), 1186 (m), 1113 (s), 1060 (m), 1038 (m), 996 (m), 
903 (m), 812 (m), 790 (m), 775 (s), 759 (s), 745 (s), 733 (s), 686 (s), 667 (s), 589 (m). MS 
(EI, 70 eV): m/z (%) = 457 (29) [M++1], 456 (100) [M+], 351 (22), 323 (12), 204 (12), 78 
(10), 77 (28), 51 (7). HRMS (ESI): calcd for C20H12F7N4O ([M+1]+) 457.08938, found 
457.08992. Anal. Calcd for C20H11F7N4O: C, 52.64; H, 2.43; N, 12.28. Found: C, 52.74; H, 
2.44; N, 12.27. 
 
6-(2-Bromophenyl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2aa) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 1-(2-bromophenyl)-4,4,4-trifluorobutane-1,3-
dione 6s (354 mg, 1.2 mmol), 2aa was isolated by column 
chromatography as green crystals (395 mg, 91%); mp 192-194 oC. 
1H NMR (300 MHz, Aceton-d6): δ = 7.30 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.1 Hz, 1H, Ar), 7.44-
7.62 (m, 4H, Ar), 7.71 (dd, 3JH,H = 7.8 Hz, 4JH,H = 1.8 Hz, 1H, Ar), 7.76 (s, 1H, H-5), 7.82 (dd, 
3JH,H = 7.8 Hz, 4JH,H = 1.1 Hz, 1H, Ar), 7.97-8.02 (m, 2H, Ar), 10.81 (s, 1H, NH). 19F NMR 
(282 MHz, DMSO-d6): δ = -61.01 (s). IR (ATR, cm-1): v~ = 3063 (w), 1651 (m), 1591 (m), 
1497 (m), 1434 (m), 1371 (m), 1311 (w), 1282 (m), 1267 (m), 1247 (m), 1184 (m), 1137 (s), 
1023 (m), 981 (m), 886 (w), 748 (s), 719 (s), 685 (m). MS (EI, 70 eV): m/z (%) = 436 (20) 
[M++1, 81Br], 435 (100) [M+, 81Br], 434 (24) [M++1, 79Br], 433 (100) [M+, 79Br], 415 (13), 
413 (12), 406 (28), 404 (28), 302 (11), 300 (12), 77 (80), 51 (18). HRMS (EI): calcd 
C19H11BrF3N3O ([M]+, 81Br) 435.00116, found 435.00089. Anal. Calcd for C19H11BrF3N3O: 
C, 52.56; H, 2.55; N, 9.68. Found: C, 52.72; H, 2.56; N, 9.64. 
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6-(2-Bromophenyl)-4-(perfluoroethyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ab) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (175 
mg, 1 mmol) and 1-(2-bromophenyl)-4,4,5,5,5-
pentafluoropentane-1,3-dione 6t (414 mg, 1.2 mmol), 2ab was 
isolated by column chromatography as yellow crystals (426 
mg, 88 %); mp 252-253 oC. 
1H NMR (250 MHz, Acetone-d6): δ = 7.31 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.1 Hz, 1H, Ar), 7.45-
7.63 (m, 4H, Ar), 7.70-7.75 (m, 2H, Ar, H-5), 7.83 (dd, 3JH,H = 7.4 Hz, 4JH,H = 1.1 Hz, 1H, 
Ar), 7.97-8.02 (m, 2H, Ar), 10.82 (s, 1H, NH). 13C NMR (62.9 MHz, Acetone-d6): δ = 107.0 
(C-3a), 118.3 (t, 3JH,H = 8.2 Hz, C-5), 120.9 (CHAr), 121.9 (CAr), 126.6, 128.9, 129.9, 132.2, 
132.6, 134.4 (CHAr), 135.4 (t, 2JH,H = 26.8 Hz, CCF2CF3), 138.2, 140.5, 156.4 (CAr), 159.4 
(C=O), 163.7 (C-7a). 19F NMR (282 MHz, Acetone-d6): δ = -83.12 (s, 3F, CF3), -111.10 (s, 
2F, CF2). IR (ATR, cm-1): v~ = 3116 (w), 3093 (w), 1668 (m), 1693 (m), 1488 (w), 1426 (w), 
1392 (w), 1358 (w), 1331 (w), 1274 (w), 1216 (m), 1185 (m), 1163 (m), 1148 (s), 1049 (s), 
1026 (m), 950 (m), 869 (w), 808 (w), 754 (s), 729 (s), 708 (m), 688 (m), 629 (m). MS (EI, 70 
eV): m/z (%) = 486 (23) [M++1, 81Br], 485 (97) [M+, 81Br], 484 (26) [M++1, 79Br], 483 (100) 
[M+, 79Br], 456 (23), 454 (24), 352 (9), 350 (8), 298 (9), 77 (75), 51 (14). HRMS (EI): calcd 
C20H11BrF5N3O ([M]+, 81Br) 484.99797, found 484.99789. Anal. Calcd for C20H11BrF5N3O: 
C, 49.61; H, 2.29; N, 8.68. Found: C, 49.80; H, 2.30; N, 8.64. 
 
6-(2-Bromophenyl)-4-(perfluoropropyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ac) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(2-bromophenyl)-4,4,5,5,6,6,6-
heptafluorohexane-1,3-dione 6u (474 mg, 1.2 mmol), 2ac was 
isolated by column chromatography as yellow crystals (422 
mg, 79 %); mp 232-234 oC. 
1H NMR (250 MHz, Acetone-d6): δ = 7.31 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.1 Hz, 1H, Ar), 7.45-
7.63 (m, 4H, Ar), 7.70-7.74 (m, 2H, Ar, H-5), 7.83 (dd, 3JH,H = 7.9 Hz, 4JH,H = 1.1 Hz, 1H, 
Ar), 7.97-8.02 (m, 2H, Ar), 10.83 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 104.5 
(C-3a), 116.6 (t, 3JH,H = 8.7 Hz, C-5), 120.5 (CHAr), 120.8 (CAr), 126.0, 128.1, 129.1, 131.5, 
131.6, 133.3 (CHAr), 136.4, 139.0, 154.8 (CAr), 156.8 (C=O), 162.2 (C-7a). 19F NMR (282 
MHz, DMSO-d6): δ = -79.44 (t, 3JF,F = 9.2 Hz, 3F, CF3), -107.68 (q, 3JF,F = 9.2 Hz, 2F, CF2), -
124.26 (s, 2F, CF2). IR (ATR, cm-1): v~ = 3069 (w), 3019 (w), 1661 (m), 1593 (m), 1497 (w), 
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1487 (w), 1427 (w), 1392 (w), 1361 (m), 1342 (w), 1278 (m), 1224 (s), 1201 (m), 1186 (m), 
1147 (m), 1107 (s), 1028 (m), 1001 (m), 913 (m), 854 (w), 792 (m), 753 (m), 736 (s), 711 
(m), 689 (m), 637 (m). MS (EI, 70 eV): m/z (%) = 536 (23) [M++1, 81Br], 535 (100) [M+, 
81Br], 534 (27) [M++1, 79Br], 533 (97) [M+, 79Br], 506 (15), 504 (15), 402 (8), 400 (9), 77 
(78), 51 (13). HRMS (EI): calcd C21H11BrF7N3O ([M]+, 81Br) 534.99478, found 534.99427. 
Anal. Calcd for C21H11BrF7N3O: C, 47.21; H, 2.08; N, 7.87. Found: C, 47.38; H, 2.12; N, 
7.78. 
 
6-(3-Bromophenyl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ad) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(3-bromophenyl)-4,4,4-
trifluorobutane-1,3-dione 6v (354 mg, 1.2 mmol), 2ad was 
isolated by column chromatography as yellow crystals (421 
mg, 97%); mp 203-205 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.32 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.0 Hz, 1H, Ar), 7.51-
7.57 (m, 3H, Ar), 7.77 (dq, 3JH,H = 7.9 Hz, 4JH,H = 1.0 Hz, 1H, Ar), 7.88-7.92 (m, 2H, Ar), 
8.09 (s, 1H, H-5), 8.28 (dq, 3JH,H = 7.9 Hz, 4JH,H = 1.0 Hz, 1H, Ar), 8.46 (t, 4JH,H = 1.8 Hz, 1H, 
Ar), 12.33 (s, 1H, NH). 19F NMR (282 MHz, DMSO-d6): δ = -61.00 (s). IR (ATR, cm-1): v~ = 
3064 (w), 1651 (m), 1604 (m), 1567 (w), 1488 (w), 1398 (w), 1365 (m), 1304 (w), 1278 (m), 
1257 (s), 1184 (m), 1148 (s), 1138 (s), 986 (m), 872 (m), 783 (m), 755 (m), 741 (m), 722 (m), 
688 (s), 665 (m), 634 (m). MS (EI, 70 eV): m/z (%) = 436 (21) [M++1, 81Br], 435 (98) [M+, 
81Br], 434 (23) [M++1, 79Br], 433 (95) [M+, 79Br], 415 (11), 413 (11), 406 (25), 404 (26), 302 
(13), 300 (11), 77 (100), 51 (22). HRMS (EI): calcd C19H11BrF3N3O ([M]+, 81Br) 435.00116, 
found 435.00133. Anal. Calcd for C19H11BrF3N3O: C, 52.56; H, 2.55; N, 9.68. Found: C, 
52.68; H, 2.57; N, 9.62. 
6-(3-Bromophenyl)-4-(perfluoroethyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ae) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(3-bromophenyl)-4,4,5,5,5-
pentafluoropentane-1,3-dione 6w (414 mg, 1.2 mmol), 2ae 
was isolated by column chromatography as green crystals 
(441 mg, 91%); mp 248-249 oC. 
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1H NMR (250 MHz, Acetone-d6): δ = 7.30 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.1 Hz, 1H, Ar), 7.49-
7.58 (m, 3H, Ar), 7.76 (ddd, 3JH,H = 7.9 Hz, 4JH,H = 1.8 Hz, 4JH,H = 1.0 Hz, 1H, Ar), 7.97-8.02 
(m, 2H, Ar), 8.09 (s, 1H, H-5), 8.30 (ddd, 3JH,H = 7.9 Hz, 4JH,H = 1.8 Hz, 4JH,H = 1.0 Hz, 1H, 
Ar), 8.48 (t, 4JH,H = 1.8 Hz, 1H, Ar), 10.75 (s, 1H, NH). 13C NMR (62.9 MHz, Acetone-d6): δ 
= 107.5 (C-3a), 114.1 (t, 3JH,H = 8.2 Hz, C-5), 120.8 (CHAr), 123.7 (CAr), 126.5, 127.5, 129.9, 
131.4, 131.9, 134.6 (CHAr), 136.8 (t, 2JH,H = 26.3 Hz, CCF2CF3), 138.2, 140.2, 156.5 (CAr), 
159.7 (C=O), 160.8 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -81.88 (s, 3F, CF3), -114.35 
(s, 2F, CF2). IR (ATR, cm-1): v~ = 3064 (w), 1658 (m), 1594 (m), 1564 (w), 1494 (w), 1424 
(w), 1401 (w), 1355 (w), 1332 (w), 1301 (w), 1276 (m), 1220 (m), 1209 (m), 1189 (m), 1163 
(m), 1149 (s), 1098 (w), 1049 (s), 957 (m), 866 (w), 793 (w), 753 (m), 732 (m), 687 (s), 637 
(m). MS (EI, 70 eV): m/z (%) = 486 (22) [M++1, 81Br], 485 (100) [M+, 81Br], 484 (25) [M++1, 
79Br], 483 (99) [M+, 79Br], 456 (20), 454 (20), 298 (12), 77 (91), 51 (16). HRMS (EI): calcd 
C20H11BrF5N3O ([M]+, 81Br) 484.99797, found 484.99776. Anal. Calcd for C20H11BrF5N3O: 
C, 49.61; H, 2.29; N, 8.68, Found: C, 49.79; H, 2.34; N, 8.67. 
 
6-(3-Bromophenyl)-4-(perfluoropropyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2af) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(3-bromophenyl)-4,4,5,5,6,6,6-
heptafluorohexane-1,3-dione 6x (474 mg, 1.2 mmol), 2af 
was isolated by column chromatography as yellow crystals 
(502 mg, 94%); mp 263-264 oC. 
IR (ATR, cm-1): v~ = 3077 (w), 3019 (w), 1659 (m), 1597 (w), 1567 (w), 1488 (w), 1423 (w), 
1401 (w), 1359 (w), 1339 (w), 1305 (w), 1274 (w), 1229 (s), 1201 (m), 1184 (m), 1147 (m), 
1113 (m), 1074 (w), 1006 (w), 923 (m), 855 (w), 811 (w), 755 (m), 734 (s), 706 (m), 684 (s), 
662 (m), 640 (m). MS (EI, 70 eV): m/z (%) = 536 (22) [M++1, 81Br], 535 (100) [M+, 81Br], 
534 (27) [M++1, 79Br], 533 (100) [M+, 79Br], 506 (14), 504 (14), 402 (8), 400 (9), 77 (81), 51 
(13). HRMS (EI): calcd C21H11BrF7N3O ([M]+, 81Br) 534.99478, found 534.99393. Anal. 
Calcd for C21H11BrF7N3O: C, 47.21; H, 2.08; N, 7.87. Found: C, 47.31; H, 2.10; N, 7.86. 
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6-(4-Bromophenyl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ag) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(4-bromophenyl)-4,4,4-
trifluorobutane-1,3-dione 6y  (354 mg, 1.2 mmol), 2ag was 
isolated by column chromatography as green crystals (343 
mg, 79%); mp 203-205 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.32 (t, 3JH,H = 7,1 Hz, 1H, Ar), 7.54 (t, 3JH,H = 7,7 Hz, 
2H, Ar), 7.79 (d, 3JH,H = 8.3 Hz, 2H, Ar), 7.90 (d, 3JH,H = 7,7 Hz, 2H, Ar), 8.05 (s, 1H, H-5), 
8.24 (d, 3JH,H = 8.3 Hz, 2H, Ph), 12.35 (s, 1H, NH). 19F NMR (282 MHz, DMSO-d6): δ = -
61.06 (s). IR (ATR, cm-1): v~ = 3043 (br), 2978 (w), 1668 (w), 1650 (w), 1645 (w), 1601 (w), 
1584 (m), 1496 (w), 1393 (w), 1369 (m), 1274 (m), 1260 (w), 1184 (w), 1157 (m), 1140 (m), 
1071 (w), 1007 (w), 981 (w), 950 (m), 829 (m), 752 (m), 715 (m), 649 (m). MS (EI, 70 eV): 
m/z (%) = 436 (21) [M++1, 81Br], 435 (98) [M+, 81Br], 434 (24) [M++1, 79Br], 433 (100) [M+, 
79Br], 415 (12), 413 (11), 406 (24), 404 (25), 302 (11), 300 (11), 77 (99), 51 (21). HRMS 
(EI): calcd C19H12BrF3N3O ([M]+, 81Br) 436.00919, found 436.00914. Anal. Calcd for 
C19H11BrF3N3O: C, 52.56; H, 2.55; N, 9.68. Found: C, 52.74; H, 2.56; N, 9.94. 
 
6-(4-Bromophenyl)-4-(perfluoroethyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ah) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(4-bromophenyl)-4,4,5,5,5-
pentafluoropentane-1,3-dione 6z (414 mg, 1.2 mmol), 2ah 
was isolated by column chromatography as yellow crystals 
(387 mg, 80%); mp 248-249 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.32 (t, 3JH,H = 7,4 Hz, 1H, Ar), 7.51-7.57 (m, 2H, Ar), 
7.76-7.80 (m, 2H, Ar), 7.88-7.91 (m, 2H, Ar), 7.99 (s, 1H, H-5), 8.20-8.24 (m, 2H, Ar), 12.38 
(s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 104.5 (C-3a), 112.2 (C-5), 120.2 (CHAr), 
124.9 (CAr), 125.8, 129.1, 129.7, 132.1 (CHAr), 134.8 (t, 2JC,F = 27.0 Hz, CCF2), 135.7, 136.6, 
155.0 (CAr), 157.4 (C=O), 159.8 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -82.60 (s, 3F, 
CF3), -110.48 (s, 2F, CF2). IR (ATR, cm-1): v~ = 3021 (w), 2921 (w), 1651 (m), 1594 (m), 
1584 (m), 1496 (w), 1431 (w), 1395 (w), 1361 (w), 1328 (w), 1274 (m), 1219 (m), 1190 (m), 
1149 (s), 1048 (s), 1008 (m), 950 (m), 831 (m), 752 (m), 732 (s), 688 (m). MS (EI, 70 eV): 
m/z (%) = 486 (21) [M++1, 81Br], 485 (97) [M+, 81Br], 484 (25) [M++1, 79Br], 483 (100) [M+, 
79Br], 456 (20), 454 (21), 298 (12), 77 (91), 51 (17). HRMS (EI): calcd C20H11BrF5N3O 
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([M]+, 81Br) 484.99797, found 484.99718. Anal. Calcd for C20H11BrF5N3O: C, 49.61; H, 2.29; 
N, 8.68. Found: C, 49.80; H, 2.30; N, 8.65. 
 
6-(4-Bromophenyl)-4-(perfluoropropyl)-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(2ai) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a 
(175 mg, 1 mmol) and 1-(4-bromophenyl)-4,4,5,5,6,6,6-
heptafluorohexane-1,3-dione 6aa (474 mg, 1.2 mmol), 2ai 
was isolated by column chromatography as yellow crystals 
(454 mg, 85%); mp 288-289 oC. 
1H NMR (250 MHz, Acetone-d6): δ = 7.30 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.1 Hz, 1H, Ar), 7.48-
7.57 (m, 2H, Ar), 7.75-7.80 (m, 2H, Ar), 7.97-8.02 (m, 2H, Ar), 8.04 (s, 1H, H-5), 8.23-8.29 
(m, 2H, Ar), 10.75 (s, 1H, NH). 13C NMR (62.9 MHz, Acetone-d6): δ = 107.5 (C-3a), 114.1 
(t, 3JH,H = 8.2 Hz, C-5), 120.8 (CHAr), 126.1 (CAr), 126.5, 129.9, 130.5, 133.1 (CHAr), 137.1, 
138.3, 156.6 (CAr), 159.8 (C=O), 161.3 (C-7a). 19F NMR (282 MHz, Acetone-d6): δ = -81.21 
(t, 3JF,F = 9.2 Hz, 3F, CF3), -105.24 (q, 3JF,F = 9.2 Hz, 2F, CF2), -125.26 (s, 2F, CF2). IR (ATR, 
cm-1): v~ = 3043 (br), 1660 (m), 1585 (m), 1497 (w), 1487 (w), 1434 (w), 1393 (w), 1363 (m), 
1341 (w), 1272 (m), 1226 (s), 1203 (m), 1181 (m), 1148 (m), 1112 (m), 1072 (w), 1003 (m), 
916 (w), 832 (m), 807 (m), 754 (m), 734 (s), 686 (m), 623 (m). MS (EI, 70 eV): m/z (%) = 
536 (23) [M++1, 81Br], 535 (100) [M+, 81Br], 534 (28) [M++1, 79Br], 533 (99) [M+, 79Br], 506 
(13), 504 (12), 77 (69), 51 (10). HRMS (EI): calcd C21H11BrF7N3O ([M]+, 81Br) 534.99478, 
found 534.99443. Anal. Calcd for C21H11BrF7N3O: C, 47.21; H, 2.08; N, 7.87. Found: C, 
47.35; H, 2.09; N, 7.86. 
 
A.2.2. General procedure for synthesis of compounds 9 
Under argon atmosphere, 4-tert-butylstyrene (0.55 ml, 3 mmol), 1H-pyrazolo[3,4-b]pyridin-
3-one 2 (1 mmol), triethylamine (0.56 ml, 4 mmol) and PdCl2(PPh3)2 (28 mg, 0.04 mol) were 
placed into a pressure tube and 4mL of dry DMF was added. Once the pressure tube was 
sealed, the mixture was heated at 140 oC for 6 – 20h (controlled by TLC). Then the solution 
was evaporated under reduced pressure and subjected to column chromatography (silica gel; 
eluent: n-heptane/ethylacetate). 
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(E)-6-(3-(4-Tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (9a) 
Starting from 2af (534 mg, 1 mmol) 9a was 
isolated by column chromatography as 
green crystals (472 mg, 77%); mp 250-252 
oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 (s, 9H, CH3), 7.32 (t, 3JH,H = 7.4 Hz, 1H, Ar), 7.38-
7.44 (m, 4H, Ar), 7.51-7.62 (m, 5H, Ar), 7.85 (d, 3JH,H = 8.0 Hz, 1H, =CH), 7.90-7.93 (m, 2H, 
Ar), 8.04 (s, 1H, H-5), 8.16 (d, 3JH,H = 8.0 Hz, 1H, =CH), 8.43 (s, 1H, Ar), 12.36 (s, 1H, NH). 
19F NMR (282 MHz, DMSO-d6): δ = -79.34 (t, 3JF,F = 9.2 Hz, 3F, CF3), -107.41 (q, 3JF,F = 9.2 
Hz, 2F, CF2), -124.05 (s, 2F, CF2). IR (ATR, cm-1): v~ = 3029 (w), 2959 (w), 1658 (m), 1595 
(m), 1497 (w), 1433 (w), 1394 (w), 1362 (m), 1274 (m), 1228 (s), 1204 (m), 1183 (m), 1147 
(m), 1113 (s), 1008 (w), 963 (w), 940 (w), 846 (w), 817 (m), 755 (m), 733 (s), 684 (s), 566 
(w). MS (EI, 70 eV): m/z (%) = 614 (31) [M++1], 613 (97) [M+], 599 (33), 598 (100), 557 
(14), 299 (14), 77 (9), 44 (8). HRMS (ESI): calcd C33H27F7N3O ([M+1]+) 614.20369, found 
614.20398. Anal. Calcd for C33H26F7N3O: C, 64.60; H, 4.27; N, 6.85. Found: C, 64.87; H, 
4.29; N, 6.82. 
 
(E)-6-(4-(4-Tert-butylstyryl)phenyl)-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (9b) 
Starting from 2ag (434 mg, 1 mmol) 9b was 
isolated by column chromatography as yellow 
crystals (416 mg, 81%); mp 270-272 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.29 (s, 9H, 
CH3), 7.26-7.33 (m, 2H, Ar), 7.38-7.43 (m, 3H, 
Ar), 7.51-7.59 (m, 4H, Ar), 7.77-7.80 (m, 2H, Ar), 7.90-7.92 (m, 2H, Ar, =CH), 8.05 (s, 1H, 
H-5), 8.28-8.31 (m, 2H, Ar, =CH), 12.26 (s, 1H, NH). 19F NMR (282 MHz, DMSO-d6): δ = -
61.10 (s). IR (ATR, cm-1): v~ = 3077 (w), 2959 (w), 1646 (m), 1593 (m), 1496 (w), 1407 (m), 
1374 (m), 1276 (m), 1260 (m), 1168 (m), 1139 (s), 978 (w), 964 (m), 871 (w), 838 (s), 748 
(s), 711 (m), 687 (m), 560 (m). MS (EI, 70 eV): m/z (%) = 514 (46) [M++1], 513 (95) [M+], 
499 (49), 498 (100), 367 (16), 249 (19), 169 (11), 77 (12), 69 (11), 44 (67), 43 (14). HRMS 
(ESI): calcd C31H27F3N3O ([M+1]+) 514.21007, found 514.20972. Anal. Calcd for 
C31H26F3N3O: C, 72.50; H, 5.10; N, 8.18. Found: C, 72.78; H, 5.12; N, 8.14. 
 
N
N
N
H
CF2CF2CF3O
t-Bu
N
N
N
H
CF3O
t-Bu
  
 103 
(E)-6-(4-(4-Tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (9c) 
Starting from 2ai (534 mg, 1 mmol) 9c was 
isolated by column chromatography as yellow 
crystals (515 mg, 84%); mp 203-205 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 (s, 9H, 
CH3), 7.28-7.33 ( m, 2H, Ar), 7.39-7.44 (m, 3H, 
Ar), 7.51-7.60 (m, 4H, Ar, =CH), 7.90-7.92 (m, 2H, Ar), 7.99 (s, 1H, H-5), 8.29-8.32 (m, 2H, 
Ar, =CH), 12.29 (s, 1H, NH). 19F NMR (282 MHz, DMSO-d6): δ = -79.35 (t, 3JF,F = 9.2 Hz, 
3F, CF3), -107.49 (q, 3JF,F = 9.2 Hz, 2F, CF2), -124.11 (t, 3JF,F = 21.5 Hz, 2F, CF2). IR (ATR, 
cm-1): v~ = 3029 (w), 2959 (w), 1658 (m), 1595 (m), 1497 (w), 1433 (w), 1394 (w), 1362 (m), 
1274 (m), 1228 (s), 1204 (m), 1183 (m), 1147 (m), 1113 (s), 1008 (w), 963 (w), 940 (w), 846 
(w), 817 (m), 755 (m), 733 (s), 684 (s), 566 (w). MS (EI, 70 eV): m/z (%) = 614 (38) [M++1], 
613 (100) [M+], 599 (28), 598 (97), 557 (21), 299 (14), 77 (19), 44 (17). HRMS (ESI): calcd 
C33H27F7N3O ([M+1]+) 614.20369, found 614.20382. Anal. Calcd for C33H26F7N3O: C, 64.60; 
H, 4.27; N, 6.85. Found: C, 64.39; H, 4.25; N, 6.83. 
 
A.2.3. General procedure for synthesis of compounds 11-13, 15 
Under argon atmosphere, appropriate alkene, 1H-pyrazolo[3,4-b]pyridin-3-one 2 (1 mmol), 
triethylamine (0.56 ml, 4 mmol) and PdCl2(PPh3)2 (28 mg, 0.04 mol) were placed into a 
pressure tube and 4mL of dry DMF was added. Once the pressure tube was sealed, the 
mixture was heated at 80-100 oC for 6 – 20h (controlled by TLC). Then the solution was 
evaporated under reduced pressure and subjected to column chromatography (silica gel; 
eluent: n-heptane/ethylacetate). 
 
(E)-Ethyl 3-(3-(3-oxo-2-phenyl-4-(trifluoromethyl)-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridin-6-yl)phenyl)acrylate (11a) 
Starting from ethylacrylate (120 mg, 1.2 mmol) and 
2ad (434 mg, 1 mmol) 11a was isolated by column 
chromatography as yellow crystals (190 mg, 42%); mp 
236-237 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.28 (t, 3JH,H = 7.1 Hz, 3H, CH3), 4.22 (q, 3JH,H = 7.1 Hz, 
2H, OCH2), 6.86 (d, 3JH,H = 16.1 Hz, 1H, =CH), 7.29-7.34 (m, 1H, Ar), 7.51-7.57 (m, 2H, Ar), 
7.62 (t, 3JH,H = 7.8 Hz, 1H, Ar), 7.79 (d, 3JH,H = 16.1 Hz, 1H, =CH), 7.89-7.92 (m, 3H, Ar), 
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8.18 (s, 1H, H-5), 8.31 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.59 (br s, 1H, Ar), 12.31 (s, 1H, NH). 13C 
NMR (62.9 MHz, DMSO-d6): δ = 14.2 (CH3), 60.2 (OCH2), 103.4 (C-3a), 111.1 (q, 3JC,F = 5.0 
Hz, C-5), 119.3 (=CH), 120.1 (CHAr), 122.0 (q, 1JC,F = 274.4 Hz, CF3), 125.8, 127.5, 129.1, 
129.3, 129.7, 130.6 (CHAr), 135.0 (CAr), 135.8 (q, 2JC,F = 35.7 Hz, CCF3), 136.6, 137.4 (CAr), 
143.7 (=CH), 155.4 (CAr), 157.5 (NC=O), 160.6 (C-7a), 166.2 (CO2Et). 19F NMR (282 MHz, 
DMSO-d6): δ = -60.94 (s). IR (ATR, cm-1): v~ = 3212 (br w), 1687 (m), 1683 (m), 1634 (w), 
1594 (w), 1499 (w), 1440 (w), 1393 (w), 1369 (m), 1315 (w), 1299 (w), 1259 (w), 1202 (m), 
1146 (s), 1083 (w), 1033 (w), 993 (w), 864 (w), 803 (w), 754 (m), 709 (m), 687 (m). MS (EI, 
70 eV): m/z (%) = 454 (69) [M++1], 453 (100) [M+], 425 (18), 408 (62), 407 (87), 379 (20), 
378 (77), 204 (17), 77 (51), 44 (11). HRMS (ESI): calcd C24H18F3N3O3 ([M]+) 453.12948, 
found 453.12914. Anal. Calcd for C24H18F3N3O3: C, 63.57; H, 4.00; N, 12.57. Found: C, 
63.84; H, 4.12; N, 7.63. 
 
 (E)-Ethyl 3-(4-(3-oxo-4-(perfluoroethyl)-2-phenyl-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridin-6-yl)phenyl)acrylate (11b) 
Starting from ethylacrylate (120 mg, 1.2 mmol) and 2ah 
(484 mg, 1 mmol) 11b was isolated by column 
chromatography as yellow crystals (171 mg, 34%), mp 
224-225 oC. 
1H NMR (300 MHz, DMSO-d6): 1.38 (t, 3JH,H = 7.2 Hz, 
3H, CH3), 4.32 (q, 3JH,H = 7.2 Hz, 2H, OCH2), 6.58 (d, 3JH,H = 15.9 Hz, 1H, =CH), 7.35-7.41 
(m, 1H, Ar), 7.51-7.61 (m, 4H, Ar), 7.65-7.88 (m, 4H, Ar, =CH), 8.20-8.23 (m, 2H, Ar). 13C 
NMR (62.9 MHz, DMSO-d6): δ = 14.7 (CH3), 61.3 (OCH2), 106.8 (C-3a), 114.0 (t, 3JC,F = 7.8 
Hz, C-5), 120.5 (=CH), 124.6, 127.7, 128.6, 129.0, 129.7 (CHAr), 134.7 (CAr), 137.3 (t, 2JC,F = 
27.2 Hz, CCF3), 137.5, 138.5 (CAr), 143.5 (=CH), 158.0 (CAr), 161.0 (NC=O), 161.3 (C-7a), 
167.0 (CO2Et). 19F NMR (282 MHz, CDCl3): δ = -83.19 (q, 3JF,F = 3.1 Hz, 3F, CF3), -111.77 
(q, 3JF,F = 3.1 Hz, 2F, CF2). MS (EI, 70 eV): m/z (%) = 504 (18) [M++1], 503 (69) [M+], 460 
(23), 459 (100), 77 (25). HRMS (ESI): calcd C25H19F5N3O3 ([M+1]+) 504.13258, found 
504.13252. Anal. Calcd for C25H18F5N3O3: C, 59.65; H, 3.60; N, 8.35. Found: C, 59.47; H, 
3.31; N, 8.67. 
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(E)-Ethyl 3-(2-(1-(3-ethoxy-3-oxopropyl)-3-oxo-2-phenyl-4-(trifluoromethyl)-2,3-
dihydro-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl)acrylate (12a) 
Starting from ethylacrylate (120 mg, 1.2 mmol) and 
2ad (434 mg, 1 mmol) 12a was isolated by column 
chromatography as yellow solid (100 mg, 18%), mp 
58-60 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 0.95 (t, 3JH,H = 
7.1 Hz, 3H, CH3), 1.29 (t, 3JH,H = 7.1 Hz, 3H, CH3), 2.40 (t, 3JH,H = 6.6 Hz, 2H, NCH2CH2), 
3.77 (q, 3JH,H = 7.1 Hz, 2H, OCH2), 4.23 (q, 3JH,H = 7.1 Hz, 2H, OCH2), 4.33 (t, 3JH,H = 6.6 Hz, 
2H, NCH2), 6.90 (d, 3JH,H = 16.1 Hz, 1H, =CH), 7.40-7.46 (m, 1H, Ar), 7.56-7.60 (m, 4H, Ar), 
7.65 (t, 3JH,H = 7.8 Hz, 1H, Ar), 7.81 (d, 3JH,H = 16.1 Hz, 1H, =CH), 7.95 (d, 3JH,H = 7.8 Hz, 
1H, Ar), 8.28 (s, 1H, H-5), 8.39 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.67 (br s, 1H, Ar). 13C NMR 
(62.9 MHz, DMSO-d6): δ = 13.6, 14.2 (CH3), 30.4, 43.8 (CH2), 60.1, 60.2 (OCH2), 104.2 (C-
3a), 112.1 (q, 3JC,F = 5.0 Hz, C-5), 119.4 (=CH), 121.8 (q, 1JC,F = 275.1 Hz, CF3), 124.5, 127.4, 
127.7, 129.3, 129.6, 129.7, 130.9 (CHAr), 134.1, 135.0 (CAr), 135.5 (q, 2JC,F = 36.2 Hz, CCF3), 
137.1 (CAr), 143.7 (=CH), 157.3 (CAr), 160.1 (NC=O), 161.0 (C-7a), 166.2, 170.4 (CO2Et). 
19F NMR (282 MHz, DMSO-d6): δ = -61.03 (s). IR (ATR, cm-1): v~ = 2980 (w), 1704 (m), 
1699 (m), 1639 (w), 1590 (m), 1487 (w), 1461 (w), 1446 (w), 1417 (w), 1368 (m), 1311 (m), 
1260 (m), 1140 (s), 1032 (m), 980 (m), 862 (w), 799 (m), 756 (m), 713 (m), 690 (m), 661 (w). 
MS (EI, 70 eV): m/z (%) = 554 (24) [M++1], 553 (76) [M+], 508 (10), 467 (29), 466 (100), 77 
(27). HRMS (EI): calcd C29H26F3N3O5 ([M]+) 553.18191, found 553.18178. Anal. Calcd for 
C29H26F3N3O5: C, 62.93; H, 4.73; N, 7.59. Found: C, 62.78; H, 4.71; N, 7.62. 
 
(E)-Ethyl 3-(4-(1-(3-ethoxy-3-oxopropyl)-3-oxo-4-(perfluoroethyl)-2-phenyl-2,3-dihydro-
1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl)acrylate (12b) 
Starting from ethylacrylate (120 mg, 1.2 mmol) and 2ah 
(484 mg, 1 mmol) 12c was isolated by column 
chromatography as yellow oil (145 mg, 24%). 
1H NMR (300 MHz, CDCl3): δ = 1.10 (t, 3JH,H = 7.2 Hz, 
3H, CH3), 1.36 (t, 3JH,H = 7.2 Hz, 3H, CH3), 2.38 (t, 3JH,H = 
7.3 Hz, 2H, NCH2CH2), 3.95 (q, 3JH,H = 7.2 Hz, 2H, OCH2), 4.30 (q, 3JH,H = 7.2 Hz, 2H, 
OCH2), 4.42 (t, 3JH,H = 7.3 Hz, 2H, NCH2), 6.56 (d, 3JH,H = 15.9 Hz, 1H, =CH), 7.33-7.39 (m, 
1H, Ar), 7.49-7.59 (m, 4H, Ar), 7.63-7.86 (m, 4H, Ar, =CH), 8.18-8.21 (m, 2H, Ar). 13C 
NMR (62.9 MHz, CDCl3): δ = 14.0, 14.5 (CH3), 30.5, 44.1 (CH2), 60.9, 61.1 (OCH2), 106.6 
(C-3a), 113.8 (t, 3JC,F = 7.8 Hz, C-5), 120.3 (=CH), 124.4, 127.5, 128.4, 128.8, 129.5 (CHAr), 
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134.5 (CAr), 137.1 (t, 2JC,F = 27.0 Hz, CCF3), 137.3, 138.3 (CAr), 143.3 (=CH), 157.8 (CAr), 
160.8 (NC=O), 161.1 (C-7a), 166.8, 170.6 (CO2Et). 19F NMR (282 MHz, CDCl3): δ = -83.19 
(q, 3JF,F = 3.1 Hz, 3F, CF3), -111.77 (q, 3JF,F = 3.1 Hz, 2F, CF2). IR (ATR, cm-1): v~ = 3212 (w), 
1690 (m), 1683 (m), 1634 (w), 1594 (w), 1499 (w), 1440 (w), 1393 (w), 1371 (m), 1315 (w), 
1301 (w), 1259 (w), 1202 (m), 1151 (s), 1083 (w), 1005 (w), 862 (w), 754 (m), 709 (m). MS 
(EI, 70 eV): m/z (%) = 604 (22) [M++1], 603 (84) [M+], 517 (30), 516 (100), 503 (13), 77 
(18). HRMS (ESI): calcd C30H27F5N3O5 ([M+1]+) 604.18654, found 604.18637. Anal. Calcd 
for C30H26F5N3O5: C, 59.70; H, 4.34; N, 6.96. Found: C, 59.58; H, 4.36; N, 6.99. 
 
Ethyl 3-(6-(2-bromophenyl)-3-oxo-4-(perfluoropropyl)-2-phenyl-2,3-dihydro-1H-
pyrazolo[3,4-b]pyridin-1-yl)propanoate (13) 
Starting from ethylacrylate (120 mg, 1.2 mmol) and 2ad (484 mg, 
1 mmol) 13 was isolated by column chromatography as yellow oil 
(444 mg, 70%). 
1H NMR (300 MHz, CDCl3): δ = 1.12 (t, 3JH,H = 7.2 Hz, 3H, CH3), 
2.39 (t, 3JH,H = 7.3 Hz, 2H, NCH2CH2), 3.96 (q, 3JH,H = 7.2 Hz, 2H, 
OCH2), 4.39 (t, 3JH,H = 7.3 Hz, 2H, NCH2), 7.34-7.41 (m, 2H, Ar), 7.48-7.59 (m, 5H, Ar), 7.66 
(dd, 3JH,H = 7.7 Hz, 4JH,H = 1.4 Hz, 1H, Ar), 7.70 (s, 1H, H-5), 7.76 (dd, 3JH,H = 7.7 Hz, 4JH,H = 
1.4 Hz, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 14.1 (CH3), 30.6, 44.1 (CH2), 61.0 
(OCH2), 106.9 (C-3a), 118.6 (t, 3JC,F = 8.5 Hz, C-5), 121.8 (CAr), 124.5, 127.6, 128.0, 129.6, 
131.3, 131.8, 134.1 (CHAr), 134.4 (CAr), 136.1 (t, 2JC,F = 27.0 Hz, CCF2), 139.2, 157.9 (CAr), 
160.4 (NC=O), 163.1 (C-7a), 170.5 (CO2Et). 19F NMR (282 MHz, CDCl3): δ = -79.35 (t, 3JF,F 
= 9.2 Hz, 3F, CF3), -107.49 (q, 3JF,F = 9.2 Hz, 2F, CF2), -124.11 (t, 3JF,F = 21.5 Hz, 2F, CF2). 
MS (EI, 70 eV): m/z (%) = 636 (14) [M++1, 81Br], 635 (52) [M+, 81Br], 634 (14) [M++1, 79Br], 
633 (51) [M+, 79Br], 549 (20), 548 (100), 547 (21), 546 (99), 77 (34). HRMS (EI): calcd 
C19H19BrF7N3O3 ([M]+, 81Br) 635.05247, found 635.05228. Anal. Calcd for C26H19BrF7N3O3: 
C, 49.23; H, 3.02; N, 6.62. Found: C, 49.36; H, 2.99; N, 5.89. 
 
3-(6-(2-Bromophenyl)-3-oxo-2-phenyl-4-(trifluoromethyl)-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridin-1-yl)propanenitrile (15) 
Starting from acrylonitrile (63.6 mg, 1.2 mmol) and 2aa (534 mg, 
1 mmol) 15 was isolated by column chromatography as green 
crystals (317 mg, 65%); mp 76-77 oC. 
1H NMR (300 MHz, CDCl3): δ = 2.57 (t, 3JH,H = 6.8 Hz, 2H, 
NCH2CH2), 4.29 (t, 3JH,H = 6.8 Hz, 2H, NCH2), 7.34-7.41 (m, 2H, Ar), 7.48-7.59 (m, 5H, Ar), 
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7.66 (dd, 3JH,H = 7.7 Hz, 4JH,H = 1.4 Hz, 1H, Ar), 7.70 (s, 1H, H-5), 7.76 (dd, 3JH,H = 7.7 Hz, 
4JH,H = 1.4 Hz, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 14.9 (CH2CN), 43.9 (NCH2), 
105.7 (C-3a), 116.5 (C≡N), 117.2 (q, 3JC,F = 5.0 Hz, C-5), 119.6 (CHAr), 121.5 (q, 1JC,F = 275.1 
Hz, CF3), 121.7 (CAr), 124.5, 128.1, 129.8, 131.5, 131.6, 134.0 (CHAr), 136.9 (q, 2JC,F = 36.6 
Hz, CCF3), 138.7, 139.1, 158.1 (CAr), 160.3 (C=O), 164.0 (C-7a). 19F NMR (282 MHz, 
CDCl3): δ = -62.49 (s). IR (ATR, cm-1): v~ = 3063 (w), 2929 (w), 1693 (m), 1590 (m), 1496 
(w), 1410 (w), 1370 (m), 1309 (w), 1281 (m), 1266 (m), 1246 (m), 1181 (w), 1142 (s), 1080 
(w), 1055 (w), 1024 (w), 982 (w), 885 (w), 755 (m), 719 (m), 688 (m). MS (EI, 70 eV): m/z 
(%) = 489 (13) [M++1, 81Br], 488 (57) [M+, 81Br], 487 (15) [M++1, 79Br], 486 (56) [M+, 79Br], 
449 (23), 448 (100), 447 (23), 446 (91), 434 (15), 432 (13), 77 (85), 65 (15), 54 (19), 51 (20). 
HRMS (EI): calcd C22H14BrF3N4O ([M]+, 81Br) 488.02791, found 488.02771. Anal. Calcd for 
C22H14BrFN4O: C, 54.23; H, 2.90; N, 11.50. Found: C, 54.38; H, 2.88; N, 11.46. 
 
A.2.4. General procedure for synthesis of compounds 22 
Appropriate 5-amino-1H-pyrazol-3(2H)-one 4 (1.2 mmol) and corresponding 4-chloro-2H-
chromen-2-one 21 were placed in a pressure tube and dissolved in absolute DMF (7 mL); 
chlorotrimethylsilane (600 mg, 5.5 mmol) was added dropwise to the solution. The tube was 
sealed and heated under an inert atmosphere at 83 oC for 4-12 h (controlled by TLC). The 
solution was evaporated under reduced pressure, treated with H2O, filtered, dried under 
reduced pressure and recrystallized from an appropriate solvent. 
 
9-Phenyl-7-(trifluoromethyl)-9,10-dihydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-6,8-
dione (22a) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (210 
mg, 1.2 mmol) and 4-chloro-3-(2,2,2-trifluoroacetyl)-2H-
chromen-2-one 21a (277 mg, 1 mmol), 22a was isolated via 
crystallization from isopropanol as green crystals (258 mg, 65%); 
mp 296-297 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 7.33-7.38 (m, 1H, Ar), 7.44-7.51 (m, 2H, Ar), 7.53-7.60 
(m, 2H, Ar), 7.71-7.77 (m, 1H, Ar), 7.89-7.92 (m, 2H, Ar), 8.45-8.48 (m, 1H, Ar). 13C NMR 
(62.9 MHz, DMSO-d6): δ = 96.8 (C-7a), 117.2 (CHAr), 118.1 (C-6a), 119.9 (CHAr), 120.9 (q, 
1JC,F = 274.8 Hz, CF3), 124.9, 125.0, 125.9, 129.1, 133.8 (CHAr), 136.3 (CAr), 138.7 (q, 2JC,F = 
37.0 Hz, CCF3), 142.7 152.6, 155.3 (CAr), 155.8 (CO-6) 157.9 (CO-8), 158.7 (C-10a). 19F 
NMR (282 MHz, DMSO-d6): δ = -55.64 (s). IR (ATR, cm-1): v~ = 3084 (w), 1749 (m), 1704 
(m), 1678 (m), 1583 (s), 1498 (m), 1467 (m), 1410 (m), 1364 (m), 1270 (m), 1234 (m), 1176 
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(m), 1147 (s), 1075 (w), 1030 (w), 989 (w), 893 (w), 818 (w), 733 (m), 684 (m), 655 (m). MS 
(EI, 70 eV): m/z (%) = 399 (4) [M++2], 398 (24) [M++1], 397 (100) [M+], 377 (45), 368 (18), 
77 (33), 73 (15), 60 (14), 44 (21), 43 (12). HRMS (ESI): calcd C20H11F3N3O3 ([M+1]+) 
398.0747, found 398.07495. Anal. Calcd for C20H10F3N3O3: C, 60.46; H, 2.54; N, 10.58. 
Found: C, 61.01; H, 2.85; N, 9.84. 
 
9-Methyl-7-(trifluoromethyl)-9,10-dihydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-6,8-
dione (22b)  
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (136 
mg, 1.2 mmol) and 4-chloro-3-(2,2,2-trifluoroacetyl)-2H-chromen-
2-one 21b (277 mg, 1 mmol), 22b was isolated via crystallization 
from isopropanol as yellow crystals (191 mg, 57%); mp >375 oC. 
IR (ATR, cm-1): v~ = 2951 (w), 2719 (w), 2673 (w), 1745 (m), 1645 (m), 1590 (m), 1552 (m), 
1464 (m), 1408 (m), 1360 (m), 1285 (w), 1264 (m), 1224 (m), 1202 (m), 1174 (m), 1143 (s), 
1108 (m), 1059 (m), 979 (w), 814 (m), 765 (m), 648 (m). MS (EI, 70 eV): m/z (%) = 337 (3) 
[M++2], 336 (31) [M++1], 335 (100) [M+], 315 (33), 287 (66), 264 (10), 43 (8). HRMS (ESI): 
calcd C15H9F3N3O3 ([M+1]+) 336.05905, found 336.05916. Anal. Calcd for C15H8F3N3O3: C, 
53.74; H, 2.41; N, 12.53. Found: C, 54.28; H, 2.36; N, 12.25. 
 
Methyl 6,8-dioxo-9-phenyl-6,8,9,10-tetrahydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-
7-carboxylate (22c) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one 4a (210 
mg, 1.2 mmol) and methyl 2-(4-chloro-2-oxo-2H-chromen-3-
yl)-2-oxoacetate 21a (267 mg, 1 mmol), 22c was isolated via 
crystallization from isopropanol as green crystals (232 mg, 
60%); mp 295-297 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.97 (s, 3H, OCH3), 7.28-7.33 (m, 1H, Ar), 7.44-7.49 
(m, 2H, Ar), 7.49-7.55 (m, 2H, Ar), 7.68-7.74 (m, 1H, Ar), 7.86-7.89 (m, 2H, Ar), 8.44-8.46 
(m, 1H, Ar). 13C NMR (62.9 MHz, DMSO-d6): δ = 53.0 (CH3), 105.9 (C-7a), 117.2 (CHAr), 
118.0 (C-6a), 120.0, 124.9, 125.1, 125.9, 129.2, 133.8 (CHAr), 134.7, 136.4, 142.8, 150.7, 
152.6 (CAr), 154.8 (CO-6) 155.9 (CO-8), 158.7 (C-10a), 164.3 (CO2CH3). IR (ATR, cm-1): 
v~ = 2928 (w), 2651 (w), 1729 (m), 1688 (w), 1651 (w), 1592 (m), 1580 (m), 1469 (w), 1417 
(w), 1366 (m), 1278 (m), 1234 (m), 1142 (w), 1106 (w), 1019 (w), 936 (w), 814 (w), 757 (m), 
732 (m), 693 (m), 659 (m). MS (EI, 70 eV): m/z (%) = 389 (4) [M++2], 388 (25) [M++1], 387 
(96) [M+], 368 (72), 366 (59), 339 (99), 337 (100), 329 (32), 258 (19), 189 (21), 77 (36), 73 
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(23), 60 (28), 44 (65), 43 (34). HRMS (ESI): calcd C21H14N3O5 ([M+1]+) 388.0928, found 
388.09211. Anal. Calcd for C21H13N3O5: C, 65.12; H, 3.38; N, 10.85. Found: C, 65.78; H, 
3.63; N, 10.004. 
 
Methyl 9-methyl-6,8-dioxo-6,8,9,10-tetrahydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-
7-carboxylate (22d)  
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one 4b (136 
mg, 1.2 mmol) and methyl 2-(4-chloro-2-oxo-2H-chromen-3-yl)-
2-oxoacetate 21b (267 mg, 1 mmol), 22d was isolated via 
crystallization from isopropanol as yellow crystals (221 mg, 68%); 
mp mp 319-321 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.44 (s, 3H, NCH3), 3.94 (s, 3H, OCH3), 7.43-7.48 (m, 
2H, Ar), 7.67-7.73 (m, 1H, Ar), 8.39-8.42 (m, 1H, Ar), 13.06 (br s, 1H, NH). 13C NMR (62.9 
MHz, DMSO-d6): δ = 30.3 (NCH3), 52.9 (OCH3), 106.0 (C-7a), 117.1 (CHAr), 118.4 (C-6a), 
124.9, 125.0, 133.5 (CHAr), 142.2, 152.5, 154.1 (CAr), 154.5 (CO-6) 155.9 (CO-8), 158.9 (C-
10a), 164.4 (CO2CH3). IR (ATR, cm-1): v~ = 2957 (w), 2725 (w), 1717 (m), 1651 (m), 1604 
(m), 1434 (w), 1365 (w), 1278 (m), 1228 (m), 1187 (w), 1137 (w), 1024 (w), 952 (w), 758 
(m). MS (EI, 70 eV): m/z (%) = 327 (2) [M++2], 326 (15) [M++1], 325 (100) [M+], 294 (13), 
267 (40), 196 (10), 43 (2). HRMS (ESI): calcd C16H12N3O5 ([M+1]+) 326.07715, found 
326.07707. Anal. Calcd for C16H11N3O5: C, 59.08; H, 3.41; N, 12.92. Found: C, 59.34; H, 
3.62; N, 12.76. 
 
A.2.5. General procedure for synthesis of compounds 33 
Appropriate 5-amino-1H-pyrazol-3(2H)-one 4 (1 mmol) and 5-bromo-1,2,3-triazine (1.2 
mmol) were placed in a flask set with reflux and dissolved in isopropanole (40 mL). The 
mixture was heated under reflux for 2 h (controlled by TLC). Then the precipitate formed was 
filtered, washed with hot ethanol, filtered and dried under reduced pressure.  
 
5-Bromo-2-phenyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (33a) 
Starting from 5-amino-2-phenyl-1H-pyrazol-3(2H)-one (175 mg, 1 
mmol) 33a was isolated as brown solid (279 mg, 96%); mp 312-314 
oC. 
MS (EI, 70 eV): m/z (%) = 292 (16) [M++1, 81Br], 291 (100) [M+, 81Br], 290 (18) [M++1, 
79Br], 289 (99) [M+, 79Br], 262 (52), 260 (53), 77 (49). HRMS (EI): calcd C12H8BrN3O ([M]+, 
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81Br) 291.11478, found 291.11482. Anal. Calcd for C12H8BrN3O: C, 49.68; H, 2.78; N, 14.48. 
Found: C, 49.97; H, 2.91; N, 14.21. 
 
5-Bromo-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (33b) 
Starting from 5-amino-2-methyl-1H-pyrazol-3(2H)-one (113 mg, 1 
mmol) 36b was isolated as brown solid (227 mg, quant.); mp >375 oC. 
MS (EI, 70 eV): m/z (%) = 229 (22) [M++1, 81Br], 228 (100) [M+, 81Br], 
227 (21) [M++1, 79Br], 226 (100) [M+, 79Br], 202 (54), 200 (54), 43 (18). HRMS (EI): calcd 
C7H6BrN3O ([M]+, 81Br) 228.02447, found 228.02449. Anal. Calcd for C7H6BrN3O: C, 36.87; 
H, 2.65; N, 18.43. Found: C, 37.04; H, 2.71; N, 18.11. 
 
A.2.6. General procedure for synthesis of compounds 37-39 
Under argon atmosphere, compound 2, 9, 11, 22 or 33 (1 mmol) was placed in a flask and dry 
acetonitrile (20 mL) and BSA (0.27 mL, 1.1 mmol) were added. If starting material did not 
dissolve by refluxing, another portion of BSA (0.27 mL, 1.1 mmol) was added. After 
refluxing for 20 minutes the solution was led to cool down to room temperature. Afterwards, 
the solution of corresponding acetylated sugar (1 mmol) in dry acetonitrile and TMSOTf 
(0.05 mL, 0.25 mmol) were added and the reaction mixture was refluxed for 2 hours 
(controlled by TLC). Then the solution was evaporated under reduced pressure and subjected 
to column chromatography (silica gel; eluent: n-heptane/ethylacetate). 
 
6-Methyl-2-phenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (37a) 
Starting from 2a (293 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-β-
D-ribofuranose (318 mg, 1mmol), 37a was isolated as colorless 
foam (452 mg, 82%); mp 84-86 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.92 (s, 3H, OAc-5’), 2.07 (s, 
3H, OAc-3’), 2.11 (s, 3H, OAc-2’), 2.80 (s, 3H, CCH3), 3.80-
3.87 (m, 1H, Ha-5’), 4.07-4.14 (m, 2H, Hb-5’, H-4’), 5.52 (t, 
3JH,H = 5.9 Hz, 1H, H-3’), 5.63 (d, 3JH,H = 4.3 Hz, 1H, H-1’), 6.35 (dd, 3JH,H = 5.9 Hz, 3JH,H = 
4.3 Hz, 1H, H-2’), 7.32-7.37 (m, 1H, Ph), 7.37 (s, 1H, H-5), 7.46-7.51 (m, 2H, Ph), 7.56-7.56 
(m, 2H, Ph).13C NMR (62.9 MHz, CDCl3): δ = 20.6, 20.6, 20.7 (CH3CO), 25.4 (CH3), 62.8 
(CH2), 69.6, 72.2, 78.4, 92.0 (CHrib), 106.2 (C-3a), 116.2 (q, 3JC,F = 5.0 Hz, C-5), 121.4 (q, 
1JC,F = 274.7 Hz, CF3), 124.5, 127.4, 129.2 (CHAr), 135.0 (CAr), 136.5 (q, 2JC,F = 36.6 Hz, 
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CCF3), 158.5 (CAr), 160.3 (CO), 165.3 (C-7a), 169.3, 169.4, 170.3 (CH3CO). 19F NMR (282 
MHz, CDCl3): δ = -62.72 (s). IR (ATR, cm-1): v~ = 3065 (w), 2943 (w), 1745 (m), 1708 (m), 
1592 (m), 1487 (w), 1430 (w), 1363 (m), 1229 (s), 1145 (s), 1043 (m), 897 (w), 753 (w), 698 
(w). MS (EI, 70 eV): m/z (%) = 551 (0.13) [M+], 293 (17), 259 (88), 139 (100), 97 (45), 77 
(21), 43 (55). HRMS (ESI): calcd C25H25F3N3O8 ([M+1]+) 552.1588, found 552.1581. Anal. 
Calcd for C25H24F3N3O8: C, 54.45; H, 4.39; N, 7.62 Found: C, 54.53; H, 4.29; N, 7.60. 
 
2,6-Biphenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (37b) 
Starting from 2c (355 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 40b was isolated as 
yellow foam (491 mg, 80%); mp 138-139 oC. 
1H NMR (500 MHz, CDCl3): δ = 1.69 (s, 3H, OAc-5’), 2.08 
(s, 3H, OAc-3’), 2.12 (s, 3H, OAc-2’), 3.81 (dd, 2JH,H = 12.2 
Hz, 3JH,H = 5.2 Hz, 1H, Ha-5’), 4.01 (dd, 2JH,H = 12.2 Hz, 3JH,H = 3.4 Hz, 1H, Hb-5’), 4.06-4.11 
(m, 1H, H-4’), 5.41 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.65 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 6.58 (dd, 
3JH,H = 6.4 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 7.35 (t, 3JH,H = 7.4 Hz, 1H, Ph), 7.50 (t, 3JH,H = 7.4 
Hz, 2H, Ph), 7.55-7.63 (m, 5H, Ph), 7.97 (s, 1H, H-5), 8.24-8.25 (m, 2H, Ph). 13C NMR (125 
MHz, CDCl3): δ = 20.3, 20.5, 20.5 (CH3CO), 62.2 (CH2), 69.2, 72.0, 78.4, 92.4 (CHrib), 107.1 
(C-3a), 113.0 (q, 3JC,F = 5.0 Hz, C-5), 121.6 (q, 1JC,F = 274.0 Hz, CF3), 124.6, 127.5, 128.0, 
129.3, 129.5, 131.6 (CHAr), 135.0, 136.4 (CAr), 137.3 (q, 2JC,F = 36.7 Hz, CCF3), 158.4 (CAr), 
160.6 (C=O), 162.3 (C-7a), 169.4, 169.4, 170.3 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -
62.65 (s). IR (ATR, cm-1): v~ = 3009 (w), 2947 (w), 1738 (m), 1699 (m), 1593 (m), 1489 (w), 
1372 (s), 1234 (s), 1216(s), 1147 (s), 1104 (m), 1033 (s), 903 (m), 879 (m), 760 (m), 728 (m), 
693 (s), 585 (m). MS (EI, 70 eV): m/z (%) = 614 (0.38) [M++1], 613 (0.15) [M+], 355 (41), 
259 (99), 157 (23), 139 (100), 97 (75), 77 (43), 43 (97). HRMS (ESI): calcd C30H27F3N3O8 
([M+1]+) 614.1745, found 614.1747. Anal. Calcd for C30H26F3N3O8: C, 58.73; H, 4.27; N, 
6.85. Found: C, 58.64; H, 4.41; N, 6.71. 
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2-Methyl-6-phenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (37c) 
Starting from 2d (293 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37c was isolated as 
yellow foam (381 mg, 69%); mp 76-78 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.69 (s, 3H, OAc-5’), 2.01 
(s, 3H, OAc-3’), 2.05 (s, 3H, OAc-2’), 3.48 (s, 3H, NCH3), 
3.94 (dd, 2JH,H = 12.2 Hz, 3JH,H = 4.8 Hz, 1H, H-5’a), 4.10 (dd, 
2JH,H = 12.2 Hz, 2JH,H = 3.0 Hz, 1H, H-5’b), 4.13-4.19 (m, 1H, H-4’), 5.46 (t, 3JH,H = 6.4 Hz, 
1H, H-3’), 5.81 (d, 3JH,H = 4.5 Hz, 1H, H-1’), 6.32 (dd, 3JH,H = 6.4 Hz, 3JH,H = 4.5 Hz, 1H, H-
2’), 7.46-7.50 m, (3H, Ph), 7.80 (s, 1H, H-5), 8.07-8.11 (m, 2H, Ph). 13C NMR (62.9 MHz, 
CDCl3): δ = 20.3, 20.4, 20.4 (COCH3), 31.2 (CH3), 62.2 (CH2), 69.2, 71.6, 78.5, 90.7 (CHrib), 
106.4 (C-3a), 112.2 (q, 3JC,F = 5.0 Hz, C-5), 121.6 (q, 1JC,F = 274.7 Hz, CF3), 127.8, 129.3, 
131.3 (CHAr), 136.5 (CAr), 136.6 (q, 2JC,F = 36.4 Hz, CCF3), 159.0 (CAr), 159.4 (C=O), 161.6 
(C-7a), 169.4, 169.3, 170.3 (COCH3). 19F NMR (282 MHz, CDCl3): δ = -62.61 (s). IR (ATR, 
cm-1): v~ = 2945 (w), 1743 (m), 1693 (m), 1595 (m), 1372 (m), 1218 (s), 1146 (m), 1039 (m), 
776 (m), 692 (m). HRMS (ESI): calcd C25H25F3N3O8 ([M+1]+) 552.1588, found 552.1582. 
Anal. Calcd for C25H24F3N3O8: C, 54.45; H, 4.39; N, 7.62. Found: C, 54.58; H, 4.31; N, 7.54. 
 
2-Methyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4,6-bis(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (37d) 
Starting from 2f (285 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-β-
D-ribofuranose (318 mg, 1mmol), 37d was isolated as yellow 
solid (500 mg, 92%); mp 103-105 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.92 (s, 3H, OAc-5’), 1.97 (s, 
3H, OAc-3’), 2.07 (s, 3H, OAc-2’), 3.53 (s, 3H, NCH3), 4.06 (dd, 
2JH,H = 13.0 Hz, 3JH,H = 6.0 Hz, 1H, H-5’a), 4.18-4.21 (m, 1H, H-
5’b), 4.22-4.24 (m, 1H, H-4’), 5.40 (t, 3JH,H = 6.2 Hz, 1H, H-3’), 5.87 (d, 3JH,H = 4.7 Hz, 1H, 
H-1’), 6.51 (dd, 3JH,H = 6.2 Hz, 3JH,H = 4.7 Hz, 1H, H-2’), 7.61 (s, 1H, H-5). 13C NMR (62.9 
MHz, CDCl3): δ = 20.2, 20.4, 20.5 (COCH3), 31.6 (CH3), 62.3 (CH2), 69.2, 71.1, 78.8, 90.9 
(CHsug), 110.6 (C-3a), 111.5 (q, 3JC,F = 2.6 Hz, C-5), 120.3 (q, 1JC,F = 275.3 Hz, CF3), 120.8 
(q, 1JC,F = 275.3 Hz, CF3), 138.4 (q, 2JC,F = 36.6 Hz, CCF3), 151.2 (q, 2JC,F = 36.6 Hz, CCF3), 
157.4 (C=O), 157.7 (C-7a), 169.2, 169.3, 170.2 (COCH3). 19F NMR (282 MHz, CDCl3): δ = -
67.80 (s), -62.43 (s). IR (ATR, cm-1): v~ = 2952 (w), 2150 (w), 2837 (br), 1745 (s), 1703 (s), 
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1606 (w), 1375 (m), 1273 (s), 1209 (s), 1145 (s), 1042 (s), 883 (m), 686 (m), 602 (m). HRMS 
(ESI): calcd C20H19F6N3NaO8 ([M+1]+) 566.0969, found 566.098. Anal. Calcd for 
C20H19F6N3O8: C, 44.21; H, 3.52; N, 7.73. Found: C, 44.37; H, 3.49; N, 7.59. 
 
2-Phenyl-6-(thiophen-2-yl)-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37e) 
Starting from 2g (361 mg, 1 mmol) and 1,2,3,5-tetra-O-
acetyl-β-D-ribofuranose (318 mg, 1mmol), 37e was isolated 
as yellow foam (582 mg, 94%); mp 88-90 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.78 (s, 3H, OAc-5’), 2.09 
(s, 3H, OAc-3’), 2.12 (s, 3H, OAc-2’), 3.89 (dd, 2JH,H = 13.0 
Hz, 3JH,H = 6.4 Hz, 1H, Ha-5’), 4.05-4.12 (m, 2H, Hb-5’, H-
4’), 5.47 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.58 (d, 3JH,H = 4.5 Hz, 1H, H-1’), 6.58 (dd, 3JH,H = 6.4 
Hz, 3JH,H = 4.5 Hz, 1H, H-2’), 7.22 (dd, 2JH,H = 5.1 Hz, 3JH,H = 3.8 Hz, 1H, Ar), 7.32-7.38 (m, 
1H, Ar), 7.47-7.52 (m, 2H, Ar), 7.58-7.63 (m, 3H, Ar), 7.79 (s, 1H, H-5), 7.93 (dd, 3JH,H = 3.8 
Hz, 3JH,H = 1.1 Hz, 1H, Ar). 13C NMR (75.5 MHz, CDCl3): δ = 20.4, 20.6 (CH3CO), 62.6 
(CH2), 69.6, 71.9, 78.9, 92.5 (CHrib), 106.7 (C-3a), 111.9 (q, 3JC,F = 5.0 Hz, C-5), 121.5 (q, 
1JC,F = 274.6 Hz, CF3), 124.5, 127.5, 129.1, 129.2, 129.4, 131.8 (CHAr), 135.1 (CAr), 137.4 (q, 
2JC,F = 36.9 Hz, CCF3), 142.3, 157.1 (CAr), 158.4 (CO), 160.6 (C-7a), 168.9, 169.4, 169.5, 
170.5 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -62.87 (s). IR (ATR, cm-1): v~ = 3100 (w), 
2944 (w), 1745 (m), 1705 (m), 1589 (m), 1537 (w), 1488 (w), 1424 (m), 1374 (m), 1221 (s), 
1144 (s), 1060 (m), 1039 (m), 899 (w), 715 (m). MS (EI, 70 eV): m/z (%) = 620 (0.30) [M+], 
362 (16), 361 (53), 360 (14), 260 (25), 259 (100), 157 (27), 139 (100), 97 (90), 77 (44), 43 
(99). HRMS (ESI): calcd C28H25F3N3O8S ([M+1]+) 620.1309, found 620.13015. Anal. Calcd 
for C28H24F3N3O8S: C, 54.28; H, 3.90; N, 6.78. Found: C, 54.42; H, 4.12; N, 6.68. 
 
2-Phenyl-6-(furan-2-yl)-1-(2,3,5-Tri-O-acetyl-β-D-ribofuranozyl)-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37f) 
Starting from 2i (345 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37f was isolated as 
colorless foam (500 mg, 83%); mp 142-143 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.72 (s, 3H, OAc-5’), 2.10 (s, 
3H, OAc-3’), 2.12 (s, 3H, OAc-2’), 3.83-3.89 (m, 1H, H-5’a), 
4.06-4.13 (m, 2H, H-5’b, H-4’), 5.51 (d, 3JH,H = 3.3 Hz, 1H, H-
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3’), 5.58 (dd, 3JH,H = 7.4 Hz, 3JH,H = 6.3 Hz, 1H, H-1’), 6.59 (dd, 3JH,H = 6.3 Hz, 3JH,H = 3.3 Hz, 
1H, H-2’), 6.68 (dd, 3JH,H = 3.3 Hz, 3JH,H = 2.0 Hz, 1H, H-4’), 7.31-7.37 (m, 1H, Ar/Hetar), 
7.47-7.52 (m, 2H, Ar/Hetar), 7.52-7.55 (m, 2H, Ar/Hetar), 7.67-7.68 (m, 2H, Ar/Hetar), 7.91 
(s, 1H, H-5). 13C NMR (62.9 MHz, CDCl3): δ = 20.2, 20.4, 20.5 (CH3CO), 62.0 (CH2), 68.9, 
72.4, 78.1, 92.5 (CHrib), 106.6 (C-3a), 111.3 (q, 3JC,F = 5.5 Hz, C-5), 113.5, 114.4 (CHAr/Hetar), 
121.3 (q, 1JC,F = 274.0 Hz, CF3), 124.4, 127.3, 129.2, (CHAr/Hetar), 134.7 (CAr/Hetar), 137.3 (q, 
2JC,F = 36.6 Hz, CCF3), 145.9 (CHAr/Hetar), 151.6, 153.0 (CAr/Hetar), 158.1 (C=O), 160.3 (C-7a), 
169.4, 169.6, 170.3 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -62.85 (s). IR (ATR, cm-1): 
v~ = 3098 (w), 2889 (w), 1751 (m), 1700 (m), 1569 (m), 1527 (w), 1497 (w), 1431 (m), 1368 
(m), 1221 (s), 1140 (s), 1059 (m), 1034 (m), 901 (w), 715 (m). MS (EI, 70 eV): m/z (%) = 604 
(0.8) [M++1], 345 (98), 316 (44), 259 (100), 157 (80), 139 (100), 97 (98), 85 (29), 77 (95), 69 
(50), 43 (100). HRMS (ESI): calcd C28H25F3N3O9 ([M+1]+) 604.15374, found 604.15529. 
Anal. Calcd for C28H24F3N3O9: C, 55.72; H, 4.01; N, 6.96. Found: C, 55.49; H, 3.95; N, 6.57. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37g) 
Starting from 2r (421 mg, 1 mmol) and 1,2,3,5-tetra-O-
acetyl-β-D-ribofuranose (318 mg, 1mmol), 40g was 
isolated as yellow foam (571 mg, 84%); mp 150-152 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.72 (s, 3H, OAc-5’), 
2.08 (s, 3H, OAc-3’), 2.13 (s, 3H, OAc-2’), 3.79 (dd, 2JH,H 
= 12.1 Hz, 3JH,H = 5.2 Hz, 1H, Ha-5’), 4.02 (dd, 2JH,H = 12.1 Hz, 3JH,H = 3.4 Hz, 1H, Hb-5’), 
4.06-4.12 (m, 1H, H-4’), 5.39 (t, 3JH,H = 6.5 Hz, 1H, H-3’), 5.62 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 
6.60 (dd, 3JH,H = 6.5 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 6.64 (t, 2JF,H = 73.3 Hz, 1H, OCF2H), 7.30-
7.33 (m, 2H, Ar), 7.36-7.39 (m, 1H, Ar), 7.48-7.53 (m, 2H, Ar), 7.59-7.63 (m, 2H, Ar), 7.93 
(s, 1H, H-5), 8.26-8.31 (m, 2H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.4, 20.5, 20.6 
(CH3CO), 62.3 (CH2), 96.3, 72.0, 78.3, 92.5 (CHrib), 107.3 (C-3a), 112.7 (q, 3JC,F = 5.0 Hz, C-
5), 115.6 (t, 1JC,F = 260.9 Hz, OCF2H), 117.7 (q, 1JC,F = 254.8 Hz, CF3), 119.9, 124.7, 127.6, 
129.4, 129.9 (CHAr), 133.4, 134.9 (CAr), 137.6 (q, 2JC,F = 35.7 Hz, CCF3), 153.9 (t, 3JC,F = 2.8 
Hz, COCF2H), 158.3 (CAr), 160.6 (C=O), 161.0 (C-7a), 169.5, 170.3 (CH3CO). 19F NMR (282 
MHz, CDCl3): δ = -81.53 (s, 2F, OCF2H), -62.68 (s, 3F, CF3). IR (ATR, cm-1): v~ = 2952 (w), 
1742 (m), 1690 (m), 1593 (m), 1497 (w), 1371 (s), 1226 (s), 1113 (s), 1022 (s), 910 (m), 887 
(m), 846 (m), 751 (m), 698 (m). MS (EI, 70 eV): m/z (%) = 680 (0.09) [M+], 421 (13), 259 
(89), 157 (13), 139 (100), 97 (47), 77 (29), 43 (92). HRMS (ESI): calcd C31H27F5N3O9 
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([M+1]+) 680.1662, found 680.1662. Anal. Calcd for C31H26F5N3O9: C, 54.79; H, 3.86; N, 
6.18 Found: C, 54.42; H, 3.62; N, 5,92. 
 
6-(4-(Difluoromethoxy)phenyl)-2-methyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37h)  
Starting from 2s (359 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37h was isolated as yellow 
foam (364 mg, 59%); mp 116-118 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.78 (s, 3H, OAc-5’), 2.10 (s, 
3H, OAc-3’), 2.13 (s, 3H, OAc-2’), 3.55 (s, 3H, NCH3), 3.98 
(dd, 2JH,H = 12.3 Hz, 3JH,H = 4.9 Hz, 1H, H-5’a), 4.17 (dd, 2JH,H = 12.3 Hz, 3JH,H = 3.3 Hz, 1H, 
H-5’b), 4.21-4.26 (1H, br m, H-4’), 5.51 (t, 3JH,H = 6.3 Hz, 1H, H-3’), 5.84 (d, 3JH,H = 4.3 Hz, 
1H, H-1’), 6.44 (dd, 3JH,H = 6.3 Hz, 3JH,H = 4.3 Hz, 1H, H-2’), 6.63 (t, 2JH,F = 73.3 Hz, 1H, 
OCF2H), 7.28-7.31 (m, 2H, Ar), 7.83 (s, 1H, H-5), 8.18-8.23 (m, 2H, Ar). 13C NMR (62.9 
MHz, CDCl3): δ = 20.3, 20.5 (COCH3), 31.0 (CH3), 62.3 (CH2), 69.2, 71.7, 78.4, 90.7 (CHrib), 
106.6 (C-3a), 111.9 (q, 3JC,F = 5.1 Hz, C-5), 115.5 (t, 1JC,F = 261.1 Hz, OCF2H), 119.8 (CHAr), 
121.5 (q, 1JC,F = 275.0 Hz, CF3), 129.6 (CHAr), 133.5 (CAr), 136.9 (q, 2JC,F = 36.5 Hz, CCF3), 
153.6 (t, 3JC,F = 2.8 Hz, COCF2H), 159.0 (CAr), 159.1 (C=O), 160.3 (C-7a), 169.4, 169.4, 
170.2 (COCH3). 19F NMR (282 MHz, CDCl3): δ = -81.49 (s, 2F, OCF2H), -62.64 (s, 3F, CF3). 
IR (ATR, cm-1): v~ = 2949 (w), 1746 (m), 1700 (s), 1590 (m), 1498 (w), 1368 (s), 1201 (s), 
1105 (s), 1014 (s), 908 (m), 873 (m), 760 (m), 668 (m). MS (EI, 70 eV): m/z (%) = 618 (0.4) 
[M++1], 617 (0.2) [M+], 359 (95), 331 (23), 259 (100), 157 (71), 139 (100), 97 (99), 85 (23), 
69 (39), 43 (100). HRMS (ESI): calcd C26H25F5N3O9 ([M+1]+) 618.15055, found 618.15131. 
Anal. Calcd for C26H24F5N3O9: C, 50.57; H, 3.92; N, 6.81. Found: C, 50.34; H, 4.05; N, 7.08. 
 
Methyl 3-oxo-2-phenyl-6-p-tolyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-2,3-dihydro-
1H-pyrazolo[3,4-b]pyridine-4-carboxylate (37i) 
Starting from 2u (359 mg, 1 mmol) and 1,2,3,5-tetra-O-
acetyl-β-D-ribofuranose (318 mg, 1mmol), 37i was isolated as 
yellow foam (537 mg, 87%); mp 100-101 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.70 (s, 3H, OAc-5’), 2.08 
(s, 3H, OAc-3’), 2.11 (s, 3H, OAc-2’), 2.45 (s, 3H, Ar-CH3), 
3.77 (dd, 2JH,H = 12.2 Hz, 3JH,H = 5.1 Hz, 1H, H-5’a), 4.00 (dd, 
2JH,H = 12.2 Hz, 3JH,H = 3.4 Hz, 1H, H-5’b), 4.05 (s, 3H, OCH3), 4.06-4.08 (br m, 1H, H-4’), 
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5.42 (t, 3JH,H = 6.5 Hz, 1H, H-3’), 5.61 (d, 3JH,H = 3.9 Hz, 1H, H-1’), 6.58 (dd, 3JH,H = 6.5 Hz, 
3JH,H = 3.9 Hz, 1H, H-2’), 7.31-7.37 (m, 3H, Ar), 7.46-7.51 (m, 2H, Ar), 7.60-7.63 (m, 2H, 
Ar), 8.01 (s, 1H, H-5), 8.14-8.16 (m, 2H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.3, 20.4, 
20.5 (CH3CO), 21.4 (CH3), 53.2 (OCH3), 62.2 (CH2), 69.2, 72.0, 78.2, 92.5 (CHrib), 107.8 (C-
3a), 115.9, 124.5, 127.2, 127.8, 129.1, 130.0 (CHAr), 133.8, 135.3, 139.4, 141.7, 159.4 (CAr), 
160.4 (C=O), 161.5 (C-7a), 165.3 (CO2CH3), 169.3, 169.3, 170.3 (CH3CO). IR (ATR, cm-1): 
v~ = 2949 (w), 1743 (m), 1704 (m), 1583 (m), 1362 (m), 1213 (s), 1043 (m), 1018 (m), 896 
(w), 824 (w), 736 (m). MS (EI, 70 eV): m/z (%) = 617 (0.79) [M+], 359 (100), 301 (15), 299 
(22), 259 (83), 139 (83), 97 (28), 77 (12), 71 (12), 43 (87). HRMS (ESI): calcd C32H32N3O10 
([M+1]+) 618.2082, found 618.2077. Anal. Calcd for C32H31N3O10: C, 62.23; H, 5.06; N, 6.80 
Found: C, 62.16; H, 5.05; N, 6.45. 
 
2,6-Biphenyl-4-(perfluoroethyl)-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (37j) 
Starting from 2v (405 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37j was isolated as yellow 
foam (544 mg, 82%); mp 156-158 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.69 (s, 3H, OAc-5’), 2.08 (s, 
3H, OAc-3’), 2.12 (s, 3H, OAc-2’), 3.81 (dd, 2JH,H = 12.1 Hz, 
3JH,H = 5.0 Hz, 1H, Ha-5’), 4.02 (dd, 2JH,H = 12.1 Hz, 3JH,H = 3.3 Hz, 1H, Hb-5’), 4.05-4.11 (m, 
1H, H-4’), 5.40 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.65 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 6.60 (dd, 3JH,H 
= 6.4 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 7.33-7.39 (m, 1H, Ph), 7.47-7.53 (m, 2H, Ph), 7.57-7.65 
(m, 5H, Ph), 7.93 (s, 1H, H-5), 8.22-8.26 (m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 
20.3, 20.6, 20.6 (CH3CO), 62.3 (CH2), 69.3, 72.1, 78.4, 92.6 (CHrib), 108.3 (C-3a), 115.0 (t, 
3JC,F = 7.8 Hz, C-5), 124.8, 127.5, 128.0, 129.3, 129.5, 131.6 (CHAr), 135.0, 136.4 (CAr), 137.3 
(q, 2JC,F = 36.7 Hz, CCF2), 158.4 (CAr), 160.6 (C=O), 162.3 (C-7a), 169.4, 169.4, 170.3 
(CH3CO). 19F NMR (235 MHz, CDCl3): δ = -111.7 0 (s, 2F, CF2), -83.17 (s, 3F, CF3). IR 
(ATR, cm-1): v~ = 2924 (w), 2853 (w), 1746 (m), 1710 (m), 1588 (m), 1579 (w), 1495 (w), 
1444 (w), 1366 (m), 1327 (m), 1201 (s), 1150 (m), 1089 (w), 1049 (m), 1015 (m), 901 (w), 
865 (w), 774 (m), 733 (m), 691 (m). MS (EI, 70 eV): m/z (%) = 664 (0.72) [M++1], 663 (0.52) 
[M+], 406 (40), 405 (71), 404 (27), 376 (19), 260 (61), 259 (93), 157 (68), 140 (40), 139 
(100), 97 (83), 77 (64), 69 (21), 43 (87). HRMS (ESI): calcd C31H27F5N3O8 ([M+1]+) 
664.1713, found 664.1709. Anal. Calcd for C31H26F5N3O8: C, 56.11; H, 3.95; N, 6.33. Found: 
C, 56.26; H, 3.97; N, 6.51. 
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2,6-Biphenyl-4-(perfluoropropyl)-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (37k) 
Starting from 2w (455 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-β-
D-ribofuranose (318 mg, 1mmol), 37k was isolated as yellow 
foam (542 mg, 76%); mp 121-123 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.69 (s, 3H, OAc-5’), 2.08 (s, 
3H, OAc-3’), 2.12 (s, 3H, OAc-2’), 3.81-3.85 (m, 1H, Ha-5’), 
4.02 (dd, 2JH,H = 12.2 Hz, 3JH,H = 3.5 Hz, 1H, Hb-5’), 4.08-4.12 
(m, 1H, H-4’), 5.41 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.65 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 6.60 (dd, 
3JH,H = 6.4 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 7.33-7.39 (m, 1H, Ph), 7.47-7.53 (m, 2H, Ph), 7.57-
7.65 (m, 5H, Ph), 7.93 (s, 1H, H-5), 8.22-8.26 (m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 
20.3, 20.6, 20.6 (CH3CO), 62.3 (CH2), 69.3, 72.1, 78.4, 92.6 (CHrib), 108.3 (C-3a), 115.0 (t, 
3JC,F = 7.8 Hz, C-5), 124.8 (CHAr), 127.5, 128.0, 129.3, 129.5, 131.6 (CHAr), 135.0, 136.4 
(CAr), 137.3 (t, 2JC,F = 36.0 Hz, CCF2), 158.4 (CAr), 160.6 (C=O), 162.3 (C-7a), 169.4, 169.4, 
170.3 (CH3CO). 19F NMR (235 MHz, CDCl3): δ = -79.96 (t, 3JF,F = 9.7 Hz, 3F, CF3), -112.74 
(dq, 2JF,F = 275.0 Hz, 3JF,F = 9.7 Hz, 1F, CF3), -115.27 (dq, 2JF,F = 275.0 Hz, 3JF,F = 9.7 Hz, 1F, 
CF3), -125.54 (s, 2F, CF2). MS (EI, 70 eV): m/z (%) = 714 (0.2) [M++1], 713 (0.1) [M+], 455 
(23), 454 (19), 260 (11), 259 (100), 157 (14), 139 (96), 97 (39), 77 (23), 43 (52). HRMS 
(ESI): calcd C32H27F7N3O8 ([M+1]+) 714.16809, found 714.1689. Anal. Calcd for 
C32H26F7N3O8: C, 53.86; H, 3.67; N, 5.89. Found: C, 53.95; H, 3.69; N, 5.87. 
 
2-Phenyl-6-(pyridin-2-yl)-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37l) 
Starting from 2x (356 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-β-
D-ribofuranose (318 mg, 1mmol), 37l was isolated as yellow 
foam (504 mg, 82%); mp 66-67 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.93 (s, 3H, OAc-5’), 2.08 (s, 
3H, OAc-3’), 2.08 (s, 3H, OAc-2’), 3.81 (dd, 2JH,H = 13.0 Hz, 
3JH,H = 6.4 Hz, 1H, Ha-5’), 4.06-4.13 (m, 2H, Hb-5’, H-4’), 5.33 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 
5.70 (d, 3JH,H = 4.3 Hz, 1H, H-1’), 6.25 (dd, 3JH,H = 6.4 Hz, 3JH,H = 4.3 Hz, 1H, H-2’), 7.36-
7.45 (m, 2H, Ar), 7.48-7.54 (m, 2H, Ar), 7.60-7.63 (m, 2H, Ar), 7.85 (td, 3JH,H = 7.8 Hz, 4JH,H 
= 1.7 Hz, 1H, Ar), 8.33 (s, 1H, H-5), 8.57 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.79-8.82 (m, 1H, Ar). 
13C NMR (62.9 MHz, CDCl3): δ = 20.5, 20.7 (CH3CO), 62.7 (CH2), 69.5, 72.0, 78.8, 92.8 
(CHrib), 111.6 (C-3a), 117.1 (q, 3JC,F = 2.8 Hz, C-5), 121.2 (q, 1JC,F = 275.6 Hz, CF3), 125.1, 
125.2, 127.5, 128.0, 129.4 (CHAr), 134.9 (CAr), 136.6, 150.1 (CHAr), 150.4 (CAr), 151.0 (q, 
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2JC,F = 35.7 Hz, CCF3), 151.3 (CAr), 159.6 (C=O), 160.0 (C-7a), 169.3, 169.4, 170.5 (CH3CO). 
19F NMR (235 MHz, CDCl3): δ = -67.62 (s). IR (ATR, cm-1): v~ = 3063 (w), 2947 (w), 1747 
(m), 1698 (w), 1588 (w), 1567 (w), 1470 (w), 1372 (w), 1269 (m), 1224 (s), 1182 (m), 1142 
(m), 1094 (m), 1038 (m), 885 (w), 787 (w), 751 (w), 730 (w). MS (EI, 70 eV): m/z (%) = 614 
(0.14) [M+], 356 (16), 355 (14), 259 (55), 157 (10), 139 (77), 97 (41), 77 (17), 43 (100). 
HRMS (ESI): calcd C29H26F3N4O8 ([M+1]+) 615.1697, found 615.17. Anal. Calcd for 
C29H25F3N4O8: C, 56.68; H, 4.10; N, 9.12. Found: C, 56.87; H, 4.15; N, 9.09. 
 
4-(Perfluoroethyl)-2-phenyl-6-(pyridin-2-yl)-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37m) 
Starting from 2y (406 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37m was isolated as 
yellow foam (545 mg, 82%); mp 65-66 oC. 
1H NMR (500 MHz, CDCl3): δ = 1.94 (s, 3H, OAc-5’), 2.06 (s, 
3H, OAc-3’), 2.07 (s, 3H, OAc-2’), 3.80 (dd, 2JH,H = 13.1 Hz, 
3JH,H = 7.1 Hz, 1H, Ha-5’), 4.08-4.15 (m, 2H, Hb-5’, H-4’), 5.45 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 
5.68 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 6.28 (dd, 3JH,H = 6.4 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 7.36-
7.44 (m, 2H, Ar), 7.49-7.54 (m, 2H, Ar), 7.59-7.62 (m, 2H, Ar), 7.35 (td, 3JH,H = 7.8 Hz, 4JH,H 
= 1.9 Hz, 1H, Ar), 8.31 (s, 1H, H-5), 8.57 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.79-8.81 (m, 1H, Ar). 
13C NMR (62.9 MHz, CDCl3): δ = 20.5, 20.5, 20.7 (CH3CO), 62.8 (CH2), 69.5, 71.7, 78.7, 
92.8 (CHrib), 111.5 (C-3a), 118.5 (C-5), 125.2, 125.3, 127.6, 128.1, 129.4 (CHAr), 134.9 (CAr), 
136.6 (CHAr), 139.2 (t, 2JC,F = 24.0 Hz, CCF2), 150.1 (CHAr), 150.4, 151.1 (CAr), 159.4 (C=O), 
160.0 (C-7a), 169.3, 169.3, 170.5 (CH3CO). 19F NMR (235 MHz, CDCl3): δ = -82.51 (s, 3F, 
CF3), -116.48 (dd, 2JF,F = 667.57 Hz, 3JF,F = 273.39 Hz, 2F, CF2). IR (ATR, cm-1): v~ = 2929 
(w), 1746 (m), 1704 (m), 1588 (w), 1567 (w), 1495 (w), 1469 (w), 1372 (m), 1331 (w), 1205 
(s), 1095 (m), 1040 (m), 1013 (s), 874 (m), 787 (w), 743 (m), 693 (m). MS (EI, 70 eV): m/z 
(%) = 664 (0.1) [M+], 532 (27), 531 (29), 439 (57), 259 (58), 157 (14), 139 (100), 97 (42), 84 
(33), 77 (16), 57 (47), 43 (88). HRMS (ESI): calcd C30H26F5N4O8 ([M+1]+) 665.1665, found 
665.1668. Anal. Calcd for C30H25F5N4O8: C, 54.22; H, 3.79; N, 8.43. Found: C, 54.34; H, 
3.80; N, 8.39. 
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4-(Perfluoropropyl)-2-phenyl-6-(pyridin-2-yl)-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37n) 
Starting from 2z (456 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37n was isolated as 
yellow foam (607 mg, 85%); mp 84-85 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.95 (s, 3H, OAc-5’), 2.05 
(s, 3H, OAc-3’), 2.06 (s, 3H, OAc-2’), 3.77-3.83 (m, 1H, Ha-
5’), 4.05-4.12 (m, 2H, Hb-5’, H-4’), 5.31 (t, 3JH,H = 6.3 Hz, 
1H, H-3’), 5.73 (d, 3JH,H = 4.3 Hz, 1H, H-1’), 6.20 (dd, 3JH,H = 6.3 Hz, 3JH,H = 4.3 Hz, 1H, H-
2’), 7.36-7.46 (m, 2H, Ar), 7.49-7.54 (m, 2H, Ar), 7.48-7.54 (m, 2H, Ar), 7.59-7.63 (m, 2H, 
Ar), 7.87 (td, 3JH,H = 7.8 Hz, 4JH,H = 1.7 Hz, 1H, Ar), 8.32 (s, 1H, H-5), 8.58 (dt, 3JH,H = 7.8 
Hz, 4JH,H = 1.0 Hz, 1H, Ar), 8.79-8.82 (m, 1H, Ar). 13C NMR (75.5 MHz, CDCl3): δ = 20.4, 
20.5, 20.7 (CH3CO), 62.8 (CH2), 69.5, 71.6, 78.7, 92.8 (CHrib), 111.4 (C-3a), 118.8 (t, 3JC,F = 
5.0 Hz, C-5), 124.8, 125.4, 127.8, 128.2, 129.4 (CHAr), 134.9 (CAr), 137.1, 149.6 (CHAr), 
139.2 (t, 2JC,F = 24.0 Hz, CCF2), 150.5, 150.8 (CAr), 159.4 (C=O), 160.0 (C-7a), 169.3, 169.3, 
170.5 (CH3CO). 19F NMR (235 MHz, CDCl3): δ = -80.12 (t, 3JF,F = 9.6 Hz, 3F, CF3), -113.04 
(dq, 2JF,F = 274.6 Hz, 3JF,F = 9.6 Hz, 1F, CF3), -115.41 (dq, 2JF,F = 274.6 Hz, 3JF,F = 9.6 Hz, 1F, 
CF3), -125.84 (s, 2F, CF2). MS (EI, 70 eV): m/z (%) = 715 (0.2) [M+1], 714 (0.16) [M+], 456 
(25), 260 (12), 259 (93), 157 (20), 139 (100), 97 (54), 77 (13), 43 (77). HRMS (ESI): calcd 
C31H26F7N4O8 ([M+1]+) 715.16334, found 715.16375. Anal. Calcd for C31H25F7N4O8: C, 
52.11; H, 3.53; N, 7.84. Found: C, 51.895; H, 3.515; N, 7.866. 
 
 (E)-6-(3-(4-tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1-(2,3,5-tri-O-acetyl-
β-D-ribofuranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37o) 
Starting from 9a (614 mg, 1 mmol) and 1,2,3,5-
tetra-O-acetyl-β-D-ribofuranose (318 mg, 
1mmol), 37o was isolated as yellow foam (610 
mg, 70%); mp 95-96 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.36 (s, 9H, 
CH3), 1.70 (s, 3H, OAc-5’), 2.06 (s, 3H, OAc-3’), 2.14 (s, 3H, OAc-2’), 3.82 (dd, 2JH,H = 12.3 
Hz, 3JH,H = 5.1 Hz, 1H, Ha-5’), 4.02 (dd, 2JH,H = 12.3 Hz, 3JH,H = 3.3 Hz, 1H, Hb-5’), 4.07-4.13 
(m, 1H, H-4’), 5.41 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.66 (d, 3JH,H = 4.1 Hz, 1H, H-1’), 6.70 (dd, 
3JH,H = 6.4 Hz, 3JH,H = 4.1 Hz, 1H, H-2’), 7.28-7.30 (m, 1H, Ar), 7.34-7.43 (m, 3H, Ar, =CH), 
7.49-7.66 (m, 8H, Ph, =CH), 7.77 (d, 3JH,H = 7.8 Hz, 1H, Ar), 7.95 (s, 1H, H-5), 8.08 (d, 3JH,H 
= 7.8 Hz, 1H, Ar), 8.33 (s, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.3, 20.5, 20.6 
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(CH3CO), 31.4 (CH3), 34.7 (C(CH3)3), 62.3 (CH2), 69.5, 72.0, 78.5, 92.6 (CHrib), 108.7 (C-
3a), 115.3 (t, 3JC,F = 8.5 Hz, C-5), 124.9, 125.8, 126.5, 126.6, 126.9, 127.3, 127.6, 128.8, 
129.4, 129.8, 129.9 (CHAr, =CH), 134.5, 135.1, 136.8 (CAr), 137.0 (t, 2JC,F = 26.3 Hz, CCF2), 
139.1, 151.3, 158.0 (CAr), 160.5 (C=O), 161.7 (C-7a), 169.5, 169.5, 170.4 (CH3CO). 19F NMR 
(282 MHz, CDCl3): δ = -79.78 (t, 3JF,F = 10.2 Hz, 3F, CF3), -108.64 (q, 3JF,F = 10.2 Hz, 2F, 
CF2), -124.24 (t, 3JF,F = 21.5 Hz, 2F, CF2). IR (ATR, cm-1): v~ = 2961 (w), 1747 (m), 1711 (w), 
1583 (w), 1362 (m), 1222 (s), 1115 (m), 1043 (w), 1024 (w), 962 (w), 736 (m). MS (EI, 70 
eV): m/z (%) = 872 (0.1) [M++1], 871 (0.1) [M+], 598 (12), 597 (14), 259 (63), 157 (16), 139 
(100), 97 (31), 77 (8), 43 (39). HRMS (ESI): calcd C44H41F7N3O8 ([M+1]+) 872.27764, found 
872.2777. Anal. Calcd for C44H40F7N3O8: C, 60.62; H, 4.62; N, 4.82. Found: C, 60.42; H, 
4.59; N, 4.85. 
 
(E)-6-(4-(4-tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1-(2,3,5-tri-O-acetyl-β-
D-ribofuranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37p) 
Starting from 9b (614 mg, 1 mmol) and 1,2,3,5-
tetra-O-acetyl-β-D-ribofuranose (318 mg, 1mmol), 
37p was isolated as yellow foam (480 mg, 55%), 
mp 121-123 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.36 (s, 9H, 
CH3), 1.70 (s, 3H, OAc-5’), 2.11 (s, 3H, OAc-3’), 2.13 (s, 3H, OAc-2’), 3.82 (dd, 2JH,H = 12.2 
Hz, 3JH,H = 5.0 Hz, 1H, Ha-5’), 4.04 (dd, 2JH,H = 12.2 Hz, 3JH,H = 3.4 Hz, 1H, Hb-5’), 4.07-4.12 
(m, 1H, H-4’), 5.43 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.64 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 6.65 (dd, 
3JH,H = 6.4 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 7.14 (d, 3JH,H = 16.4 Hz, 1H, =CH), 7.28 (d, 3JH,H = 
16.4 Hz, 1H, =CH), 7.33-7.38 (m, 1H, Ar), 7.43 (d, 3JH,H = 8.3 Hz, 2H, Ar), 7.48-7.53 (m, 4H, 
Ph), 7.61-7.65 (m, 2H, Ar), 7.72 (d, 3JH,H = 8.3 Hz, 2H, Ar), 7.92 (s, 1H, H-5), 8.27 (d, 3JH,H = 
8.3 Hz, 2H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.4, 20.6, 20.6 (CH3CO), 31.4 (CH3), 
34.9 (C(CH3)3), 62.2 (CH2), 69.4, 72.1, 78.4, 92.7 (CHrib), 108.4 (C-3a), 114.9 (t, 3JC,F = 8.9 
Hz, C-5), 124.8, 125.9, 126.7, 126.9, 127.5, 127.6, 128.5, 129.4, 131.0 (CHAr, =CH), 134.2, 
134.9, 135.1 (CAr), 137.0 (t, 2JC,F = 26.3 Hz, CCF2), 141.1, 151.7, 158.1 (CAr), 160.6 (C=O), 
161.2 (C-7a), 169.5, 169.6, 170.4 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -79.79 (t, 3JF,F 
= 10.2 Hz, 3F, CF3), -108.72 (q, 3JF,F = 10.2 Hz, 2F, CF2), -124.29 (t, 3JF,F = 20.4 Hz, 2F, CF2). 
MS (EI, 70 eV): m/z (%) = 871 (0.2) [M+], 614 (45), 613 (94), 598 (28), 597 (47), 260 (22), 
259 (61), 157 (58), 139 (100), 97 (64), 77 (49), 43 (99). HRMS (ESI): calcd C44H41F7N3O8 
([M+1]+) 872.27764, found 872.2777. Anal. Calcd for C44H40F7N3O8: C, 60.62; H, 4.62; N, 
4.82. Found: C, 60.87; H, 4.64; N, 4.88. 
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(E)-6-(4-(4-tert-butylstyryl)phenyl)-4-(trifluoromethyl)-2-phenyl-1-(2,3,5-tri-O-acetyl-β-
D-ribofuranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (37q) 
Starting from 9c (513 mg, 1 mmol) and 1,2,3,5-
tetra-O-acetyl-β-D-ribofuranose (318 mg, 
1mmol), 37q was isolated as yellow foam (633 
mg, 82%); mp 156-158 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.35 (s, 9H, 
CH3), 1.71 (s, 3H, OAc-5’), 2.10 (s, 3H, OAc-3’), 2.13 (s, 3H, OAc-2’), 3.82 (dd, 2JH,H = 12.1 
Hz, 3JH,H = 5.0 Hz, 1H, Ha-5’), 4.02 (dd, 2JH,H = 12.1 Hz, 3JH,H = 3.3 Hz, 1H, Hb-5’), 4.08-4.12 
(m, 1H, H-4’), 5.43 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.63 (d, 3JH,H = 3.9 Hz, 1H, H-1’), 6.63 (dd, 
3JH,H = 6.4 Hz, 3JH,H = 3.9 Hz, 1H, H-2’), 7.32-7.44 (m, 3H, Ar, =CH), 7.47-7.54 (m, 4H, Ar, 
=CH), 7.61-7.65 (m, 2H, Ar), 7.71 (d, 3JH,H = 8.5 Hz, 2H, Ar), 7.98 (s, 1H, H-5), 8.04 (s, 1H, 
Ar), 8.26 (d, 3JH,H = 8.5 Hz, 2H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.4, 20.6, 20.6 
(CH3CO), 31.4 (CH3), 34.9 (C(CH3)3), 62.2 (CH2), 69.4, 72.1, 78.4, 92.7 (CHrib), 108.6 (C-
3a), 115.0 (q, 3JC,F = 5.0 Hz, C-5), 124.8, 125.9, 126.7, 126.9, 127.5, 127.6, 128.5, 129.4, 
131.0 (CHAr, =CH), 134.2, 134.9, 135.1 (CAr), 137.0 (q, 2JC,F = 36.0 Hz, CCF3), 141.1, 151.7, 
158.1 (CAr), 160.6 (C=O), 161.2 (C-7a), 169.5, 169.6, 170.4 (CH3CO). 19F NMR (282 MHz, 
CDCl3): δ = -62.87 (s). MS (EI, 70 eV): m/z (%) = 771 (0.1) [M+], 513 (20), 498 (13), 260 
(19), 259 (100), 97 (48), 77 (11), 44 (12), 43 (70). HRMS (ESI): calcd C42H41F3N3O8 
([M+1]+) 772.28403, found 772.28443.Anal. Calcd for C42H40F3N3O8: C, 65.36; H, 5.22; N, 
5.44. Found: C, 65.522; H, 5.198; N, 5.419. 
  
(E)-Ethyl 3-(2-(3-oxo-2-phenyl-4-(trifluoromethyl)-1-(2,3,5-tri-O-acetyl-β-D-
ribofuranozyl)-2,3-dihydro-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl)acrylate (37r) 
Starting from 11a (453 mg, 1 mmol) and 1,2,3,5-
tetra-O-acetyl-β-D-ribofuranose (318 mg, 1mmol), 
37r was isolated as yellow foam (480 mg, 79%); 
mp 134-136 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.36 (t, 3JH,H = 7.1 
Hz, 3H, CH3), 1.72 (s, 3H, OAc-5’), 2.08 (s, 3H, OAc-3’), 2.12 (s, 3H, OAc-2’), 3.79 (dd, 
2JH,H = 12.1 Hz, 3JH,H = 5.3 Hz, 1H, Ha-5’), 3.79 (dd, 2JH,H = 12.1 Hz, 3JH,H = 3.3 Hz, 1H, Hb-
5’), 4.06-4.13 (m, 1H, H-4’), 4.30 (q, 3JH,H = 7.1 Hz, 2H, OCH2), 5.35 (t, 3JH,H = 6.3 Hz, 1H, 
H-3’), 5.67 (d, 3JH,H = 4.0 Hz, 1H, H-1’), 6.56 (dd, 3JH,H = 6.3 Hz, 3JH,H = 4.0 Hz, 1H, H-2’), 
6.59 (d, 3JH,H = 16.1 Hz, 1H, =CH), 7.36 (tt, 3JH,H = 7.4 Hz, 4JH,H = 1.6 Hz, 1H, Ar), 7.48-7.54 
(m, 2H, Ar), 7.59-7.65 (m, 3H, Ar), 7.75 (d, 3JH,H = 7.8 Hz, 1H, Ar), 7.86 (d, 3JH,H = 16.1 Hz, 
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1H, =CH), 7.98 (s, 1H, H-5), 8.26 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.33 (br s, 1H, Ar). 13C NMR 
(62.9 MHz, CDCl3): δ = 14.2 (CH3), 20.4, 20.5, 20.5 (CH3CO), 60.2, 62.2 (CH2), 69.2, 72.0, 
78.4, 92.4 (CHrib), 103.4 (C-3a), 111.1 (q, 3JC,F = 5.0 Hz, C-5), 119.3 (=CH), 120.1 (CHAr), 
122.0 (q, 1JC,F = 274.4 Hz, CF3), 125.8, 127.5, 129.1, 129.3, 129.7, 130.6 (CHAr), 135.0 (CAr), 
135.8 (q, 2JC,F = 35.7 Hz, CCF3), 136.6, 137.4 (CAr), 143.7 (=CH), 155.4 (CAr), 157.5 (NC=O), 
160.6 (C-7a), 166.2 (CO2Et), 169.4, 169.4, 170.3 (CH3CO). 19F NMR (235 MHz, CDCl3): δ = 
-61.76 (s). MS (EI, 70 eV): m/z (%) = 711 (0.12) [M+], 453 (28), 260 (25), 259 (100), 97 (34), 
77 (29), 44 (12), 43 (66). HRMS (ESI): calcd C35H33F3N3O10 ([M+1]+) 712.2139, found 
712.2142. Anal. Calcd for C35H32F3N3O10: C, 59.07; H, 4.53; N, 5.90. Found: C, 59.255; H, 
4.551; N, 5.884. 
 
5-Bromo-2-phenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (37s) 
Starting from 33a (290 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-β-D-
ribofuranose (318 mg, 1mmol), 37s was isolated as pink foam (241 
mg, 44%); mp 150-152 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.95 (s, 3H, OAc-5’), 2.05 (s, 3H, 
OAc-3’), 2.09 (s, 3H, OAc-2’), 3.83-3.90 (m, 1H, Ha-5’), 4.02-4.10 
(m, 2H, Hb-5’, H-4’), 5.37 (t, 3JH,H = 5.9 Hz, 1H, H-3’), 5.60 (d, 3JH,H = 4.7 Hz, 1H, H-1’), 
6.28 (dd, 3JH,H = 5.9 Hz, 3JH,H = 4.7 Hz, 1H, H-2’), 7.33-7.39 (m, 1H, Ar), 7.47-7.59 (m, 2H, 
Ar), 8.34 (d, 4JH,H = 2.3 Hz, 1H, H-4), 8.72 (d, 4JH,H = 2.3 Hz, 1H, H-6). Anal. Calcd for 
C23H22BrN3O8: C, 50.38; H, 4.04; N, 7.66. Found: C, 50.61; H, 4.12; N, 7.45. 
 
9-Phenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-7-(trifluoromethyl)-9,10-
dihydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-6,8-dione (37t) 
Starting from 22a (397 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37t was isolated as yellow 
foam (497 mg, 76%); mp 99-101 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.70 (s, 3H, OAc-5’), 2.12 (s, 
6H, OAc-2’, OAc-3’), 3.88 (dd, 2JH,H = 12.2 Hz, 3JH,H = 4.3 Hz, 
1H, Ha-5’), 4.07 (dd, 2JH,H = 12.2 Hz, 3JH,H = 4.3 Hz, 1H, Hb-5’), 4.11-4.17 (m, 1H, H-4’), 
5.43 (dd, 3JH,H = 7.18 Hz, 3JH,H = 6.4 Hz, 1H, H-3’), 5.67 (d, 3JH,H = 3.8 Hz, 1H, H-1’), 6.57 
(dd, 3JH,H = 6.4 Hz, 3JH,H = 3.8 Hz, 1H, H-2’), 7.39-7.44 (m, 2H, Ph), 7.47-7.61 (m, 5H, Ph), 
7.68-7.74 (m, 1H, Ph), 8.75-8.79 (m, 1H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 20.3, 20.5, 
20.6 (CH3CO), 62.2 (CH2), 69.2, 71.7, 78.3, 92.7 (CHrib), 95.7 (C-7a), 117.3 (CHAr), 117.7 
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(C-6a), 121.1 (q, 1JC,F = 275.9 Hz, CF3), 125.2, 125.7, 126.7, 128.4, 129.6 (CHAr), 134.7 (CAr), 
134.9 (CHAr), 153.3, 155.2, 156.5 (CAr), 156.9 (CO-6) 157.0 (CO-8), 161.2 (C-10a), 169.5, 
169.6, 170.3 (COCH3). 19F NMR (282 MHz, CDCl3): δ = -56.84 (s). IR (ATR, cm-1): v~ = 
2944 (w), 1744 (m), 1713 (m), 1583 (m), 1494 (w), 1456 (w), 1366 (m), 1226 (s), 1156 (s), 
1058 (m), 1041 (m), 1023 (m), 891 (m), 761 (m), 693 (m). MS (EI, 70 eV): m/z (%) = 656 
(0.2) [M++1], 655 (0.1) [M+], 397 (31), 396 (17), 260 (23), 259 (100), 157 (30), 140 (16), 139 
(88), 97 (82), 77 (58), 69 (13), 43 (72). HRMS (ESI): calcd C31H25F3N3O10 ([M+1]+) 
656.14866, found 656.14851. Anal. Calcd for C31H24F3N3O10: C, 56.80; H, 3.69; N, 6.41. 
Found: C, 57.15; H, 3.82; N, 6.27. 
 
9-Methyl-7-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-(trifluoromethyl)-9,10-
dihydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-6,8-dione (37u) 
Starting from 22b (335 mg, 1 mmol) and 1,2,3,5-tetra-O-
acetyl-β-D-ribofuranose (318 mg, 1mmol), 37u was isolated 
as yellow foam (404 mg, 68%); mp 125-126 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.81 (s, 3H, OAc-5’), 2.09 
(s, 3H, OAc-2’), 2.17 (s, 3H, OAc-3’), 3.58 (s, 3H, NCH3), 
4.10 (dd, 2JH,H = 12.3 Hz, 3JH,H = 4.7 Hz, 1H, Ha-5’), 4.22-
4.31 (m, 2H, Hb-5’, H-4’), 5.55 (t, 3JH,H = 6.5 Hz, 1H, H-3’), 5.96 (d, 3JH,H = 4.3 Hz, 1H, H-
1’), 6.38 (dd, 3JH,H = 6.5 Hz, 3JH,H = 4.3 Hz, 1H, H-2’), 7.38 (dd, 3JH,H = 8.3 Hz, 4JH,H = 0.8 
Hz, 1H, Ar), 7.44-7.49 (m, 1H, Ar), 7.65-7.71 (m, 1H, Ar), 8.68 (dd, 3JH,H = 8.1 Hz, 4JH,H = 
1.5 Hz, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.3, 20.5, 20.6 (CH3CO), 33.0 (NCH3), 
62.2 (CH2), 69.2, 71.7, 78.3, 92.7 (CHrib), 95.7 (C-7a), 117.6 (CHAr), 118.3 (C-6a), 121.1 (q, 
1JC,F = 276.0 Hz, CF3), 125.6, 126.4, 134.3 (CHAr), 143.9, 153.2, 155.9, 158.9 (CAr), 156.9 
(CO-6) 157.0 (CO-8), 161.2 (C-10a), 169.3, 170.2, 170.5 (COCH3). 19F NMR (282 MHz, 
CDCl3): δ = -56.86 (s). MS (EI, 70 eV): m/z (%) = 593 (0.1) [M+], 336 (28), 335 (21), 259 
(100), 157 (61), 140 (22), 139 (94), 97 (79), 77 (36) 43 (62). HRMS (ESI): calcd 
C26H23F3N3O10 ([M+1]+) 594.12859, found 594.12854. Anal. Calcd for C26H22F3N3O10: C, 
52.62; H, 3.74; N, 7.08. Found: C, 53.01; H, 3.80; N, 6.92. 
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Methyl 6,8-dioxo-9-phenyl-1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-6,8,9,10-tetrahydro 
chromeno[3,4-e]pyrazolo[3,4-b]pyridine-7-carboxylate (37v) 
Starting from 22c (387 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (318 mg, 1mmol), 37v was isolated as yellow 
foam (510 mg, 79%); mp 144-146 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.68 (s, 3H, OAc-5’), 2.12 (s, 
3H, OAc-2’), 2.14 (s, 3H, OAc-3’), 3.86 (dd, 2JH,H = 12.0 Hz, 
3JH,H = 5.2 Hz, 1H, Ha-5’), 4.06 (dd, 2JH,H = 12.0 Hz, 3JH,H = 5.2 Hz, 1H, Hb-5’), 4.10-4.16 (m, 
1H, H-4’), 4.13 (s, 3H, OCH3), 5.54 (t, 3JH,H = 6.7 Hz, 1H, H-3’), 5.61 (d, 3JH,H = 3.0 Hz, 1H, 
H-1’), 6.65 (br s, 1H, H-2’), 7.36-7.44 (m, 2H, Ph), 7.48-7.60 (m, 5H, Ph), 7.66-7.73 (m, 1H, 
Ph), 8.79-8.82 (m, 1H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 20.3, 20.5, 20.6 (CH3CO), 
53.9 (OCH3), 62.2 (CH2), 69.2, 71.7, 78.3, 92.7 (CHrib), 95.7 (C-7a), 117.3 (CHAr), 117.7 (C-
6a), 125.2, 125.7, 126.7, 128.4, 129.6 (CHAr), 134.7 (CAr), 134.9 (CHAr), 153.3, 155.2, 156.5 
(CAr), 159.1 (CO-6), 159.3 (CO-8), 164.3 (C-10a), 169.5 (CO2CH3), 170.0, 170.2, 170.3 
(COCH3). MS (EI, 70 eV): m/z (%) = 646 (0.3) [M++1], 645 (0.1) [M+], 387 (89), 356 (13), 
329 (32), 300 (14), 260 (15), 259 (88), 157 (22), 156 (18), 140 (13), 139 (87), 115 (21), 97 
(68), 85 (35), 77 (43), 69 (20), 43 (100). HRMS (ESI): calcd C32H28N3O12 ([M+1]+) 
646.16675, found 646.16614. Anal. Calcd for C32H27N3O12: C, 59.54; H, 4.22; N, 6.51. 
Found: C, 59.69; H, 4.41; N, 6.20. 
 
Methyl 1-(2,3,5-tri-O-acetyl-β-D-ribofuranozyl)-9-methyl-6,8-dioxo-6,8,9,10-
tetrahydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-7-carboxylate (37w) 
Starting from 22d (325 mg, 1 mmol) and 1,2,3,5-tetra-O-
acetyl-β-D-ribofuranose (318 mg, 1mmol), 37w was isolated 
as yellow foam (473 mg, 81%); mp 100-101 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.77 (s, 3H, OAc-5’), 2.12 
(s, 3H, OAc-2’), 2.17 (s, 3H, OAc-3’), 3.55 (s, 3H, NCH3), 
4.04 (dd, 2JH,H = 12.3 Hz, 3JH,H = 4.9 Hz, 1H, Ha-5’), 4.15 (s, 
3H, CO2CH3), 4.06 (dd, 2JH,H = 12.3 Hz, 3JH,H = 3.2 Hz, 1H, Hb-5’), 4.27-4.32 (m, 1H, H-4’), 
5.65 (t, 3JH,H = 6.4 Hz, 1H, H-3’), 5.86 (d, 3JH,H = 4.3 Hz, 1H, H-1’), 6.52 (dd, 2JH,H = 6.4 Hz, 
3JH,H = 4.3 Hz, 1H, H-2’), 7.38-7.41 (m, 1H, Ar), 7.45-7.50 (m, 1H, Ar), 7.64-7.69 (m, 1H, 
Ar), 8.71-8.75 (m, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): 20.5, 20.6 (CH3CO), 31.0 (NCH3), 
53.9 (OCH3), 62.4 (CH2), 69.3, 71.8, 78.7, 90.4 (CHRib), 109.5 (C-7a), 117.6 (CHAr), 118.3 
(C-6a), 125.6, 126.4, 134.3 (CHAr), 143.9, 153.2, 155.9, 158.9 (CAr), 159.1 (CO-6), 159.3 
(CO-8), 164.3 (C-10a), 169.5 (CO2CH3), 169.6, 170.3 (CH3CO). IR (ATR, cm-1): v~ = 2953 
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(w), 1738 (m), 1732 (m), 1694 (w), 1607 (w), 1592 (w), 1435 (w), 1396 (m), 1269 (m), 1220 
(s), 1156 (w), 1136 (w), 1092 (w), 1042 (m), 1031 (m), 897 (w), 762 (m). MS (EI, 70 eV): 
m/z (%) = 583 (0.1) [M+], 325 (100), 310 (57), 265 (24), 259 (86), 157 (41), 101 (74), 96 (45), 
85 (21), 73 (21), 57 (41), 43 (100). HRMS (ESI): calcd C27H26N3O12 ([M+1]+) 584.1511, 
found 584.15099. Anal. Calcd for C27H25N3O12: C, 55.58; H, 4.32; N, 7.20. Found: C, 55.934; 
H, 4.531; N, 6.992. 
 
6-Methyl-2-phenyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38a) 
Starting from 2a (293 mg, 1 mmol) and 1,2,3,4,6-penta-O-acetyl-
β-D-glucose (390 mg, 1mmol), 38a was isolated as yellow foam 
(474 mg, 76%); mp 96-97 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.77 (s, 3H, OAc-6’), 1.97 (s, 
6H, OAc-4’, OAc-3’), 1.98 (s, 3H, OAc-2’), 2.79 (s, 3H, CH3), 
3.99-4.09 (m, 3H, Ha-6’, Hb-6’, H-5’), 4.93 (t, 3JH,H = 9.6 Hz, 1H, 
H-4’), 5.13 (t, 3JH,H = 9.6 Hz, 1H, H-3’), 5.44-5.50 (m, 1H, H-2’), 5.94 (br s, 1H, H-1’), 7.32-
7.37 (m, 1H, Ph), 7.33 (s, 1H, H-5), 7.44-7.49 (m, 2H, Ph), 7.52-7.57 (m, 2H, Ph). 13C NMR 
(62.9 MHz, CDCl3): δ = 20.1, 20.5, 20.5, 20.6 (COCH3), 25.4 (CH3), 61.5 (CH2), 67.6, 69.2, 
73.8, 74.3, 86.8 (CHgl), 104.5 (C- 3a), 116.1 (q, 3JC,F = 5.0 Hz, C-5), 121.4 (q, 1JC,F = 274.6 
Hz, CF3), 125.2, 127.6, 128.9 (CHAr), 135.1 (CAr), 136.3 (q, 2JC,F = 36.6 Hz, CCF3), 158.3 (C-
6), 160.3 (C=O), 165.6 (C-7a), 168.3, 169.3, 170.3, 170.3 (COCH3). 19F NMR (282 MHz, 
CDCl3): δ = -62.76 (s). IR (ATR, cm-1): v~ = 3068 (w), 2943 (w), 1750 (m), 1710 (m), 1593 
(m), 1489 (w), 1363 (m), 1208 (s), 1144 (m), 1032 (s), 896 (m), 750 (m), 702 (m), 598 (m). 
MS (EI, 70 eV): m/z (%) = 624 (0.28) [M+], 331 (50), 293 (31), 169 (100), 127 (25), 109 (83), 
77 (14), 43 (84). HRMS (ESI): calcd C28H29F3N3O10 ([M+1]+) 624.18, found 624.1805. Anal. 
Calcd for C28H28F3N3O10: C, 53.93; H, 4.53; N, 6.74. Found: C, 54.06; H, 4.47; N, 6.69. 
 
2,6-Biphenyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (38b) 
Starting from 2c (355 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38b was isolated as 
yellow foam (548 mg, 80%); mp 122-123 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.84 (s, 3H, OAc-6’), 1.91 (s, 
3H, OAc-4’), 1.94 (s, 3H, OAc-3’), 1.96 (s, 3H, OAc-2’), 3.61 
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(br s, 1H, H-5’), 3.91-4.08 (m, 3H, Ha-6’, Hb-6’, H-4’), 4.86-4.92 (m, 1H, H-3’), 5.04-5.22 
(m, 2H, H-2’, H-1’), 7.31 (t, 3JH,H = 7.5 Hz, 1H, Ph), 7.43 (t, 3JH,H = 7.5 Hz, 2H, Ph), 7.51-
7.53 (m, 5H, Ph), 7.87 (s, 1H, H-5), 8.14-8.17 (m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 
20.2, 20.5, 20.5, 20.5 (COCH3), 61.5 (CH2), 67.7, 69.4, 73.9, 74.3, 86.8 (CHgl), 106.0 (C-3a), 
113.1 (C-5), 121.5 (q, 1JC,F = 274.6 Hz, CF3), 125.0, 127.6, 127.9, 129.1, 129.3, 131.4 (CHAr), 
136.7 (CAr), 137.1 (q, 2JC,F = 36.3 Hz, CCF3), 158.2 (C-6), 160.6 (C=O), 162.5 (C-7a), 168.4, 
169.2, 170.2, 170.3 (COCH3). 19F NMR (282 MHz, CDCl3): δ = -62.69 (s). IR (ATR, cm-1): 
v~ = 2969 (w), 2950 (w), 1740 (s), 1592 (w), 1368 (m), 1217 (s), 1154 (m), 1065 (s), 1032 (s), 
902 (m). MS (EI, 70 eV): m/z (%) = 686 (0.4) [M+], 355 (46), 331 (79), 271 (11), 169 (100), 
127 (40), 109 (88), 77 (28), 43 (92). HRMS (ESI): calcd C33H31F3N3O10 ([M+1]+) 686.1956, 
found 686.1953. Anal. Calcd for C33H30F3N3O10: C, 57.81; H, 4.41; N, 6.13. Found: C, 57.87; 
H, 4.37; N, 6.18. 
 
 
2-Methyl-6-phenyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38c) 
Starting from 2d (293 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38c was isolated as 
colorless foam (486 mg, 78%); mp 99-101 oC. 
1H NMR (CDCl3, 250 MHz): δ = 1.44 (s, 3H, OAc-6’), 1.92 
(s, 3H, OAc-4’), 1.99 (s, 3H, OAc-3’), 2.00 (s, 3H, OAc-2’), 
3.52 (s, 3H, NCH3), 3.87-3.93 (m, 1H, H-5’), 4.09-4.26 (m, 
2H, Ha-6’, Hb-6’), 5.15 (t, 3JH,H = 9.6 Hz, 1H, H-4’), 5.27 (t, 3JH,H = 9.6 Hz, 1H, H-3’), 5.48 
(br s, 1H, H-2’), 5.93 (d, 3JH,H = 9.3 Hz, 1H, H-1’), 7.48-7.55 (m, 3H, Ph), 7.75 (s, 1H, H-5), 
8.03-8.08 (m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 19.6, 20.5, 20.5, 20.6 (CH3CO), 
33.0 (NCH3), 61.6 (CH2), 67.7, 69.0, 73.4, 74.8, 85.9 (CHgl), 104.7 (C-8), 112.1 (q, 3JC,F = 4.9 
Hz, C-5), 121.5 (q, 1JC,F = 274.7 Hz, CF3), 127.8, 129.2, 131.3 (CHAr), 136.7 (q, 2JC,F = 36.5 
Hz, CCF3), 136.7 (CAr), 159.4 (C-6), 159.5 (CO), 162.0 (C-9), 168.2, 169.3, 170.1, 170.5 
(CH3CO). 19F NMR (282 MHz, CDCl3): δ = -62.69 (s). IR (ATR, cm-1): v~ = 2960 (w), 1748 
(m), 1695 (m), 1595 (m), 1443 (w), 1410 (w), 1372 (m), 1213 (s), 1149 (m), 1031 (s), 776 
(m), 692 (m). MS (EI, 70 eV): m/z (%) = 624 (0.24) [M+], 331 (36), 293 (29), 169 (100), 127 
(20), 109 (71), 43 (79). HRMS (ESI): calcd C28H29F3N3O10 ([M+1]+) 624.17996, found 
624.18007. Anal. Calcd for C28H28F3N3O10: C, 53.93; H, 4.53; N, 6.74. Found: C, 54.16; H, 
4.72; N, 6.75. 
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2-Phenyl-6-(thiophen-2-yl)-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38e) 
Starting from 2g (361 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38e was isolated as 
colorless foam (595 mg, 86%); mp 151-153 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.84 (s, 3H, OAc-6’), 1.91 
(s, 3H, OAc-4’), 1.94 (s, 3H, OAc-3’), 1.96 (s, 3H, OAc-2’), 
3.61 (br s, 1H, H-5’), 3.91-4.08 (m, 3H, Ha-6’, Hb-6’, H-4’), 
4.86-4.92 (m, 1H, H-3’), 5.04-5.22 (m, 2H, H-2’, H-1’), 7.23 (dd, 3JH,H = 4.9 Hz, 3JH,H = 3.8 
Hz, 1H, Hetar), 7.34-7.39 (m, 1H, Ar), 7.47-7.52 (m, 2H, Ar), 7.55-7.58 (m, 2H, Ar), 7.65 
(dd, 2JH,H = 4.9 Hz, 4JH,H = 1.0 Hz, 1H, Hetar), 7.77 (s, 1H, H-5), 7.91 (dd, 3JH,H = 3.8 Hz, 
4JH,H = 1.0 Hz, 1H, Hetar). 13C NMR (62.9 MHz, CDCl3): δ = 16.1 (CH3), 20.2, 20.7, 20.8 
(CH3CO), 32.1 (NCH3), 66.7, 69.0, 71.8, 72.8, 80.3 (CHgl), 105.6 (C-8), 111.9 (q, 3JC,F = 5.0 
Hz, C-5), 121.6 (q, 1JC,F = 274.6 Hz, CF3), 127.6, 129.1, 131.1 (CHAr), 136.6 (q, 2JC,F = 36.3 
Hz, CCF3), 136.9 (CAr), 159.3 (C-6), 159.7 (CO), 161.4 (C-9), 168.9, 169.0, 169.5 (CH3CO). 
19F NMR (282 MHz, CDCl3): δ = -62.87 (s). IR (ATR, cm-1): v~ = 3106 (w), 2956 (w), 1756 
(m), 1715 (m), 1589 (m), 1536 (w), 1493 (w), 1426 (m), 1377 (m), 1210 (s), 1155 (m), 1060 
(m), 1034 (s), 953 (w), 907 (w), 706 (w). MS (EI, 70 eV): m/z (%) = 692 (0.5) [M++1], 691 
(0.1) [M+], 362 (20), 361 (53), 360 (17), 332 (25), 331 (89), 170 (18), 169 (100), 127 (38), 
109 (91), 97 (10), 77 (27), 43 (76). HRMS (ESI): calcd C31H29F3N3O10S ([M+1]+) 692.15203, 
found 692.15251. Anal. Calcd for C31H28F3N3O10S: C, 53.83; H, 4.08; N, 6.08. Found: C, 
54.12; H, 4.18; N, 5.94. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-
4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38g) 
Starting from 2r (421 mg, 1 mmol) and 1,2,3,4,6-
penta-O-acetyl-β-D-glucose (390 mg, 1mmol), 38g 
was isolated as colorless foam (556 mg, 74%); mp 
100-102 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.84 (s, 3H, OAc-
6’), 1.91 (s, 3H, OAc-4’), 1.94 (s, 3H, OAc-3’), 1.96 
(s, 3H, OAc-2’), 3.58 (br s, 1H, H-5’), 3.94-3.95 (m, 2H, Ha-6’, Hb-6’), 4.87-4.93 (m, 1H, H-
4’), 5.03-5.22 (m, 2H, H-3’, H-2’), 5.65 (d, 3JH,H = 8.3 Hz, 1H, H-1’), 6.59 (t, 2JF,H = 73.3 Hz, 
1H, OCF2H), 7.27-7.34 (m, 3H, Ar), 7.41-7.47 (m, 2H, Ar), 7.50-7.53 (m, 2H, Ar), 7.82 (s, 
1H, H-5), 8.17-8.20 (m, 2H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.5, 20.6, 20.7 
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(COCH3), 61.4 (CH2), 67.8, 70.2, 72.7, 74.3, 91.7 (CHgl), 111.4 (C-3a), 112.9 (C-5), 115.6 (t, 
1JC,F = 260.9 Hz, OCF2H), 119.8 (CHAr), 121.4 (q, 1JC,F = 275.0 Hz, CF3), 124.9, 127.7, 129.2, 
129.8 (CHAr), 133.8 (CAr), 137.2 (q, 2JC,F = 36.5 Hz, CCF3), 153.6 (t, 3JC,F = 2.8 Hz, 
COCF2H), 158.0, 160.5 (CAr), 161.2 (C=O), 168.5 (C-7a), 168.9, 169.3, 170.0, 170.5 
(COCH3). 19F NMR (282 MHz, CDCl3): δ = -81.38 (s, 2F, OCF2H), -62.68 (s, 3F, CF3). IR 
(ATR, cm-1): v~ = 3069 (w), 2943 (w), 1748 (m), 1705 (m), 1593 (m), 1494 (w), 1368 (m), 
1210 (s), 1115 (m), 1030 (s), 904 (w), 841 (w), 596 (w). MS (EI, 70 eV): m/z (%) = 752 
(0.48) [M+], 732 (2), 421 (61), 331 (100), 271 (27), 169 (99), 127 (70), 109 (99), 77 (49), 43 
(92). HRMS (ESI): calcd C34H31F5N3O11 ([M+1]+) 752.1873, found 752.1884. Anal. Calcd 
for C34H30F5N3O11: C, 54.33; H, 4.02; N, 5.59. Found: C, 54.67; H, 3.96; N, 5.44. 
 
6-(4-(Difluoromethoxy)phenyl)-2-methyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-
4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38h) 
Starting from 2s (359 mg, 1 mmol) and 1,2,3,4,6-penta-
O-acetyl-β-D-glucose (390 mg, 1mmol), 38h was 
isolated as yellow foam (476 mg, 69%); mp 89-91 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.47 (s, 3H, OAc-6’), 
1.93 (s, 3H, OAc-4’), 1.99 (s, 6H, OAc-3’, OAc-2’), 
3.52 (s, 3H, NCH3), 3.86-3.92 (m, 1H, H-5’), 4.12 (dd, 2JH,H = 12.5 Hz, 3JH,H = 2.0 Hz, 1H, 
Ha-6’), 4.22 (dd, 2JH,H = 12.5 Hz, 3JH,H = 4.3 Hz, 1H, Hb-6’), 5.14 (t, 3JH,H = 9.6 Hz, 1H, H-4’), 
5.28 (t, 3JH,H = 9.6 Hz, 1H, H-3’), 5.55 (br s, 1H, H-2’), 5.85 (br s, 1H, H-1’), 6.57 (t, 2JH,F = 
73.2 Hz, 1H, OCF2H), 7.23-7.26 (m, 2H, Ar), 7.71 (s, 1H, H-5), 8.08-8.11 (m, 2H, Ar). 13C 
NMR (62.9 MHz, CDCl3): δ = 19.7, 20.5, 20.6 (COCH3), 32.9 (NCH3), 61.6 (CH2), 67.7, 
69.0, 73.4, 74.8, 85.8 (CHgl), 111.3 (C-3a), 111.7 (C-5), 115.5 (t, 1JC,F = 261.4 Hz, OCF2H), 
119.8 (CHAr), 121.4 (q, 1JC,F = 274.4 Hz, CF3), 129.5 (CHAr), 133.7 (CAr), 136.9 (q, 2JC,F = 
36.6 Hz, CCF3), 153.5 (t, 3JC,F = 2.7 Hz, COCF2H), 159.3 (CAr), 159.4 (C=O), 160.7 (C-7a), 
168.3, 169.3, 170.2, 170.5 (COCH3). 19F NMR (282 MHz, CDCl3): δ = -81.48 (s, 2F, 
OCF2H), -62.70 (s, 3F, CF3). IR (ATR, cm-1): v~ = 2964 (w), 1754 (m), 1717 (m), 1586 (m), 
1500 (w), 1371 (m), 1214 (s), 1117 (s), 1023 (s), 917 (m), 881 (m), 782 (m), 674 (m). MS (EI, 
70 eV): m/z (%) = 690 (0.7) [M+], 359 (93), 331 (100), 169 (100), 139 (42), 127 (89), 109 
(100), 97 (42), 43 (100). HRMS (ESI): calcd C29H29F5N3O11 ([M+1]+) 690.17168, found 
690.17333. Anal. Calcd for C29H28F5N3O11: C, 50.51; H, 4.09; N, 6.09. Found: C, 50.77; H, 
4.37; N, 6.36. 
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Methyl 3-oxo-2-phenyl-6-p-tolyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-2,3-
dihydro-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (38i) 
Starting from 2u (359 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38i was isolated as 
yellow foam (648 mg, 94%); mp 101-103 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.90 (s, 3H, OAc-6’), 1.99 
(s, 6H, OAc-4’, OAc-3’), 1.99 (s, 3H, OAc-2’), 2.47 (s, 3H, 
CH3), 3.67 (br s, 1H, H-5’), 3.96-4.01 (m, 2H, Ha-6’, Hb-6’), 
4.03 (s, 3H, OMe), 4.93 (t, 3JH,H = 9.4 Hz, 1H, H-4’), 5.15 (t, 3JH,H = 9.4 Hz, 1H, H-3’), 5.53 
(br s, 1H, H-2’), 5.89 (br s, 1H, H-1’), 7.33-7.40 (m, 3H, Ar), 7.46-7.51 (m, 2H, Ar), 7.56-
7.59 (m, 2H, Ar), 7.95 (s, 1H, H-5), 8.11-8.14 (m, 2H, Ph). 13C NMR (75.5 MHz, CDCl3): 
20.4, 20.6, 20.7, 20.7 (COCH3), 31.6 (CH3), 53.3 (OCH3), 61.6 (CH2), 67.9, 69.5, 74.1, 74.4, 
87.1 (CHgl), 106.4 (C-3a), 116.1 (C-5), 125.3, 127.6, 127.9, 129.1, 130.1 (CHAr), 134.4, 
139.4, 141.7, 145.6, 159.6 (CAr), 160.6 (C=O), 162.1 (C-7a), 165.4 (CO2CH3), 168.6, 169.4, 
170.4, 170.5 (CH3CO). IR (ATR, cm-1): v~ = 2952 (w), 2922 (w), 2853 (w), 1744 (m), 1705 
(m), 1583 (m), 1362 (m), 1209 (s), 1033 (s), 904 (w), 825 (w), 761 (w), 736 (w), 597 (w). MS 
(EI, 70 eV): m/z (%) = 689 (1.2) [M+], 359 (29), 331 (50), 169 (100), 127 (18), 109 (69), 77 
(7), 43 (69). HRMS (ESI): calcd C35H36N3O12 ([M+1]+) 690.2294, found 690.2292. Anal. 
Calcd for C35H35N3O12: C, 60.95; H, 5.12; N, 6.09. Found: C, 61.17; H, 5.09; N, 5.98. 
 
2-Phenyl-6-(pyridin-2-yl)-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38l) 
Starting from 2x (356 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38l was isolated as 
yellow foam (467 mg, 68%); mp 88-90 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.73 (s, 3H, OAc-6’), 1.97 
(s, 3H, OAc-4’), 1.98 (s, 3H, OAc-3’), 1.99 (s, 3H, OAc-2’), 
3.70-3.74 (m, 1H, H-5’), 4.02 (d, 3JH,H = 3.2 Hz, 2H, Ha-6’, 
Hb-6’), 4.90 (t, 3JH,H = 9.4 Hz, 1H, H-4’), 5.18 (t, 3JH,H = 9.4 Hz, 1H, H-3’), 5.62 (br s, 1H, H-
2’), 5.94 (br s, 1H, H-1’), 7.37-7.45 (m, 2H, Ar), 7.48-7.53 (m, 2H, Ar), 7.56-7.59 (m, 2H, 
Ar), 7.85 (td, 3JH,H = 7.8 Hz, 4JH,H = 1.7 Hz, 1H, Ar), 8.28 (s, 1H, H-5), 8.50 (d, 3JH,H = 7.8 Hz, 
1H, Ar), 7.85 (ddd, 3JH,H = 4.7 Hz, 4JH,H = 1.7 Hz, 4JH,H = 0.9 Hz, 1H, Ar). 13C NMR (75.5 
MHz, CDCl3): δ = 20.3, 20.6, 20.7, 20.7 (COCH3), 61.4 (CH2), 67.6, 69.3, 73.8, 74.4, 87.3 
(CHgl), 113.5 (C-3a), 117.1 (C-5), 121.1 (q, 1JC,F = 275.1 Hz, CF3), 125.5, 126.0, 127.7, 128.3, 
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129.2, 137.4, 149.5 (CHAr), 149.9, 150.0 (CAr), 151.4 (q, 2JC,F = 35.8 Hz, CCF3), 157.5 (CAr), 
159.7 (C=O), 159.9 (C-7a), 168.4, 169.3, 170.4, 170.5 (COCH3). 19F NMR (282 MHz, 
CDCl3): δ = -67.78 (s). MS (EI, 70 eV): m/z (%) = 687 (0.24) [M+1], 686 (0.13) [M+], 356 
(20), 331 (28), 169 (100), 157 (16), 127 (16), 115 (28), 109 (45), 98 (17), 43 (100). HRMS 
(ESI): calcd C32H30F3N4O10 ([M+1]+) 687.19085, found 687.1915. Anal. Calcd for 
C32H29F3N4O10: C, 55.98; H, 4.26; N, 8.16. Found: C, 55.82; H, 4.21; N, 8.19. 
  
(E)-6-(3-(4-tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1-(2,3,4,6-tetra-O-
acetyl-α-D-glucopyranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38o) 
Starting from 9a (614 mg, 1 mmol) and 
1,2,3,4,6-penta-O-acetyl-β-D-glucose (390 
mg, 1mmol), 38o was isolated as yellow 
foam (670 mg, 71%); mp 99-100 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.73 (s, 
3H, OAc-6’), 1.97 (s, 3H, OAc-4’), 1.98 (s, 
3H, OAc-3’), 1.99 (s, 3H, OAc-2’), 3.70-3.74 (m, 1H, H-5’), 4.02 (d, 3JH,H = 3.2 Hz, 2H, Ha-
6’, Hb-6’), 4.90 (t, 3JH,H = 9.4 Hz, 1H, H-4’), 5.18 (t, 3JH,H = 9.4 Hz, 1H, H-3’), 5.62 (br s, 1H, 
H-2’), 5.94 (br s, 1H, H-1’), 7.28 (d, 3JH,H = 16.4 Hz, 1H, =CH), 7.33-7.38 (m, 1H, Ar), 7.43 
(d, 3JH,H = 8.3 Hz, 2H, Ar), 7.48-7.53 (m, 4H, Ph), 7.61-7.65 (m, 2H, Ar), 7.72 (d, 3JH,H = 8.3 
Hz, 2H, Ar), 7.92 (s, 1H, H-5), 8.27 (d, 3JH,H = 8.3 Hz, 2H, Ar). 13C NMR (62.9 MHz, 
CDCl3): δ = 20.4, 20.6, 20.6 (CH3CO), 31.4 (CH3), 34.9 (C(CH3)3), 62.2 (CH2), 69.4, 72.1, 
78.4, 92.7 (CHgl), 108.4 (C-3a), 114.9 (t, 3JC,F = 8.9 Hz, C-5), 124.8, 125.9, 126.7, 126.9, 
127.5, 127.6, 128.5, 129.4, 131.0 (CHAr, =CH), 134.2, 134.9, 135.1 (CAr), 137.0 (t, 2JC,F = 26.3 
Hz, CCF2), 141.1, 151.7, 158.1 (CAr), 160.6 (C=O), 161.2 (C-7a), 169.5, 169.6, 170.4 
(CH3CO). 19F NMR (282 MHz, CDCl3): δ = -79.79 (t, 3JF,F = 10.2 Hz, 3F, CF3), -108.76 (br s, 
2F, CF2), -124.24 (s, 2F, CF2). IR (ATR, cm-1): v~ = 2957 (w), 1755 (m), 1714 (w), 1584 (w), 
1495 (w), 1434 (w), 1363 (m), 1271 (w), 1209 (s), 1147 (w), 1116 (m), 1034 (m), 953 (m), 
906 (w), 737 (w), 691 (w), 597 (w). (EI, 70 eV): m/z (%) = 944 (1.1) [M++1], 943 (1.3) [M+], 
614 (37), 613 (69), 612 (38), 598 (54), 597 (34), 332 (44), 331 (93), 271 (60), 211 (30), 170 
(67), 169 (100), 145 (30), 139 (27), 127 (72), 110 (93), 97 (20), 77 (35), 43 (94). HRMS 
(ESI): calcd C47H45F7N3O10 ([M+1]+) 944.29877, found 944.29898. Anal. Calcd for 
C47H44F7N3O10: C, 59.81; H, 4.70; N, 4.45. Found: C, 59.71; H, 4.72; N, 4.42. 
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(E)-6-(4-(4-tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1-(2,3,4,6-tetra-O-
acetyl-α-D-glucopyranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (38p) 
Starting from 9b (614 mg, 1 mmol) and 
1,2,3,4,6-penta-O-acetyl-β-D-glucose (390 mg, 
1mmol), 38p was isolated as yellow foam (585 
mg, 62%); mp 124-126 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.27 (s, 3H, 
OAc-6’), 1.36 (s, 9H, CH3), 1.92 (s, 3H, OAc-
4’), 1.99 (s, 3H, OAc-3’), 2.02 (s, 3H, OAc-2’), 3.69 (br s, 1H, H-5’), 3.99-4.05 (m, 2H, Ha-
6’, Hb-6’), 4.97 (br s, H-4’), 5.18 (t, 3JH,H = 9.4 Hz, 1H, H-3’), 5.62 (br s, 1H, H-2’), 5.94 (br 
s, 1H, H-1’), 7.17 (d, 3JH,H = 16.2 Hz, 1H, =CH), 7.32-7.60 (m, 10H, Ar), 7.75 (d, 3JH,H = 8.5 
Hz, 2H, Ar), 7.89 (s, 1H, H-5), 8.24 (d, 3JH,H = 8.5 Hz, 2H, Ar). 13C NMR (75.5 MHz, 
CDCl3): δ = 20.7, 20.7, 20.8 (CH3CO), 31.4 (CH3), 34.9 (C(CH3)3), 61.7 (CH2), 68.0, 74.1, 
74.5, 93.2 (CHgl), 109.1 (C-3a), 115.1 (C-5), 125.3, 125.9, 126.7, 126.9, 127.4, 127.8, 128.5, 
129.2, 131.0 (CHAr, =CH), 134.3, 135.3, 135.4, 141.0, 151.7, 159.1 (CAr), 160.7 (C=O), 161.6 
(C-7a), 169.4, 170.4, 170.5 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -79.79 (t, 3JF,F = 10.2 
Hz, 3F, CF3), -108.76 (br s, 2F, CF2), -124.24 (s, 2F, CF2). IR (ATR, cm-1): v~ = 2958 (w), 
1755 (m), 1715 (m), 1582 (m), 1495 (w), 1417 (w), 1365 (m), 1211 (s), 1183 (m), 1148 (m), 
1116 (m), 1033 (m), 954 (m), 903 (w), 837 (m), 736 9m), 561 (m). MS (EI, 70 eV): m/z (%) = 
943 (0.4) [M+], 614 (17), 613 (46), 599 (12), 598 (41), 455 (16), 369 (72), 331 (66), 318 (24), 
317 (100), 287 (17), 271 (18), 205 (20), 203 (20), 170 (16), 169 (78), 127 (23), 109 (82), 77 
(27), 44 (43), 43 (88), 41 (12). HRMS (ESI): calcd C47H45F7N3O10 ([M+1]+) 944.29877, 
found 944.29642.Anal. Calcd for C47H44F7N3O10: C, 59.81; H, 4.70; N, 4.45. Found: C, 
59.62; H, 4.67; N, 4.49. 
 
9-Phenyl-1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-7-(trifluoromethyl)-9,10-
dihydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-6,8-dione (38t) 
Starting from 22a (397 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38t was isolated as 
yellow foam 473 mg (65%); mp 89-91 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.25 (s, 3H, OAc-6’), 1.93 (s, 
3H, OAc-4’), 2.01 (s, 3H, OAc-3’), 2.03 (s, 3H, OAc-2’), 3.70 
(br m, 1H, H-5’) 4.06-4.07 (m, 2H, Ha-6’, Hb-6’), 5.03 (br m, 
1H, H-4’), 5.19 (t, 3JH,H = 9.4 Hz, 1H, H-3’), 5.62 (br s, 1H, H-2’), 5.98 (br s, 1H, H-1’), 7.40-
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7.57 (m, 7H, Ar), 7.70-7.76 (m, 1H, Ar), 8.72 (d, 3JH,H = 7.6 Hz, 1H, Ar). 13C NMR (62.9 
MHz, CDCl3): δ = 19.7, 20.5, 20.6 (COCH3), 61.6 (CH2), 67.7, 69.0, 73.4, 74.8, 85.8 (CHgl), 
95.7 (C-7a), 117.3 (CHAr), 117.7 (C-6a), 121.1 (q, 1JC,F = 276.0 Hz, CF3), 125.2, 125.7, 126.7, 
128.4, 129.6 (CHAr), 134.7 (CAr), 134.9 (CHAr), 153.3, 155.2, 156.5 (CAr), 156.9 (CO-6) 157.0 
(CO-8), 161.2 (C-10a), 168.3, 169.3, 170.2, 170.5 (COCH3). 19F NMR (282 MHz, CDCl3): δ 
= -56.86 (s). MS (EI, 70 eV): m/z (%) = 728 (0.3) [M++1], 727 (0.1) [M+], 398 (37), 397 (92), 
396 (32), 377 (44), 332 (34), 331 (99), 271 (29), 170 (69), 169 (100), 145 (38), 139 (45), 127 
(89), 115 (20), 110 (30), 109 (100), 98 (23), 97 (59), 85 (16), 81 (34), 77 (88), 69 (12), 60 
(13), 43 (99). HRMS (ESI): calcd C34H29F3N3O12 ([M+1]+) 728.16978, found 728.16907. 
Anal. Calcd for C34H28F3N3O12: C, 56.13; H, 3.88; N, 5.78. Found: C, 56.40; H, 4.00; N, 5.45. 
 
Methyl 1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-6,8-dioxo-9-phenyl-6,8,9,10-
tetrahydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-7-carboxylate (38v) 
Starting from 22c (387 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38v was isolated as 
yellow foam (524 mg, 73%); mp 142-144 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.62 (s, 3H, OAc-6’), 2.02 (s, 
3H, OAc-4’), 2.07 (s, 6H, OAc-3’, OAc-2’), 3.96-4.01 (m, 1H, 
H-5’), 4.22 (dd, 2JH,H = 12.5 Hz, 3JH,H = 2.1 Hz, 1H, Ha-6’), 
4.34 (dd, 2JH,H = 12.5 Hz, 3JH,H = 4.4 Hz, 1H, Hb-6’), 5.24 (t, 3JH,H = 9.6 Hz, 1H, H-4’), 5.37 (t, 
3JH,H = 9.6 Hz, 1H, H-3’), 5.62 (br s, 1H, H-2’), 6.00 (d, 3JH,H = 7.9 Hz, 1H, H-1’), 7.40-7.57 
(m, 7H, Ar), 7.70-7.76 (m, 1H, Ar), 8.72 (d, 3JH,H = 7.6 Hz, 1H, Ar). 13C NMR (62.9 MHz, 
CDCl3): δ = 19.7, 20.5, 20.6 (COCH3), 53.2 (OCH3), 61.6 (CH2), 67.7, 69.0, 73.4, 74.8, 85.8 
(CHgl), 95.7 (C-7a), 117.3 (CHAr), 117.7 (C-6a), 125.2, 125.7, 126.7, 128.4, 129.6 (CHAr), 
134.7 (CAr), 134.9 (CHAr), 153.3, 155.2, 156.5 (CAr), 156.9 (CO-6) 157.0 (CO-8), 161.2 (C-
10a), 168.5 (CO2CH3), 169.3, 170.2, 170.5 (COCH3). Anal. Calcd for C35H31N3O14: C, 58.58; 
H, 4.35; N, 5.86. found: C, 58.76; H, 4.61; N, 5.54. 
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Methyl 1-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranozyl)-9-methyl-6,8-dioxo-6,8,9,10-
tetrahydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-7-carboxylate (38w) 
Starting from 22d (325 mg, 1 mmol) and 1,2,3,4,6-penta-O-
acetyl-β-D-glucose (390 mg, 1mmol), 38w was isolated as 
yellow foam (373 mg, 57%); mp 99-101 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.60 (s, 3H, OAc-6’), 2.01 (s, 
3H, OAc-4’), 2.07 (s, 6H, OAc-3’, OAc-2’), 3.58 (s, 3H, 
NCH3), 3.97-4.03 (m, 1H, H-5’), 4.13 (s, 3H, OCH3), 4.20 (dd, 
2JH,H = 12.5 Hz, 3JH,H = 2.1 Hz, 1H, Ha-6’), 4.31 (dd, 2JH,H = 12.5 Hz, 3JH,H = 4.4 Hz, 1H, Hb-
6’), 5.24 (t, 3JH,H = 9.6 Hz, 1H, H-4’), 5.37 (t, 3JH,H = 9.6 Hz, 1H, H-3’), 5.62 (br s, 1H, H-2’), 
6.00 (d, 3JH,H = 7.9 Hz, 1H, H-1’), 7.39-7.42 (m, 1H, Ar), 7.47-7.52 (m, 1H, Ar), 7.66-7.72 
(m, 1H, Ar), 8.62-8.65 (m, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.0, 20.7, 20.8 
(COCH3), 33.0 (NCH3), 53.9 (OCH3), 61.6 (CH2), 67.7, 69.0, 73.4, 75.2, 85.7 (CHgl), 109.3 
(C-7a), 117.6 (CHAr), 118.2 (C-6a), 125.4, 126.2, 134.4 (CHAr), 134.7, 153.3, 156.1, 158.8 
(CAr), 159.4 (CO-6), 159.7 (CO-8), 164.2 (C-10a), 168.5 (CO2CH3), 169.4, 170.3, 170.6 
(COCH3). IR (ATR, cm-1): v~ = 2928 (w), 1730 (m), 1701 (m), 1612 (w), 1430 (m), 1388 (m), 
1278 (m), 1218 (s), 1156 (m), 1110 (w), 1042 (m), 1031 (w), 997 (m), 897 (m), 758 (m). MS 
(EI, 70 eV): m/z (%) = 656 (0.6) [M++1], 655 (0.1) [M+], 331 (79), 325 (14), 294 (14), 293 
(21), 271 (17), 169 (100), 139 (16), 127 (46), 109 (87), 43 (56). HRMS (ESI): calcd 
C30H30N3O14 ([M+1]+) 656.17223, found 656.17313. Anal. Calcd for C30H29N3O14: C, 54.96; 
H, 4.46; N, 6.41. Found: C, 55.13; H, 4.60; N, 6.28. 
 
6-Methyl-2-phenyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (39a) 
Starting from 2a (293 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-α-L-
rhamnose (332 mg, 1mmol), 39a was isolated as yellow foam (385 
mg, 68%); mp 185-187 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.12 (d, 3JH,H = 6.8 Hz, 3H, CH3-
5’), 1.97 (s, 3H, OAc-4’), 2.05 (s, 3H, OAc-3’), 2.05 (s, 3H, OAc-2’), 
2.77 (s, 3H, CH3), 3.87-3.97 (m, 1H, H-5’), 4.70 (t, 3JH,H = 4.1 Hz, 1H, H-4’), 5.58 (t, 1H, 
3JH,H = 4.1 Hz, H-3’), 5.65 (d, 3JH,H = 8.3 Hz, 1H, H-1’), 6.86 (dd, 3JH,H = 8.3 Hz, 3JH,H = 3.6 
Hz, 1H, H-2’), 7.32-7.38 (m, 2H, Ph), 7.45-7.51 (m, 2H, Ph), 7.54-7.59 (m, 2H, H-5, Ph). 13C 
NMR (75.5 MHz, CDCl3): δ = 16.4 (CH3-rhamn), 20.7, 20.8, 21.0 (CH3CO), 25.5 (CH3), 67.2, 
69.2, 72.4, 72.5, 81.7 (CHrhamn), 105.7 (C-3a), 116.1 (q, 3JC,F = 5.0 Hz, C-5), 121.6 (q, 1JC,F = 
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275.0 Hz, CF3), 125.3, 127.8, 129.2 (CHAr), 135.5, (CAr), 136.5 (q, 2JC,F = 36.3 Hz, CCF3), 
158.7 (C-6), 161.0 (C=O), 165.4 (C-7a), 169.1, 169.3, 169.7 (CH3CO). 19F NMR (235 MHz, 
CDCl3): δ = -62.73 (s). IR (ATR, cm-1): v~ = 2934 (w), 1747 (m), 1715 (m), 1593 (w), 1486 
(w), 1378 (m), 1361 (m), 1251 (m), 1218 (s), 1149 (m), 1136 (s), 1121 (m), 1049 (s), 1024 
(m), 922 (m), 894 (m), 752 (m). MS (EI, 70 eV): m/z (%) = 565 (0.2) [M+], 293 (21), 273 
(57), 171 (21), 153 (97), 111 (87), 83 (32), 77 (29), 43 (100). HRMS (ESI): calcd 
C26H27F3N3O8 ([M+1]+) 566.17448, found 566.1747. Anal. Calcd for C26H26F3N3O8: C, 
55.22; H, 4.63; N, 7.43. Found: C, 55.19; H, 4.70; N, 7.30. 
 
2,6-Biphenyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (39b) 
Starting from 2c (355 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-
α-L-rhamnose (332 mg, 1mmol), 39b was isolated as yellow 
foam (276 mg, 44%); mp 93-94 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.18 (d, 3JH,H = 7.0 Hz, 3H, 
CH3-5’), 1.89 (s, 3H, OAc-4’), 2.07 (s, 3H, OAc-3’), 2.08 (s, 
3H, OAc-2’), 3.96-4.04 (m, 1H, H-5’), 4.72 (t, 3JH,H = 3.3 Hz, 
1H, H-4’), 5.58 (t, 1H, 3JH,H = 3.3 Hz, H-3’), 5.65 (d, 3JH,H = 9.4 Hz, 1H, H-1’), 6.86 (dd, 3JH,H 
= 9.4 Hz, 3JH,H = 3.6 Hz, 1H, H-2’), 7.40 (t, 3JH,H = 7.4 Hz, 1H, Ph), 7.52-7.69 (m, 7H, Ph), 
7.98 (s, 1H, H-5), 8.26-8.29 (m, 2H, Ph). 13C NMR (75.5 MHz, CDCl3): δ = 15.8 (CH3), 20.6, 
20.7, 20.8 (CH3CO), 66.7, 68.9, 71.9, 72.8, 80.2 (CHrhamn), 106.8 (C-3a), 112.7 (q, 3JC,F = 5.0 
Hz, C-5), 121.5 (q, 1JC,F = 275.0 Hz, CF3), 124.6, 127.4, 127.8, 129.0, 129.1, 131.3 (CHAr), 
135.0, 136.8 (CAr), 137.0 (q, 2JC,F = 36.3 Hz, CCF3), 158.2 (C-6), 161.1 (C=O), 161.9 (C-7a), 
168.9, 169.0, 169.4 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -62.66 (s). IR (ATR, cm-1): 
v~ = 3068 (w), 2943 (w), 1750 (m), 1710 (m), 1593 (m), 1489 (w), 1363 (m), 1208 (s), 1144 
(m), 1032 (s) 1120 (m), 1051 (m), 1024 (s), 923 (m), 752 (m). MS (EI, 70 eV): m/z (%) = 628 
(0.32) [M++1], 627 (0.3) [M+], 355 (21), 273 (90), 171 (29), 153 (96), 111 (91), 83 (25), 77 
(18), 43 (100). HRMS (ESI): calcd C31H29F3N3O8 ([M+1]+) 628.1901, found 628.1911. Anal. 
Calcd for C31H28F3N3O8: C, 59.33; H, 4.50; N, 6.70. Found: C, 59.48; H, 4.38; N, 6.44. 
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2-Methyl-6-phenyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (39c) 
Starting from 2d (293 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-
α-L-rhamnose (332 mg, 1mmol), 39c was isolated as yellow 
foam (322 mg, 57%); mp 81-83 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.31 (d, 3JH,H = 7.0 Hz, 3H, 
CH3-5’), 1.61 (s, 3H, OAc-4’), 1.85 (s, 3H, OAc-3’), 1.97 (s, 
3H, OAc-2’), 3.41 (s, 3H, NCH3), 4.02-4.10 (m, 1H, H-5’), 4.70 
(t, 3JH,H = 3.7 Hz, 1H, H-4’), 5.45 (t, 1H, 3JH,H = 3.7 Hz, H-3’), 5.81 (d, 3JH,H = 8.5 Hz, 1H, H-
1’), 6.15 (dd, 3JH,H = 8.5 Hz, 3JH,H = 3.5 Hz, 1H, H-2’), 7.33-7.37 (m, 3H, Ph), 7.66 (s, 1H, H-
5), 7.93-7.96 (m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 16.1 (CH3), 20.2, 20.7, 20.8 
(CH3CO), 32.1 (NCH3), 66.7, 69.0, 71.8, 72.8, 80.3 (CHrhamn), 105.6 (C-3a), 111.9 (q, 3JC,F = 
5.0 Hz, C-5), 121.6 (q, 1JC,F = 274.6 Hz, CF3), 127.6, 129.1, 131.1 (CHAr), 136.6 (q, 2JC,F = 
36.3 Hz, CCF3), 136.9 (CAr), 159.3 (C-6), 159.7 (C=O), 161.4 (C-7a), 168.9, 169.0, 169.5 
(CH3CO). 19F NMR (282 MHz, CDCl3): δ = -62.63 (s). IR (ATR, cm-1): v~ = 2983 (w), 2942 
(w), 1747 (m), 1694 (m), 1595 (m), 1444 (w), 1410 (w), 1372 (m), 1213 (s), 1145 (s), 1050 
(m), 1032 (m), 913 (m), 775 (m), 692 (m). MS (EI, 70 eV): m/z (%) = 565 (0.3) [M+], 293 
(34), 273 (75), 111 (94), 83 (24), 77 (54), 43 (100). HRMS (ESI): calcd C26H27F3N3O8 
([M+1]+) 566.17448, found 566.1746. Anal. Calcd for C26H26F3N3O8: C, 55.22; H, 4.63; N, 
7.43. Found: C, 55.43; H, 4.77; N, 6.97. 
 
2-Phenyl-6-(thiophen-2-yl)-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (39e) 
Starting from 2g (361 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-
α-L-rhamnose (332 mg, 1mmol), 39e was isolated as yellow 
foam (595 mg, 86%); mp 156-158 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.16 (d, 3JH,H = 7.2 Hz, 3H, 
CH3-5’), 1.99 (s, 3H, OAc-4’), 2.03 (s, 3H, OAc-3’), 2.04 (s, 
3H, OAc-2’), 3.97-4.05 (m, 1H, H-5’), 4.69 (t, 3JH,H = 3.3 Hz, 
1H, H-4’), 5.55 (t, 1H, 3JH,H = 3.3 Hz, H-3’), 5.63 (d, 3JH,H = 9.6 Hz, 1H, H-1’), 6.67 (dd, 3JH,H 
= 9.6 Hz, 3JH,H = 3.3 Hz, 1H, H-2’), 7.21 (dd, 3JH,H = 4.9 Hz, 3JH,H = 3.8 Hz, 1H, Hetar), 7.33-
7.39 (m, 1H, Ar), 7.48-7.53 (m, 2H, Ar), 7.59-7.64 (m, 3H, Ar, Hetar), 7.77 (s, 1H, H-5), 7.90 
(dd, 3JH,H = 3.8 Hz, 4JH,H = 0.9 Hz, 1H, Hetar). 13C NMR (62.9 MHz, CDCl3): δ = 16.1 (CH3), 
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20.7, 21.0 (CH3CO), 69.2, 72.3, 73.1, 80.3 (CHrhamn), 106.3 (C-3a), 111.5 (q, 3JC,F = 5.0 Hz, 
C-5), 121.6 (q, 1JC,F = 274.6 Hz, CF3), 124.8, 127.5, 128.7, 129.0, 129.2, 131.6 (CHAr), 135.2 
(CAr), 136.6 (q, 2JC,F = 36.0 Hz, CCF3), 142.9, 156.9 (CAr), 158.3 (C=O), 161.1 (C-7a), 169.1, 
169.2, 169.7 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -62.87 (s). MS (EI, 70 eV): m/z (%) 
= 634 (0.24) [M++1], 633 (0.2) [M+], 496 (18), 362 (32), 361 (71), 360 (21), 332 (15), 274 
(39), 273 (97), 213 (56), 171 (75), 154 (25), 153 (100), 129 (25), 127 (17), 111 (99), 83 (70), 
77 (62), 43 (98). HRMS (ESI): calcd C29H27F3N3O8S ([M+1]+) 634.1465, found 634.1466. 
Anal. Calcd for C29H26F3N3O8S: C, 54.97; H, 4.14; N, 6.63. Found: C, 54.71; H, 4.08; N, 
6.72. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (39g) 
Starting from 2r (421 mg, 1 mmol) and 1,2,3,4-tetra-O-
acetyl-α-L-rhamnose (332 mg, 1mmol), 39g was isolated 
as yellow foam (423 mg, 61%); mp 93-94 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.14 (d, 3JH,H = 7.0 Hz, 
3H, CH3), 1.87 (s, 3H, OAc-4’), 2.04 (s, 3H, OAc-3’), 
2.06 (s, 3H, OAc-2’), 3.92-4.00 (m, 1H, H-5’), 4.70 (t, 
3JH,H = 3.3 Hz, 1H, H-3’), 5.55 (t, 3JH,H = 3.3 Hz, 1H, H-4’), 5.59 (d, 3JH,H = 9.4 Hz, 1H, H-1’), 
6.63 (t, 2JF,H = 73.1 Hz, 1H, OCF2H), 6.84 (dd, 3JH,H = 9.4 Hz, 3JH,H = 3.3 Hz, 1H, H-2’), 7.30-
7.33 (m, 2H, Ar), 7.35-7.40 (m, 1H, Ar), 7.49-7.54 (m, 2H, Ar), 7.62-7.65 (m, 2H, Ar), 7.91 
(1H, s, H-5), 8.25-8.30 (2H, m, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 15.9 (CH3), 20.7, 
20.7, 20.8 (CH3CO), 66.8, 69.0, 72.0, 73.1, 80.2 (CHrhamn), 107.2 (C-3a), 112.5 (q, 3JC,F = 5.0 
Hz, C-5), 115.6 (t, 1JC,F = 261.3 Hz, OCF2H), 119.9 (CHAr), 121.6 (q, 1JC,F = 275.2 Hz, CF3), 
124.8, 127.6, 129.3, 129.7 (CHAr), 134.0, 135.1 (CAr), 137.4 (q, 2JC,F = 36.3 Hz, CCF3), 153.6 
(t, 3JC,F = 2.8 Hz, COCF2H), 158.2 (C-6), 160.7 (C=O), 161.2 (C-7a), 169.2, 169.2, 169.5 
(CH3CO). 19F NMR (282 MHz, CDCl3): δ = -81.64 (d, 2JH,F = 12.3 Hz, 2F, OCF2H), -62.66 
(s, 3F, CF3). IR (ATR, cm-1): v~ = 2944 (w), 2640 (w), 1749 (m), 1704 (m), 1593 (m), 1372 
(m), 1212 (s), 1146 (m), 1118 (m), 1042 (s), 912 (w), 841 (w). 
MS (EI, 70 eV): m/z (%) = 694 (0.12) [M+], 421 (32), 273 (76), 171 (31), 153 (91), 111 (91), 
83 (28), 77 (32), 43 (100). HRMS (ESI): calcd C32H29F5N3O9 ([M+1]+) 694.1818, found 
694.1829. Anal. Calcd for C32H28F5N3O9: C, 55.41; H, 4.07; N, 6.06. Found: C, 55.46; H, 
4,06; N, 5.90. 
 
N
N
N
CF3O
OCF2H
O
OAc
Me
AcO
OAc
  
 137 
6-(4-(Difluoromethoxy)phenyl)-2-methyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-
(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (39h) 
Starting from 2s (359 mg, 1 mmol) and 1,2,3,4-tetra-O-
acetyl-α-L-rhamnose (332 mg, 1mmol), 39h was 
isolated as yellow foam (404 mg, 64%); mp 190-192 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.49 (d, 3JH,H = 7.0 
Hz, 3H, CH3), 1.84 (s, 3H, OAc-4’), 2.03 (s, 3H, OAc-
3’), 2.16 (s, 3H, OAc-2’), 3.60 (s, 3H, NCH3), 4.19-4.27 
(m, 1H, H-5’), 4.89 (t, 3JH,H = 3.7 Hz, 1H, H-3’), 5.64 (t, 3JH,H = 3.7 Hz, 1H, H-4’), 5.93 (d, 
3JH,H = 8.5 Hz, 1H, H-1’), 6.42 (dd, 3JH,H = 8.5 Hz, 3JH,H = 3.7 Hz, 1H, H-2’), 6.61 (t, 2JF,H = 
73.1 Hz, 1H, OCF2H), 7.27-7.30 (m, 2H, Ar), 7.80 (1H, s, H-5), 8.13-8.18 (2H, m, Ar). 13C 
NMR (62.9 MHz, CDCl3): δ = 16.3 (CH3), 20.5, 20.9, 20.9 (CH3CO), 32.1 (NCH3), 66.8, 
69.1, 72.0, 72.8, 80.5 (CHrhamn), 106.1 (C-3a), 111.8 (q, 3JC,F = 5.0 Hz, C-5), 115.6 (t, 1JC,F = 
261.3 Hz, OCF2H), 119.9 (CHAr), 121.8 (q, 1JC,F = 275.2 Hz, CF3), 129.5 (CHAr), 134.1 (CAr), 
136.9 (q, 2JC,F = 36.6 Hz, CCF3), 153.4 (t, 3JC,F = 2.8 Hz, COCF2H), 159.3 (C-6), 159.8 
(C=O), 160.3 (C-7a), 169.2, 169.2, 169.7 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -81.56 
(2F, s, OCF2H), -62.65 (3F, s, CF3). IR (ATR, cm-1): v~ = 2947 (w), 1748 (m), 1694 (m), 1597 
(m), 1373 (m), 1216 (s), 1124 (m), 1049 (s), 915 (w), 841 (m). MS (EI, 70 eV): m/z (%) = 631 
(0.1) [M+], 359 (25), 273 (80), 213 (13), 171 (27), 153 (100), 111 (93), 83 (31), 43 (87). 
HRMS (ESI): calcd C27H27F5N3O9 ([M+1]+) 632.1662, found 632.16622. Anal. Calcd for 
C27H26F5N3O9: C, 51.35; H, 4.15; N, 6.65. Found: C, 51.54; H, 4.29; N, 6.86. 
 
Methyl 3-oxo-2-phenyl-6-p-tolyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-2,3-
dihydro-1H-pyrazolo[3,4-b]pyridine-4-carboxylate (39i) 
Starting from 2u (359 mg, 1 mmol) and 1,2,3,4-tetra-O-
acetyl-α-L-rhamnose (332 mg, 1mmol), 39i was isolated as 
yellow foam (373 mg, 59%); mp 98-100 oC.  
1H NMR (300 MHz, CDCl3): δ = 1.12 (d, 3JH,H = 6.8 Hz, 3H, 
5’-CH3), 1.92 (s, 3H, OAc-4’), 2.02 (s, 3H, OAc-3’), 2.04 (s, 
3H, OAc-2’), 2.44 (s, 3H, Ar-CH3), 3.92-3.99 (m, 1H, H-5’), 
4.04 (s, 3H, CO2CH3), 4.69 (t, 3JH,H = 3.6 Hz, 1H, H-3’), 5.55 (t, 3JH,H = 3.6 Hz, 1H, H-4’), 
5.62 (d, 3JH,H = 9.2 Hz, 1H, H-1’), 6.76 (dd, 3JH,H = 9.2 Hz, 3JH,H = 3.6 Hz, 1H, H-2’), 7.33-
7.38 (m, 3H, Ar), 7.47-7.52 (m, 2H, Ar), 7.60-7.64 (m, 2H, Ar), 7.98 (s, 1H, H-5), 8.12-8.15 
(m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 16.3 (CH3), 20.8, 20.8, 20.8 (CH3CO), 21.6 
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(CH3rhamn), 53.3 (OCH3), 67.0, 69.3, 72.4, 72.6, 81.0 (CHrhamn), 107.7 (C-3a), 115.9 (C-5), 
125.0, 127.4, 127.8, 129.2, 129.9 (CHAr), 134.5, 135.8, 139.4, 141.6, 159.6 (CAr), 161.2 
(C=O), 161.5 (C-7a), 165.6 (CO2CH3), 169.2, 169.3, 169.7 (CH3CO). IR (ATR, cm-1): v~ = 
2923 (w), 2852 (w), 1740 (s), 1703 (m), 1583 (m), 1364 (m), 1210 (s), 1048 (s), 947 (m), 912 
(m), 825 (m), 734 (m). HRMS (ESI): calcd C33H34N3O10 ([M+1]+) 632.2239, found 632.2238. 
Anal. Calcd for C33H33N3O10: C, 62.75; H, 5.27; N, 6.65. Found: C, 62.80; H, 5.19; N, 6.47. 
 
4-(Perfluoroethyl)-2,6-phenyl-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (39j) 
Starting from 2v (405 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-
α-L-rhamnose (332 mg, 1mmol), 39j was isolated as yellow 
foam (576 mg, 85%); mp 172-174 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.16 (d, 3JH,H = 7.1 Hz, 3H, 
CH3), 1.86 (s, 3H, OAc-4’), 2.04 (s, 3H, OAc-3’), 2.04 (s, 3H, 
OAc-2’), 3.94-3.99 (m, 1H, H-5’), 4.69 (t, 3JH,H = 3.4 Hz, 1H, 
H-3’), 5.54 (t, 3JH,H = 3.4 Hz, 1H, H-4’), 5.65 (d, 3JH,H = 9.5 Hz, 1H, H-1’), 6.81 (dd, 3JH,H = 
9.5 Hz, 3JH,H = 3.4 Hz, 1H, H-2’), 7.34-7.40 (m, 1H, Ar), 7.48-7.66 (m, 7H, Ar), 7.91 (s, 1H, 
H-5), 8.23-8.27 (m, 2H, Ar). 13C NMR (75.5 MHz, CDCl3): δ = 20.4, 20.5, 20.7 (CH3CO), 
62.8 (CH2), 69.5, 71.6, 78.7, 92.8 (CHrib), 111.4 (C-3a), 118.8 (t, 3JC,F = 7.8 Hz, C-5), 124.8, 
125.4, 127.8, 128.2, 129.4 (CHAr), 134.9 (CAr), 137.1, 149.6 (CHAr), 139.2 (t, 2JC,F = 24.0 Hz, 
CCF2), 150.5, 150.8 (CAr), 159.4 (C=O), 160.0 (C-7a), 169.3, 169.3, 170.5 (CH3CO). 19F 
NMR (235 MHz, CDCl3): δ = -111.7 0 (s, 2F, CF2), -83.17 (s, 3F, CF3). MS (EI, 70 eV): m/z 
(%) = 677 (0.2) [M+], 405 (88), 376 (23), 273 (82), 171 (35), 153 (100), 111 (89), 83 (34), 77 
(22), 43 (48). HRMS (ESI): calcd C32H29F5N3O8 ([M+1]+) 678.1846, found 678.1849.Anal. 
Calcd for C32H28F5N3O8: C, 56.72; H, 4.17; N, 6.20. Found: C, 56.59; H, 4.19; N, 6.17. 
 
2-Phenyl-6-(pyridin-2-yl)-1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-4-
(Trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (39l) 
Starting from 2x (356 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-α-
L-rhamnose (332 mg, 1mmol), 39l was isolated as yellow foam 
(528 mg, 84%); mp 68-69 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.17 (d, 3JH,H = 6.9 Hz, 3H, 
CH3), 1.93 (s, 3H, OAc-4’), 2.05 (s, 3H, OAc-3’), 2.05 (s, 3H, 
OAc-2’), 3.94-4.03 (m, 1H, H-5’), 4.68 (t, 3JH,H = 3.4 Hz, 1H, H-
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3’), 5.51 (t, 3JH,H = 3.4 Hz, 1H, H-4’), 5.78 (d, 3JH,H = 9.3 Hz, 1H, H-1’), 6.21 (dd, 3JH,H = 9.5 
Hz, 3JH,H = 3.4 Hz, 1H, H-2’), 7.37-7.62 (m, 6H, Ar), 7.86 (td, 3JH,H = 7.9 Hz, 4JH,H = 1.7 Hz, 
1H, Ar), 8.28 (s, 1H, H-5), 8.53 (dt, 3JH,H = 7.9 Hz, 4JH,H = 0.9 Hz, 1H, Ar), 8.79-8.81 (m, 1H, 
Ar). 13C NMR (62.9 MHz, CDCl3): δ = 15.8 (CH3), 20.6, 20.7, 20.8 (CH3CO), 66.7, 68.9, 
71.9, 72.8, 80.2 (CHrhamn), 106.8 (C-3a), 112.7 (q, 3JC,F = 5.0 Hz, C-5), 121.5 (q, 1JC,F = 275.0 
Hz, CF3), 124.6, 127.4, 127.8, 129.0, 129.1, 131.3 (CHAr), 135.0, 136.8 (CAr), 137.0 (q, 2JC,F = 
36.3 Hz, CCF3), 153.6 (t, 3JC,F = 2.8 Hz, COCF2H), 158.2 (C-6), 161.1 (C=O), 161.9 (C-7a), 
168.9, 169.0, 169.4 (CH3CO). 19F NMR (282 MHz, CDCl3): δ = -67.79 (s). MS (EI, 70 eV): 
m/z (%) = 629 (0.21) [M+1], 628 (0.4) [M+], 356 (33), 273 (57), 213 (13), 171 (21), 153 
(100), 111 (90), 83 (23), 77 (12), 43 (89). HRMS (ESI): calcd C30H28F3N4O8 ([M+1]+) 
629.18537, found 629.18622. Anal. Calcd for C30H27F3N4O8: C, 57.33; H, 4.33; N, 8.91. 
Found: C, 57.12; H, 4.30; N, 8.95. 
 
4-(Perfluoroethyl)-2-phenyl-6-(pyridin-2-yl)-1-(2,3,4-tri-O-acetyl-α-L-
rhamnopyranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (39m) 
Starting from 2y (406 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-α-
L-rhamnose (332 mg, 1mmol), 39m was isolated as yellow foam 
(563 mg, 83%); mp 72-74 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.17 (d, 3JH,H = 6.9 Hz, 3H, 
CH3), 1.88 (s, 3H, OAc-4’), 2.03 (s, 3H, OAc-3’), 2.04 (s, 3H, 
OAc-2’), 3.97 (dq, 3JH,H = 6.9 Hz, 3JH,H = 3.4 Hz, 1H, H-5’), 4.66 
(t, 3JH,H = 3.4 Hz, 1H, H-3’), 5.47 (t, 3JH,H = 3.4 Hz, 1H, H-4’), 5.83 (d, 3JH,H = 9.5 Hz, 1H, H-
1’), 6.15 (dd, 3JH,H = 9.5 Hz, 3JH,H = 3.4 Hz, 1H, H-2’), 7.36-7.46 (m, 2H, Ar), 7.49-7.55 (m, 
2H, Ar), 7.58-7.63 (m, 2H, Ar), 7.85 (td, 3JH,H = 7.9 Hz, 4JH,H = 1.7 Hz, 1H, Ar), 8.31 (s, 1H, 
H-5), 8.53 (dt, 3JH,H = 7.9 Hz, 4JH,H = 0.9 Hz, 1H, Ar), 8.79-8.82 (m, 1H, Ar). 13C NMR (62.9 
MHz, CDCl3): δ = 15.8 (CH3), 20.6, 20.7, 20.8 (CH3CO), 66.7, 68.9, 71.9, 72.8, 80.2 
(CHrhamn), 111.5 (C-3a), 118.5 (C-5), 125.2, 125.3, 127.6, 128.1, 129.4 (CHAr), 134.9 (CAr), 
136.6 (CHAr), 139.2 (t, 2JC,F = 24.0 Hz, CCF2), 150.1 (CHAr), 150.4, 151.1 (CAr), 159.4 (C=O), 
160.0 (C-7a), 168.9, 169.0, 169.4 (CH3CO). 19F NMR (235 MHz, CDCl3): δ = -82.67 (s, 3F, 
CF3), -116.48 (q, 2F, CF2). MS (EI, 70 eV): m/z (%) = 678 (0.5) [M+], 407 (15), 406 (35), 273 
(68), 213 (15), 171 (22), 153 (100), 111 (55), 57 (20), 43 (51), 41 (17). HRMS (ESI): calcd 
C31H28F5N4O8 ([M+1]+) 679.18218, found 679.18303. Anal. Calcd for C31H27F5N4O8: C, 
54.87; H, 4.01; N, 8.26. Found: C, 54.60; H, 3.99; N, 8.28. 
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4-(Perfluoropropyl)-2-phenyl-6-(pyridin-2-yl)-1-(2,3,4-tri-O-acetyl-α-L-
rhamnopyranozyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (39n) 
Starting from 2z (456 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-α-
L-rhamnose (332 mg, 1mmol), 39n was isolated as yellow foam 
(612 mg, 84%); mp 76-78 oC. 
1H NMR (250 MHz, CDCl3): δ = 1.19 (d, 3JH,H = 6.9 Hz, 3H, 
CH3), 1.85 (s, 3H, OAc-4’), 2.01 (s, 3H, OAc-3’), 2.04 (s, 3H, 
OAc-2’), 3.91-4.01 (m, 1H, H-5’), 4.66 (t, 3JH,H = 3.3 Hz, 1H, H-3’), 5.46 (t, 3JH,H = 3.3 Hz, 
1H, H-4’), 5.87 (d, 3JH,H = 9.5 Hz, 1H, H-1’), 6.10 (dd, 3JH,H = 9.5 Hz, 3JH,H = 3.3 Hz, 1H, H-
2’), 7.36-7.46 (m, 2H, Ar), 7.49-7.55 (m, 2H, Ar), 7.59-7.63 (m, 2H, Ar), 7.85 (td, 3JH,H = 7.8 
Hz, 4JH,H = 1.8 Hz, 1H, Ar), 8.29 (s, 1H, H-5), 8.55 (dt, 3JH,H = 7.8 Hz, 4JH,H = 0.9 Hz, 1H, 
Ar), 8.79-8.82 (m, 1H, Ar). 13C NMR (62.8 MHz, CDCl3): δ = 15.8 (CH3), 20.6, 20.7, 20.8 
(CH3CO), 66.7, 68.9, 71.9, 72.8, 80.2 (CHrhamn), 111.4 (C-3a), 118.8 (t, 3JC,F = 5.0 Hz, C-5), 
124.8, 125.4, 127.8, 128.2, 129.4 (CHAr), 134.9 (CAr), 137.1, 149.6 (CHAr), 139.2 (t, 2JC,F = 
24.0 Hz, CCF2), 150.5, 150.8 (CAr), 159.4 (C=O), 160.0 (C-7a), 168.9, 169.0, 169.4 (CH3CO). 
19F NMR (235 MHz, CDCl3): δ = -80.02 (t, 3JF,F = 9.7 Hz, 3F, CF3), -112.64 (dq, 2JF,F = 275.0 
Hz, 3JF,F = 9.7 Hz, 1F, CF3), -115.27 (dq, 2JF,F = 275 Hz, 3JF,F = 9.7 Hz, 1F, CF3), -125.50 (s, 
2F, CF2). MS (EI, 70 eV): m/z (%) = 728 (0.8) [M+], 456 (41), 273 (82), 171 (22), 153 (100), 
111 (88), 83 (24), 77 (13), 43 (94). HRMS (ESI): calcd C32H28F7N4O8 ([M+1]+) 729.17899, 
found 729.17998. Anal. Calcd for C32H27F7N4O8: C, 52.75; H, 3.74; N, 7.69. Found: C, 52.52; 
H, 3.72; N, 7.72. 
 
Methyl 1-(2,3,4-tri-O-acetyl-α-L-rhamnopyranozyl)-6,8-dioxo-9-phenyl-6,8,9,10-
tetrahydrochromeno[3,4-e]pyrazolo[3,4-b]pyridine-7-carboxylate (39v) 
Starting from 22c (387 mg, 1 mmol) and 1,2,3,4-tetra-O-acetyl-
α-L-rhamnose (332 mg, 1mmol), 39v was isolated as yellow 
foam (442 mg, 67%); mp 138-140 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.17 (d, 3JH,H = 7.1 Hz, 3H, 5’-
CH3), 1.99 (s, 3H, OAc-4’), 2.05 (s, 3H, OAc-3’), 2.07 (s, 3H, 
OAc-2’), 3.96-4.04 (m, 1H, H-5’), 4.11 (s, 3H, CO2CH3), 4.72 (t, 3JH,H = 3.2 Hz, 1H, H-3’), 
5.59 (t, 3JH,H = 3.2 Hz, 1H, H-4’), 5.65 (d, 3JH,H = 9.6 Hz, 1H, H-1’), 6.85-6.87 (m, 1H, H-2’), 
7.37-7.71 (m, 8H, Ar), 8.67-8.71 (m, 1H, Ar). 13C NMR (62.9 MHz, CDCl3): δ = 20.8, 20.8, 
20.8 (CH3CO), 21.6 (CH3rhamn), 53.3 (OCH3), 67.0, 69.3, 72.4, 72.6, 81.0 (CHrhamn), 95.7 (C-
7a), 117.3 (CHAr), 117.7 (C-6a), 125.2, 125.7, 126.7, 128.4, 129.6 (CHAr), 134.7 (CAr), 134.9 
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(CHAr), 153.3, 155.2, 156.5 (CAr), 156.9 (CO-6) 157.0 (CO-8), 161.2 (C-10a), 167.9 
(CO2CH3), 169.2, 169.3, 169.7 (CH3CO). HRMS (ESI): calcd C33H30N3O12 ([M+1]+) 
660.1824, found 660.18265. Anal. Anal. Calcd for C33H29N3O12: C, 60.09; H, 4.43; N, 6.37. 
Found: C, 60.35; H, 4.72; N, 6.19. 
 
A.2.7. General procedure for synthesis of compounds 40-42 
Acetylated nucleoside 37-39 (0.5 mmol) was dissolved in 20mL MeOH and 5 mL of 
ammonia (7N solution in MeOH) was added. The mixture was stirred at room temperature 
overnight and, if necessary, for up to 24h more (controlled by TLC). Afterwards, the solution 
was evaporated under reduced pressure and crystallized from CH2Cl2/MeOH, or subjected to 
column chromatography (silica gel; eluent: n-heptane/ethylacetate). 
 
6-Methyl-2-phenyl-1-β-D-ribofuranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (40a) 
 Starting from 37a (276 mg, 1 mmol), 40a was isolated via 
column chromatography as yellow solid (204 mg, 96%); mp 98-
100 oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.74 (s, 3H, CH3), 3.01-3.06 
(m, 1H, Ha-5’), 3.15-3.20 (m, 1H, Hb-5’), 3.60-3.65 (m, 1H, H-
4’), 3.86 (dd, 2JH,H = 8.9 Hz, 3JH,H = 5.1 Hz, 1H, H-3’), 4.56 (t, 
3JH,H = 5.7 Hz, 1H, OH-5’), 4.83 (dd, 2JH,H = 11.6 Hz, 3JH,H = 5.9 Hz, 1H, H-2’), 5.04 (d, 3JH,H 
= 5.1 Hz, 1H, OH-3’), 5.35 (d, 3JH,H = 6.2 Hz, 1H, OH-2’), 5.48 (d, 3JH,H = 6.0 Hz, 1H, H-1’), 
7.38-7.46 (m, 1H, Ph), 7.52-7.59 (m, 4H, Ph), 7.67 (s, 1H, H-5). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 24.8 (CH3), 61.3 (CH2), 69.8, 70.7, 84.6, 93.7 (CHrib), 104.3 (C-8), 116.0 (q, 
3JC,F = 5.6 Hz, C-5), 121.6 (q, 1JC,F = 274.4 Hz, CF3), 124.8, 127.2, 128.9 (CHAr), 134.1 (q, 
2JC,F = 35.6 Hz, CCF3), 135.4 (CAr), 158.0 (C-6), 160.5 (CO), 165.6 (C-9). 19F NMR (282 
MHz, DMSO-d6): δ = -61.33 (s). IR (ATR, cm-1): v~ = 3369 (br w), 3066 (w), 2929 (w), 1679 
(m), 1592 (m), 1488 (w), 1362 (m), 1144 (s), 1035 (m). MS (EI, 70 eV): m/z (%) = 425 (0.12) 
[M+], 293 (25), 259 (76), 139 (100), 97 (68), 77 (28), 43 (60). HRMS (ESI): calcd 
C19H19F3N3O5 ([M+1]+) 426.1271, found 426.1273. Anal. Calcd for C19H18F3N3O5: C, 53.65; 
H, 4.27; N, 9.88. Found: C, 53.59; H, 4.23; N, 9.46. 
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2,6-Biphenyl-1-β-D-ribofuranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-
one (40b) 
 Starting from 37b (307 mg, 0.5 mmol), 40b was isolated via 
crystallization (CH2Cl2/MeOH) as colorless solid (224 mg, 92%); 
mp 215-217 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.97-3.02 (m, 1H, Ha-5’), 
3.11-3.16 (m, 1H, Hb-5’), 3.64 (q, 3JH,H = 5.0 Hz, 1H, H-4’), 3.91 
(q, 3JH,H = 5.0 Hz, 1H, H-3’), 4.53 (t, 3JH,H = 5.7 Hz, 1H, OH-5’), 5.04 (q, 3JH,H = 5.9 Hz, 1H, 
H-2’), 5.11 (d, 3JH,H = 5.3 Hz, 1H, OH-3’), 5.45 (d, 3JH,H = 6.2 Hz, 1H, OH-2’), 5.57 (d, 3JH,H 
= 5.7 Hz, 1H, H-1’), 7.41-7.47 (m, 1H, Ph), 7.56-7.65 (m, 7H, Ph), 8.25 (s, 1H, H-5), 8.32-
8.35 (m, 2H, Ph). 13C NMR (62.9 MHz, DMSO-d6): δ = 61.1 (CH2), 69.7, 70.8, 84.4, 93.9 
(CHrib), 105.7 (C-3a), 112.7 (q, 3JC,F = 5.0 Hz, C-5), 121.7 (q, 1JC,F = 274.7 Hz, CF3), 124.9, 
127.3, 127.8, 129.0, 129.2, 131.4 (CHAr), 135.0 (q, 2JC,F = 35.9 Hz, CCF3), 135.3, 136.2, 157.8 
(CAr), 160.7 (C=O), 161.2 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.10 (s). IR (ATR, 
cm-1): v~ = 3375 (br w), 2958 (w), 1677 (s), 1593 (m), 1377 (m), 1269 (m), 1174 (m), 1139 
(m), 1093 (s), 1037 (m), 1018 (m), 983 (m), 887 (m), 754 (m), 690 (m), 666 (m). MS (EI, 70 
eV): m/z (%) = 487 (0.13) [M+], 355 (40), 259 (99), 139 (100), 97 (74), 77 (49), 43 (93). 
HRMS (ESI): calcd C24H21F3N3O5 ([M+1]+) 488.14278, found 488.14286. Anal. Calcd for 
C24H20F3N3O5: C, 59.14; H, 4.14; N, 8.62. Found: C, 60.04; H, 4.09; N, 8.37. 
 
2-Methyl-6-phenyl-1-β-D-ribofuranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (40c) 
Starting from 37c (276 mg, 0.5 mmol), 40c was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (203 mg, 95%); mp 
226-228 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.41-3.46 (m, 1H, Ha-5’), 
3.52 (s, 3H, CH3), 3.54-3.58 (m, 1H, Hb-5’), 3.84 (q, 3JH,H = 3.9 Hz, 
1H, H-4’), 4.03-4.08 (m, 1H, H-3’), 4.64 (q, 3JH,H = 6.4 Hz, 1H, H-
2’), 4.84 (t, 3JH,H = 5.3 Hz, 1H, OH-5’), 5.16 (d, 3JH,H = 5.0 Hz, 1H, OH-3’), 5.27 (d, 3JH,H = 
6.4 Hz, 1H, OH-2’), 6.00 (d, 3JH,H = 6.4 Hz, 1H, H-1’), 7.56-7.58 (m, 3H, Ph), 8.04 (s, 1H, H-
5), 8.22-8.25 (m, 2H, Ph). 13C NMR (75.5 MHz, DMSO-d6): δ = 32.0 (CH3), 61.2 (CH2), 
69.5, 70.6, 84.5, 92.2 (CHrib), 104.5 (C-3a), 111.4 (q, 3JC,F = 5.0 Hz, C-5), 120.1 (q, 1JC,F = 
274.7 Hz, CF3), 127.7, 129.1, 131.0 (CHAr), 134.7 (q, 2JC,F = 35.6 Hz, CCF3), 136.5, 158.6 
(CAr), 158.7 (C=O), 160.5 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.03 (s). IR (ATR, 
cm-1): v~ = 3334 (br w), 3075 (w), 2929 (w), 1694 (s), 1594 (m), 1371 (m), 1263 (m), 1227 
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(m), 1150 (m), 1103 (s), 1044 (s), 992 (m), 879 (m), 754 (m), 691 (m), 654 (s). MS (EI, 70 
eV): m/z (%) = 425 (0.14) [M+], 293 (34), 259 (90), 139 (100), 97 (45), 77 (19), 43 (39). 
HRMS (ESI): calcd C19H19F3N3O5 ([M+1]+) 426.12713, found 426.1278. Anal. Calcd for 
C19H18F3N3O5: C, 53.65; H, 4.27; N, 9.88. found: C, 53.69; H, 4.32; N, 9.64. 
 
2-Phenyl-1-β-D-ribofuranozyl-6-(thiophen-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (40e) 
Starting from 37e (310 mg, 0.5 mmol), 40e was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (220 mg, 89%); 
mp 227-229 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.99-3.04 (m, 1H, Ha-5’), 
3.21-3.26 (m, 1H, Hb-5’), 3.62 (dd, 3JH,H = 9.9 Hz, 3JH,H = 5.8 
Hz, 1H, H-4’), 3.96 (dd, 3JH,H = 9.6 Hz, 3JH,H = 5.2 Hz, 1H, H-
3’), 4.53 (t, 3JH,H = 5.6 Hz, 1H, OH-5’), 5.05-5.12 (m, 2H, H-2’, OH-3’), 5.36 (d, 3JH,H = 5.9 
Hz, 1H, OH-2’), 5.48 (d, 3JH,H = 5.9 Hz, 1H, H-1’), 7.31 (dd, 3JH,H = 4.9 Hz, 3JH,H = 4.0 Hz, 
1H, Hetar), 7.38-7.44 (m, 1H, Ar), 7.53-7.60 (m, 4H, Ar), 7.96 (dd, 3JH,H = 5.0 Hz, 4JH,H = 0.9 
Hz, 1H, Hetar), 8.22 (s, 1H, H-5), 7.93 (dd, 3JH,H = 3.8 Hz, 4JH,H = 0.9 Hz, 1H, Hetar). 13C 
NMR (62.9 MHz, DMSO-d6): δ = 61.3 (CH2), 69.8, 70.9, 84.6, 93.9 (CHrib), 105.0 (C-3a), 
111.4 (q, 3JC,F = 5.0 Hz, C-5), 121.7 (q, 1JC,F = 274.7 Hz, CF3), 124.7, 127.2, 129.1, 129.3, 
130.4, 132.6 (CHAr), 135.0 (CAr), 135.2 (q, 2JC,F = 36.0 Hz, CCF3), 142.1, 156.4 (CAr), 157.6 
(C=O), 160.3 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.21 (s). IR (ATR, cm-1): v~ = 
3411 (br w), 2958 (w), 1674 (s), 1594 (m), 1538 (m), 1495 (w), 1427 (m), 1393 (m), 1379 
(m), 1367 (m), 1269 (m), 1139 (m), 1103 (m), 1090 (m), 1038 (m), 981 (m), 887 (m), 849 
(m), 755 (m), 708 (s). MS (EI, 70 eV): m/z (%) = 493 (0.2) [M+], 362 (36), 361 (100), 341 
(15), 332 (37), 77 (31). HRMS (ESI): calcd C22H19F3N3O5S ([M+1]+) 494.0992, found 
494.0993. Anal. Calcd for C22H18F3N3O5S: C, 53.55; H, 3.68; N, 8.52. Found: C, 53.74; H, 
3.69; N, 8.47. 
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6-(Furan-2-yl)-2-phenyl-1-β-D-ribofuranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (40f) 
Starting from 37f (302 mg, 0.5 mmol), 40f was isolated via 
column chromatography as yellow solid (223 mg, 93%); mp 207-
209 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.98-3.06 (m, 1H, Ha-5’), 
3.17-3.25 (m, 1H, Hb-5’), 3.61-3.66 (m, 1H, H-4’), 3.96 (dd, 3JH,H 
= 9.1 Hz, 3JH,H = 5.1 Hz, 1H, H-3’), 4.52 (t, 3JH,H = 5.9 Hz, 1H, OH-5’), 4.98-5.04 (m, 1H, H-
2’), 5.09 (d, 3JH,H = 5.1 Hz, 1H, OH-3’), 5.41 (d, 3JH,H = 5.9 Hz, 1H, OH-2’), 5.46 (d, 3JH,H = 
5.9 Hz, 1H, H-1’), 6.86 (dd, 3JH,H = 3.5 Hz, 4JH,H = 1.8 Hz, 1H, Hetar), 7.40-7.45 (m, 1H, Ar), 
7.54-7.61 (m, 4H, Ar), 7.64 (dd, 3JH,H = 3.5 Hz, 4JH,H = 0.8 Hz, 1H, Hetar), 7.96 (s, 1H, H-5), 
8.10 (dd, 4JH,H = 1.8 Hz, 4JH,H = 0.8 Hz, 1H, Hetar). 13C NMR (62.9 MHz, DMSO-d6): δ = 
61.2 (CH2), 69.8, 70.9, 84.6, 93.8 (CHrib), 104.9 (C-8), 110.8 (C-5), 121.6 (q, 1JC,F = 274.4 Hz, 
CF3), 113.4, 114.5, 124.7, 127.2, 129.0, 135.2 (CHAr), 135.2 (q, 2JC,F = 35.7 Hz, CCF3), 135.2, 
147.2, 151.1, 152.2 (CAr), 157.6 (CO), 160.5 (C-9). 19F NMR (282 MHz, DMSO-d6): δ = -
61.48 (s). IR (ATR, cm-1): v~ = 3453 (br w), 2926 (w), 1668 (m), 1652 (m), 1603 (m), 1571 
(m), 1425 (w), 1365 (s), 1296 (w), 1266 (m), 1146 (s), 1041 (s), 1015 (s), 880 (m). MS (EI, 
70 eV): m/z (%) = 477 (0.1) [M+], 345 (100), 316 (26), 77(19). HRMS (ESI): calcd 
C22H19F3N3O6 ([M+1]+) 478.12205, found 478.12215. Anal. Calcd for C22H18F3N3O6: C, 
55.35; H, 3.80; N, 8.80. Found: C, 55.62; H, 4.00; N, 8.62. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-1-β-D-ribofuranozyl-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (40g) 
Starting from 37g (340 mg, 0.5 mmol), 40g was isolated via 
crystallization (CH2Cl2/MeOH) as colorless solid (271 mg, 
98%); mp 185-187 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.93-3.00 (m, 1H, Ha-
5’), 3.06-3.14 (1H, m, Hb-5’), 3.61 (q, 3JH,H = 5.2 Hz, 1H, 
H-4’), 3.88 (q, 3JH,H = 5.2 Hz, 1H, H-3’), 4.50 (t, 3JH,H = 5.7 Hz, 1H, OH-5’), 4.99 (q, 3JH,H = 
6.0 Hz, 1H, H-2’), 5.08 (d, 3JH,H = 5.2 Hz, 1H, OH-3’), 5.41 (d, 3JH,H = 6.0 Hz, 1H, OH-2’), 
5.52 (d, 3JH,H = 6.0 Hz, H-1’), 7.38-7.41 (m, 3H, Ar), 7.43 (t, 2JF,H = 73.6 Hz, 1H, OCF2H), 
7.53-7.61 (m, 4H, Ar), 8.24 (s, 1H, H-5), 8.38-8.41 (m, 2H, Ph). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 61.1 (CH2), 96.7, 70.8, 84.4, 94.0 (CHrib), 105.7 (C-3a), 112.7 (q, 3JC,F = 5.5 
Hz, C-5), 116.1 (t, 1JC,F = 258.0 Hz, OCF2H), 118.8 (CHAr), 121.7 (q, 1JC,F = 275.1 Hz, CF3), 
124.9, 127.3, 129.0, 129.9 (CHAr), 133.0, 135.3 (CAr), 135.4 (q, 2JC,F = 35.7 Hz, CCF3), 153.4 
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(t, 3JC,F = 3.2 Hz, COCF2H), 157.8 (C-6), 160.2 (C=O), 160.6 (C-7a). 19F NMR (282 MHz, 
DMSO-d6): δ = -61.09 (s, 3F, CF3), -82.85 (s, 2F, OCF2H). IR (ATR, cm-1): v~ = 3334 (br w), 
3075 (w), 2929 (w), 1694 (s), 1594 (m), 1371 (m), 1263 (m), 1227 (m), 1150 (m), 1103 (s), 
1044 (s), 1009 (s), 844 (m), 729 (m), 669 (m). MS (EI, 70 eV): m/z (%) = 553 (0.03) [M+], 
421 (100), 362 (22), 77 (27). HRMS (ESI): calcd C25H21F5N3O6 ([M+1]+) 554.1345, found 
554.1347. Anal. Calcd for C25H20F5N3O6: C, 54.26; H, 3.64; N, 7.59. Found: C, 54.107; H, 
3.646; N, 7.239. 
 
3-Oxo-2-phenyl-1-β-D-ribofuranozyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-b]pyridine-
4-carboxylic acid (40i) 
Starting from 37i (309 mg, 0.5 mmol), 40i was isolated 
via crystallization (CH2Cl2/MeOH) as yellow solid (213 
mg, 89%); mp 267-268 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.41 (s, 3H, CH3), 
2.89-2.97 (m, 1H, Ha-5’), 3.07-3.14 (m, 1H, Ha-5’), 3.59 
(q, 3JH,H = 4.9 Hz, 1H, H-4’), 3.87 (q, 3JH,H = 4.9 Hz, 1H, 
H-3’), 4.49 (t, 3JH,H = 4.9 Hz, 1H, OH-5’), 5.02-5.08 (m, 2H, H-2’, OH-3’), 5.42 (d, 3JH,H = 
6.0 Hz, 1H, OH-2’), 5.51 (d, 3JH,H = 5.7 Hz, 1H, H-1’), 7.40-7.43 (m, 2H, Ar), 7.46-7.49 (m, 
1H, Ar), 7.56-7.64 (m, 4H, Ar), 8.12-8.15 (m, 2H, Ar), 8.37 (s, 1H, H-5), 11.93 (s, 1H, 
CO2H). 13C NMR (62.9 MHz, DMSO-d6): δ = 20.9 (CH3), 61.2 (CH2), 69.7, 70.8, 84.3, 94.0 
(CHrib), 106.2 (C-3a), 116.2, 125.4, 127.3, 127.7, 129.1, 129.9 (CHAr), 133.9, 134.7, 141.0, 
141.8, 160.3 (CAr), 160.4 (C=O), 160.6 (C-7a), 163.3 (CO2H). IR (ATR, cm-1): v~ = 3275 (br 
w), 3036 (w), 1662 (s), 1563 (m), 1495 (m), 1348 (m), 1303 (m), 1272 (m), 1037 (s), 685 (m), 
828 (m), 749 (s), 725 (s), 694 (s). MS (EI, 70 eV): m/z (%) = 477 (0.16) [M+], 359 (100), 259 
(85), 139 (79), 97 (28), 77 (20), 43 (94). Anal. Calcd for C25H23N3O7: C, 62.89; H, 4.86; N, 
8.80. Found: C, 62.64; H, 5.09; N, 8.54. 
 
2,6-Biphenyl-4-(perfluoroethyl)-1-β-D-ribofuranozyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-
one (40j) 
Starting from 37j (332 mg, 0.5 mmol), 40j was isolated via 
column chromatography as yellow solid (245 mg, 91%); mp 
178-180 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.92-2.99 (m, 1H, Ha-5’), 
3.05-3.13 (m, 1H, Hb-5’), 3.58-3.63 (m, 1H, H-4’), 3.84-3.89 
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(m, 1H, H-3’), 4.50 (t, 3JH,H = 5.7 Hz, 1H, OH-5’), 4.94-5.00 (m, 1H, H-2’), 5.07 (d, 3JH,H = 
5.3 Hz, 1H, OH-3’), 5.40 (d, 3JH,H = 6.2 Hz, 1H, OH-2’), 5.56 (d, 3JH,H = 5.7 Hz, 1H, H-1’), 
7.39-7.44 (m, 1H, Ph), 7.53-7.64 (m, 7H, Ph), 8.18 (s, 1H, H-5), 8.30-8.33 (m, 2H, Ph). 13C 
NMR (62.9 MHz, DMSO-d6): δ = 61.2 (CH2), 69.7, 70.8, 84.4, 94.0 (CHrib), 106.8 (C-3a), 
114.4 (C-5), 125.0, 127.3, 127.9, 129.0, 129.3, 131.5 (CHAr), 135.0, 136.4 (CAr), 135.7 (t, 2JC,F 
= 36.5 Hz, CCF2CF3), 157.5 (CAr), 160.6 (C=O), 160.9 (C-7a). 19F NMR (235 MHz, CDCl3): 
δ = -82.49 (s, 3F, CF3), -110.27 (s, 2F, CF2). IR (ATR, cm-1): v~ = 3195 (br), 2918 (w), 1695 
(m), 1667 (m), 1590 (m), 1427 (w), 1386 (w), 1362 (m), 1324 (m), 1262 (w), 1202 (s), 1148 
(m), 1093 (m), 1065 (m), 1053 (m), 1027 (m), 998 (s), 894 (w), 866 (m), 731 (s), 691 (m), 
667 (m). MS (EI, 70 eV): m/z (%) = 537 (0.1) [M+], 406 (70), 405 (100), 376 (39), 149 (26), 
77 (42), 43 (17). HRMS (ESI): calcd C25H21F5N3O5 ([M+1]+) 538.1396, found 538.1397. 
Anal. Calcd for C25H20F5N3O5: C, 55.87; H, 3.75; N, 7.82. Found: C, 56.04; H, 3.72; N, 7.78. 
 
2,6-Biphenyl-4-(perfluoropropyl)-1-β-D-ribofuranozyl-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (40k) 
Starting from 37k (357 mg, 0.5 mmol), 40k was isolated via 
column chromatography as yellow solid (249 mg, 85%); mp 
146-148 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.93-3.01 (m, 1H, Ha-5’), 
3.07-3.15 (m, 1H, Hb-5’), 3.58-3.64 (m, 1H, H-4’), 3.86-3.91 
(m, 1H, H-3’), 4.50 (t, 3JH,H = 5.7 Hz, 1H, OH-5’), 4.98-5.04 
(m, 1H, H-2’), 5.08 (d, 3JH,H = 5.3 Hz, 1H, OH-3’), 5.42 (d, 3JH,H = 6.2 Hz, 1H, OH-2’), 5.54 
(d, 3JH,H = 5.7 Hz, 1H, H-1’), 7.39-7.45 (m, 1H, Ph), 7.54-7.63 (m, 7H, Ph), 8.23 (s, 1H, H-5), 
8.30-8.33 (m, 2H, Ph). 13C NMR (62.9 MHz, DMSO-d6): δ = 61.1 (CH2), 69.7, 70.8, 84.4, 
93.9 (CHrib), 105.7 (C-3a), 112.7 (C-5), 124.9, 127.3, 127.8, 129.0, 129.2, 131.4 (CHAr), 
135.0 (t, 2JC,F = 36.1 Hz, CCF2), 135.3, 136.2, 157.8 (CAr), 160.7 (C=O), 161.2 (C-7a). 19F 
NMR (282 MHz, DMSO-d6): δ = -79.78 (t, 3JF,F = 10.2 Hz, 3F, CF3), -108.64 (q, 3JF,F = 10.2 
Hz, 2F, CF2), -124.24 (t, 3JF,F = 21.5 Hz, 2F, CF2). MS (EI, 70 eV): m/z (%) = 587 (0.1) [M+], 
456 (20), 455 (100), 77 (19). HRMS (ESI): calcd C26H21F7N3O5 ([M+1]+) 588.13639, found 
588.13645. Elemental analysis: Calculated for C26H20F7N3O5: C, 56.11; H, 3.95; N, 6.33, 
found: C, 56.269; H, 3.966; N, 6.301. 
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2-Phenyl-6-(pyridin-2-yl)-1-β-D-ribofuranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (40l) 
Starting from 37l (307 mg, 0.5 mmol), 40l was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (227 mg, 93%); 
mp 267-268 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.00-3.07 (m, 1H, Ha-5’), 
3.19-3.27 (m, 1H, Hb-5’), 3.60-3.65 (m, 1H, H-4’), 3.87-3.92 
(m, 1H, H-3’), 4.55 (t, 3JH,H = 4.6 Hz, 1H, OH-5’), 4.90-4.93 
(m, 1H, H-2’), 5.06 (d, 3JH,H = 4.9 Hz, 1H, OH-3’), 5.42-5.45 (m, 2H, OH-2’, H-1’), 7.40-7.45 
(m, 1H, Ar), 7.54-7.62 (m, 5H, Ar), 7.99 (td, 3JH,H = 7.8 Hz, 4JH,H = 1.9 Hz, 1H, Ar), 8.16 (s, 
1H, H-5), 8.48 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.81-8.83 (m, 1H, Ar). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 61.1 (CH2), 69.7, 70.8, 84.4, 93.9 (CHrib), 105.7 (C-3a), 112.7 (q, 3JC,F = 5.0 
Hz, C-5), 121.7 (q, 1JC,F = 274.7 Hz, CF3), 124.9, 127.3, 127.8, 129.0, 129.2, 131.4 (CHAr), 
135.0 (q, 2JC,F = 35.9 Hz, CCF3), 135.3, 136.2 (CAr), 150.1 (CHAr), 157.8 (CAr), 160.7 (C=O), 
161.2 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -66.55 (s). MS (EI, 70 eV): m/z (%) = 488 
(0.1) [M+], 357 (21), 356 (100), 355 (14), 251 (35), 203 (21), 78 (20), 77 (48), 51 (16). HRMS 
(ESI): calcd C23H20F3N4O5 ([M+1]+) 489.138, found 489.1383. Anal. Calcd for 
C23H19F3N4O5: C, 56.56; H, 3.92; N, 11.47. Found: C, 56.78; H, 3.93; N, 11.41. 
 
4-(Perfluoroethyl)-2-phenyl-6-(pyridin-2-yl)-1-β-D-ribofuranozyl-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (40m) 
Starting from 37m (333 mg, 0.5 mmol), 40m was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (245 mg, 
93%); mp 205-207 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.04 (dd, 2JH,H = 11.5 
Hz, 3JH,H = 6.0 Hz, 1H, Ha-5’), 3.25 (dd, 2JH,H = 11.5 Hz, 3JH,H 
= 5.4 Hz, 1H, Hb-5’), 3.58-3.64 (m, 1H, H-4’), 3.87 (t, 3JH,H = 
4.7 Hz, 1H, OH-5’), 4.57 (br s, 1H, H-2’), 4.92 (br s, 1H, OH-3’), 5.04 (br s, 1H, OH-2’), 5.43 
(d, 3JH,H = 5.7 Hz, 1H, H-1’), 7.41-7.46 (m, 1H, Ar), 7.54-7.63 (m, 5H, Ar), 7.99 (td, 3JH,H = 
7.8 Hz, 4JH,H = 1.9 Hz, 1H, Ar), 8.18 (s, 1H, H-5), 8.50 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.81-8.84 
(m, 1H, Ar). 13C NMR (62.9 MHz, DMSO-d6): δ = 61.3 (CH2), 69.5, 70.7, 84.5, 94.2 (CHrib), 
111.5 (C-3a), 116.9 (t, 3JC,F = 3.7 Hz, C-5), 125.3, 125.4, 127.2, 127.6, 129.1, (CHAr), 134.9 
(CAr), 136.5 (CHAr), 148.3 (t, 2JC,F = 25.4 Hz, CCF2CF3), 149.9 (CAr), 150.1 (CHAr), 150.2 
(CAr), 158.9 (C=O), 159.5 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -81.93 (s, 3F, CF3), -
113.88 - -117.02 (m, 2F, CF2). IR (ATR, cm-1): v~ = 3391 (br w), 2933 (w), 1666 (m), 1587 
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(m), 1469 (w), 1382 (w), 1354 (w), 1328 (m), 1261 (w), 1221 (m), 1189 (s), 1148 (m), 1114 
(m), 1096 (m), 1045 (m), 1015 (s), 889 (m), 865 (m), 785 (m), 745 (s), 713 (m). MS (EI, 70 
eV): m/z (%) = 538 (0.09) [M+], 407 (33), 406 (100), 301 (45), 273 (16), 78 (11), 77 (34), 44 
(30), 43 (19). HRMS (ESI): calcd C24H20F5N4O5 ([M+1]+) 539.1348, found 539.1352. Anal. 
Calcd for C24H19F5N4O5: C, 53.54; H, 3.56; N, 10.41. Found: C, 53.68; H, 3.58; N, 10.38. 
 
4-(Perfluoropropyl)-2-phenyl-6-(pyridin-2-yl)-1-β-D-ribofuranozyl-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (40n) 
Starting from 37n (358 mg, 0.5 mmol), 40n was isolated via 
column chromatography as yellow solid (271 mg, 92%); mp 
178-180 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.03 (dd, 2JH,H = 11.0 Hz, 
3JH,H = 5.9 Hz, 1H, Ha-5’), 3.24 (dd, 2JH,H = 11.0 Hz, 3JH,H = 4.5 
Hz, 1H, Ha-5’), 3.57-3.62 (m, 1H, H-4’), 3.85 (br s, 1H, OH-
5’), 4.56 (br s, 1H, H-2’), 4.86-4.90 (m, 1H, H-3’), 5.02-5.04 (m, 1H, OH-3’), 5.40 (br s, 1H, 
OH-2’), 5.43 (d, 3JH,H = 5.4 Hz, 1H, H-1’), 7.41-7.46 (m, 1H, Ar), 7.54-7.63 (m, 5H, Ar), 
7.48-7.54 (m, 2H, Ar), 7.99 (td, 3JH,H = 7.8 Hz, 4JH,H = 1.8 Hz, 1H, Ar), 8.16 (s, 1H, H-5), 8.51 
(dt, 3JH,H = 7.8 Hz, 4JH,H = 1.0 Hz, 1H, Ar), 8.82-8.84 (m, 1H, Ar). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 61.2 (CH2), 69.5, 70.7, 84.5, 94.2 (CHrib), 111.5 (C-3a), 117.2 (C-5), 125.3, 
125.4, 127.2, 127.6, 126.1 (CHAr), 134.9 (CAr), 136.5 (CHAr), 149.8 (CAr), 150.1 (CHAr), 
150.1 (CAr), 139.2 (t, 2JC,F = 24.0 Hz, CCF2), 158.9 (C=O), 159.4 (C-7a). 19F NMR (235 MHz, 
DMSO-d6): δ = -79.52 (t, 3JF,F = 9.2 Hz, 3F, CF3), -113.27 (ddq, 2JF,F = 611.0 Hz, 2JF,F = 273.8 
Hz, 3JF,F = 9.2 Hz, 2F, CF2), -125.38 (s, 2F, CF2). MS (EI, 70 eV): m/z (%) = 588 (0.12) [M+], 
457 (57), 456 (100), 369 (39), 351 (35), 317 (76), 204 (21), 77 (46). HRMS (ESI): calcd 
C25H20F7N4O5 ([M+1]+) 589.13164, found 589.13184. Anal. Calcd for C25H19F7N4O5: C, 
51.03; H, 3.25; N, 9.52. Found: C, 51.19; H, 3.28; N, 9.56. 
 
(E)-6-(3-(4-tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1-β-D-ribofuranozyl-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (40o) 
Starting from 37o (436 mg, 0.5 mmol), 40o 
was isolated via column chromatography as 
yellow solid (343 mg, 92%); mp 212-214 
oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 
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(s, 9H, CH3), 3.01 (dt, 2JH,H = 11.1 Hz, 3JH,H = 5.3 Hz, 1H, Ha-5’), 3.11 (dt, 2JH,H = 11.1 Hz, 
3JH,H = 5.3 Hz, 1H, Hb-5’), 3.64 (dd, 3JH,H = 9.6 Hz, 3JH,H = 5.3 Hz, 1H, H-4’), 3.93 (q, 3JH,H = 
4.8 Hz, 1H, H-3’), 4.53 (t, 3JH,H = 5.0 Hz, 1H, OH-5’), 5.02-5.09 (m, 2H, H-2’, OH-3’), 5.45 
(d, 3JH,H = 6.0 Hz, 1H, OH-2’), 5.57 (d, 3JH,H = 5.7 Hz, 1H, H-1’), 7.34-7.47 (m, 5H, Ar, 
=CH), 7.54-7.65 (m, 7H, Ar, =CH), 7.87 (d, 3JH,H = 7.8 Hz, 1H, Ar), 8.21 (d, 3JH,H = 7.8 Hz, 
1H, Ar), 8.26 (s, 1H, H-5), 8.49 (s, 1H, Ar). 13C NMR (62.9 MHz, DMSO-d6): δ = 31.0 
(CH3), 34.4 (C(CH3)3), 61.9 (CH2), 69.8, 70.9, 84.5, 94.0 (CHrib), 107.2 (C-3a), 114.7 (m, C-
5), 125.0, 125.5, 125.9, 126.4, 126.8, 127.0, 127.3, 129.0, 129.1, 129.5, 129.7 (CHAr, =CH), 
134.1 (CAr), 134.9 (t, 2JC,F = 26.1 Hz, CCF3), 135.4, 136.6, 138.3, 150.6, 157.4 (CAr), 160.5 
(C=O), 160.8 (C-7a). 19F NMR (282 MHz, CDCl3): δ = -79.38 (t, 3JF,F = 9.2 Hz, 3F, CF3), -
107.26 (q, 3JF,F = 9.2 Hz, 2F, CF2), -123.82 (t, 3JF,F = 22.0 Hz, 2F, CF2). MS (EI, 70 eV): m/z 
(%) = 745 (0.1) [M+], 614 (41), 613 (100), 599 (24), 598 (81), 78 (25), 63 (31), 44 (24). 
HRMS (ESI): calcd C38H35F7N3O5 ([M+1]+) 746.24595, found 746.24587. Anal. Calcd for 
C38H34F7N3O5: C, 61.21; H, 4.60; N, 5.64. Found: C, 61.41; H, 4.67; N, 5.66. 
 
 (E)-6-(4-(4-tert-butylstyryl)phenyl)-4-(perfluoropropyl)-2-phenyl-1-β-D-ribofuranozyl-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (40p) 
Starting from 37p (436 mg, 0.5 mmol), 40p 
was isolated via column chromatography as 
yellow solid (328 mg, 88%); mp 208-210 
oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 (s, 
9H, CH3), 2.97 (dd, 2JH,H = 11.2 Hz, 3JH,H = 
5.6 Hz, 1H, Ha-5’), 3.12 (dd, 2JH,H = 11.2 Hz, 3JH,H = 5.6 Hz, 1H, Hb-5’), 3.63 (dd, 3JH,H = 9.6 
Hz, 3JH,H = 5.6 Hz, 1H, H-4’), 3.85-3.89 (m, 1H, H-3’), 4.51 (br s, 1H, OH-5’), 4.94-5.08 (m, 
2H, H-2’, OH-3’), 5.37-5.44 (m, 1H, OH-2’), 5.56-5.59 (m, 1H, H-1’), 7.22-7.62 (m, 11H, 
=CH, =CH, Ar), 7.84 (d, 3JH,H = 8.5 Hz, 2H, Ar), 8.20 (s, 1H, H-5), 8.36 (d, 3JH,H = 8.5 Hz, 
2H, Ar). 13C NMR (62.9 MHz, DMSO-d6): δ = 31.0 (CH3), 34.4 (C(CH3)3), 61.2 (CH2), 69.8, 
70.9, 84.5, 94.0 (CHrib), 106.9 (C-3a), 114.4 (t, 3JC,F = 8.9 Hz, C-5), 124.9, 125.2, 125.5, 
126.6, 127.1, 127.2, 128.3, 128.4, 129.0, 130.5 (CHAr, =CH), 134.0, 134.7, 135.5, 140.4, 
150.8, 157.5 (CAr), 160.4 (C=O), 160.6 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -79.40 
(t, 3JF,F = 9.2 Hz, 3F, CF3), -107.36 (q, 3JF,F = 9.2 Hz, 2F, CF2), -123.89 (t, 3JF,F = 22.0 Hz, 2F, 
CF2). IR (ATR, cm-1): v~ = 3390 (br w), 2960 (w), 1705 (m), 1699 (m), 1583 (s), 1495 (w), 
1413 (w), 1363 (m), 1272 (w), 1229 (s), 1201 (m), 1180 (m), 1149 (m), 1113 (s), 1094 (m), 
1028 (m), 966 (m), 951 (m), 878 (w), 834 (m), 734 (s), 694 (m), 662 (m), 559 (m). MS (EI, 70 
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eV): m/z (%) = 745 (0.1) [M+], 613 (88), 259 (61), 157 (38), 139 (100), 97 (37), 77 (32), 43 
(57). HRMS (ESI): calcd C38H35F7N3O5 ([M+1]+) 746.24595, found 746.24631. Anal. Calcd 
for C38H34F7N3O5: C, 61.21; H, 4.60; N, 5.64. Found: C, 60.95; H, 4.62; N, 5.67. 
 
9-Phenyl-1-β-D-ribofuranozyl-7-(trifluoromethyl)-9,10-dihydrochromeno[3,4-
e]pyrazolo[3,4-b]pyridine-6,8-dione (40t) 
Starting from 37t (328 mg, 0.5 mmol), 40t was isolated via 
column chromatography as yellow solid (251 mg, 95%); mp 
215-216 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.74 (s, 3H, CH3), 3.01-
3.06 (m, 1H, Ha-5’), 3.15-3.20 (m, 1H, Hb-5’), 3.60-3.65 (m, 
1H, H-4’), 3.86 (dd, 2JH,H = 8.9 Hz, 3JH,H = 5.1 Hz, 1H, H-3’), 4.56 (t, 3JH,H = 5.7 Hz, 1H, OH-
5’), 4.83 (dd, 2JH,H = 11.6 Hz, 3JH,H = 5.9 Hz, 1H, H-2’), 5.04 (d, 3JH,H = 5.1 Hz, 1H, OH-3’), 
5.35 (d, 3JH,H = 6.2 Hz, 1H, OH-2’), 5.48 (d, 3JH,H = 6.0 Hz, 1H, H-1’), 7.36-7.44 (m, 2H, Ph), 
7.48-7.60 (m, 5H, Ph), 7.66-7.73 (m, 1H, Ph), 8.79-8.82 (m, 1H, Ph). 13C NMR (62.9 MHz, 
CDCl3): δ = 61.1 (CH2), 69.5, 70.8, 85.0, 91.9 (CHrib), 95.7 (C-7a), 117.3 (CHAr), 117.7 (C-
6a), 121.1 (q, 1JC,F = 275.9 Hz, CF3), 125.2, 125.7, 126.7, 128.4, 129.6 (CHAr), 134.7 (CAr), 
134.9 (CHAr), 153.3, 155.2, 156.5 (CAr), 156.9 (CO-6) 157.0 (CO-8), 161.2 (C-10a). 19F NMR 
(282 MHz, DMSO-d6): δ = -61.59 (s). Anal. Calcd for C25H18F3N3O7: C, 56.72; H, 3.43; N, 
7.94. Found: C, 56.84; H, 3.48; N, 7.78. 
 
9-Methyl-1-β-D-ribofuranozyl-7-(trifluoromethyl)-9,10-dihydrochromeno[3,4-
e]pyrazolo[3,4-b]pyridine-6,8-dione (40u) 
Starting from 37u (297 mg, 0.5 mmol), 40u was isolated via 
column chromatography as yellow solid (215 mg, 92%); mp 
112-114 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.46-3.60 (m, 5H, NCH3, 
Ha-5’, Hb-5’), 3.88-3.89 (m, 1H, H-4’), 4.10 (br s, 1H, H-3’), 
4.59 (t, 3JH,H = 4.7 Hz, 1H, OH-5’), 4.87 (br s, 1H, H-2’), 5.22-
5.33 (m, 2H, OH-3’, OH-2’), 6.15 (d, 3JH,H = 6.4 Hz, 1H, H-1’), 7.46-7.52 (m, 2H, Ar), 7.76 
(t, 3JH,H = 7.6 Hz, 1H, Ar), 8.47 (t, 3JH,H = 7.6 Hz, 1H, Ar). 13C NMR (62.9 MHz, DMSO-d6): 
δ = 32.9 (NCH3), 61.1 (CH2), 69.5, 70.8, 85.0, 91.9 (CHrib), 109.6 (C-7a), 116.7 (CHAr), 117.8 
(C-6a), 121.3 (q, 1JC,F = 278.9 Hz, CF3), 125.0, 125.6, 134.2 (CHAr), 138.3 (q, 2JC,F = 37.5 Hz, 
CCF3), 152.5, 155.4, 156.6 (CAr), 157.9 (CO-6) 158.2 (CO-8), 159.8 (C-10a). 19F NMR (282 
MHz, DMSO-d6): δ = -55.59 (s). HRMS (ESI): calcd C20H17F3N3O10 ([M+1]+) 468.10131, 
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found 468.10121. Anal. Calcd for C20H16F3N3O7: C, 51.40; H, 3.45; N, 8.99. Found: C, 51.61; 
H, 3.50; N, 8.79. 
 
9-Methyl-1-β-D-ribofuranozyl-6,8-dioxo-6,8,9,10-tetrahydrochromeno[3,4-
e]pyrazolo[3,4-b]pyridine-7-carboxamide (40w) 
Starting from 37w (292 mg, 0.5 mmol), 40w was isolated via 
column chromatography as yellow solid (210 mg, 95%); mp 
148-149 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.46-3.60 (m, 5H, 
NCH3, Ha-5’, Hb-5’), 3.88-3.89 (m, 1H, H-4’), 4.10 (br s, 1H, 
H-3’), 4.59 (t, 3JH,H = 4.7 Hz, 1H, OH-5’), 4.87 (br s, 1H, H-
2’), 5.22-5.33 (m, 2H, OH-3’, OH-2’), 6.15 (d, 3JH,H = 6.4 Hz, 1H, H-1’), 7.38-7.41 (m, 1H, 
Ar), 7.45-7.50 (m, 1H, Ar), 7.64-7.69 (m, 1H, Ar), 8.71-8.75 (m, 1H, Ar), 10.23 (br s, 2H, 
NH2). 13C NMR (62.9 MHz, DMSO-d6): 31.0 (NCH3), 62.4 (CH2), 69.3, 71.8, 78.7, 90.4 
(CHRib), 109.5 (C-7a), 117.6 (CHAr), 118.3 (C-6a), 125.6, 126.4, 134.3 (CHAr), 143.9, 153.2, 
155.9, 158.9 (CAr), 159.1 (CO-6), 159.3 (CO-8), 164.3 (C-10a), 171.2 (CONH2). IR (ATR, 
cm-1): v~ = 3214 (br w), 2932 (w), 1704 (m), 1668 (m), 1610 (m), 1362 (m), 1332(w), 1262 
(w), 1201 (s), 1157 (m), 1085 (m), 1053 (m), 979 (s), 894 (w), 871 (w), 731 (s), 658 (m). MS 
(EI, 70 eV): m/z (%) = 443 (0.2) [M+1+], 442 (0.1) [M+], 325 (12), 310 (66), 294 (21), 293 
(100), 265 (41), 196 (30), 101 (45), 96 (20), 73 (20), 57 (34), 55 (21), 45 (54), 44 (31), 43 
(61). HRMS (ESI): calcd C20H19N4O8 ([M+1]+) 443.11978, found 443.12002. Anal. Calcd for 
C20H18N4O8: C, 54.30; H, 4.10; N, 12.66. Found: C, 54.19; H, 3.92; N, 12.21. 
 
1-α-D-Glucopyranozyl-6-methyl-2-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (41a) 
Starting from 38a (312 mg, 0.5 mmol), 41a was isolated via 
column chromatography as colorless solid (207 mg, 91%); mp 
146-148 oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.72 (s, 3H, CH3), 2.74 (br 
s, 1H, H-5’), 3.06-3.22 (m, 3H, H-3’, Ha-6’, Hb-6’) 3.56-3.62 (m, 
1H, H-4’), 4.39 (t, 3JH,H = 5.8 Hz, 1H, OH-6’), 4.92 (d, 3JH,H = 
5.8 Hz, 1H, H-2’), 5.10 (d, 3JH,H = 4.7 Hz, 1H, H-1’), 5.33-5.35 (m, 1H, OH-4’), 5.65 (br s, 
2H, OH-3’, OH-2’), 7.35-7.40 (m, 1H, Ph), 7.47-7.52 (m, 2H, Ph), 7.58 (s, 1H, H-5), 7.61-
7.64 (m, 2H, Ph). 13C NMR (62.9 MHz, DMSO-d6): δ = 25.0 (CH3), 61.1 (CH2), 69.7, 70.5, 
77.3, 79.7, 89.1 (CHgl), 102.6 (C-3a), 115.3 (q, 3JC,F = 5.0 Hz, CF3C-5), 121.8 (q, 1JC,F = 274.6 
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Hz, CF3), 125.8, 127.3, 128.5 (CHAr), 134.0 (q, 2JC,F = 35.7 Hz, CCF3), 135.5, 157.6 (CAr), 
159.6 (C=O), 165.4 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.23 (s). IR (ATR, cm-1): 
v~ = 3350 (br w), 2903 (w), 1674 (m), 1593 (m), 1493 (w), 1384 (m), 1337 (w), 1287 (w), 
1254 (w), 1143 (s), 1119 (m), 1077 (s), 1025 (s), 896 (w), 755 (m), 702 (s), 575 (m). MS (EI, 
70 eV): m/z (%) = 455 (0.3) [M+], 294 (100), 293 (55), 273 (25), 264 (78), 85 (32), 77 (99), 
73 (34), 57 (20), 43 (11). HRMS (ESI): calcd C20H21F3N3O6 ([M+1]+) 456.1377, found 
456.1377. Anal. Calcd for C20H20F3N3O6: C, 52.75; H, 4.43; N, 9.23. Found: C, 49.51; H, 
4.28; N, 8.39. 
 
1-α-D-Glucopyranozyl-2,6-biphenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (41b) 
Starting from 38b (343 mg, 0.5 mmol), 41b was isolated 
via column chromatography as yellow solid (243 mg, 
94%); mp 158-160 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.82-2.89 (m, 1H, H-
5’), 3.09-3.22 (m, 3H, Ha-6’, Hb-6’, H-4’), 3.56-3.62 (m, 
1H, H-3’), 4.39 (t, 3JH,H = 5.8 Hz, 1H, OH-6’), 4.94 (d, 
3JH,H = 5.8 Hz, 1H, H-1’), 5.16-5.18 (m, 1H, H-2’), 5.50-5.51 (m, 1H, OH-4’), 5.66 (br s, 2H, 
OH-3’, OH-2’), 7.40 (t, 3JH,H = 7.4 Hz, 1H, Ph), 7.51-7.56 (m, 2H, Ph), 7.60-7.62 (m, 3H, Ph), 
7.67-7.70 (m, 2H, Ph), 8.16 (s, 1H, H-5), 8.30-8.33 (m, 2H, Ph). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 61.0 (CH2), 69.8, 70.8, 77.3, 79.7, 89.2 (CHgl), 104.2 (C-3a), 112.1 (q, 3JC,F = 
5.1 Hz, C-5), 121.8 (q, 1JC,F = 274.2 Hz, CF3), 125.6, 127.4, 128.0, 128.7, 129.2, 131.3 
(CHAr), 135.2 (q, 2JC,F = 36.6 Hz, CCF3), 136.6, 155.0, 157.3 (CAr), 159.7 (CO), 161.2 (C-7a). 
19F NMR (282 MHz, DMSO-d6): δ = -61.04 (s). IR (ATR, cm-1): v~ = 3391 (br w), 2922 (w), 
1681 (m), 1592 (m), 1494 (w), 1444 (w), 1372 (s), 1263 (m), 1145 (s), 1067 (s), 1042 (s), 883 
(m), 775 (m), 751 (m), 690 (s). MS (EI, 70 eV): m/z (%) = 517 (0.10) [M+], 355 (100), 326 
(11), 77 (13), 71 (12), 57 (15), 43 (23). HRMS (ESI): calcd C25H23F3N3O6 ([M+1]+) 
518.15335, found 518.15315. Anal. Calcd for C25H22F3N3O6: C, 58.03; H, 4.29; N, 8.12. 
Found: C, 58.27; H, 4.51; N, 8.34. 
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1-α-D-Glucopyranozyl-2-methyl-6-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (41c) 
Starting from 38c (312 mg, 0.5 mmol), 41c was isolated via 
column chromatography as yellow solid (212 mg, 93%); mp 
199-202 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.20-3.28 (m, 1H, H-5’), 
3.29-3.38 (m, 1H, Ha-6’), 3.43-3.47 (m, 1H, Hb-6’), 3.51-3.60 
(m, 1H, H-4’), 3.53 (s, 3H, CH3), 3.69 (br s, 1H, OH-4’), 3.76-
3.82 (m, 1H, H-3’), 4.66 (t, 3JH,H = 5.7 Hz, 1H, OH-6’), 5.10-5.13 (m, 2H, H-2’, OH-3’), 5.18 
(d, 3JH,H = 5.7 Hz, 1H, OH-2’), 5.68 (d, 3JH,H = 8.9 Hz, 1H, H-1’), 7.58-7.61 (m, 3H, Ph), 8.02 
(s, 1H, H-5), 8.28-8.31 (m, 2H, Ph). 13C NMR (62.9 MHz, DMSO-d6): δ = 32.7 (CH3), 60.9 
(CH2), 69.6, 71.1, 77.2, 79.8, 88.0 (CHgl), 103.3 (C-3a), 110.8 (C-5), 121.8 (q, 1JC,F = 274.2 
Hz, CF3), 127.8, 129.0, 131.0 (CHAr), 134.6 (q, 2JC,F = 35.7 Hz, CCF3), 136.6, 158.5 (CAr), 
158.5 (C=O), 160.3 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -60.97 (s). IR (ATR, cm-1): 
v~ = 3271 (br w), 2907 (w), 1661 (m), 1638 (s), 1596 (m), 1417 (m), 1372 (m), 1253 (m), 
1277 (m), 1258 (m), 1237 (m), 1145 (s), 1076 (s), 1050 (s), 1015 (s), 904 (m), 775 (s), 687 
(s). MS (EI, 70 eV): m/z (%) = 455 (0.4) [M+], 294 (98), 293 (48), 273 (31), 264 (77), 85 (25), 
77 (100), 73 (21), 57 (20), 43 (48). HRMS (ESI): calcd C20H21F3N3O6 ([M+1]+) 456.1377, 
found 456.13728. Anal. Calcd for C20H20F3N3O6: C, 52.75; H, 4.43; N, 9.23. Found: C, 52.54; 
H, 4.36; N, 8.99. 
 
1-α-D-Glucopyranozyl-2-phenyl-6-(thiophen-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (41e) 
Starting from 38e (346 mg, 0.5 mmol), 41e was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (236 mg, 90%); 
mp 140-142 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.19-3.25 (m, 1H, H-5’), 
3.27-3.32 (m, 1H, Ha-6’), 3.40-3.46 (m, 1H, Hb-6’), 3.52-3.56 
(m, 1H, H-4’), 3.64-3.67 (m, 1H, H-3’), 4.37-4.80 (m, 1H, H-
2’), 4.65 (t, 3JH,H = 5.4 Hz, 1H, OH-6’), 5.10 (d, 3JH,H = 5.4 Hz, 2H, OH-4’, OH-3’), 5.15 (d, 
3JH,H = 5.4 Hz, 1H, OH-2’), 5.64 (d, 3JH,H = 9.0 Hz, 1H, H-1’), 7.30 (dd, 3JH,H = 4.9 Hz, 3JH,H = 
4.0 Hz, 1H, Hetar), 7.38-7.44 (m, 1H, Ar), 7.53-7.60 (m, 4H, Ar), 7.96 (dd, 3JH,H = 4.9 Hz, 
4JH,H = 0.9 Hz, 1H, Hetar), 8.22 (s, 1H, H-5), 7.93 (dd, 3JH,H = 3.8 Hz, 4JH,H = 0.9 Hz, 1H, 
Hetar). 13C NMR (62.9 MHz, DMSO-d6): δ = 60.9 (CH2), 69.6, 71.1, 77.2, 79.8, 88.0 (CHgl), 
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104.8 (C-3a), 111.5 (q, 3JC,F = 5.0 Hz, C-5), 121.5 (q, 1JC,F = 274.5 Hz, CF3), 124.7, 127.2, 
129.1, 129.3, 130.4, 132.6 (CHAr), 135.0 (CAr), 135.2 (q, 2JC,F = 36.0 Hz, CCF3), 142.1, 156.4 
(CAr), 157.6 (C=O), 160.3 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.21 (s). IR (ATR, 
cm-1): v~ = 3365 (br w), 2918 (m), 2851 (w), 1682 (m), 1589 (m), 1537 (m), 1494 (w), 1489 
(w), 1423 (m), 1378 (m), 1346 (m), 1265 (m), 1143 (s), 1039 (s), 854 (m), 753 (m), 713 (m). 
MS (EI, 70 eV): m/z (%) = 523 (0.1) [M+], 362 (21), 361 (100), 332 (11), 77 (10). HRMS 
(ESI): calcd C23H21F3N3O6S ([M+1]+) 524.10977, found 524.11001. Anal. Calcd for 
C23H20F3N3O6S: C, 52.77; H, 3.85; N, 8.03. Found: C, 52.86; H, 3.87; N, 7.91. 
 
1-α-D-Glucopyranozyl-6-(4-(difluoromethoxy)phenyl)-2-phenyl-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (41g) 
Starting from 38g (376 mg, 0.5 mmol), 41g was isolated 
via column chromatography as yellow solid (280 mg, 
96%); mp 148-150 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.82-2.89 (m, 1H, 
H-5’), 3.12-3.25 (m, 3H, Ha-6’, Hb-6’, H-4’), 3.56-3.62 
(m, 1H, H-3’), 4.39 (t, 3JH,H = 5.6 Hz, 1H, OH-6’), 4.94 (d, 3JH,H = 5.6 Hz, 1H, H-1’), 5.16 (br 
s, 1H, H-2’), 5.50 (br s, 1H, OH-4’), 5.67 (br s, 2H, OH-3’, OH-2’), 7.38-7.43 (m, 3H, Ar), 
7.43 (t, 1JH,H = 73.7 Hz, 1H, OCF2H), 7.51-7.56 (m, 2H, Ar), 7.66-7.69 (m, 2H, Ar), 8.17 (s, 
1H, H-5), 8.39-8.42 (m, 2H, Ar). 13C NMR (75.5 MHz, DMSO-d6): δ = 61.0 (CH2), 69.7, 
70.8, 77.3, 79.7, 89.2 (CHgl), 104.0 (C-8), 112.0 (q, 3JC,F = 5.0 Hz, C-5), 116.1 (t, 1JC,F = 258.0 
Hz, OCF2H), 118.7 (CHAr), 121.7 (q, 1JC,F = 274.6 Hz, CF3), 125.6, 127.4, 128.7, 130.0, 133.3 
(CHAr), 135.3 (q, 2JC,F = 35.2 Hz, CCF3), 153.3 (t, 3JC,F = 3.3 Hz, COCF2H), 157.3 (C-6), 
159.6 (CO), 160.1 (C-9). 19F NMR (282 MHz, DMSO-d6): δ = -61.0 (s, 3F, CF3), -82.8 (s, 2F, 
OCF2H). IR (ATR, cm-1): v~ = 3389 (br w), 2927 (w), 1679 (w), 1594 (m), 1374 (m), 1264 
(w), 1097 (m), 1048 (s), 841 (m). MS (EI, 70 eV): m/z (%) = 583 (0.05) [M+], 421 (100), 392 
(6), 77 (26). HRMS (ESI): calcd C26H23F5N3O7 ([M+1]+) 584.1451, found 584.1455. Anal. 
Calcd for C26H22F5N3O7: C, 53.52; H, 3.80; N, 7.20. Found: C, 53.76; H, 3.69; N, 7.15. 
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1-α-D-Glucopyranozyl-6-(4-(difluoromethoxy)phenyl)-2-methyl-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (41h) 
Starting from 38h (345 mg, 0.5 mmol), 41h was isolated 
via column chromatography as yellow solid (245 mg, 
94%); mp 229-231 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.19-3.25 (m, 1H, 
H-5’), 3.27-3.32 (m, 1H, Ha-6’), 3.40-3.46 (m, 1H, Hb-
6’), 3.50 (s, 3H, NCH3), 3.52-3.56 (m, 1H, H-4’), 3.64-3.67 (m, 1H, H-3’), 4.37-4.80 (m, 1H, 
H-2’), 4.65 (t, 3JH,H = 5.6 Hz, 1H, OH-6’), 5.10 (d, 3JH,H = 5.1 Hz, 2H, OH-4’, OH-3’), 5.15 
(d, 3JH,H = 5.3 Hz, 1H, OH-2’), 5.64 (d, 3JH,H = 8.7 Hz, 1H, H-1’), 7.33-7.36 (m, 2H, Ar), 7.40 
(t, 2JH,F = 73.7 Hz, 1H, OCF2H), 8.00 (s, 1H, H-5), 8.34-8.37 (m, 2H, Ar). 13C NMR (62.9 
MHz, DMSO-d6): δ = 32.7 (NCH3), 60.9 (CH2), 69.6, 71.1, 77.2, 79.8, 88.0 (CHgl), 103.3 (C-
3a), 110.6 (q, 3JC,F = 5.0 Hz, C-5), 116.1 (t, 1JC,F = 258.2 Hz, OCF2H), 118.7 (CHAr), 126.2 (q, 
1JC,F = 275.1 Hz, CF3), 129.9 (CHAr), 133.4 (CAr), 134.7 (q, 2JC,F = 35.3 Hz, CCF3), 153.1 (t, 
3JC,F = 3.2 Hz, COCF2H), 158.5 (CAr), 158.6 (C=O), 159.3 (C-7a). 19F NMR (282 MHz, 
DMSO-d6): δ = -60.95 (s, 3F, CF3), -82.75 (s, 2F, OCF2H). IR (ATR, cm-1): v~ = 3342 (br w), 
2936 (w), 2889 (w), 1693 (m), 1659 (m), 1593 (m), 1374 (m), 1268 (m), 1226 (m), 1169 (m), 
1143 (m), 1103 (s), 1068 (s), 1036 (s), 1012 (m), 841 (m), 671 (m). MS (EI, 70 eV): m/z (%) 
= 521 (0.4) [M+], 360 (37), 359 (100), 331 (17), 85 (21), 73 (28), 61 (15), 57 (18), 43 (37). 
HRMS (ESI): calcd C21H21F5N3O7 ([M+1]+) 522.12942, found 522.13064. Anal. Calcd for 
C21H20F5N3O7: C, 48.38; H, 3.87; N, 8.06. Found: C, 47.88; H, 3.90; N, 7.86. 
 
1-α-D-Glucopyranozyl-3-oxo-2-phenyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridine-4-carboxylic acid (41i) 
Starting from 38i (345 mg, 0.5 mmol), 41i was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (241 mg, 97%); 
mp 188-190 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.43 (s, 3H, CH3), 2.83 
(br s, 1H, H-5’), 3.13-3.25 (m, 3H, Ha-6’, Hb-6’, H-4’), 3.34 (br 
s, 1H, H-3’), 3.58-3.63 (m, 1H, H-2’), 4.43 (t, 3JH,H = 5.7 Hz, 
1H, OH-6’), 4.96 (d, 3JH,H = 5.5 Hz, 1H, OH-4’), 5.19 (d, 3JH,H = 4.3 Hz, 1H, OH-3’), 5.48 (br 
s, 1H, OH-2’), 5.64 (d, 3JH,H = 8.9 Hz, 1H, H-1’), 7.43 (m, 2H, Ar), 7.46-7.49 (m, 1H, Ar), 
7.58 (t, 3JH,H = 7.6 Hz, 2H, Ar), 7.71 (d, 3JH,H = 7.6 Hz, 2H, Ar), 8.15-8.20 (m, 3H, Ar), 8.33 
(s, 1H, H-5), 10.23 (s, 1H, CO2H). 13C NMR (62.9 MHz, DMSO-d6): δ = 21.0 (CH3), 61.1 
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(CH2), 69.8, 70.7, 77.3, 79.6, 89.1 (CHgl), 104.7 (C-3a), 115.7, 126.2, 127.4, 127.9, 128.7, 
129.8 (CHAr), 134.3, 134.7, 141.0, 141.5, 159.4 (CAr), 160.1 (C=O), 160.5 (C-7a), 163.4 
(CO2H). IR (ATR, cm-1): v~ = 3306 (br w), 3065 (w), 2917 (w), 1667 (m), 1565 (s), 1493 (m), 
1367 (m), 1278 (m), 1185 (w), 1069 (s), 1040 (s), 891 (w), 826 (m), 750 (m), 694 (m), 658 
(m), 577 (s). MS (EI, 70 eV): m/z (%) = 508 (0.13) [M++1], 507 (0.48) [M+], 506 (0.47) [M+-
1], 345 (86), 344 (100), 299 (35), 77 (41). HRMS (ESI): calcd C26H27N4O7 ([M+1]+) 
507.1874, found 507.1877. Anal. Calcd for C26H25N3O8: C, 61.53; H, 4.97; N, 8.28. Found: 
C, 61.90; H, 5.02; N, 8.35. 
 
1-α-D-Glucopyranozyl-2-phenyl-6-(pyridin-2-yl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (41l) 
Starting from 38l (344 mg, 0.5 mmol), 41l was isolated via 
column chromatography as yellow solid (220 mg, 85%); mp 
148-150 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.20-3.26 (m, 1H, H-5’), 
3.27-3.32 (m, 1H, Ha-6’), 3.40-3.46 (m, 1H, Hb-6’), 3.52-3.56 
(m, 1H, H-4’), 3.64-3.67 (m, 1H, H-3’), 4.37-4.80 (m, 1H, H-
2’), 4.65 (t, 3JH,H = 5.6 Hz, 1H, OH-6’), 5.10 (d, 3JH,H = 5.1 Hz, 2H, OH-4’, OH-3’), 5.15 (d, 
3JH,H = 5.3 Hz, 1H, OH-2’), 5.64 (d, 3JH,H = 8.7 Hz, 1H, H-1’), 7.40-7.45 (m, 1H, Ar), 7.54-
7.62 (m, 5H, Ar), 7.99 (td, 3JH,H = 7.8 Hz, 4JH,H = 1.9 Hz, 1H, Ar), 8.16 (s, 1H, H-5), 8.48 (d, 
3JH,H = 7.8 Hz, 1H, Ar), 8.81-8.83 (m, 1H, Ar). 13C NMR (62.9 MHz, DMSO-d6): δ = 60.9 
(CH2), 69.6, 71.1, 77.2, 79.8, 88.0 (CHrib), 105.7 (C-3a), 112.9 (q, 3JC,F = 5.0 Hz, C-5), 121.7 
(q, 1JC,F = 274.7 Hz, CF3), 124.9, 127.3, 127.8, 129.0, 129.2, 131.4 (CHAr), 135.0 (q, 2JC,F = 
35.9 Hz, CCF3), 135.3, 136.2 (CAr), 150.1 (CHAr), 157.8 (CAr), 160.7 (C=O), 161.2 (C-7a). 19F 
NMR (282 MHz, DMSO-d6): δ = -66.55 (s). MS (EI, 70 eV): m/z (%) = 518 (0.1) [M+], 357 
(80), 356 (100), 355 (17), 252 (23), 251 (63), 223 (16), 203 (16), 77 (34). HRMS (ESI): calcd 
C24H22F3N4O6 ([M+1]+) 519.1486, found 519.1492. Anal. Calcd for C24H21F3N4O6: C, 55.60; 
H, 4.08; N, 10.81. Found: C, 55.42; H, 4.10; N, 10.85. 
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1-α-D-Glucopyranozyl-9-phenyl-7-(trifluoromethyl)-9,10-dihydrochromeno[3,4-
e]pyrazolo[3,4-b]pyridine-6,8-dione (41t) 
Starting from 38t (292 mg, 0.5 mmol), 41t was isolated via 
column chromatography as yellow solid (240 mg, 89%); mp 88-
89 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.20-3.26 (m, 1H, H-5’), 
3.28-3.31 (m, 1H, Ha-6’), 3.40-3.45 (m, 1H, Hb-6’), 3.52-3.56 (m, 
1H, H-4’), 3.64-3.67 (m, 1H, H-3’), 4.37-4.80 (m, 1H, H-2’), 4.65 (t, 3JH,H = 5.7 Hz, 1H, OH-
6’), 5.10 (d, 3JH,H = 5.1 Hz, 2H, OH-4’, OH-3’), 5.15 (d, 3JH,H = 5.3 Hz, 1H, OH-2’), 5.64 (d, 
3JH,H = 8.7 Hz, 1H, H-1’),  7.40-7.57 (m, 7H, Ar), 7.70-7.76 (m, 1H, Ar), 8.72 (d, 3JH,H = 7.6 
Hz, 1H, Ar). 13C NMR (62.9 MHz, DMSO-d6): δ = 61.6 (CH2), 67.7, 69.0, 73.4, 74.8, 85.8 
(CHgl), 95.7 (C-7a), 117.3 (CHAr), 117.7 (C-6a), 121.1 (q, 1JC,F = 276.0 Hz, CF3), 125.2, 
125.7, 126.7, 128.4, 129.6 (CHAr), 134.7 (CAr), 134.9 (CHAr), 153.3, 155.2, 156.5 (CAr), 156.9 
(CO-6) 157.0 (CO-8), 161.2 (C-10a). 19F NMR (282 MHz, CDCl3): δ = -60.12 (s). MS (EI, 70 
eV): m/z (%) = 559 (0.1) [M+], 398 (32), 397 (100), 396 (41), 170 (58), 169 (99), 139 (20), 
109 (88), 98 (21), 97 (42), 77 (49), 43 (58). HRMS (ESI): calcd C26H21F3N3O8 ([M+1]+) 
560.12348, found 560.12352. Anal. Calcd for C26H20F3N3O8: C, 55.82; H, 3.60; N, 7.51. 
Found: C, 55.61; H, 3.54; N, 7.55. 
 
1-α-D-Glucopyranozyl-9-methyl-6,8-dioxo-6,8,9,10-tetrahydrochromeno[3,4-
e]pyrazolo[3,4-b]pyridine-7-carboxylic acid (41w) 
Starting from 38w (328 mg, 0.5 mmol), 41w was isolated via 
crystallization (CH2Cl2/MeOH) as yellow solid (199 mg, 91%); 
mp 124-125 oC. 
1H NMR (250 MHz, DMSO-d6): δ = 3.20-3.29 (m, 1H, H-5’), 
3.38-3.44 (m, 2H, Ha-6’, Hb-6’), 3.50 (s, 3H, NCH3), 3.52-3.59 
(m, 2H, H-4’, H-3’), 3.75-3.81 (m, 1H, H-2’), 4.66 (t, 3JH,H = 4.8 
Hz, 1H, OH-6’), 5.14-5.16 (m, 2H, OH-4’, OH-3’), 5.29 (d, 3JH,H = 4.6 Hz, 1H, OH-2’), 5.75-
5.80 (m, 1H, H-1’), 7.33-7.36 (m, 2H, Ar), 8.00 (s, 1H, H-5), 8.34-8.37 (m, 2H, Ar). 13C 
NMR (62.9 MHz, DMSO-d6): 22.5 (NCH3), 62.9 (CH2), 69.6, 71.0, 77.2, 79.8, 97.1 (CHGlu), 
107.4 (C-7a), 116.9 (CHAr), 118.3 (C-6a), 124.9, 125.8, 133.8 (CHAr), 144.1, 148.4, 152.6, 
154.6 (CAr), 157.8 (CO-6), 159.4 (CO-8), 164.6 (C-10a), 171.5 (CO2H). MS (EI, 70 eV): m/z 
(%) = 437 (0.1) [M+], 310 (67), 293 (100), 265 (44), 196 (37), 73 (20), 63 (21), 60 (23), 44 
(64), 43 (29). HRMS (ESI): calcd C21H21N4O9 ([M+1]+) 473.1303, found 473.1302. Anal. 
Calcd for C21H19N3O10: C, 53.28; H, 4.05; N, 8.88. Found: C, 53.60; H, 4.21; N, 8.69. 
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2,6-Biphenyl-1-α-L-rhamnopyranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (42a) 
Starting from 39a (283 mg, 0.5 mmol), 42a was isolated via column 
chromatography as colorless foam (198, 90%); mp 86-87 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 0.93 (d, 3JH,H = 6.6 Hz, 3H, 
CH3 (Rhamn)), 2.71 (s, 3H, CH3), 3.21-3.25 (m, 1H, H-5’), 3.32 (t, 
3JH,H = 3.1 Hz, 1H, H-4’), 3.70 (dd, 3JH,H = 5.4 Hz, 3JH,H = 3.3 Hz, 
1H, H-3’), 4.61-4.67 (m, 1H, H-2’), 4.95 (d, 3JH,H = 4.2 Hz, 2H, 
OH-4’, OH-3’), 5.04 (d, 3JH,H = 6.2 Hz, 1H, OH-2’), 5.53 (d, 3JH,H = 9.1 Hz, 1H, H-1’), 7.34-
7.40 (m, 1H, Ph), 7.49-7.54 (m, 2H, Ph), 7.58-7.61 (m, 3H, H-5, Ph). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 16.7 (CH3(rhamn)), 25.0 (CH3), 65.6, 72.4, 72.7, 75.2, 82.1 (CHrhamn), 103.7 (C-
3a), 110.7 (q, 3JC,F = 5.0 Hz, C-5), 121.8 (q, 1JC,F = 274.9 Hz, CF3), 127.7, 129.1, 131.0 
(CHAr), 134.6 (q, 2JC,F = 36.1 Hz, CCF3), 136.7 (CAr), 158.3 (C-6), 158.8 (C=O), 160.2 (C-7a). 
19F NMR (282 MHz, DMSO-d6): δ = -61.28 (s). IR (ATR, cm-1): v~ = 3401 (br w), 2933 (w), 
1681 (m), 1674 (m), 1592 (m), 1489 (w), 1428 (w), 1381 (m), 1359 (m), 1243 (m), 1142 (s), 
1116 (m), 1037 (s), 999 (m), 890 (m), 719 (m), 693 (m). HRMS (ESI): calcd C20H21F3N3O5 
([M+1]+) 440.14278, found 440.14272. Anal. Calcd for C20H20F3N3O5: C, 54.67; H, 4.59; N, 
9.56. Found: C, 54.77; H, 4.60; N, 9.52. 
 
2,6-Biphenyl-1-α-L-rhamnopyranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (42b) 
Starting from 39b (314 mg, 0.5 mmol), 42b was isolated via 
column chromatography as yellow solid (234, 93%); mp 142-144 
oC. 
1H NMR (300 MHz, DMSO-d6): δ = 0.97 (d, 3JH,H = 6.6 Hz, 3H, 
CH3), 3.30-3.38 (m, 2H, H-4’, OH-3’), 3.46-3.51 (m, 1H, H-5’), 
3.82-3.83 (m, 1H, H-3’), 4.97-5.02 (m, 2H, H-2’, OH-4’), 5.23 (d, 
3JH,H = 6.3 Hz, 1H, OH-2’), 5.54 (d, 3JH,H = 9.1 Hz, 1H, H-1’), 7.41 (t, 3JH,H = 7.4 Hz, Ph), 
7.54-7.67 (m, 7H, Ph), 8.18 (s, 1H, H-5), 8.34-8.36 (m, 2H, Ph). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 17.5 (CH3), 65.4, 73.4, 74.1, 74.2, 84.9 (CHrhamnose), 104.9 (C-3a), 112.0 (C-
5), 121.7 (q, 1JC,F = 275.0 Hz, CF3), 125.1, 127.2, 127.9, 128.9, 129.1, 131.2 (CHAr), 135.2 (q, 
2JC,F = 36.0 Hz, CCF3), 135.3, 136.5, 157.6 (CAr), 160.8 (C=O), 161.1 (C-7a). 19F NMR (282 
MHz, DMSO-d6): δ = -61.07 (s). IR (ATR, cm-1): v~ = 3391 (br w), 2931 (w), 1674 (m), 1591 
(s), 1494 (w), 1443 (w), 1373 (s), 1262 (m), 1142 (s), 1035 (s), 878 (m), 774 (m), 687 (s). MS 
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(EI, 70 eV): m/z (%) = 501 (1.4) [M+], 355 (23), 273 (96), 171 (21), 153 (100), 111 (79), 83 
(22), 77 (22), 43 (100). HRMS (ESI): calcd C25H23F3N3O5 ([M+1]+) 502.15843, found 
502.15964. Anal. Calcd for C25H22F3N3O5: C, 59.88; H, 4.42; N, 8.38. Found: C, 60.23; H, 
4.24; N, 8.19. 
 
2-Methyl-6-phenyl-1-α-L-rhamnopyranozyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (42c) 
Starting from 39c (283 mg, 0.5 mmol), 42c was isolated via 
column chromatography as yellow solid (248 mg, 90%); mp 
182-184 oC. 
1H NMR (300 MHz, DMSO-d6): 1.40 (d, 3JH,H = 6.8Hz, 3H, CH3 
(rhamn)), 3.55 (s, 3H, NCH3), 3.55-3.58 (m, 1H, H-4’), 3.76-
3.78 (m, 1H, OH-3’), 3.92-3.93 (m, 1H, H-5’), 4.00-4.03 (m, 1H, H-3’), 4.33-4.43 (m, 1H, H-
2’), 4.88 (d, 3JH,H = 6.6Hz, 1H, OH-2’), 5.11-5.14 (m, 2H, H-2’, OH-4’), 6.07 (d, 3JH,H = 
9.1Hz, 1H, H-1’), 7.56-7.58 (m, 2H, Ph), 8.00 (s, 1H, H-5), 8.23-8.26 (m, 2H, Ph). 13C NMR 
(62.9 MHz, DMSO-d6): δ = 16.7 (CH3), 32.2 (NCH3), 65.6, 72.4, 72.7, 75.2, 82.1 (CHrhamn), 
103.7 (C-3a), 110.7 (q, 3JC,F = 5.0 Hz, C-5), 121.8 (q, 1JC,F = 275.1 Hz, CF3), 127.7, 129.1, 
131.0 (CHAr), 134.6 (q, 2JC,F = 35.2 Hz, CCF3), 136.7 (CAr), 158.3 (C-6), 158.8 (C=O), 160.2 
(C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -60.95 (s). IR (ATR, cm-1): v~ = 3367 (br w), 
2938 (w), 1683 (m), 1595 (m), 1410 (w), 1369 (m), 1263 (m), 1230 (w), 1173 (m), 1113 (m), 
1053 (s), 1034 (m), 1020 (m), 979 (m), 872 (m), 778 (m), 696 (s). MS (EI, 70 eV): m/z (%) = 
439 (0.2) [M+], 293 (100), 265 (37), 222 (16), 84 (89), 78 (84), 66 (98), 63 (88), 43 (29). 
HRMS (ESI): calcd C20H21F3N3O5 ([M+1]+) 440.14278, found 440.14274. Anal. Calcd for 
C20H20F3N3O5: C, 54.67; H, 4.59; N, 9.56. Found: C, 54.52; H, 4.59; N, 9.64. 
 
2-Phenyl-1-α-L-rhamnopyranozyl-6-(thiophen-2-yl)-4-(trifluoromethyl)-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (42e) 
Starting from 39e (317 mg, 0.5 mmol), 42e was isolated via 
column chromatography as yellow solid (246 mg, 97%); mp 
197-199 oC. 
1H NMR (250 MHz, DMSO-d6): δ = 0.96 (d, 3JH,H = 6.5 Hz, 
3H, CH3), 3.27 (br m, 1H, H-4’), 3.30-3.38 (m, 2H, H-4’), 3.43-
3.52 (m, 1H, H-5’), 4.77 (br s, 1H, H-3’), 4.79-4.85 (m, 1H, H-
2’), 4.97 (d, 3JH,H = 2.8 Hz, 2H, OH-3’, OH-4’), 5.18 (d, 3JH,H = 6.0 Hz, 1H, OH-2’), 5.58 (d, 
3JH,H = 9.0 Hz, 1H, H-1’), 7.27-7.31 (m, 1H, Ar/Hetar), 7.36-7.41 (m, 1H, Ar/Hetar), 7.50-764 
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(m, 4H, Ar/Hetar), 7.93 (d, 3JH,H = 4.9 Hz, 1H, Hetar), 8.15 (s, 1H, H-5), 8.30 (d, 3JH,H = 3.3 
Hz, 1H, Hetar). 13C NMR (62.9 MHz, DMSO-d6): δ = 17.7 (CH3), 65.4, 73.7, 73.9, 74.7, 85.2 
(CHrh), 104.2 (C-3a), 110.8 (q, 3JC,F = 5.0 Hz, C-5), 122.6 (q, 1JC,F = 274.6 Hz, CF3), 125.1, 
127.1, 128.8, 129.2, 130.1, 132.6 (CHAr), 135.1 (q, 2JC,F = 35.7 Hz, CCF3), 135.5, 142.4, 
156.4 (CAr), 157.7 (C=O), 160.6 (C-7a). 19F NMR (282 MHz, CDCl3): δ = -61.25 (s). IR 
(ATR, cm-1): v~ = 3390 (br w), 3078 (w), 2915 (w), 1668 (w), 1591 (w), 1538 (w), 1496 (w), 
1426 (w), 1379 (w), 1348 (w), 1268 (w), 1141 (m), 1115 (m), 1037 (m), 998 (w), 891 (w), 
711 (s). MS (EI, 70 eV): m/z (%) = 633 (0.2) [M+], 362 (22), 361 (100), 332 (17), 77 (19), 57 
(17), 43 (19). HRMS (ESI): calcd C23H21F3N3O5S ([M+1]+) 508.1149, found 508.1146. Anal. 
Calcd for C23H20F3N3O5S: C, 54.43; H, 3.97; N, 8.28. Found: C, 54.61; H, 3.99; N, 8.25. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-1-α-L-rhamnopyranozyl-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (42g) 
Starting from 39g (317 mg, 0.5 mmol), 42g was isolated 
via column chromatography as yellow solid (250 mg, 
88%); mp 120-122 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 0.96 (d, 3JH,H = 6.8 
Hz, 3H, CH3), 3.30-3.34 (m, 1H, H-4’), 3.42-3.48 (m, 1H, 
H-5’), 3.81-3.82 (m, 1H, H-3’), 4.94-5.02 (m, 3H, H-2’, OH-3’, OH-4’), 5.24 (d, 3JH,H = 6.0 
Hz, 1H, OH-2’), 5.52 (d, 3JH,H = 8.9 Hz, 1H, H-1’), 7.36-7.40 (m, 3H, Ar), 7.43 (t, 2JF,H = 73.7 
Hz, 1H, OCF2H), 7.52-7.58 (m, 2H, Ar), 7.64-7.68 (m, 2H, Ar), 8.18 (s, 1H, H-5), 8.41-8.44 
(m, 2H, Ar). 13C NMR (75.5 MHz, DMSO-d6): δ = 17.5 (CH3), 65.5, 73.5, 74.2, 74.3, 85.0 
(CHrhamn), 104.8 (C-3a), 112.0 (q, 3JC,F = 5.0 Hz, C-5), 116.1 (t, 1JC,F = 258.6 Hz, OCF2H), 
118.6 (CHAr), 121.8 (q, 1JC,F = 274.5 Hz, CF3), 125.1, 127.2, 128.9, 130.0 (CHAr), 133.3, 
135.3 (CAr), 135.3 (q, 2JC,F = 35.8 Hz, CCF3), 153.3 (t, 3JC,F = 3.3 Hz, COCF2H), 157.6 (C-6), 
160.0 (C=O), 160.8 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.11 (s, 3F, CF3), -82.77 
(s, 2F, OCF2H). IR (ATR, cm-1): v~ = 3401 (br w), 3069 (w), 2934 (w), 1674 (m), 1593 (m), 
1373 (m), 1263 (m), 1225 (m), 1112 (s), 1033 (s), 890 (m), 839 (m). MS (EI, 70 eV): m/z (%) 
= 567 (0.13) [M+], 421 (100), 362 (22), 77 (27). HRMS (ESI): calcd C26H23F5N3O6 ([M+1]+) 
568.1502, found 568.1506. Anal. Calcd for C26H22F5N3O6: C, 55.03; H, 3.91; N, 7.40. Found: 
C, 53.18; H, 3.78; N, 7.32. 
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6-(4-(Difluoromethoxy)phenyl)-2-methyl-1-α-L-rhamnopyranozyl-4-(trifluoromethyl)-
1H-pyrazolo[3,4-b]pyridin-3(2H)-one (42h) 
Starting from 39h (316 mg, 0.5 mmol), 42h was 
isolated via column chromatography as yellow solid 
(230 mg, 91%); mp 235-237 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.40 (d, 3JH,H = 
6.9 Hz, 3H, CH3), 3.54 (s, 3H, NCH3), 3.56-3.59 (m, 
1H, H-5’), 3.92 (dd, 3JH,H = 6.9 Hz, 3JH,H = 3.4 Hz, 1H, 
H-4’), 3.97-4.04 (m, 1H, H-3’), 4.36-4.42 (m, 1H, H-2’), 4.88 (d, 3JH,H = 6.9 Hz, OH-3’), 5.13 
(dd, 3JH,H = 6.5 Hz, 3JH,H = 3.9 Hz, 2H, OH-4’, OH-2’), 6.05 (d, 3JH,H = 8.9 Hz, 1H, H-1’), 
7.37 (d, 3JH,H = 8.9 Hz, 2H, Ar), 7.39 (t, 2JF,H = 73.7 Hz, 1H, OCF2H), 8.02 (s, 1H, H-5), 8.33 
(dt, 3JH,H = 8.9 Hz, 4JH,H = 1.9 Hz, 2H, Ar). 13C NMR (75.5 MHz, DMSO-d6): δ = 16.7 (CH3), 
32.2 (NCH3), 65.6, 72.3, 72.6, 75.2, 82.2 (CHrhamn), 103.6 (C-3a), 110.6 (q, 3JC,F = 5.0 Hz, C-
5), 116.1 (t, 1JC,F = 258.2 Hz, OCF2H), 118.7 (CHAr), 121.9 (q, 1JC,F = 275.1 Hz, CF3), 129.7 
(CHAr), 133.4, (CAr), 134.7 (q, 2JC,F = 35.7 Hz, CCF3), 153.1 (t, 3JC,F = 3.4 Hz, COCF2H), 
158.2 (C-6), 158.7 (C=O), 159.2 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -61.24 (s, 3F, 
CF3), -82.64 (s, 2F, OCF2H). GC/MS (EI) m/z (%) = 506 (0.1) [M+], 359 (100), 265 (30), 150 
(36), 84 (68), 66 (72), 43 (22). HRMS (ESI): calcd C21H21F5N3O6 ([M+1]+) 506.1345, found 
506.13435. Anal. Calcd for C21H20F5N3O6: C, 49.91; H, 3.99; N, 8.31. Found: C, 49.79; H, 
4.05; N, 8.34. 
 
3-Oxo-2-phenyl-1-α-L-rhamnopyranozyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridine-4-carboxylic acid (42i) 
Starting from 39i (316 mg, 0.5 mmol), 42i was isolated via 
crystallization (CH2Cl2/MeOH) as colorless solid (442 mg, 
90%); mp 328-330 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 0.95 (d, 3JH,H = 6.6 Hz, 
3H, CH3-6’), 2.40 (s, 3H, CH3-4’’), 3.29-3.32 (m, 1H, H-4’), 
3.45-3.53 (m, 1H, H-5’), 3.81-3.82 (m, 1H, H-3’), 4.97-5.04 
(m, 3H, H-2’, OH-3’, OH-4’), 5.23 (d, 3JH,H = 6.0 Hz, 1H, OH-2’), 5.53 (d, 3JH,H = 8.9 Hz, 1H, 
H-1’), 7.38-7.41 (m, 2H, Ar), 7.44-7.47 (m, 1H, Ar), 7.55-7.60 (m, 2H, Ar), 7.66-7.68 (m, 
2H, Ar), 8.15-8.18 (m, 3H, Ar), 8.33 (s, 1H, H-5), 10.22 (s, 1H, CO2H). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 17.6 (CH3), 21.0 (CH3rhamnose), 65.5, 73.6, 74.1, 74.4, 85.0 (CHrhamn), 105.3 
(C-3a), 115.7 (C-5), 125.7, 127.5, 127.7, 129.0, 129.8 (CHAr), 134.3, 134.8, 141.0, 141.6 
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(CAr), 163.4 (C=O), 160.4 (C-7a), 163.4 (CO2H). IR (ATR, cm-1): v~ = 3333 (br w), 3183 (w), 
3062 (w), 1668 (m), 1581 (m), 1496 (w), 1370 (m), 1277 (m), 1211 (m), 1062 (m), 1041 (m), 
1024 (s), 979 (m), 745 (m), 690 (m), 657 (m), 605 (s), 571 (s). MS (EI, 70 eV): m/z (%) = 491 
(0.4) [M+], 344 (100), 315 (32), 301 (14), 272 (14), 168 (17), 77 (60). Anal. Calcd for 
C26H25N3O7: C, 63.54; H, 5.13; N, 8.55. Found: C, 63.64; H, 5.10; N, 8.26. 
 
A.2.8. General procedure for synthesis of compounds 43-45 
Compounds 37i, 38i, 39i (0.5 mmol) were dissolved in 20mL MeOH and 5 mL of hydrazine 
hydrate was added. The mixture was stirred at room temperature overnight. The precipitate 
formed was filtrated, washed with CH2Cl2 and recrystallized from CH2Cl2/MeOH to afford 
bright-yellow solids.  
 
3-Oxo-2-phenyl-1-β-D-ribofuranozyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-b]pyridine-
4-carbohydrazide (43) 
Starting from 37i (309 mg, 0.5 mmol), 43 was isolated as 
yellow solid (245 mg, quant.); mp 238-239 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.42 (s, 3H, CH3), 2.89-
2.97 (m, 1H, Ha-5’), 3.07-3.14 (m, 1H, Ha-5’), 3.59 (q, 3JH,H 
= 4.9 Hz, 1H, H-4’), 3.87 (q, 3JH,H = 4.9 Hz, 1H, H-3’), 4.47 
(t, 3JH,H = 4.9 Hz, 1H, OH-5’), 4.96 (d, 3JH,H = 4.0 Hz, 2H, 
NH2), 5.02-5.08 (m, 2H, H-2’, OH-3’), 5.42 (d, 3JH,H = 6.0 Hz, 1H, OH-2’), 5.50 (d, 3JH,H = 
5.7 Hz, 1H, H-1’), 7.41-7.43 (m, 2H, Ar), 7.47-7.49 (m, 1H, Ar), 7.57-7.64 (m, 4H, Ar), 8.12-
8.15 (m, 2H, Ar), 8.37 (s, 1H, H-5), 11.93 (t, 3JH,H = 4.0 Hz, 1H, NH). 13C NMR (62.9 MHz, 
DMSO-d6): δ = 20.9 (CH3), 61.1 (CH2), 69.7, 70.8, 84.3, 93.9 (CHrib), 105.6 (C-3a), 115.6, 
125.4, 127.3, 127.9, 129.1, 129.9 (CHAr), 133.9, 134.5, 140.0, 141.0, 160.0 (CAr), 160.3 
(C=O), 160.6 (C-7a), 160.8 (CONHNH2). IR (ATR, cm-1): v~ = 3271 (br w), 2945 (w), 2837 
(w), 1668 (m), 1643 (m), 1563 (s), 1488 (m), 1362 (m), 1273 (m), 1016 (s), 865 (m), 822 (m), 
736 (s), 695 (s). MS (EI, 70 eV): m/z (%) = 491 (0.13) [M+], 359 (100), 259 (88), 139 (69), 97 
(28), 77 (18), 43 (91). HRMS (ESI): calcd C25H26N5O6 ([M+1]+) 492.1878, found 492.1884. 
Anal. Calcd for C25H25N5O6: C, 61.09; H, 5.13; N, 14.25. Found: C, 61.34; H, 5.00; N, 14.07. 
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1-α-D-Glucopyranozyl-3-oxo-2-phenyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridine-4-carbohydrazide (44) 
Starting from 38i (345 mg, 0.5 mmol), 44 was isolated as 
yellow solid (260 mg, quant.); mp 270-271 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 2.42 (s, 3H, CH3), 
2.80 (br s, 1H, H-5’), 3.10-3.21 (m, 3H, Ha-6’, Hb-6’, H-4’), 
3.41 (br s, 1H, H-3’), 3.56-3.62 (m, 1H, H-2’), 4.41 (t, 3JH,H 
= 5.6 Hz, 1H, OH-6’), 4.94 (d, 3JH,H = 5.5 Hz, 1H, OH-4’), 
5.17 (d, 3JH,H = 3.4 Hz, 1H, OH-3’), 5.45 (br s, 1H, OH-2’), 5.62-5.65 (m, 3H, H-1’, NH2), 
7.40-7.50 (m, 3H, Ar), 7.58 (t, 3JH,H = 7.6 Hz, 2H, Ar), 7.70 (d, 3JH,H = 7.6 Hz, 2H, Ar), 8.15-
8.20 (m, 2H, Ar), 8.42 (s, 1H, H-5), 13.25 (s, 1H, NH). 13C NMR (62.9 MHz, DMSO-d6): δ = 
21.0 (CH3), 61.1 (CH2), 69.8, 70.7, 77.3, 79.7, 89.1 (CHgl), 104.2 (C-3a), 116.0 (C-5), 126.6, 
127.5, 128.3, 128.9, 129.8 (CHAr), 134.3, 137.7, 140.1, 141.0, 158.6 (CAr), 158.6 (C=O), 
159.1 (C-7a), 160.7 (CONHNH2). IR (ATR, cm-1): v~ = 3416 (br w), 2943 (w), 2798 (w), 
1704 (w), 1651 (m), 1634 (m), 1568 (s), 1489 (w), 1364 (m), 1345 (m), 1280 (m), 1055 (s), 
1012 (s), 821 (m), 740 (s), 701 (s). MS (EI, 70 eV): m/z (%) = 521 (2) [M+], 399 (100), 384 
(29), 359 (27), 355 (51), 344 (34), 326 (12), 301 (53), 239 (12), 141 (14), 77 (18), 69 (12), 60 
(12), 44 (11). Anal. Calcd for C26H27N5O7: C, 59.88; H, 5.22; N, 13.43. Found: C, 60.09; H, 
5.15; N, 12.77. 
 
3-Oxo-2-phenyl-1-α-L-rhamnopyranozyl-6-p-tolyl-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridine-4-carbohydrazide (45) 
Starting from 39i (316 mg, 0.5 mmol), 45 was isolated as yellow 
solid (252 mg, quant.); mp 252-253 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 0.94 (d, 3JH,H = 6.5 Hz, 3H, 
CH3-6’), 2.41 (s, 3H, CH3-4’’), 3.29-3.33 (m, 1H, H-4’), 3.46-
3.51 (m, 1H, H-5’), 3.80-3.81 (m, 1H, H-3’), 4.97-5.01 (m, 5H, 
H-2’, OH-3’, OH-4’, NH2), 5.24 (d, 3JH,H = 6.0 Hz, 1H, OH-2’), 
5.52 (d, 3JH,H = 8.8 Hz, 1H, H-1’), 7.38-7.48 (m, 3H, Ar), 7.55-7.61 (m, 2H, Ar), 7.66-7.68 
(m, 2H, Ar), 8.17 (d, 3JH,H = 8.2 Hz, 2H, Ar), 8.34 (s, 1H, H-5), 12.11 (br s, 1H, NH). 13C 
NMR (62.8 MHz, DMSO-d6): δ = 17.6, 21.0 (CH3), 65.5, 73.5, 74.1, 74.4, 84.9 (CHRhamn), 
104.7 (C-3a), 115.1 (C-5), 125.7, 127.5, 127.9, 129.0, 129.8 (CHAr), 134.3, 134.6, 139.9, 
141.0, 160.2 (CAr), 160.4 (C=O), 160.5 (C-7a), 160.7 (CONHNH2). IR (ATR, cm-1): v~ = 3390 
(br w), 2911 (w), 2810 (w), 1657 (m), 1651 (m), 1580 (s), 1494 (w), 1357 (m), 1285 (m), 
1252 (w), 1184 (w), 1128 (w), 1047 (m), 979 (w), 822 (w), 728 (m), 693 (m). MS (EI, 70 eV): 
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m/z (%) = 505 (0.2) [M+], 400 (80), 399 (100), 385 (52), 384 (82), 344 (52), 343 (76), 328 
(20), 302 (64), 301 (88), 272 (32), 239 (71), 105 (19), 77 (62). HRMS (ESI): calcd 
C26H27N5O6 ([M+1]+) 506.20214, found 506.20217. Anal. Calcd for C26H25N5O6: C, 61.77; 
H, 5.38; N, 13.85. Found: C, 61.92; H, 5.41; N, 13.81. 
 
A.2.9. General procedure for synthesis of compounds 51 
Under argon atmosphere, pyrazolo[3,4-b]pyridin-3-one 2 (1 mmol) and K2CO3 (414 mg, 3 
mmol) were placed in a Schlenk flask and 15 mL of dry DMF was added. Appropriate alkyl 
bromide (1.1 mmol) was added dropwise the mixture was stirred at 90 oC for 4-10h 
(controlled by TLC). Then the solution was evaporated under reduced pressure, treated with 
H2O, filtered, dried under reduced pressure and subjected to column chromatography (silica 
gel; eluent: n-heptane/ethylacetate). 
 
6-Methyl-2-phenyl-1-(3-phenylpropyl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (51a)  
Starting from 2a (293 mg, 1 mmol) and (3-bromopropyl)benzene 
(219 mg, 1.1 mmol), 51a was isolated as yellow oil (370 mg, 
90%). 
1H NMR (300 MHz, CDCl3): δ = 1.63 (quin, 3JH,H = 7.6 Hz, 2H, 
CH2CH2CH2), 2.41 (t, 3JH,H = 7.6 Hz, 2H, CH2), 2.71 (s, 3H, 
CH3), 4.04 (t, 3JH,H = 7.6 Hz, 2H, NCH2), 6.93-6.97 (m, 2H, Ph), 
7.13-7.22 (m, 4H, Ph), 7.31-7.37 (m, 1H, Ph), 7.45-7.55 (m, 4H, 
H-5, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 25.5 (CH3), 26.8, 32.7 (CH2), 47.6 (NCH2), 
103.8 (C-3a), 114.7 (q, 3JC,F = 5.0 Hz, C-5), 121.8 (q, 1JC,F = 274.6 Hz, CF3), 124.5, 126.2, 
127.3, 128.1, 128.5, 129.4 (CHAr), 134.5 (CAr), 136.4 (q, 2JC,F = 36.2 Hz, CCF3), 140.5, 158.3 
(CAr), 160.6 (C=O), 165.4 (C-7a). 19F NMR (282 MHz, CDCl3): δ = -62.72 (s). Anal. Calcd 
for C23H20F3N3O: C, 67.14; H, 4.90; N, 10.21. Found: C, 67.41; H, 4.99; N, 10.16. 
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2,6-Biphenyl-1-phenethyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(51b) 
Starting from 2c (355 mg, 1 mmol) and (2-bromoethyl)benzene 
(204 mg, 1.1 mmol), 51b was isolated as green solid (409 mg, 
89%); mp 124-126 oC. 
1H NMR (300 MHz, CDCl3): δ = 2.70 (t, 3JH,H = 7.2 Hz, 2H, CH2), 
4.38 (t, 3JH,H = 7.2 Hz, 2H, NCH2), 6.94-6.97 (m, 2H, Ph), 7.00-
7.11 (m, 3H, Ph), 7.34-7.40 (m, 1H, Ph), 7.50-7.60 (m, 7H, Ph), 7.71 (s, 1H, H-5), 8.08-8.12 
(m, 2H, Ph). 13C NMR (75.5 MHz, CDCl3): δ = 32.7 (CH2), 49.3 (NCH2), 104.7 (C-3a), 111.4 
(q, 3JC,F = 5.0 Hz, C-5), 121.8 (q, 1JC,F = 275.0 Hz, CF3), 124.4, 126.8, 127.3, 127.8, 128.5, 
128.9, 129.2, 129.4, 131.1 (CHAr), 134.5 (CAr), 136.9 (q, 2JC,F = 36.0 Hz, CCF3), 137.4, 158.1 
(CAr), 161.0 (C=O), 162.2 (C-7a). 19F NMR (282 MHz, CDCl3): δ = -62.77 (s). IR (ATR, cm-
1): v~ = 3065 (w), 3003 (w), 1673 (s), 1591 (m), 1579 (m), 1494 (w), 1452 (m), 1423 (w), 
1367 (m), 1358 (m), 1283 (m), 1269 (m), 1214 (w), 1181 (m), 1141 (s), 1133 (s), 1080 (w), 
1057 (m), 878 (m), 775 (m), 758 (m), 715 (m), 694 (s). MS (EI, 70 eV): m/z (%) = 460 (11) 
[M++1], 459 (43) [M+], 369 (35), 368 (100), 355 (8), 105 (21), 104 (13), 77 (17), 43 (6). 
HRMS (ESI): calcd C27H20F3N3O ([M+1]+) 459.15530, found 459.15556. Anal. Calcd for 
C27H20F3N3O: C, 70.58; H, 4.39; N, 9.15. Found: C, 70.56; H, 4.28; N, 8.88. 
 
2,6-Biphenyl-1-(3-phenylpropyl)-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-
one (51c) 
Starting from 2c (355 mg, 1 mmol) and (3-bromopropyl)benzene 
(219 mg, 1.1 mmol), 51c was isolated as green solid (417 mg, 
88%); mp 112-114 oC. 
1H NMR (300 MHz, CDCl3): δ = 1.71 (quin, 3JH,H = 7.5 Hz, 2H, 
CH2CH2CH2), 2.46 (t, 3JH,H = 7.5 Hz, 2H, CH2), 4.13 (t, 3JH,H = 
7.5 Hz, 2H, NCH2), 6.96-7.00 (m, 2H, Ph), 7.14-7.22 (m, 3H, 
Ph), 7.33-7.39 (m, 1H, Ph), 7.49-7.59 (m, 7H, Ph), 7.81 (s, 1H, H-5), 8.05-8.11 (m, 2H, Ph). 
13C NMR (62.9 MHz, CDCl3): δ = 26.8, 32.7 (CH2), 47.6 (NCH2), 104.6 (C-3a), 111.6 (q, 
3JC,F = 5.0 Hz, C-5), 121.9 (q, 1JC,F = 275.0 Hz, CF3), 124.5, 126.2, 127.3, 127.8, 128.2, 128.6, 
129.2, 129.4, 131.2 (CHAr), 134.5 (CAr), 137.2 (q, 2JC,F = 36.2 Hz, CCF3), 137.3, 140.4, 158.2 
(CAr), 160.7 (C=O), 162.4 (C-7a). 19F NMR (282 MHz, CDCl3): δ = -62.66 (s). IR (ATR, cm-
1): v~ = 3061 (w), 2926 (w), 1690 (s), 1591 (m), 1581 (m), 1496 (w), 1444 (w), 1417 (w), 
1373 (m), 1343 (m), 1274 (m), 1262 (m), 1141 (s), 1075 (w), 1048 (m), 1036 (m), 866 (w), 
770 (m), 758 (s), 714 (m), 684 (s), 659 (m). MS (EI, 70 eV): m/z (%) = 474 (24) [M++1], 743 
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(74) [M+], 369 (23), 368 (100), 355 (35), 326 (12), 91 (60), 77 (38). HRMS (ESI): calcd 
C28H23F3N3O ([M+1]+) 474.17877, found 474.17869. Anal. Calcd for C28H22F3N3O: C, 71.03; 
H, 4.68; N, 8.87. Found: C, 71.31; H, 4.79; N, 8.89. 
 
Methyl 2-(3-oxo-2,6-diphenyl-4-(trifluoromethyl)-2,3-dihydro-1H-pyrazolo[3,4-
b]pyridin-1-yl)acetate (51d) 
Starting from 2c (355 mg, 1 mmol) and methyl 2-
bromoacetate (168 mg, 1.1 mmol), 51d was isolated as 
colorless solid (338 mg, 79%); mp 118-120 oC. 
1H NMR (300 MHz, CDCl3): δ = 3.75 (s, 3H, CH3), 4.31 (d, 
2JH,H = 17.8 Hz, 1H, CH2-a), 5.15 (d, 2JH,H = 17.8 Hz, 1H, CH2-
b), 7.31-7.37 (m, 1H, Ph), 7.42-7.52 (m, 7H, Ph), 7.64 (s, 1H, 
H-5), 8.02-8.06 (m, 2H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 48.6 (CH2), 52.6 (OCH3), 
107.3 (C-3a), 110.5 (q, 3JC,F = 6.0 Hz, C-5), 122.6 (q, 1JC,F = 274.4 Hz, CF3), 127.1, 127.4, 
128.0, 129.0, 129.6, 130.9 (CHAr), 137.1, 140.1 (CAr), 140.8 (q, 2JC,F = 33.9 Hz, CCF3), 155.6 
(CAr), 159.0 (NC=O), 160.1 (C-7a), 168.5 (OC=O). 19F NMR (282 MHz, CDCl3): δ = -60.60 
(s). IR (ATR, cm-1): v~ = 3361 (w), 1699 (w), 1674 (m), 1650 (m), 1584 (m), 1566 (m), 1493 
(m), 1466 (w), 1410 (m), 1368 (m), 1315 (w), 1260 (s), 1192 (w), 1143 9s), 1113 (m), 1074 
(m), 961 (w), 918 (w), 864 (w), 778 (m), 714 (m), 688 (m). MS (EI, 70 eV): m/z (%) = 428 
(21) [M++1], 427 (100) [M+], 407 (14), 381 (26), 368 (34), 277 (18), 223 (21), 104 (13), 77 
(29), 44 (14). Anal. Calcd for C22H16F3N3O3: C, 61.83; H, 3.77; N, 9.83. Found: C, 62.22; H, 
3.90; N, 9.78. 
 
1-Phenethyl-2-phenyl-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 
(51e) 
Starting from 2e (347 mg, 1 mmol) and (2-bromoethyl)benzene (204 
mg, 1.1 mmol), 51e was isolated as green solid (392 mg, 87%); mp 
123-125 oC. 
1H NMR (300 MHz, CDCl3): δ = 2.67 (t, 3JH,H = 6.8 Hz, 2H, CH2), 
4.42(t, 3JH,H = 6.8 Hz, 2H, NCH2), 6.89-6.93 (m, 2H, Ph), 7.01-7.09 
(m, 3H, Ph), 7.40-7.47 (m, 1H, Ph), 7.48 (s, 1H, H-5), 7.56-7.58 (m, 
4H, Ph). 13C NMR (62.9 MHz, CDCl3): δ = 27.1, 32.6 (CH2), 47.6 (NCH2), 108.7 (C-3a), 
110.4-110.6 (m, C-5), 120.6 (q, 1JC,F = 275.5 Hz, CF3), 121.1 (q, 1JC,F = 275.5 Hz, CF3), 125.1, 
126.4, 128.0, 128.2, 128.6, 129.7 (CHAr), 133.6 (CAr), 136.4 (q, 2JC,F = 36.2 Hz, CCF3), 139.9 
(CAr), 152.3 (q, 2JC,F = 36.2 Hz, CCF3), 156.6 (C=O), 158.8 (C-7a). 19F NMR (282 MHz, 
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CDCl3): δ = -62.70 (s), -68.10 (s). IR (ATR, cm-1): v~ = 3058 (w), 2947 (w), 1688 (m), 1593 
(w), 1496 (w), 1463 (w), 1432 (w), 1352 (w), 1277 (s), 1211 (m), 1184 (m), 1139 (s), 1118 
(s), 1090 (m), 1080 (m), 1056 (m), 1003 (w), 961 (w), 881 (m), 757 (m), 739 (m), 712 (m), 
703 (s), 694 (m), 661 (m). MS (EI, 70 eV): m/z (%) = 452 (24) [M++1], 451 (47) [M+], 361 
(17), 360 (100), 105 (48), 93 (15), 77 (28). HRMS (ESI): calcd C22H15F6N3O: ([M+1]+) 
451.11138, found 451.11162. Anal. Calcd for C22H15F6N3O: C, 58.54; H, 3.35; N, 9.31. 
Found: C, 58.74; H, 3.37; N, 9.28. 
 
2-Phenyl-1-(3-phenylpropyl)-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-
one (51f) 
Starting from 2e (347 mg, 1 mmol) and (3-bromopropyl)benzene (219 
mg, 1.1 mmol), 51f was isolated as yellow oil (424 mg, 91%). 
1H NMR (300 MHz, CDCl3): δ = 1.70 (quin, 3JH,H = 7.6 Hz, 2H, 
CH2CH2CH2), 2.44 (t, 3JH,H = 7.6 Hz, 2H, CH2), 4.12 (t, 3JH,H = 7.6 Hz, 
2H, NCH2), 6.93-6.96 (m, 2H, Ph), 7.11-7.22 (m, 3H, Ph), 7.38-7.44 
(m, 1H, Ph), 7.49-7.56 (m, 4H, Ph), 7.68 (s, 1H, H-5). 13C NMR (62.9 
MHz, CDCl3): δ = 27.1, 32.6 (CH2), 47.6 (NCH2), 108.7 (C-3a), 110.4-110.6 (m, C-5), 120.6 
(q, 1JC,F = 275.5 Hz, CF3), 121.1 (q, 1JC,F = 275.5 Hz, CF3), 125.1, 126.4, 128.0, 128.2, 128.6, 
129.7 (CHAr), 133.6 (CAr), 136.4 (q, 2JC,F = 36.2 Hz, CCF3), 139.9 (CAr), 152.3 (q, 2JC,F = 36.2 
Hz, CCF3), 156.6 (C=O), 158.8 (C-7a). 19F NMR (282 MHz, CDCl3): δ = -62.49 (s), -67.93 
(s). MS (EI, 70 eV): m/z (%) = 466 (18) [M++1], 465 (52) [M+], 390 (21), 389 (100), 105 (48), 
93 (20), 77 (35), 43 (27). HRMS (ESI): calcd C23H18F6N3O: ([M+1]+) 466.1298, found 
466.1295. Anal. Calcd for C23H17F6N3O: C, 59.36; H, 3.68; N, 9.03. Found: C, 59.52; H, 
3.71; N, 8.78. 
 
A.2.10. General procedure for synthesis of compounds 59 
Under argon atmosphere, pyrazolo[3,4-b]pyridin-3-one 2 (1 mmol) and Hatszch ester (1.0 g, 4 
mmol), and PTSA (19.0 mg, 10 mol%) were placed in a flask, dissolved in benzene (50 mL) 
and heated at 60 oC for 16-72 h (controlled by TLC). Afterwards, the solution was evaporated 
under reduced pressure and subjected to column chromatography (silica gel; eluent: n-
heptane/ethylacetate). After isolation from column, products 59 were recrystallized from i-
PrOH.  
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6-Methyl-2-phenyl-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-
3(2H)-one (59a) 
Starting from 2a (293 mg, 1 mmol), 59a was isolated as pale 
brown solid (285 mg, 96%); mp 156-158 oC. 
1H NMR (300 MHz, DMSO-d6,): δ = 1.22 (d, 3JH,H = 6.4 Hz, 3H, 
CH3), 1.45 (dt, 2JH,H = 13.0 Hz, 3JH,H = 10.8 Hz, 1H, Ha-5), 2.11 
(ddd, 2JH,H = 13.0 Hz, 3JH,H = 6.0 Hz, 3JH,H = 2.3 Hz, 1H, Hb-5), 3.40-3.45 (m, 1H, H-6), 3.48-
3.59 (m, 1H, H-4), 7.03 (t, 3JH,H = 7.5 Hz, 1H, Ph), 7.06 (s, 1H, H-7), 7.34 (t, 3JH,H = 7.5 Hz, 
2H, Ph), 7.59 (d, 3JH,H = 7.5 Hz, 2H, Ph), 9.74 (s, 1H, H-1). 13C NMR (62.9 MHz, DMSO-d6): 
δ = 20.7 (CH3), 31.0 (CH2), 34.9 (q, 2JC,F = 28.8 Hz, CCF3), 46.0 (CCH3), 76.8 (C-3a), 117.7, 
122.5 (CHAr), 127.1 (q, 1JC,F = 280.0 Hz, CF3), 128.5 (CHAr), 139.8 (C-1’), 158.9 (C=O), 
163.7 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -67.26 (s). IR (ATR, cm-1): v~ = 3122 (w), 
2973 (w), 1568 (s), 1557 (s), 1495 (m), 1259 (m), 1143 (m), 1116 (s), 749 (m), 690 (s). MS 
(EI, 70 eV): m/z (%) = 298 (23) [M++1], 297 (100) [M+], 282 (39) [M+-CH3], 200 (17), 172 
(18), 122 (23), 105 (22), 77 (50), 51 (7). HRMS (ESI): calcd C14H14F3N3O ([M+1]+) 
297.10835, found 297.108682. Anal. Calcd for C14H14F3N3O: C, 56.56; H, 4.75; N, 14.14. 
Found: C, 56.82; H, 4.95; N, 13.85. 
 
2,6-Diphenyl-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-3(2H)-
one (59b) 
Starting from 2c (355 mg, 1 mmol), 59b was isolated as pale 
brown solid (252 mg, 70%); mp 121-123 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.85 (dt, 2JH,H = 13.0 Hz, 
3JH,H = 9.8 Hz, 1H, Ha-5), 2.22 (ddd, 2JH,H = 13.0 Hz, 3JH,H = 5.8 
Hz, 3JH,H = 2.7 Hz, 1H, Hb-5), 3.60-3.73 (m, 1H, H-6), 4.56 (dd, 3JH,H = 9.8 Hz, 3JH,H = 2.7 Hz, 
1H, H-4), 7.05 (t, 3JH,H = 7,4 Hz, 1H, Ph), 7.32-7.45 (m, 7H, Ar), 7.49 (s, 1H, H-7), 7.61 (d, 
3JH,H = 7,4 Hz, 2H, Ph), 9.88 (s, 1H, H-1). 13C NMR (75.5 MHz, DMSO-d6): δ = 32.1 (CH2), 
35.0 (q, 2JC,F = 29.5 Hz, CCF3), 54.0 (C-6), 77.0 (C-3a), 117.8, 122.6, 126.6 (CHAr), 126.9 (q, 
1JC,F = 280.0 Hz, CF3), 127.7, 128.5 (CHAr), 139.6, 141.7 (CAr), 159.0 (C=O), 163.6 (C-7a). 
19F NMR (282 MHz, DMSO-d6): δ = -67.15 (s). IR (ATR, cm-1): v~ = 3031 (w), 2860 (w), 
1592 (m), 1568 (m), 1556 (m), 1495 (m), 1257 (m), 1150 (m), 1115 (s), 747 (s), 697 (s). MS 
(EI, 70 eV): m/z (%) = 360 (25) [M++1], 359 (100) [M+], 174 (16), 122 (16), 105 (25), 77 
(41), 51 (6). HRMS (ESI): calcd C19H17F3N3O ([M+1]+) 360.13182, found 360.13184. Anal. 
Calcd for C19H16F3N3O: C, 63.51; H, 4.49; N, 11.69. Found: C, 63.76; H, 4.37; N, 11.33. 
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6-(3,4-Dimethoxyphenyl)-3-oxo-2-phenyl-2,3,4,5,6,7-hexahydro-1H-pyrazolo[3,4-
b]pyridine-4-carboxylic acid (59c) 
Starting from 2m (405 mg, 1 mmol), 59c was isolated as 
colorless solid (186 mg, 47%); mp 228-230 oC. 
1H NMR (500 MHz, DMSO-d6): δ = 1.90 (dt, 2JH,H = 13.1 
Hz, 3JH,H = 10.5 Hz, 1H, H-5a), 2.23 (ddd, 2JH,H = 13.1 Hz, 
3JH,H = 5.6 Hz, 3JH,H = 2.8 Hz, 1H, H-5b), 3.61 (dd, 3JH,H = 10.5 Hz, 3JH,H = 5.6 Hz, 1H, H-6), 
3.76 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 4.47 (dd, 3JH,H = 10.5 Hz, 3JH,H = 2.8 Hz, 1H, H-4), 
6.92-6.96 (m, 2H, Ar), 7.01 (s, 1H, 2’-H), 7.09 (t, 3JH,H = 7,4 Hz, 1H, Ph), 7.38 (t, 3JH,H = 7,9 
Hz, 2H, Ar), 7.42 (br s, 1H, H-7), 7.61 (d, 3JH,H = 7,9 Hz, 2H, Ar), 10.23 (br s, 1H, H-1). 13C 
NMR (125.8 MHz, DMSO-d6): δ = 35.7 (CH2), 36.4 (C-6), 55.0 (C-4), 55.5, 55.6 (OCH3), 
81.0 (C-3a), 110.4, 111.7, 118.0, 118.7, 123.1, 128.7 (CHAr), 134.3, 138.9, 148.3, 148.8 (CAr), 
157.3 (C=O), 164.2 (C-7a), 173.7 (CO2H). IR (ATR, cm-1): v~ = 3226 (w), 3100 (w), 2953 
(w), 1722 (m), 1602 (m), 1574 (s), 1514 (m), 1495 (m), 1267 (m), 1230 (m), 1172 (m), 1152 
(m), 1092 (m), 1026 (m), 748 (m). MS (EI, 70 eV): m/z (%) = 396 (52) [M++1], 395 (98) 
[M+], 351 (74), 350 (77), 349 (100), 347 (68), 334 (59), 257 (21), 231 (81), 221 (25), 177 
(71), 175 (76), 164 (69), 151 (26), 93 (22), 91 (22), 77 (50), 73 (27), 60 (27), 44 (21), 43 (16). 
HRMS (ESI): calcd C21H22N3O5 ([M+1]+) 396.1554, found 396.1554. Anal. Calcd for 
C21H21N3O5: C, 63.79; H, 5.35; N, 10.63. Found: C, 63.99; H, 3.37; N, 10.77. 
 
6-(4-(Difluoromethoxy)phenyl)-2-phenyl-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-
pyrazolo[3,4-b]pyridin-3(2H)-one (59d) 
Starting from 2o (421 mg, 1 mmol), 59d was isolated as 
pale brown solid (276 mg, 65%); mp 114-116 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.91 (dt, 2JH,H = 
13.2 Hz, 3JH,H = 10.0 Hz, 1H, Ha-5), 2.27 (ddd, 2JH,H = 
13.2 Hz, 3JH,H = 5.9 Hz, 3JH,H = 3.2 Hz, 1H, Hb-5), 3.64-3.78 (m, 1H, H-6), 4.64 (dd, 3JH,H = 
10.0 Hz, 3JH,H = 3.2 Hz, 1H, H-4), 7.11 (t, 3JH,H = 7.4 Hz, 1H, Ar), 7.25-7.27 (m, 2H, Ar), 7.30 
(t, 1JF,H = 74.1 Hz, 1H, OCF2H), 7.38-7.43 (m, 2H, Ar), 7.52-7.55 (m, 3H, Ar, H-7), 7.64-7.68 
(m, 2H, Ar), 9.96 (s, 1H, H-1). 13C NMR (75.5 MHz, DMSO-d6): δ = 31.9 (CH2), 35.0 (q, 
2JC,F = 29.9 Hz, CCF3), 53.3 (C-6), 77.2 (C-3a), 116.4 (t, 1JC,F = 257.8 Hz, OCF2H), 117.9, 
118.9, 122.8, 128.4, 128.6 (CHAr), 127.0 (q, 1JC,F = 280.1 Hz, CF3), 138.8, 139.6 (CAr), 148.8 
(C=O), 150.3 (t, 3JC,F = 3.3 Hz, COCF2H), 158.8 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = 
-67.10 (s, 3F, CF3), -82.03 (s, 2F, OCF2H). IR (ATR, cm-1): v~ = 3067 (w), 2979 (w), 1574 
(m), 1556 (m), 1497 (m), 1369 (w), 1335 (w), 1259 (m), 1219 (m), 1176 (m), 1112 (s), 1032 
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(s), 748 (m), 691 (m). MS (EI, 70 eV): m/z (%) = 426 (24) [M++1], 425 (100) [M+], 282 (5), 
255 (8), 174 (27), 122 (10), 105 (10), 77 (30), 51 (5). HRMS (ESI): calcd C20H16F5N3O2: 
([M+1]+) 425.11572, found 425.116207. Anal. Calcd for C20H16F5N3O2: C, 56.47; H, 3.79; N, 
9.88. Found: C, 56.59; H, 3.62; N, 9.65. 
 
3-Oxo-2-phenyl-6-m-tolyl-2,3,4,5,6,7-hexahydro-1H-pyrazolo[3,4-b]pyridine-4-
carboxylic acid (59e) 
Starting from 2s (373 mg, 1 mmol), 59e was isolated as pale 
brown solid (192 mg, 51%); mp 250-251 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.86 (dt, 2JH,H = 13.1 
Hz, 3JH,H = 10.5 Hz, 1H, Ha-5), 2.17 (ddd, 2JH,H = 13.1 Hz, 
3JH,H = 5.7 Hz, 3JH,H = 2.6 Hz, 1H, Hb -5), 2.33 (s, 3H, CH3), 
3.48 (dd, 3JH,H = 10.5 Hz, 3JH,H = 5.7 Hz, 1H, H-6), 4.51 (dd, 3JH,H = 10.5 Hz, 3JH,H = 2.6 Hz, 
1H, H-4), 7.06-7.15 (m, 2H, H-7, Ar), 7.18-7.30 (m, 3H, Ar), 7.35-7.40 (m, 2H, Ar), 7.47-
7.50 (m, 1H, Ar), 7.59-7.62 (m, 2H, Ar), 10.25 (s, 1H, H-1). 13C NMR (62.9 MHz, DMSO-
d6): δ = 21.1 (CH3), 35.7 (CH2), 36.4 (CH-6), 55.5 (CH-4), 80.9 (C-3a), 118.0, 123.2, 123.8, 
127.2, 128.3, 128.4, 128.7 (CHAr), 137.6, 138.9, 141.9 (CAr), 157.3 (C=O), 164.2 (C-7a), 
173.7 (CO2H). IR (ATR, cm-1): v~ = 3044 (w), 2981 (w), 2855 (w), 1651 (w), 1634 (m), 1589 
(w), 1548 (w), 1498 (m), 1379 (m), 1347 (m), 1230 (m), 1092 (w), 1012 (w), 887 (w), 790 
(m), 752 (m), 706 (m), 690 (m). MS (EI, 70 eV): m/z (%) = 350 (7) [M++1], 349 (35) [M+], 
304 (17), 303 (69), 301 (11), 78 (97), 63 (100), 61 (12), 45 (11). HRMS (ESI): calcd 
C20H19N3O3 ([M+1]+) 349.14339, found 349.142380. Anal. Calcd for C20H19N3O3: C, 68.75; 
H, 5.48; N, 12.03. Found: C, 68.81; H, 5.57; N, 11.89. 
 
Methyl 3-oxo-2-phenyl-6-p-tolyl-2,3,4,5,6,7-hexahydro-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (59f) 
Starting from 2u (359 mg, 1 mmol), 59f was isolated as 
colorless solid (265 mg, 73%); mp 218-220 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.98 (dt, 2JH,H = 12.9 
Hz, 3JH,H = 8.0 Hz, 1H, Ha-5), 2.17 (ddd, 2JH,H = 12.9 Hz, 
3JH,H = 6.0 Hz, 3JH,H = 3.0 Hz, 1H, H-5b), 2.29 (s, 3H, CH3), 
3.42 (s, 3H, OCH3), 3.48 (dd, 3JH,H = 8.0 Hz, 3JH,H = 6.0 Hz, 1H, H-6), 4.51 (dd, 3JH,H = 8.0 
Hz, 3JH,H = 3.0 Hz, 1H, H-4), 7.02 (t, 3JH,H = 7.5 Hz, 1H, Ar), 7.16 (d, 3JH,H = 7.5 Hz, 2H, Ar), 
7.24 (d, 3JH,H = 7.5 Hz, 2H, Ar), 7.31-7.38 (m, 3H, H-7, Ar), 7.61 (d, 3JH,H = 7.5 Hz, 2H, Ar), 
9.75 (s, 1H, H-1). 13C NMR (62.9 MHz, DMSO-d6): δ = 20.7 (CH3), 35.0 (CH2), 35.4 (CH-6), 
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51.3 (OCH3), 54.0 (CH-4), 81.5 (C-3a), 117.2, 122.3, 126.5, 128.5, 128.8 (CHAr), 136.5, 
138.8, 139.8 (CAr), 157.5 (C=O), 164.2 (C-7a), 173.4 (CO2CH3). IR (ATR, cm-1): v~ = 3326 
(w), 3026 (w), 2947 (w), 1720 (m), 1667 (w), 1587 (s), 1556 (m), 1495 (m), 1484 (m), 1328 
(m), 1273 (m), 1200 (m), 1172 (m), 1092 (m), 820 (m), 752 (s), 694 (m), 655 (m). MS (EI, 70 
eV): m/z (%) = 364 (21) [M++1], 363 (100) [M+], 303 (60), 276 (20), 245 (49), 207 (65), 185 
(14), 129 (33), 91 (17), 77 (25), 51 (8). HRMS (ESI): calcd C21H22N3O3 ([M+1]+) 364.1656, 
found 364.1651. Anal. Calcd for C21H21N3O3: C, 69.41; H, 5.82; N, 11.56, found: C, 69.036; 
H, 6.016; N, 11.421. 
 
6-(Naphthalen-2-yl)-2-phenyl-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (59g) 
Starting from 6-(naphthalen-2-yl)-2-phenyl-4-(tri 
fluoromethyl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one 2aj 
(405 mg, 1 mmol), 59g was isolated as colorless solid (233 
mg, 57%); mp 120-122 oC. 
1H NMR (300 MHz, DMSO-d6): δ = 1.98 (dt, 3JH,H = 13.2 Hz, 3JH,H = 9.6 Hz, 1H, Ha-5), 2.29-
2.34 (m, 1H, Hb-5), 3.64-3.82 (m, 1H, H-4), 4.73-4.77 (m, 1H, H-6), 7.06 (t, 3JH,H = 7.4 Hz, 
1H, Ar), 7.34-7.39 (m, 2H, Ar), 7.49-7.65 (m, 6H, H-7, Ar), 7.92-7.97 (m, 4H, Ar), 9.94 (s, 
1H, H-1). 13C NMR (62.9 MHz, DMSO-d6): δ = 31.8 (q, 3JC,F = 5 Hz, CH2), 35.0 (q, 2JC,F = 
29.5 Hz, CCF3), 54.0 (C-6), 77.0 (C-3a), 117.7, 122.6, 124.9, 125.2, 126.0, 126.3 (CHAr), 
126.9 (q, 1JC,F = 280.0 Hz, CF3), 127.6, 127.8, 128.1, 128.5 (CHAr), 132.6, 132.9, 139.3, 139.6 
(CAr), 159.0 (C=O), 163.6 (C-7a). 19F NMR (282 MHz, DMSO-d6): δ = -67.09 (s). IR (ATR, 
cm-1): v~ = 3054 (w), 2929 (w), 1568 (m), 1556 (m), 1496 (m), 1365 (w), 1316 (m), 1260 (m), 
1195 (m), 1151 (m), 1115 (s), 1002 (w), 858 (m), 817 (m), 745 (s), 692 (m). MS (EI, 70 eV): 
m/z (%) = 410 (28) [M++1], 409 (100) [M+], 235 (33), 174 (23), 154 (19), 77 (36). HRMS 
(EI): calcd C23H18F3N3O ([M]+) 409.13965, found 409.13914. Anal. Calcd for C23H18F3N3O: 
C, 67.48; H, 4.43; N, 10.26. Found: C, 67.61; H, 4.39; N, 9,98. 
N
H
N
N
H
CF3O
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Appendix 2: Crystallographic data 
 
Crystal data and structure refinement for 2g  
 
Identification code  is_ls164  
Empirical formula  C17H10F3N3OS · C2H6OS 
Formula weight  439.47  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Triclinic  
Space group (H.-M.)  P-1  
Space group (Hall)  -P 1  
Unit cell dimensions:  a = 10.3182 (4) Å α = 115.6070 (10)°  
  b = 10.3297 (2) Å β = 99.4920 (10)°  
  c = 10.9223 (2) Å γ = 104.1050 (10)°  
Volume  968.33 (5) Å3 
Z  2  
Calculated density 1.507 mg/m3 
Absorption coefficient 0.32 mm-1 
F(000)  452  
Crystal size  0.54 x 0.18 x 0.06 mm  
Θ range for data collection 2.34° to 30.00°  
Index ranges -14 ≤ h ≤14, -14 ≤ k ≤14, -15 ≤ l ≤15  
Reflections collected  20690  
Independent reflections  4823 [R(int) = 0.0276] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9808 and 0.8443 
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  5623 / 0 / 268 
Goodness-of-fit on F2  1.035  
Final R indices [I>2sigma(I)] R1 = 0.0367, wR2 = 0.0910  
R indices (all data)  R1 = 0.0450, wR2 = 0.0960  
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 Crystal data and structure refinement for 37f 
 
Identification code  is_ls265  
Empirical formula  C28H24F3N3O9  
Formula weight  603.50  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Orthorombic  
Space group (H.-M.)  P212121  
Space group (Hall)  P2ac2ab  
Unit cell dimensions:  a = 7.0420 (6) Å α = 90°  
  b = 11.1180 (11) Å β = 90°  
  c = 34.714 (4) Å γ = 90°  
Volume  2717.9 (5) Å3 
Z  4  
Calculated density 1.475 mg/m3 
Absorption coefficient 0.124 mm-1 
F(000)  1248  
Crystal size  0.35 x 0.09 x 0.06 mm  
Θ range for data collection 2.54° to 30.00°  
Index ranges -9 ≤ h ≤7, -15 ≤ k ≤15, -48 ≤ l ≤48  
Reflections collected  42455  
Independent reflections  5242 [R(int) = 0.0582] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9926 and 0.9579  
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  7921 / 0 / 392 
Goodness-of-fit on F2  1.033  
Final R indices [I>2sigma(I)] R1 = 0.0482, wR2 = 0.0796  
R indices (all data)  R1 = 0.0946, wR2 = 0.0943  
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Crystal data and structure refinement for 37g 
 
Identification code  is_ls054  
Empirical formula  C31H26F5N3O9  
Formula weight  679.55  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Monoclinic  
Space group (H.-M.)  P21  
Space group (Hall)  P2yb 
Unit cell dimensions:  a = 12.3854 (4) Å α = 90°  
  b = 8.1987 (3) Å β = 96.4430 (10)°  
  c = 14.8841 (5) Å γ = 90°  
Volume  1501.85 (9) Å3 
Z  2  
Calculated density 1.503 mg/m3 
Absorption coefficient 0.131 mm-1 
F(000)  700  
Crystal size  0.46 x 0.41 x 0.11 mm  
Θ range for data collection 2.75° to 31.54°  
Index ranges -8 ≤ h ≤18, -11 ≤ k ≤12, -21 ≤ l ≤21  
Reflections collected  19825  
Independent reflections  8700 [R(int) = 0.0164] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9858 and 0.9423  
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  9515 / 1 / 436 
Goodness-of-fit on F2  1.018  
Final R indices [I>2sigma(I)] R1 = 0.0355, wR2 = 0.0867  
R indices (all data)   R1 = 0.0412, wR2 = 0.0911 
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Crystal data and structure refinement for 40b 
 
Identification code  ls079  
Empirical formula  C24H20F3N3O5 · C2H6O  
Formula weight  533.50  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Monoclinic  
Space group (H.-M.)  P21  
Space group (Hall)  P2yb 
Unit cell dimensions:  a = 5.9439 (7) Å α = 90°  
  b = 20.179 (3) Å β = 101.546 (7)°  
  c = 10.5014 (13) Å γ = 90°  
Volume  1234.0 (3) Å3 
Z  2  
Calculated density 1.436 mg/m3 
Absorption coefficient 0.117 mm-1 
F(000)  556  
Crystal size  0.74 x 0.14 x 0.12 mm  
Θ range for data collection 2.83° to 32.50°  
Index ranges -7 ≤ h ≤8, -27 ≤ k ≤30, -15 ≤ l ≤15  
Reflections collected  16244 
Independent reflections  6406 [R(int) = 0.0234] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9861 and 0.9182  
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  8263 / 1 / 360 
Goodness-of-fit on F2  1.018  
Final R indices [I>2sigma(I)] R1 = 0.0433, wR2 = 0.0903 
R indices (all data)  R1 = 0.0655, wR2 = 0.1023  
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Crystal data and structure refinement for 40t 
 
Identification code  is_ls278 
Empirical formula  C25H18F3N3O7 · H2O  
Formula weight  547.44  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Monoclinic  
Space group (H.-M.)  P21  
Space group (Hall)  P2yb 
Unit cell dimensions:  a = 7.8151 (3) Å α = 90°  
  b = 11.9529 (4) Å β = 90.141 (2)°  
  c = 24.9115 (9) Å γ = 90°  
Volume  2327.05 (15) Å3 
Z  4 
Calculated density 1.563 mg/m3 
Absorption coefficient 0.133 mm-1 
F(000)  1128 
Crystal size  0.69 x 0.33 x 0.06 mm  
Θ range for data collection 0.82° to 32.50°  
Index ranges -11 ≤ h ≤11, -18 ≤ k ≤15, -37 ≤ l ≤37  
Reflections collected  42695  
Independent reflections  12403 [R(int) = 0.0296] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9921 and 0.9139  
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  14820 / 7 / 743 
Goodness-of-fit on F2  1.044  
Final R indices [I>2sigma(I)] R1 = 0465, wR2 = 0.0973  
R indices (all data)  R1 = 0624, wR2 = 0.1044  
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Crystal data and structure refinement for 42g 
 
Identification code  is_ls062 
Empirical formula  C26H22F5N3O6  
Formula weight  567.47  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Orthorombic  
Space group (H.-M.)  P212121  
Space group (Hall)  P2ac2ab  
Unit cell dimensions:  a = 10.0280 (2) Å α = 90°  
  b = 11.7016 (3) Å β = 90°  
  c = 20.3084 (5) Å γ = 90°  
Volume  2383.06 (10) Å3 
Z  4 
Calculated density 1.582 mg/m3 
Absorption coefficient 0.138 mm-1 
F(000)  1168 
Crystal size  0.27 x 0.12 x 0.06 mm  
Θ range for data collection 2.66° to 30.00°  
Index ranges -12 ≤ h ≤14, -16 ≤ k ≤14, -28 ≤ l ≤28  
Reflections collected  28834 
Independent reflections  5026 [R(int) = 0.0607] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9917 and 0.9636  
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  6943 / 0 / 374 
Goodness-of-fit on F2  1.038  
Final R indices [I>2sigma(I)] R1 = 0539, wR2 = 0.1104  
R indices (all data)  R1 = 0892, wR2 = 0.1280  
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 Crystal data and structure refinement for 51b 
 
Identification code  ch_ls293 
Empirical formula  C27H20F3N3O  
Formula weight  459.46  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Orthorombic  
Space group (H.-M.)  Pbca  
Space group (Hall)  -P2ac2ab 
Unit cell dimensions:  a = 20.2511 (4) Å α = 90°  
  b = 10.6301 (4) Å β = 90°  
  c = 20.8518 (4) Å γ = 90°  
Volume  4488.79 (15) Å3 
Z  8 
Calculated density 1.360 mg/m3 
Absorption coefficient 0.101 mm-1 
F(000)  1904 
Crystal size  0.53 x 0.35 x 0.20 mm  
Θ range for data collection 2.78° to 30.00°  
Index ranges -28 ≤ h ≤28, -14 ≤ k ≤13, -29 ≤ l ≤29  
Reflections collected  61693 
Independent reflections  4572 [R(int) = 0.0412] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9800 and 0.9482  
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  6538 / 0 / 307 
Goodness-of-fit on F2  1.025  
Final R indices [I>2sigma(I)] R1 = 0.0415, wR2 = 0.0951  
R indices (all data)  R1 = 0.0707, wR2 = 0.1146  
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Crystal data and structure refinement for 59a 
 
Identification code  is_ls0133 
Empirical formula  C14H14F3N3O · CH4O 
Formula weight  329.32  
Temperature  173(2) K  
Wavelength 0.71073 Å  
Crystal system  Monoclinic 
Space group (H.-M.)  P21/c  
Space group (Hall)  -P2ybc 
Unit cell dimensions:  a = 5.070 (5) Å α = 90°  
  b = 8.125 (8) Å β = 92.82 (3)°  
  c = 36.71 (3) Å γ = 90°  
Volume  1511 (2) Å3 
Z  4 
Calculated density 1.448 mg/m3 
Absorption coefficient 0.122 mm-1 
F(000)  688 
Crystal size  0.74 x 0.15 x 0.14 mm  
Θ range for data collection 4.45° to 29.00°  
Index ranges -6 ≤ h ≤6, -11 ≤ k ≤10, -50 ≤ l ≤47  
Reflections collected  14346 
Independent reflections  3048 [R(int) = 0.0378] 
Absorption correction  Multi-scan  
Max. and min. transmission  0.9831 and 0.9149 
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  3960 / 0 / 222 
Goodness-of-fit on F2  1.076  
Final R indices [I>2sigma(I)] R1 = 0.0577, wR2 = 0.1358  
R indices (all data)  R1 = 0.0762, wR2 = 0.1419  
 
 
 
